RISK FACTORS AND CONTEMPORARY MANAGEMENT OF LOW BACK PAIN by Gustavo De Carvalho, Machado
RISK FACTORS AND CONTEMPORARY MANAGEMENT OF 
LOW BACK PAIN 
Gustavo de Carvalho Machado, BPhty (Hons) 
A thesis submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
School of Public Health, Sydney Medical School 
The University of Sydney 
November 2016
Supervisors’ Statement
As supervisors of Gustavo de Carvalho Machado’s doctoral work, we certify that we consider 
his thesis “Risk Factors and Contemporary Management of Low Back Pain” sufficiently well 
presented to be examined, and certify that it does not exceed the prescribed word limit or any 
extended word limit for which prior approval has been granted. 
Associate Professor Manuela Ferreira
Institute of Bone and Joint Research6\GQH\0HGLFDO6FKRRO
The University of Sydney
_______________________________________ Date: 30 November 2016
Professor Christopher Maher
6FKRRORI3XEOLF+HDOWK6\GQH\0HGLFDO6FKRRO
The University of Sydney
_______________________________________ Date: 30 November 2016
Associate Professor Paulo Ferreira
'LVFLSOLQHRI3K\VLRWKHUDS\Faculty of Health Sciences
The University of Sydney
_______________________________________ Date: 30 November 2016
ii
Candidate’s Statement
I, Gustavo de Carvalho Machado, hereby declare that this submission is my own work and that 
it contains no material previously published or written by another person except where 
acknowledged in the text. Nor does it contain material which has been accepted for the award 
of another degree. 
I, Gustavo de Carvalho Machado, understand that if I am awarded a higher degree for my thesis 
entitled “Risk Factors and Contemporary Management of Low Back Pain” being lodged 
herewith for examination, the thesis will be lodged in the University library and be available 
immediately for use. I agree that the University Librarian (or in the case of a department, the 
Head of the Department) may supply a photocopy or microform of the thesis to an individual 
for research or study or to a library. 
_____________________________________ 
Date: 30 November 2016
iii
Table of Contents 
Supervisors’ Statement .............................................................................................................. ii
Candidate’s Statement .............................................................................................................. iii
Table of Contents ..................................................................................................................... iv
Acknowledgements ................................................................................................................. vii
Publications and Presentations ................................................................................................. ix
Preface ..................................................................................................................................... xii
Abstract .................................................................................................................................. xiv
Chapter One: Introduction ...................................................................................................... 1
1.1 Introduction to low back pain .......................................................................................... 2
1.2 The prevalence of low back pain ..................................................................................... 2
1.3 The socioeconomic burden of low back .......................................................................... 3
1.4 The definition and classification of low back pain .......................................................... 3
1.5 The mechanisms and risk factors for low back pain ....................................................... 6
1.6 Pharmacological interventions for low back pain ........................................................... 9
1.7 The clinical prognosis of low back pain ........................................................................ 11
1.8 Surgical interventions for low back pain ....................................................................... 12
1.9 The rates of surgical procedures for low back pain ....................................................... 13
1.10 Aims of the thesis ........................................................................................................ 14
1.11 References ................................................................................................................... 16
Chapter Two: Transient physical and psychosocial activities increase the risk of non-
persistent and persistent low back pain: a case-crossover study with 12 months follow-up .. 24
Abstract ................................................................................................................................ 26
Introduction ......................................................................................................................... 27
Materials and methods ......................................................................................................... 27
Results ................................................................................................................................. 29
Discussion ............................................................................................................................ 31
Acknowledgments ............................................................................................................... 33
References ........................................................................................................................... 33
Chapter Three: &DQUHFXUUHQFHDIWHUDQDFXWHHSLVRGHRIORZEDFNSDLQEHSUHGLFWHG" An
inception cohort study ............................................................................................................. 34
Abstract ................................................................................................................................ 37
Introduction ......................................................................................................................... 38
Methods ............................................................................................................................... 39
Results ................................................................................................................................. 42
Discussion ............................................................................................................................ 44
Acknowledgments  .............................................................................................................. 49
References ........................................................................................................................... 50
iv
Tables .................................................................................................................................. 53
Appendix ............................................................................................................................. 57
Figure .................................................................................................................................. 59
Chapter Four: Efficacy and safety of paracetamol for spinal pain and osteoarthritis: 
systematic review and meta-analysis of randomised placebo controlled trials ....................... 60
Abstract ................................................................................................................................ 62
Introduction ......................................................................................................................... 62
Methods ............................................................................................................................... 63
Results ................................................................................................................................. 65
Discussion ............................................................................................................................ 70
References ........................................................................................................................... 73
Appendix ............................................................................................................................. 75
Chapter Five: Nonsteroidal anti-inflammatory drugs for spinal pain: D systematic review
and meta-analysis .................................................................................................................... 82
Abstract ................................................................................................................................ 84
Introduction ......................................................................................................................... 84
Methods ............................................................................................................................... 84
Results ................................................................................................................................. 86
Discussion ............................................................................................................................ 88
Acknowledgments ............................................................................................................... 91
References ........................................................................................................................... 91
Search Strategy .................................................................................................................... 94
Supplementary Tables ......................................................................................................... 95
Supplementary Figures ...................................................................................................... 103
Chapter Six: Patients with sciatica still experience pain and disability 5 years after surgery: 
D systematic review with meta-analysis of cohort studies .................................................... 106
Abstract .............................................................................................................................. 108
Introduction ....................................................................................................................... 109
Methods ............................................................................................................................. 109
Results ............................................................................................................................... 110
Discussion and conclusions ............................................................................................... 112
Acknowledgments ............................................................................................................. 115
References ......................................................................................................................... 115
Appendix ........................................................................................................................... 118
Chapter Seven: Effectiveness of surgery for lumbar spinal stenosis: a systematic review and 
meta-analysis ......................................................................................................................... 126
Abstract .............................................................................................................................. 128
Introduction ....................................................................................................................... 129
Materials and methods ....................................................................................................... 130
Results ............................................................................................................................... 131
v
Discussion .......................................................................................................................... 140
Conclusions ....................................................................................................................... 141
References ......................................................................................................................... 142
Appendix ........................................................................................................................... 146
Chapter Eight: Trends, complications, and costs for hospital admission and surgery for 
lumbar spinal stenosis ............................................................................................................ 149
Abstract .............................................................................................................................. 151
Introduction ....................................................................................................................... 151
Methods ............................................................................................................................. 152
Results ............................................................................................................................... 153
Discussion .......................................................................................................................... 154
Key Points.......................................................................................................................... 157
References ......................................................................................................................... 157
Chapter Nine: Conclusions .................................................................................................. 158
9.1 Overview of principal findings .................................................................................... 159
9.2 Implications and directions for future research ........................................................... 160
9.3 Concluding remarks ..................................................................................................... 166
9.4 References ................................................................................................................... 167
Appendix A .......................................................................................................................... 169
Appendix B .......................................................................................................................... 172
Appendix C .......................................................................................................................... 176
Appendix D .......................................................................................................................... 178
Appendix E .......................................................................................................................... 181
Appendix F........................................................................................................................... 185
vi
Acknowledgements
Ma, I could not have done this without you. Thank you so much for all your support and
patience during the last four years. I truly admire you in so many ways and you inspire me to 
work harder every day. You make me a better person and I am grateful that you chose me as 
your husband. You are my best friend, as a team we will grow stronger, and together we will 
have a beautiful family. I love you forever. This thesis is dedicated to you.
Mum and Dad, you are my greatest examples in life. Thank you for always believing in me and
for the many sacrifices you have made to support my decisions. Vi, you are the best brother one 
could ever ask for, and you really inspire me. I will be eternally grateful for all your support 
and for always motivating me to pursue my dreams. Despite the huge distance between us, the 
three of you have always been in my heart and very close to me, and I thought of you every 
single day. I love you and hope I have made you proud.
Manuela, Paulo and Chris, I am appreciative of your guidance during my PhD candidature.
Manuela and Paulo, you are my great examples of perseverance and success. I could not thank
you enough for your mentorship and all the opportunities you gave me since the early stages of
my career. Chris, you are a great leader and I have learnt a lot from you. For all this, I will be
forever grateful.
Steve and Chris Williams, a huge thanks for your mentorship and priceless advice, accompanied 
with so much fun and, of course, beer. Anne Moseley, thank you for the opportunity to work 
with PEDro and for the amazing bushwalks we did in the Blue Mountains. Colleen, Martin and 
Debra, thank you for your support and supervision during my teaching experience in the 
vii
Discipline of Physiotherapy at the Faculty of Health Sciences. Jose Liberato Jr, thank you for 
being a remarkable teacher, you have shown me the value of our profession in helping people 
get better and stay well.
This journey would not have been the same without my fellow PhD students Zambelli and
Marcinha, Daniel and Paula, Bruno and Tie, Patricia, Juliana, Steph, Mike, Matt, Aron, and
Tarci. You guys have made my candidature so much more enjoyable and I will miss you!
Marilie, Jen, Marnee, Matt, Amabile, and Anita, thank you for adding some fun in to my
teaching days at the Faculty of Health Sciences.
To my Brazilian Jiu-jitsu coaches at Gracie Barra Belo Horizonte (Claudio Mattos, Marcelo 
Azevedo, Vinicius Draculino) and students at Zeus Martial Arts Academy, and Costa Prasoulas,
you kept my mind in place and reminded me about important aspects of life: discipline, focus,
determination, and loyalty. To my friends, Marcelo and Mayumi, Bernardo and Nadia, Matheus 
and Marcela, Igor and Mariana, Rafael, Damien and Larissa, Paul and Imelda, thank you for 
your friendship and for sharing with me some great moments in this great country.
viii
Publications and Presentations
Parts of the work presented in this thesis have been published or accepted for publication in 
peer-reviewed journals and/ or presented in conferences.
Published or accepted papers
Machado GC, Maher CG, Ferreira PH, et al. Can recurrence after an acute episode of low back 
pain be predicted? Phys Ther 2017;[In press].
Machado GC, Ferreira PH, Maher CG, et al. Nonsteroidal anti-inflammatory drugs for spinal 
pain: a systematic review and meta-analysis. Ann Rheum Dis 2017;76:1269-78.
Machado GC, Maher CG, Ferreira PH, et al. Trends, complications, and costs for hospital 
admission and surgery for lumbar spinal stenosis. Spine 2017;[Epub ahead of print].
Machado GC, Ferreira ML. No clinical benefits of surgery over rehabilitation for lumbar spinal 
stenosis (PEDro synthesis). Br J Sports Med 2017;51:541-42.
Machado GC, Ferreira PH, Yoo RIJ, et al. Surgical options for lumbar spinal stenosis. Cochrane 
Database Syst Rev 2016;11:CD012421.
Machado GC, Ferreira PH, Maher CG, et al. Transient physical and psychosocial activities 
increase the risk of non-persistent and persistent low back pain: a case-crossover study with 12 
months follow-up. Spine J 2016;16:1445-52.
ix
Machado GC, Witzleb AJ, Fritsch C, et al. Patients with sciatica still experience pain and 
disability 5 years after surgery: a systematic review with meta-analysis of cohort studies. Eur J 
Pain 2016;20:1700-09.
Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain 
and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. 
BMJ 2015;350:h1225.
Machado GC, Maher CG, Ferreira ML. Paracetamol, spinal pain, and osteoarthritis: Authors' 
reply to Adam and to Veal and Thompson. BMJ 2015;350:h2223.
Machado GC, Maher CG, Ferreira ML. Lack of efficacy of paracetamol for low back pain and 
osteoarthritis. J Pioneer Med Sci 2015;5:142-43.
Machado GC, Ferreira PH, Harris IA, et al. Effectiveness of surgery for lumbar spinal stenosis: 
a systematic review and meta-analysis. PLoS ONE 2015;10:e0122800.
Machado GC, Ferreira ML. Physiotherapy improves eating disorders and quality of life in 
bulimia and anorexia nervosa. Br J Sports Med 2014;48:1519-20.
Presentations
Machado GC, Ferreira PH, Maher CG, Hunter DJ, Day RO, Pinheiro MB, Ferreira ML. Safety 
and efficacy of nonsteroidal anti-inflammatory drugs for spinal pain: a systematic review with 
meta-analysis of randomised placebo-controlled trials. In: Proceedings of XIV International 
x
Forum for Back & Neck Pain Research in Primary Care, June 2016. Buxton, United Kingdom. 
Poster Presentation.
Machado GC, Witzleb AJ, Fritsch C, Maher CG, Ferreira PH, Ferreira ML. The clinical course 
of patients with sciatica treated surgically: a systematic review with meta-analysis of cohort 
studies. In: Proceedings of Australian Physiotherapy Association Conference, October 2015. 
Gold Coast, Australia. Oral Presentation.
Machado GC, Ferreira PH, Maher CG, Latimer J, Steffens D, Koes BW, Li Q, Ferreira ML. 
Triggers for an episode of persistent low back pain: 12-month follow-up of a case-crossover 
study. In: Proceedings of Australian Physiotherapy Association Conference, October 2015. 
Gold Coast, Australia. Oral Presentation.
Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CWC, Day RO, McLachlan AJ, 
Ferreira ML. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: a systematic 
review and meta-analysis. In: Proceedings of III Population Health Congress, September 2015. 
Hobart, Australia. Poster Presentation.
Machado GC, Ferreira PH, Harris IA, Pinheiro MB, Koes BW, van Tulder M, Rzewuska M, 
Maher CG, Ferreira ML. Decompression techniques in the management of lumbar spinal 
stenosis: a systematic review and meta-analysis of randomised controlled trials. In: Proceedings 
of XIII International Forum for Back Pain Research in Primary Care, October 2014. Campos 
do Jordao, Brazil. Poster Presentation.
xi
Preface
This thesis is arranged in nine chapters, written so that each chapter can be read independently. 
The studies in this thesis involve two topics: risk factors (Chapter Two and Chapter Three),
and contemporary management of low back pain (Chapter Four to Chapter Eight). The 
University of Sydney allows published papers that arose from the candidature to be included in 
the thesis.
Chapter One is an introduction to the thesis and provides an overview of the definitions, 
epidemiology, and economic burden of low back pain, as well as a background related to the 
risk factors, prognosis, and contemporary management associated with this condition. Chapter 
Two is a case-crossover study with 12-month follow-up identifying transient physical and 
psychosocial risk factors for an episode of persistent low back pain in primary care settings.
This study is presented as published in The Spine Journal. Chapter Three is an inception 
cohort study conducted to estimate the 1-year incidence of recurrence of low back pain and to 
investigate predictors associated with future recurrences within one year. This study is 
presented in the format required by Physical Therapy where it was accepted for publication.
Chapter Four consists of a systematic review investigating the safety and efficacy of 
paracetamol in patients with low back or neck pain, or osteoarthritis. This study is presented as 
published in BMJ. Chapter Five is a systematic review investigating the safety and efficacy of 
nonsteroidal anti-inflammatory drugs in patients with low back or neck pain, with or without 
radicular symptoms. This study is presented as published in Annals of the Rheumatic Diseases.
Chapter Six is a systematic review investigating the long-term prognosis in terms of pain and 
disability in patients who received surgery for sciatica. This study is presented as published in 
European Journal of Pain. Chapter Seven investigates the safety and efficacy of various 
xii
surgical options for patients with lumbar spinal stenosis through a systematic review. This study 
is presented as published in PLoS ONE. Chapter Eight is a population-based data linkage study 
conducted to identify the trends, complications, and costs of hospital admission and surgery for 
lumbar spinal stenosis. This study is presented as published in Spine. Chapter Nine is an 
overview of the thesis, and discusses the clinical implications of the findings and directions for 
future research.
Each chapter contains its own reference list. Appendices that were published as online 
supplementary material, and other relevant outputs are included at the end of the relevant 
chapter. Additional appendices unrelated to individual chapters are included at the end of the 
thesis. Ethical approval was obtained from the Human Research Ethics Committee of the 
University of Sydney for the studies reported in Chapter Two and Chapter Three prior to 
commencement. Ethical approval was obtained from the New South Wales Population and
Health Services Research Ethics Committee for the study reported in Chapter Eight prior to 
commencement. The remaining chapters did not require ethical approval.
xiii
Abstract
Low back pain is common and causes more burden in terms of years lived with disability than
any other health condition globally. In most cases, the patho-anatomical cause of low back 
pain cannot be determined. Less commonly, specific spinal pathologies can be identified as 
the cause of low back pain, including conditions involving neurologic compromise, such as 
sciatica and lumbar spinal stenosis. Despite extensive research over the past decades, 
questions remain in terms of the underlying mechanisms, risk factors, and current treatment 
options for these conditions. The broad aim of this thesis, therefore, is to contribute to a better 
understanding of factors associated with low back pain onset and the safety and efficacy of 
contemporary management strategies.
Risk factors associated with the onset of a new episode of low back pain can be divided into
those involving long-term exposure (e.g., smoking) and those involving transient or brief 
exposure to the risk factor (e.g., a fall). A recent case-crossover study identified that 
commonly endorsed physical and psychosocial triggers (e.g., awkward postures, distracted 
during an activity) increase substantially the risk of sudden onset low back pain, with odds 
ratios ranging from 2.7 to 25.0. This study focussed on triggers for an acute episode of low 
back pain and did not consider the triggers that increased the risk of an episode of longer 
duration. This is an important issue as most of the costs of low back pain are associated with 
persistent cases. The study presented in Chapter Two includes the 12-month follow-up of 
this case-crossover study and examined the association between the previously identified 
triggers and the risk of a low back pain episode that persisted for greater than six weeks. This 
study was based on data from 782 patients presenting to primary care clinics for a new 
episode of low back pain, who were successfully followed-up. Conditional logistic regression 
xiv
models suggested that previously identified psychosocial and physical triggers, such as being 
fatigued or tired during an activity or manual tasks involving awkward postures, increased the 
risk of persistent episodes of low back pain, with odds ratios (OR) ranging from 2.9 (95% 
confidence interval [CI]: 1.3–6.4) to 11.7 (95% CI: 5.4–25.3). The results were similar to 
those for acute episodes of low back pain, suggesting that controlling exposures to these 
triggers may prevent not only the cases of low back that resolve within six weeks, but also the 
cases that persist, which are believed to cause the greatest burden of this condition.
While a great proportion of patients with low back pain experience recovery within six weeks,
recurrence of low back pain is common. However, estimates of recurrence within one year
range from 26% to 84%. Part of this variability can be attributed to different definitions of
episodes of low back pain used across studies. Moreover, only a few studies have used
appropriate methodology to investigate predictors of recurrence. The study presented in
Chapter Three determined the 1-year incidence of recurrence in participants who had 
recently recovered from an acute episode of low back pain, and identified predictors of future
recurrences. This was an inception cohort study with 12 months follow-up. Recurrence was
defined based on a 12-month recall of a new episode of pain or a new episode of care seeking
with data from 469 participants. The 1-year incidence of recurrence of low back pain was 
33%, and the recurrence rate for a new episode of care seeking for low back pain was 18%. 
Multivariable regression analysis revealed that having more than two previous episodes of 
low back pain increased the odds of a future recurrence by 3.2 (95% CI: 2.1–4.8). This factor 
was also associated with recurrent episodes of care seeking (OR: 2.9, 95% CI: 1.7–4.8). No 
other factors were associated with recurrence. This study contributes to the lack of research on 
recurrence of low back pain.
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Patients with low back pain seeking primary health care are often recommended paracetamol 
as the first line analgesic medication. This medicine is also widely used to treat osteoarthritis.
However, a randomised trial published in 2014 concluded that paracetamol was ineffective 
for acute low back pain, and there was also conflicting evidence for its use in osteoarthritis. 
The systematic review with meta-analysis of randomised placebo-controlled trials presented 
in Chapter Four investigated the safety and efficacy of paracetamol in patients with low 
back pain, as well as neck pain, or osteoarthritis. Searching eight databases revealed 13 trials 
that met the inclusion criteria. Pain and disability scores were converted to a 0 to 100 scale, 
and a 9-point threshold was used to define smallest worthwhile effect. Pooling showed no 
effects of paracetamol on pain (mean difference [MD]: –0.5, 95% CI: –2.9 to 1.9) or disability 
(MD: 0.4, 95% CI: –0.9 to 1.7) for acute low back pain. No trials investigated the effects of 
paracetamol for patients with neck pain. Paracetamol had small and not clinically important 
effects for osteoarthritis in pain relief (MD: –3.7, 95% CI: –5.5 to –1.9) or disability reduction 
(MD: –2.9, 95% CI: –4.9 to –0.9). Patients taking paracetamol were 3.8 times (95% CI: 1.9–
7.4) more likely to have abnormal test results of liver function compared with placebo. The 
results of this systematic review support the reconsideration of recommendations to use 
paracetamol for these conditions. The study was published with an editorial and has received
various prizes, including the BMJ 1st prize for the most accesses in 2015.
The impact of withdrawing recommendations for paracetamol from clinical guidelines of low
back pain is that the use of nonsteroidal anti-inflammatory drugs (NSAIDs), second line
analgesic, is set to increase. A comprehensive review and appraisal of the literature on the
efficacy and safety of NSAIDs was therefore paramount. Moreover, the effects of NSAIDs for
some forms of spinal pain, such as acute low back pain and neck pain, remain uncertain.
Chapter Five, therefore, presents a systematic review with meta-analysis of randomised
xvi
placebo-controlled trials that aimed to determine the efficacy and safety of NSAIDs for low
back pain, as well as neck pain, with or without radicular pain. Systematic searches were
conducted in five large databases and 35 randomised trials were included in the review. Pain
and disability outcomes were converted to a 0 to 100 scale, and a between-group difference of
10 points was used as the smallest worthwhile effect. Numbers needed to treat were also
calculated providing the number of participants treated with NSAIDs who would achieve a
clinically important pain reduction compared with placebo. Pooling revealed that for every six
participants (95% CI: 4 to 10) treated with NSAIDs, only one would benefit from it, 
considering a between-group difference of 10 points (i.e., compared with placebo) for clinical 
importance in the short-term. Moreover, only in three of the 14 analyses looking at different 
types of spinal pain, outcomes, or time points were the pooled treatment effects marginally 
above our threshold for clinical importance. Additionally, taking NSAIDs increased the risk 
of developing gastrointestinal adverse events by 2.5 times (95% CI: 1.2–5.2).
The initial management of low back pain usually focuses on conservative treatments, 
including analgesic medications. When conservative treatments are unsuccessful, surgery may 
be considered. Sciatica is a common indication for spine surgery, but at present the clinical 
course of this condition following surgery remains largely unknown. Therefore, the 
systematic review with meta-analysis of cohort studies presented in Chapter Six investigated 
the clinical course of pain and disability in patients who had surgery for sciatica. The searches 
were conducted in three large databases and 40 publications (39 cohort studies) were 
included. Pain and disability scores were converted to a common 0 to 100 scale and modelled 
as a function of time. Generalised estimating equations revealed that the pooled mean leg pain 
intensity before surgery was 75.2 (95% CI: 68.1 to 82.4) and the mean disability was 55.1 
(95% CI: 52.3 to 58.0). Pooled mean leg pain (15.3, 95% CI: 8.5 to 22.1) and disability (15.5, 
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95% CI: 13.3 to 17.6) reduced substantially after three months. At five years, patients still 
reported moderate levels of leg pain (21.0, 95% CI: 12.5 to 29.5) and disability (13.1, 95% 
CI: 10.6 to 15.5). These findings suggest that patients with sciatica experience rapid 
improvements in the first three months after surgery, but are not likely to experience full 
recovery (i.e., absence of pain or disability) in the long-term.
Lumbar spinal stenosis is the fastest-growing indication for spine surgery among older 
people. However, surgeons usually rely on their own preferences to decide on the best 
surgical technique for their patient. The systematic review and meta-analysis presented in 
Chapter Seven investigated the efficacy of surgery for lumbar spinal stenosis, and the 
effectiveness of various surgical options for this condition. The searches conducted on seven 
databases revealed limited evidence, as no surgical placebo-controlled trials were found. The 
24 randomised trials included in the review compared various surgical options for lumbar 
spinal stenosis. Pain and disability scores were converted to a 0 to 100 scale. Pooling 
suggested that fusion offered no additional benefits over decompression surgery alone on pain 
(MD: –0.3, 95% CI: –7.3 to 6.7) or disability (MD: 3.3, 95% CI: –6.1 to 12.6). The 
interspinous process spacers alone were not more effective than conventional decompression 
in pain relief (MD: –0.6, 95% CI: –8.1 to 7.0) or disability reduction (MD: 1.3, 95% CI: –4.5 
to 7.0), but showed small effects when compared with decompression plus fusion on 
disability (MD: 5.7, 95% CI: 1.3 to 10.0). This review was originally published in PLoS ONE
in 2015, but has since then been updated and published in the Cochrane Database of 
Systematic Reviews, presented in this thesis as an appendix. The updated results provide 
current evidence on the surgical options for lumbar spinal stenosis, and could be used to guide 
clinical decision-making in this contentious area.
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Even though the effects of surgical procedures for patients with lumbar spinal stenosis remain
unclear, the rates of fusion procedures have increased in the United States in recent times. It is 
unknown, however, whether these trends are happening elsewhere. Moreover, further 
information on complications could better inform surgeons, referring physicians, and patients 
about risks of surgical procedures. The population-based health record linkage study 
presented in Chapter Eight determined the trends in hospital admission and surgery for 
lumbar spinal stenosis in Australia, and investigated associated complications and health care 
use. The Centre for Health Record Linkage was used to link data of admissions, discharges, 
and transfers records from all public and private hospitals in New South Wales between 2003 
and 2013. In one decade, the age-standardised rate of hospital admissions for lumbar spinal 
stenosis increased from 34.8 to 39.3 per 100,000 people. In 2013, the total costs for lumbar 
spinal stenosis were AU $46.1 million. Decompression rates increased from 19.0 to 22.1 per 
100,000 people during 2003–2013, while the rates of simple fusion doubled, from 1.3 to 2.8 
per 100,000 people. The most significant increase, however, occurred for complex fusion,
from 0.6 to 2.4 per 100,000 people – a 4-fold increase in the same 10-year period. Mean 
hospital costs with decompression surgery were AU $12,168, while simple and complex 
fusion cost AU $30,811 and AU $32,350, respectively. Complex fusion procedures increased 
the odds of major complications by 4.1 (95% CI: 1.7–10.1) compared with decompression 
alone. This study confirms that in Australia the number of complex fusion procedures is 
increasing at a much faster rate than any other surgical procedure for lumbar spinal stenosis, 
though it is associated with increased risk of major complications and resource use.
Overall, the studies presented in this thesis provide a substantial contribution to the
understanding of the mechanisms and risk factors of low back pain. The identification of 
transient risk factors for persistent low back pain could help develop better preventive 
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strategies. Although a great proportion of patients experience recovery within six weeks, it is 
now clear that a third is expected to have a recurrence, with multiple previous episodes being 
the only significant predictor of future recurrences. This thesis also contributes to a better 
understanding of current management strategies for low back pain. Paracetamol is ineffective 
for acute low back pain, but NSAIDs provide small effects in pain relief and disability 
reduction. Recommendations in clinical practice guidelines on pharmacological interventions 
should be reviewed. Although patients refractory to conservative treatments are frequently 
referred to surgery, the postoperative clinical course of sciatica is not as favourable as 
previously thought. Furthermore, despite the lack of evidence on surgical options for lumbar 
spinal stenosis, fusion surgery is increasing at an alarming rate in Australia.
xx
CHAPTER ONE
Introduction
1
1.1 Introduction to low back pain
Low back pain is a common condition affecting millions of people and is associated with a 
major socioeconomic burden globally.1 In Australia, low back pain is the second most common 
symptom for a primary care consultation.2 Low back pain also accounts for 2.3% of all 
physician consultations in the United States.3,4 The burden to the patient is also substantial and 
low back pain is still the main cause of disability and work loss in many countries.5 While 
serious spinal pathologies leading to low back pain (e.g., vertebral fracture and malignancy) 
are uncommon in primary care, about 9% of patients will have some type of neurologic 
compromise, where sciatica and lumbar spinal stenosis are the most common diagnoses.6 The 
remaining 90% will present with non-specific low back pain, when the anatomical structure 
causing the pain cannot be identified.1 A better understanding of risk factors and mechanisms 
of low back pain is crucial in order to prevent this burdesome condition.
The initial management of low back pain usually involves the use of simple analgesics. 
However, the safety and efficacy of commonly used analgesics (e.g., paracetamol) for low back 
pain have been questioned by a recent randomised trial.7 Likewise, the safety and efficacy of 
complex interventions, including surgery for lower back conditions is still controversial and 
the focus of much debate.8 This thesis will contribute to a better understanding of factors 
associated with low back pain onset and the safety and efficacy of contemporary management 
strategies.
1.2 The prevalence of low back pain
Every year, about 6% of the population develops a first-ever episode of low back pain.9 Most 
people, however, will experience multiple episodes of low back pain throughout their lives, 
resulting in a lifetime prevalence of 84%.10 A systematic review of 165 studies yielded an 
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estimate of the point-prevalence of low back pain of 12%, while the 1-month prevalence was 
estimated at 23%.11 Low back pain associated with neurologic compromise, on the other hand, 
is less prevalent. For instance, while the annual prevalence of non-specific low back pain is 
38%,11 sciatica affects about 10% of the population annually.12 Another less common cause of 
low back pain is lumbar spinal stenosis, which affects only 4% of the general adult population
every year,13 though the prevalence can be much higher in those older than 60 years of age.14
1.3 The socioeconomic burden of low back pain
Globally, low back pain causes more disease burden than any other health condition, where 
burden is measured as years lived with disability.15 The burden of low back pain has increased 
by 57% between 1990 and 2013, from 46.1 million to 72.3 million years lived with disability.16
This condition continues to be the leading cause of disability in most countries according to 
the 2015 Global Burden of Diseases study.5 The direct (health care) and indirect (reduction of 
work or household productivity) costs associated with low back pain are large and seem to be 
growing.17 However, estimates of economic costs vary greatly between different countries.4
For example, indirect costs in the United States are as high as US $28.2 billion, while the direct 
costs are estimated at US $90.6 billion.4 In Australia, the estimated costs associated with 
productivity loss are AU $8.2 billion (US $6.2 billion), whereas annual costs of health care are 
AU $1.0 billion (US $800 million).18
1.4 The definition and classification of low back pain
Low back pain is usually defined as a primary complaint of pain between the costal margin and 
the inferior gluteal folds, with or without leg pain.19 An episode of low back pain is defined as 
low back pain lasting at least 24 hours in duration.19 A recurrent episode is the return of low 
back pain with minimum pain intensity following a period of least one month without pain (0
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or 1, 0–10 scale).20 Such definitions are commonly used in international clinical practice 
guidelines and will be used in the work presented in this thesis.21,22
Low back pain is also classified according to its duration, though time frames are inconsistently 
reported in the literature.21 For instance, the duration of symptoms used to define the transition 
from an acute (or non-persistent) to chronic (or persistent) episode of low pain has been 
reported as 72 hours,23 while others have used a cut off of three months.24 Given that patients 
with low back pain improve markedly in the first six weeks,25 this thesis defines a non-
persistent episode of low back pain as that lasting less than six weeks. Hence, persistent low 
back pain is defined as an episode lasting six weeks or longer.19
1.4.1 Using a diagnostic triage to classify low back pain
Another classification of low back pain consists of using a diagnostic triage to identify non-
specific low back pain episodes from cases of neurologic compromise or serious spinal 
pathology.21,22 Non-specific low back pain is used to define those cases without clear specific 
cause, and comprises 90% of patients with low back pain presenting to primary care.1,26
Neurologic compromise affects about 9% of patients with low back pain,27 whereas serious 
spinal pathologies, such as vertebral fracture or malignancy, affect ~1% of patients presenting 
to primary care with low back pain.6
Sciatica is the most common type of neurologic compromise affecting the lumbar spine.27 This 
condition is defined as radiating pain into the leg that may present with neurological symptoms, 
such as paraesthesia, weakness and reduction of reflexes.28 Sciatica is a commonly used term 
but reflects an out of date view of the mechanism of the condition.29 A more contemporary 
term is lumbosacral radicular syndrome or radiculopathy. However, given the common use of 
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the term sciatica in the literature, this thesis uses this term to define patients with unilateral 
radiating pain below the knee with or without low back pain or neurological symptoms.
Another form of neurologic compromise, more common in the older population, is lumbar 
spinal stenosis. This condition is defined as the narrowing of the central spinal canal, lateral 
recesses, or intervertebral foramen, causing compression of neurovascular tissues.13 Central 
lumbar spinal stenosis causes compression of the spinal cord or cauda equina by hypertrophy 
of bony or ligamentous tissues.30 The most common symptom of central lumbar spinal stenosis 
is intermittent neurogenic claudication – radiating bilateral leg pain exacerbated by standing, 
walking, or lumbar extension, and relieved by forward flexion or sitting.31 Lateral or foraminal 
lumbar spinal stenosis, on the other hand, compromises nerve roots, and symptoms may 
resemble those of unilateral radiculopathy.13 Often these subgroups are lumped together to 
create heterogeneous cohorts simply defined as lumbar spinal stenosis.
Serious pathologies of the lumbar spine include infection, inflammatory diseases, cauda equina 
syndrome, axial spondyloarthritis, vertebral fracture and malignancy. These conditions, 
however, only affect a small minority (~1%) of patients with low back pain presenting to 
primary care.6 Vertebral fracture and malignancy are the most common serious pathologies 
affecting the lumbar spine,32,33 and screening for red flags is endorsed in most clinical 
guidelines in order to identify patients more likely to have these conditions.21 However, only a 
small subset of red flags (older age, prolonged corticosteroid use, severe trauma, presence of a 
contusion, or history of malignancy) have been found to be associated with increased likelihood 
of vertebral fracture or malignancy.34
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The focus of the work presented in this thesis is on the risk factors and current management 
strategies for non-specific low back pain, sciatica and lumbar spinal stenosis, which together, 
comprise the most prevalent and burdensome conditions that affect the lumbar spine.
1.5 The mechanisms and risk factors for low back pain
There is an unclear understanding of the underlying mechanisms associated with low back pain. 
Low back pain may originate from various spinal structures including intervertebral discs, 
muscles, bones, ligaments or neural tissues. The identification of the exact anatomical source 
of pain, however, is impractical in clinical practice, given the weak association between clinical 
tests and reference tests for each diagnosis (e.g., facet joint or sacroiliac joint pain).35,36
The factors currently known to increase the risk of low back pain onset have not helped the 
development of effective preventive strategies.37 One possible explanation is that most of these 
factors are related to long-term exposures (e.g., smoking) or are non-modifiable factors (e.g., 
age, gender, comorbidities).9,26,38 A well-conducted systematic review of 41 cohort studies 
revealed 21 significant risk factors for low back pain, but most cohorts used pain of any 
duration to ascertain future low back pain.38 Moreover, cohorts studies are often vulnerable to 
confounding issues. The Triggers for Low Back Pain was the first study to overcome these
common limitations by investigating transient exposure to modifiable factors likely to trigger 
a new episode of low back pain using a case-crossover design.39 The findings revealed that 
manual and psychological factors, such vigorous physical activity or being distracted during a 
task, significantly increased the risk of a new onset of low back pain, with odds ratio ranging 
from 2.7 (95% CI: 2.0–3.6) to 25.0 (95% CI: 3.4–184.5).39 However, the link between these 
triggers and persistent cases of low back pain remained unclear, given the Triggers study 
focused on acute episodes.
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Identifying triggers for persistent low back pain is particularly important, since these cases 
account for 75% of the socioeconomic burden of this condition.40 Therefore, Chapter Two
presents a 12-month follow-up of the Triggers for Low Back Pain study that identified the 
triggers associated with onset of an episode of low back pain that persisted greater than six 
weeks in duration. The study also compared the risk estimates for persistent low back pain with 
those linked to non-persistent cases. Findings from this study are likely to aid understanding of 
the mechanisms of low back pain, and facilitate the development of effective preventive 
interventions for this condition.
Patients with a new episode of low back pain experience large improvements in the first few 
weeks after the onset of symptoms.25 In fact, about two thirds of these patients recover 
completely within six weeks,41 a finding confirmed by the study presented in Chapter Two.
However, our understanding of predictors of recovery is still poor.42 Furthermore, we know 
that once recovered, patients will often report recurrent episodes.43 There are, however, 
inconsistent estimates of recurrence of low back pain reported in the literature, and a lack of 
large high quality cohort studies investigating predictors of recurrence.43
To date only one large inception cohort study has investigated recurrence of low back pain 
using an appropriate methodology.44 Stanton et al. suggested that 33% (95% CI: 28–38) of 
those who recover from an acute episode would have a recurrence of low back pain within the 
next 12 months.44 Other studies have failed to include a representative sample45 or to use 
standardised definitions of recovery or recurrence.46 This resulted in misleading estimates of 
recurrence ranging from 26% to 84%.43 Furthermore, previous studies investigating recurrence 
of low back pain have included participants with persistent pain who are less likely to recover, 
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and thus ineligible to have a recurrence.43 Therefore, there is a lack of agreement on incidence 
estimates of recurrence of low back pain.
Previous studies have important methodological flaws and do not provide sufficient 
information on potential risk factors for the recurrence of low back pain.43 For instance, Van 
den Heuvel et al. have shown that certain work-related physical movements are associated with 
recurrence (odds ranged from 1.4 to 4.1). However, they have used a non-standardised 
definition of recurrence of low back pain (i.e., regular or prolonged low back pain in the 
previous 12 months).44 Only two cohort studies have investigated risk factors for recurrence of 
low back pain using appropriate methodology.45,46 These studies have found that having 
previous episodes of low back pain doubled the odds (95% CI: 1.2–3.4) of future 
recurrences.45,46 Although other factors have been investigated, including pain intensity, 
smoking, perceived global health or risk of recurrence, red flags, and physical activity; no other 
risk factors for recurrent low back pain have been identified.45 Imaging findings have been 
identified as potentially relevant factors to consider for the risk of recurrence of low back 
pain.46 Other relevant factors likely to increase the risk of recurrence have never been studied, 
such as presence of radiculopathy, use of medications, and anxiety. Therefore, the risk factors 
for a recurrent episode of low back pain remain largely unknown.
The inconsistent incidence estimates, and the largely unknown risk factors for recurrence of 
low back pain hamper the effective management of this condition. For instance, most 
interventions aiming to reduce incidence of low back pain are ineffective.37 There is indeed a 
paucity of research in this area, thus Chapter Three presents a prospective inception cohort 
study that investigated the incidence of recurrence of low back pain within one year, and 
predictors (not previously studied) of recurrence. The study included a large sample of patients 
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who had recovered from an acute episode of low back pain in primary care settings. The results 
of this study will inform patients and clinicians about the incidence of recurrence of low back
pain, and the factors associated with future recurrences.
1.6 Pharmacological interventions for low back pain
Patients with low back pain seeking primary care are often managed with simple analgesics, 
such as paracetamol and NSAIDs.48 Despite the wide use of these analgesics in clinical 
practice, there are still uncertainties about their safety and efficacy. Clinical guidelines often 
recommend paracetamol as the first line analgesic medication for low back pain, whereas 
NSAIDs are often considered the second choice.21,22 Paracetamol is the most widely used over-
the-counter medicine for low back pain, mainly because of the common belief that it is a safe 
medicine. NSAIDs, on the other hand, are one of the most frequently prescribed analgesic in 
primary care to treat low back pain.49,50
The safety of paracetamol has been recently challenged by a systematic review of long-term 
cohort studies including data for 665,000 adults.51 Roberts et al. revealed that the use of 
paracetamol increases the relative rate of mortality by 1.63 (95% CI: 1.58–1.68) compared with 
not taking paracetamol.51 The study also showed that standard-dose paracetamol therapy (i.e.,
500–1000 mg every 4–6 hours; maximum, 4000 mg daily) is associated with an increased risk
of cardiovascular, gastrointestinal, and renal adverse effects.51 Therapeutic doses of 
paracetamol are also known to increase alanine aminotransferase activity (ALT), a commonly 
used biomarker for liver injury (i.e., ALT more than three times the upper limit of the reference 
value).52 Although there are uncertainties about the clinical implication of the transient 
elevations of ALT, a systematic review of 30,865 patients taking therapeutic doses of 
paracetamol has reported no cases of acute liver failure.53 However, the evidence on ALT 
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activity in specific populations treated with paracetamol, such as musculoskeletal pain, has 
never been summarised.
The clinical benefits of paracetamol for common musculoskeletal conditions have been 
questioned recently. For instance, a large randomised trial including 1,652 participants showed 
that paracetamol is no more effective than placebo for acute low back pain.7 Furthermore, there 
have been discussions on whether paracetamol should be kept in the most recent NICE 
guidance for the management of osteoarthritis,54 due to its questionable efficacy. In this 
context, Chapter Four presents a systematic review with meta-analysis of randomised 
placebo-controlled trials investigating the efficacy and safety of paracetamol for low back pain, 
neck pain, and osteoarthritis.55
The use of NSAIDs for low back pain has decreased in the last decade,56 though it is expected 
to rise since paracetamol seems to offer no clinical benefits over placebo.7 Furthermore, there 
has been an increased awareness of risks associated with opioid use,57 which is recommended 
as third choice analgesic for low back pain. Additionally, the NICE clinical guidelines, for 
instance, are now recommending NSAIDs as the first choice analgesic for low back pain and 
sciatica.58 However, there are still concerns about the safety of this drug, given its association 
with cardiovascular and serious gastrointestinal adverse effects.59
The clinical benefits of NSAIDs seem to be small for patients with chronic low back pain or 
sciatica, according to the latest Cochrane reviews.60,61 However, its effects on other forms of 
spinal pain, such as neck pain or acute low back pain, remain unclear. Therefore, there is a need 
to understand the effects and safety of NSAIDs in the management of spinal pain. In Chapter 
Five a systematic review with meta-analysis of randomised placebo-controlled trials 
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investigated the efficacy and associated adverse effects of NSAIDs for lower back or neck pain, 
with or without radicular symptoms. Given topical and injection formulations are often used 
for these patients, the review also included trials testing various delivery routes of NSAIDs.
Although the use of simple analgesics is extremely popular for low back pain, surgery is often 
recommended for cases of neurologic compromise (i.e., lumbar spinal stenosis and sciatica)
that is refractory to conservative treatments, which are believed to have a worse prognosis.62
1.7 The clinical prognosis of low back pain
Clinical guidelines21,22 often report a favourable course of low back pain managed in primary 
care that is not consistent with the most recent evidence. Data for 15 cohorts with acute low 
back pain revealed a rapid reduction of pain in the first weeks.63 Pooled mean pain score was 
52 (95% CI: 48 to 57; 0–100 scale) at baseline, and 23 (95% CI: 21 to 25) at six weeks.63
However, improvements seem to slow beyond this point,25 and about a third of patients never 
fully recover within 12 months.41 The clinical course of persistent low back pain is slightly less 
favourable. About 60% of patients with low back pain still report moderate levels of pain and 
disability by 12 months.25,63 Patients who fail to improve with conservative treatment are often 
referred to surgery. In fact, this is more often the case for patients with sciatica, who are 3.9 
times (95% CI: 1.3–11.4) more likely to be referred to surgery compared with those reporting 
low back pain alone.62
Surgery for sciatica usually involves the removal of the herniated disc via discectomy – the 
most common surgical procedure for this condition.28 With advances in surgical technologies, 
minimally invasive procedures for sciatica have been developed, such as microdiscectomy and 
endoscopic procedures.64 Despite the popularity of these surgical procedures, recent 
randomised trials have shown that surgery does not lead to better long-term clinical outcomes 
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compared with conservative treatments for sciatica.65,66 Moreover, one trial reported that 
intraoperative complications (e.g., dural tear) occurred in 4% of patients.58 This same trial also 
reported a postoperative complication rate of 5%, and a 12-month reoperation rate of 4%, 
whereas no adverse effects were noted in the conservative treatment group.58
There is not clear consensus on the long-term prognosis of patients with sciatica after surgery. 
As a result, surgeons often provide their own opinions and expectations about the course of 
pain and disability following a surgical procedure. The problem is that surgeons’ predictions 
are often overly optimistic and poorly correlate (kappa = 0.03) with patients’ outcomes after 
surgery.67 The unclear understanding of the postoperative course of sciatica hampers clinical 
decision-making and the communication between patients and surgeons. Thus, Chapter Six 
presents a systematic review with meta-analysis of large prospective cohort studies 
investigating the course of pain and disability of patients with sciatica up to five years after 
surgery. The study also investigates whether different surgical procedures lead to different 
clinical courses. The results of this study will better inform surgeons and patients about the 
most likely long-term prognosis of sciatica after surgery, despite the lack of robust evidence in 
terms of its safety and efficacy.
1.8 Surgical interventions for low back pain
Surgery for lumbar spinal stenosis is the fastest growing spine surgery worldwide in older 
people.68 Despite the increasing number of surgical procedures for lumbar spinal stenosis, there 
is no clear consensus on its indications, especially on whether or not to add fusion to
decompression surgery.69 There is also a range of surgical decompression techniques available, 
such as spinous process-splitting laminectomy, endoscopic laminectomy, and unilateral or 
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bilateral laminotomy. However, the decision of the most appropriate surgical decompression 
procedure seems to be based on surgeons’ own preferences and opinions.70
The specific efficacy of surgery (i.e., excluding improvement due to natural history and 
placebo) for lumbar spinal stenosis remains unclear. Moreover, there is uncertainty about the 
effectiveness (i.e., extent to which an intervention achieves its intended effect in the usual 
clinical setting) of newer surgical techniques or devices compared with conventional surgical 
procedures. Therefore, Chapter Seven presents a systematic review and meta-analysis of 
randomised controlled-trials investigating the efficacy and safety of surgery compared with no 
treatment, sham or placebo surgery, as well as the comparative effectiveness of various surgical 
options for lumbar spinal stenosis. After this systematic review was published, the Cochrane 
Back and Neck Group invited the authors to update and transform the review into a Cochrane 
review, which is presented in Appendix F in this thesis.
1.9 The rates of surgical procedures for low back pain
Although surgery for low back pain seems to offer similar clinical outcomes as conservative 
treatments,8 the rates of surgical procedures have been increasing.71 In the United States, the 
most dramatic increase was noted for fusion procedures,72 and similar trends have also been 
observed in other countries.73 In Australia, there has been an increase of surgical fusion for low 
back pain. However, the number of publicly performed fusion procedures increased by only 
2% compared with a 167% increase in private facilities over the same 10-year period.74
There are several factors that could explain the reasons why lumbar fusion surgery is increasing 
at a much faster rate than other surgical procedures for low back pain. These reasons include 
surgical technological advances, financial incentives, and marketing of surgical devices. 
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Studies investigating trends in surgery for low back pain have consistently reported a marked 
increase in the rates of fusion surgery in older people,72-74 among whom lumbar spinal stenosis 
is the most frequent indication for spine surgery.68
To date very few studies have investigated the trends in hospital admission and surgery for 
lumbar spinal stenosis,68,75,76 and the majority were conducted in the United States.68,75 The 
trends in the United States are for decreased use of decompression alone and increased use of 
decompression plus fusion.68,75 It is still unclear, however, whether these trends are also 
happening elsewhere, thus limiting the global understanding of changes in surgical rates for 
this condition.
The use of more complex surgical procedures for lumbar spinal stenosis has been associated 
with an increased risk of complications and mortality.68 Deyo et al. reported that the addition 
of complex fusion (i.e., fusion of three or more spinal levels, or a combined anterior and 
posterior approach) tripled the risk (95% CI 2.50–3.49) of life-threatening complications 
compared with decompression alone. Complex fusion was also more costly (US $80,888) than 
conventional decompression alone (US $23,724). These figures are largely unknown in 
Australia. Therefore, Chapter Eight presents a population-based health record linkage study 
investigating the trends in hospital admission and surgical procedures for lumbar spinal 
stenosis, as well as complications and resource use, in New South Wales Australia.
1.10 Aims of the thesis
The aims of this thesis were to:
1. Investigate the association between physical and psychosocial triggers and the risk of
persistent low back pain episodes in primary care (Chapter Two).
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2. Determine the 12-month incidence of recurrence after an acute episode of low back
pain, and to identify predictors of recurrences (Chapter Three).
3. Systematically review and appraise the literature on the efficacy and safety of
commonly used medications for low back pain, including paracetamol (Chapter Four)
and NSAIDs (Chapter Five).
4. Systematically review and appraise the literature on the clinical course of pain and
disability in patients with sciatica undergoing surgery (Chapter Six).
5. Systematically review and appraise the literature on the efficacy and safety of surgery
for lumbar spinal stenosis, as well as the effectiveness of various surgical options for 
this condition (Chapter Seven).
6. Determine the trends in hospital admission and surgery for lumbar spinal stenosis, as
well as investigate associated complications and resource use in New South Wales 
Australia (Chapter Eight).
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Abstract BACKGROUND CONTEXT: A previous study has shown that transient physical and psychoso-
cial activities increased the risk of developing low back pain. However, the link between these factors
in triggering nonpersistent or persistent episodes remains unclear.
PURPOSE: We aimed to investigate the association of transient exposures to physical and psycho-
social activities with the development of nonpersistent or persistent low back pain.
STUDY DESIGN: This was a case-crossover study with 12 months follow-up.
PATIENT SAMPLE: We included 999 consecutive participants seeking care for a sudden onset
of low back pain.
OUTCOME MEASURES: Development of low back pain was the outcome measure.
MATERIALS AND METHODS: At baseline, participants reported transient exposures to 12 pre-
defined activities over the 4 days preceding pain onset. After 12 months, participants were asked
whether they had recovered and the date of recovery. Exposures in the 2-hour period preceding pain
onset (case window) were compared with the 2-hour period, 24 hours before pain onset (control window)
in a case-crossover design for all participants. Conditional logistic regression was used to calculate
odds ratios (ORs) and 95% confidence intervals (CI), and interaction analyses were used to compare
estimates of nonpersistent (i.e., <6 weeks duration) and persistent cases. This study received funding
from Australia’s National Health and Medical Research Council (APP1003608).
RESULTS: There were 832 participants (83%) who completed the 12 months follow-up success-
fully. Of these, 430 participants had nonpersistent low back pain (<6 weeks duration), whereas 352
reported persistent symptoms (≥6 weeks duration). Exposure to several transient activities, such as
manual tasks involving heavy loads, awkward postures, live people or animals, moderate or vigor-
ous physical activity, and being fatigued or tired during a task or activity, significantly increased the
risk of both nonpersistent and persistent low back pain, with ORs ranging from 2.9 to 11.7. Overall,
the risk of developing a persistent or a nonpersistent episode of low back pain associated with the
included physical factors did not differ significantly.
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CONCLUSIONS: Our results revealed that previously identified triggers contribute equally to the
development of both nonpersistent and persistent low back pain. Future prevention strategies should
focus on controlling exposure to these triggers as they have the potential to decrease the burden as-
sociated with both acute and chronic low back pain. © 2016 Elsevier Inc. All rights reserved.
Keywords: Case-crossover; Cohort; Epidemiology; Low back pain; Primary care; Risk factors; Triggers
Introduction
Low back pain is the leading contributor to global dis-
ability [1]. An acute episode typically improves considerably
in the first 6 weeks after presentation to primary care [2], but
over 60% of patients do not experience complete recovery
(defined as return to work, no disability, and no pain) [3]. Pa-
tients with persistent low back pain contribute substantially
to disease burden and treatment costs. For instance, 75% of
direct and indirect low back pain costs are attributed to pa-
tients with persistent pain, and it is estimated to be as high
as USD$80 billion annually [4,5].
One way to potentially reduce this burden is to control ex-
posure to risk factors in the hope of preventing episodes of
low back pain. Most of the current prevention approaches aim
to control exposure to long-term risk factors [6,7]. An example
would be redesigning the workplace to reduce exposure to
prolonged sitting or repeated lifting [8]. However, not all risk
factors involve prolonged exposure, but rather transient ex-
posure. We have demonstrated in a case-crossover study,
that transient exposure to physical and psychosocial activi-
ties, such as manual tasks involving heavy loads or being
distracted or fatigued during an activity, significantly in-
creases the odds of developing an episode of low back pain
in the few hours following activity [9].
Our previous results, however, were limited to identifying
the risk associated with the onset of a new episode of low back
pain, regardless of the duration of the episode. Given that we
recruited participants within the first week from pain onset, we
were unaware of howmany of those participants would in fact
develop persistent, troublesome pain and how many would
recover rapidly. Therefore, no information on the transient risks
for low back pain was provided in terms of the duration of the
low back pain episode. To address this limitation we have con-
ducted a 12-month follow-up to the original Triggers for low
back pain study [9] and present the results in this paper.
The aim of the current study, therefore, was to investi-
gate the increased risk of transient exposures to a range of
physical and psychosocial activities in triggering episodes of
low back pain that are short-lived or those that persist. We
also aimed to compare if nonpersistent and persistent cases
share the same triggers.
Materials and methods
Study design
This study is a follow-up of the Triggers for low back pain
study [9]. The Triggers for low back pain study used a case-
crossover design to evaluate the increase in risk of a sudden
episode of low back pain associated with transient exposure
to 12 standard physical and psychosocial activities. These stan-
dard transient activities were selected based on a list of
the most hazardous tasks in the workplace, provided in the
Australian National Code of Practice [10].
Transient physical activities:
• Manual tasks involving:
o Heavy loads
o Awkward postures
o Objects not close to the body
o Handling of people or animals
o Unstable or unbalanced or difficult to grasp or hold
loads
• Moderate physical activity
• Vigorous physical activity
• A slip, trip, or fall
• Sexual activity
Transient psychosocial activities:
• Alcohol consumption
• Distracted during an activity or task
• Fatigued or tired during an activity or task
The Triggers for low back pain study employed a case-
crossover design. Case-crossover studies enable controlling
for potential confounders, such as genetic and lifestyle in-
fluences, as each participant acts as his or her own control
[11]. Therefore, no further statistical adjustments for con-
founders are necessary, which makes this design ideal for
quantifying the increased risk caused by transient expo-
sures to putative risk factors.
Briefly, in the Triggers for low back pain study, the base-
line characteristics of participants and exposureswere collected
from a telephone interview within 7 days of the onset of the
low back pain episode. Participants were asked to report ex-
posures to the 12 predefined putative triggers over the 96 hours
preceding pain onset. The increase in risk was investigated by
comparing exposure to these standard triggers in the 2-hour
period before pain onset (case window) with exposure in the
2-hour period 24 hours before pain onset (control window).
In the present study, participants were interviewed by tele-
phone 12 months after the baseline interview. At this time
point, participants were asked if they had recovered from the
original episode, and if so the date of recovery. Recovery was
defined as being pain-free for at least one month within the
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course of the episode [12]. We then selected participants who
reported experiencing rapid recovery (low back pain lasting
up to 6 weeks), and those who had persistent symptoms greater
than 6 weeks. We selected 6 weeks as a cutoff time point ac-
cording to current guidelines of low back pain [13]. In addition,
we performed secondary exploratory analyses using 3 and
12 months as a cutoff to define our groups of nonpersistent
and persistent low back pain.
Setting and participants
Consecutive adult patients presenting to 300 primary care
clinics for a new episode of sudden onset low back pain were
recruited inNewSouthWales,Australia betweenOctober 2011
andNovember 2012.Anewepisodeof lowbackpainwasdefined
as a primary complaint of pain between the 12th rib and the
buttock crease, with or without leg pain, causing the patient to
seek health care or take medication, and preceded by a period
of at least 1 month without low back pain [12]. Patients were
included in the study if they comprehended English,
presented within 7 days from pain onset, and reported pain of
at least moderate intensity (measured using item 7 of the Short-
Form 36 [SF-36] questionnaire) [14] in the first 24 hours of
the current episode. Patients were excluded from the study if
they presented with serious spinal pathology (e.g., metastatic,
inflammatory, or infectious diseases of the spine, cauda equina
syndrome, or spinal fracture).All participants providedwritten
informed consent for participation in the study. This study was
approved by theHumanResearchEthics Committee of theUni-
versity of Sydney (protocol number 05–2011/ 13742).
Baseline and follow-up assessments
At baseline, trained research staff conducted telephone in-
terviews using a standardized questionnaire to collect
sociodemographic and clinical characteristics of the current
low back pain episode. Low back pain severity and interfer-
ence with work were based on modified items 7 and 8 from
the SF-36 questionnaire [14]. Tension or anxiety and feel-
ings of depression were measured based on the Orebro
Musculoskeletal Pain Questionnaire [15]. The participants were
then asked to identify the date and time of pain onset. Also
during this interview, data on exposures to a variety of tran-
sient activities were collected, and patients reported being
exposed or not exposed to the 12 predefined putative trig-
gers, as well as the time of occurrence and duration, over the
96 hours preceding the onset of low back pain. At this stage,
attempts were made to minimize recall bias by asking par-
ticipants to refer to their agenda, calendar, and or smartphones
to enhance their memory of the activities they have per-
formed before pain onset. The baseline interview script was
piloted with 20 participants with low back pain and adjust-
ments were made to improve clarity and participant recall.
At 12 months, a second telephone interview was con-
ducted. Participants were called up to four times and voicemails
or emails were sent as a reminder of the interview. We asked
participants if they had low back pain at the moment, how
severe it was, and how much pain interfered with normal work
during the previous week. These questions were based on
modified items 7 and 8 from the SF-36 questionnaire [14].
If participants experienced recovery from the original episode,
we then asked how long they took to recover, and from this
we calculated the duration of the episode for each partici-
pant. Recovery was defined as being pain-free for at least 1
month, and this information was provided to participants during
the interview [12].
Data synthesis
Data were entered in an electronic database using FileMaker
Pro version 12 (FileMaker Inc, Santa Clara, CA, USA).Where
time to recover was reported as weeks or months, these were
transformed into days. Participants (n=14) who reported im-
precise recovery dates (e.g., responses such as “few months”
and “several weeks”) were treated as missing data. Check-
ing of data was performed by randomly selecting a subsample
Context
Back pain is a prevalent medical issue affecting the ma-
jority of individuals in society at one time or another.While
a number of triggers for back pain have been described,
their role in leading to persistent episodes of back pain has
not been sufficiently explored. In this context, the authors
sought to evaluate the role of transient physical and
psychosocial activities as triggers for persistent or
nonpersistent episodes of back pain.
Contribution
This study include close to 1,000 patients seeking care for
an epidosde of low back pain. Of these, 430 participants
had nonpersistent back pain while 352 had persistent
pain. The authors conclude that previously identified
triggers equally contribute to the development of both
nonpersistent and persistent low back pain.
Implications
The results of this study may not necessarily be translat-
able given the clinical context and methodological design.
While the authors maintain that their findings have clin-
ical utility, the fact remains that the study only involved
patients who developed back pain and chose to present for
evaluation. This then represents an incomplete population-
based study as no effective controls who did not develop
back pain, or chose to seek care, are included in this anal-
ysis. Further confirmatory work in other clinical contexts
are likely necessary as a result.
—The Editors
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(20%) of the sample and independently double-checking it
for inconsistencies. No significant inconsistencies (0.8% of
disagreement) were found during this stage.
Statistical analysis
Descriptive statistics were used to report the characteris-
tics of participants, including means and standard deviations
(SDs) for continuous variables, and frequencies and propor-
tions (%) for categorical variables. Differences between
baseline characteristics of participants with nonpersistent and
those with persistent low back pain were analyzed using in-
dependent t test for continuous variables and chi-square test
for categorical variables. A positive significance level was
assumed at a p<.05.
Participants who recovered within 6 weeks were catego-
rized as nonpersistent cases, and those who reported low back
pain lasting greater than 6 weeks were categorized as per-
sistent cases [13]. In these two subsets of participants, the
frequency of exposure to each putative trigger was calcu-
lated for the case (0–2 hours before the pain onset) and control
windows (24–26 hours before the pain onset). Conditional
logistic regression models were constructed to quantify the
risk of low back pain onset associated with each trigger, where
each participant represented a matched set of data for case
and control exposures. Odds ratios (OR) and 95% confi-
dence intervals (CIs) were calculated by comparing exposure
in the case window with the control window. Interaction anal-
yses were then conducted to assess the difference in estimates
between patients with nonpersistent low back pain and those
with persistent pain. STATA13 (StataCorp LP, College Station,
TX, USA) was used for all analyses.
Secondary exploratory analyses
Because there is no consensus view on the duration of
pain required for an episode to be considered persistent, we
conducted sensitivity analyses using cutoffs of (1) 3 months
and (2) 12 months as the start point for persistent low back
pain.
Results
A total of 1,639 patients from 300 clinics in New South
Wales, Australia were screened by trained clinicians between
October 2011 and November 2012. Of these, 999 patients
(mean age 45.3, 54% men) had non-specific low back pain
of at least moderate intensity for less than 7 days and were
thus eligible to participate. In total, 832 participants (83%)
were followed-up successfully at 12 months (Figure). The main
reasons for lost to follow-up were participants being unavail-
able to respond (n=139) or declining to participate (n=28).
As one participant had missing data on recovery and 49 did
not report sufficient data to calculate the duration of the
episode, our total sample comprised 782 participants report-
ing complete data. Only gender and employment status were
statistically different between participants included in the final
analysis (n=782) compared with those not included (n=217).
A higher proportion of men (57% vs. 43%, p<.001) and em-
ployed participants (85% vs. 78%, p=.009) were included in
the final analysis.All other baseline characteristics were similar
between these two subgroups.
Of our total sample of 782 participants, 430 (55%) had
recovered within 6 weeks, whereas 352 (45%) had persis-
tent symptoms lasting greater than 6 weeks. The baseline
characteristics of these two subgroups were compared,
and we found that the characteristics with statistical and
clinical significance between the two groups were gender and
compensable low back pain. The baseline characteristics for
the two groups of participants are shown in Table 1.
Risk of developing nonpersistent low back pain
The exposure frequency and ORs with 95% CI quantify-
ing the increase in risk of developing nonpersistent low back
pain associated with exposure to the 12 standard putative trig-
gers are shown in Table 2. Exposure to 8 of the 12 transient
activities significantly increased the risk of developing non-
persistent low back pain.
In terms of physical triggers, manual tasks involving objects
not close to body, live people or animal, heavy loads, and
awkward postures resulted in ORs ranging from 3.0 (95% CI
1.1 to 8.3) to 5.6 (95% CI 3.4 to 9.1). However, tasks in-
volving unstable or difficult to hold loads were not associated
with nonpersistent low back pain (OR 2.3, 95% CI 0.9 to 5.6).
Exposure to vigorous physical activity was slightly more risky
than exposure to moderate or vigorous physical activity. We
could not calculate the ORs for exposures to a slip, trial, or
Figure. Flowchart of participants through the study.
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fall because of absence of events in the control window. Sexual
activity was not associated with nonpersistent low back pain
(OR 1.7, 95% CI 0.4 to 7.0).
In regard to psychosocial triggers, alcohol consumption
was not a risk factor for nonpersistent low back pain (OR 1.7,
95% CI 0.4 to 7.0). On the other hand, being distracted (OR
9.0, 95% CI 1.1 to 71.0) or fatigued or tired (OR 7.3, 95%
CI 2.5 to 20.6) during a task or activity were strongly asso-
ciated in triggering a nonpersistent episode.
Risk of developing persistent low back pain
The exposure frequency and ORs with 95% CI quantify-
ing the increase in risk of developing persistent low back pain
associated with exposure to the 12 standard putative trig-
gers are shown in Table 3. Exposure to 6 of the 12 transient
activities significantly increased the risk of developing low
back pain lasting equal or greater than 6 weeks.
For physical triggers, manual tasks involving live people
or animals, heavy loads, and awkward postures were highly
associated with persistent pain, with OR up to 11.7 (95% CI
5.4 to 25.3). Exposure to vigorous physical activity was as
risky as exposure to moderate or vigorous physical activity.
Sexual activity was not associated with persistent low back
pain (OR 0.5, 95% CI 0.1 to 2.7).
In regard to psychosocial triggers, alcohol consumption
was not a risk factor for persistent low back pain (OR 0.7,
95% CI 0.1 to 4.0), and being fatigue or tired during a
task or activity showed a slight association (OR 2.9, 95% CI
1.3 to 6.4).We could not calculate the ORs for the remaining
triggers because of few events in the case or control windows.
Differences between nonpersistent and persistent low
back pain
Overall, our results revealed that in general, physical trig-
gers were more largely associated with persistent low back
pain, whereas psychosocial factors were more strongly as-
sociated with nonpersistent cases. For example, the odds of
developing persistent low back pain when exposed to manual
tasks involving awkward postures (OR 11.7) were twice the
odds of developing a short-lived episode (OR 5.6). More-
over, the odds of developing nonpersistent low back pain when
fatigued or tired during an activity (OR 7.3) was 2.5 times
greater than the odds for persistent low back pain (OR 2.9).
However, our interaction analysis revealed no statistically sig-
nificant differences between these estimates.
Secondary exploratory analyses
Table 4 shows the results of our second exploratory anal-
yses according to our different definitions of persistent low
back pain. In our fist exploratory analysis, we defined per-
sistent low back pain as episodes lasting greater than 3 months.
Using this definition, 563 (72%) participants had recovered
and 219 (28%) experienced persistent low back pain. In the
interaction analysis, our results confirmed that the triggers
identified are similarly associated with the development of
nonpersistent or persistent episodes of low back pain, with
no statistically significant difference between the estimates.
The only statistically significant difference was for being fa-
tigued or tired during an activity, which was only associated
with an episode of nonpersistent low back pain (OR 9.7 95%
CI 3.5 to 27.3).
In our second sensitivity analysis, we defined persistent
cases as low back pain lasting 12 months or more. Of our
total sample, 733 (88%) participants had recovered by 12
Table 1
Baseline characteristics of the participants with nonpersistent (<6 weeks)
and those with persistent low back pain (≥6 weeks)
Patients’ characteristics
Nonpersistent
pain
(<6 w,
n=430*)
Persistent
pain
(≥6 w,
n=352*)
Age, mean (SD), y 45.8 (13.3) 44.5 (13.4)
Male, no. (%) 267 (62.1) 181 (51.4)
Body-mass index, mean (SD), kg/m2 26.1 (4.5) 26.6 (5.1)
Duration of current episode, mean (SD), d 4.7 (2.7) 5.1 (2.7)
Number of previous episodes, mean (SD) 5.6 (9.3) 6.5 (20.1)
Days to seek care, mean (SD) 2.8 (2.0) 3.2 (2.2)
Pain scores (0–10), mean (SD) 5.0 (2.2) 5.6 (2.1)
Currently taking medication, no. (%) 175 (40.7) 179 (50.9)
Currently employed, no. (%) 372 (86.5) 295 (83.8)
Workers compensation, no. (%) 23 (5.3) 46 (13.1)
Occupation
Not employed, no. (%) 58 (13.5) 57 (16.2)
Clerical and administrative worker,
no. (%)
36 (8.4) 42 (11.9)
Community and personal service
worker, no. (%)
14 (3.1) 19 (5.4)
Labourer, no. (%) 16 (3.7) 7 (2.0)
Machinery operator and driver,
no. (%)
12 (2.8) 11 (3.1)
Manager, no. (%) 70 (15.9) 57 (16.2)
Professional, no. (%) 168 (16.3) 112 (31.8)
Sales worker, no. (%) 18 (4.2) 19 (5.4)
Technician and trade worker, no. (%) 38 (8.8) 28 (7.9)
Pain severity in first 24 h†
Moderate, no. (%) 166 (38.6) 112 (31.8)
Severe, No. (%) 215 (50.0) 186 (52.8)
Very severe, no. (%) 49 (11.4) 54 (15.3)
Pain interfering work first 24 h†
Not at all, no. (%) 10 (2.3) 5 (1.4)
A little bit, no. (%) 48 (11.2) 28 (8.0)
Moderately, no. (%) 109 (25.3) 88 (25.0)
Quite a bit, no. (%) 174 (40.5) 128 (36.4)
Extremely, no. (%) 89 (20.7) 103 (29.3)
Tense/anxious scores, mean (SD)‡ 3.7 (2.6) 4.4 (2.5)
Depression scores, mean (SD)‡ 2.4 (2.6) 3.0 (2.8)
SD, standard deviation. SF, Short-Form.
Note: Values in bold indicate statistically significant differences (p<.05)
in baseline characteristics between participants with persistent pain and those
with nonpersistent pain.
* Missing data for 50 patients, therefore only 782 participants were in-
cluded in the final analyses.
† Based on modified items 7 and 8 from SF-36: “How much low back
pain have you had in the past week?” and “During the past week, how much
did low back pain interfere with your normal work (including work outside
the home and housework)?”
‡ Based on the Orebro Musculoskeletal Pain Questionnaire.
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months and only 98 (12%) still experienced persistent symp-
toms. Similarly, we found no statistically significant differences
between the estimates in our interaction analysis, revealing
that the triggers we identified are equally associated with non-
persistent and persistent low back pain.
Discussion
This study is the first to provide estimates of the in-
creased risk in developing persistent low back pain associated
with transient exposures to physical and psychosocial
activities. Moreover, we show for the first time a compari-
son in the risk of developing nonpersistent or persistent low
back pain associated with these factors. Our results re-
vealed that these triggers are important factors to be controlled,
as they can contribute to the development of both non-
persistent and persistent episodes of low back pain.
We identified eight triggers that are highly associated with
the development of nonpersistent low back pain, and six factors
that are strongly associated in triggering persistent epi-
sodes. Overall, participants experiencing a short-lived episode
and those having persistent symptoms share the same trig-
Table 2
Exposure frequency and odds ratios (ORs) with its 95% confidence interval (CI) for each trigger in the case (0–2 hours) and control (24–26 hours) windows
for participants with nonpersistent low back pain (<6 weeks)
Triggers
Nonpersistent low back pain (<6 w, n=430)
Case no. (%) Control no. (%) OR (95% CI)
Physical factors
Manual tasks involving
Heavy loads 76 (17.7) 29 (6.7) 3.9 (2.3–6.8)†
Awkward posture 123 (28.6) 36 (8.37) 5.6 (3.4–9.1)†
Objects not close to the body 17 (4.0) 7 (1.6) 3.0 (1.1–8.3)†
Live people or animals 34 (7.9) 25 (5.8) 4.0 (1.1–14.2)†
Unstable or difficult to hold loads 18 (4.2) 9 (2.1) 2.3 (0.9–5.6)
Moderate or vigorous physical activity 111 (25.8) 67 (15.6) 2.4 (1.6–3.7)
Vigorous physical activity only 45 (10.5) 18 (4.2) 3.5 (1.8–6.8)†
Slip or trip or fall* 14 (3.3) 0.0 (0.0) –
Sexual activity 5 (1.2) 3 (0.7) 1.7 (0.4–7.0)
Psychosocial factors
Consumption of alcohol 5 (1.2) 3 (0.7) 1.7 (0.4–7.0)
Distracted during an activity or task 11 (2.6) 3 (0.7) 9.0 (1.1–71.0)†
Fatigue or tired during an activity or task 55 (12.8) 30 (7.0) 7.3 (2.5–20.6)†
* Due to small frequencies of exposures in either case or control windows, this trigger could not be included in the conditional logistic regression
analysis.
† Indicates statistically significant results.
Table 3
Exposure frequency and odds ratios (ORs) with its 95% confidence interval (CI) for each trigger in the case (0–2 hours) and control (24–26 hours) windows
for participants with persistent low back pain (≥6 weeks)
Triggers
Persistent low back pain (≥6 w, n=352)
Case no. (%) Control no. (%) OR (95% CI)
Physical factors
Manual tasks involving
Heavy loads 70 (19.9) 25 (7.1) 6.6 (3.2–13.9)†
Awkward posture 94 (26.7) 19 (5.4) 11.7 (5.4–25.3)†
Objects not close to the body* 17 (4.8) 6 (1.7) –
Live people or animals 35 (9.9) 27 (7.7) 5.0 (1.1–22.8)†
Unstable or difficult to hold loads* 25 (7.1) 8 (2.3) –
Moderate or vigorous physical activity 82 (23.3) 44 (12.5) 3.2 (1.9–5.6)†
Vigorous physical activity only 43 (12.2) 23 (6.5) 3.5 (1.6–7.7)†
Slip or trip or fall* 12 (3.4) 1 (0.3) –
Sexual activity 2 (0.6) 4 (1.1) 0.5 (0.1–2.7)
Psychosocial factors
Consumption of alcohol 2 (0.6) 3 (0.9) 0.7 (0.1–4.0)
Distracted during an activity or task* 13 (3.7) 1 (0.3) –
Fatigue or tired during an activity or task 39 (11.1) 24 (6.8) 2.9 (1.3–6.4)†
* Due to small frequencies of exposures in both case and control windows, this trigger could not be included in the conditional logistic regression
analysis.
† Indicates statistically significant results.
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gers (manual tasks involving heavy loads, awkward posture,
live people or animal, moderate or vigorous physical activ-
ity, and being fatigued during a task or activity). This result
could be used for developing future prevention programs, and
could potentially prevent not only the cases of low back pain
that are short-lived, but also persistent cases. Specifically, edu-
cating people in the potentially hazardous activities that can
trigger both persistent and nonpersistent low back pain would
be important, as these triggers are readily modifiable risk
factors.
Our study included a total sample of 999 consecutive pa-
tients with low back pain who presented to primary care within
7 days from pain onset. A key strength of the current study
was our ability to include 83% of the original participants
in the 12-month follow-up. Among those who refused to par-
ticipate in the follow-up or were lost to follow-up, there were
less men and less employed people. It is not clear if these
characteristics are predictors of recovery, and whether these
participants developed persistent pain. Therefore, it is unclear
if our results might have been different if they were in-
cluded. Another strength of this study is the low risk of bias
achieved by the use of a case-crossover study design, where
the participant acts as his or her own control. In this study
design, the chance of bias due to confounding is reduced,
and no further adjustments were necessary in our analyses
[11].
An acknowledged limitation of our study is the potential
for recall bias.At 12 months follow-up, participants were asked
to report whether they had recovered from low back pain and
also the date of their recovery, and some participants had dif-
ficulty reporting dates precisely. However, a previous study
has shown that recall of past low back pain experience was
fairly reproducible over a 12-month period (k=0.82) [16].
Another component that could have affected recovery is the
type of treatment participants received; however, no data on
types of treatment or referrals were collected during the in-
terviews. Nevertheless, in a case-crossover design, participants
are compared to themselves, therefore between-patient dif-
ferences, such as treatment received, are unlikely to change
our results. Furthermore, our study was limited by the number
of participants with persistent low back pain in the analysis.
For example, only 98 participants had persistent symptoms
in our secondary sensitivity analysis. Our estimates, there-
fore, resulted in relatively wide confidence intervals. Also,
because of the time required to interview participants about
exposures over a 96-hour period we were only able to collect
data on exposure to 12 preselected triggers.
This is the first study to investigate the effects of short-
term exposure to physical and psychosocial factors,
experienced before pain onset, on the risk of developing an
episode of low back pain that will persist. It is also the first
study to compare short-lived with persistent cases. Our study
differs conceptually from prognostic studies that usually in-
vestigate characteristics post onset of low back pain on the
risk of developing a persistent episode of low back pain. Prog-
nostic factors identified in these studies may help in
prognostication and treatment selection, whereas the trig-
gers for persistent low back pain we identified have a role
in prevention of the original episode.
The key finding of this study was that most triggers that
increased the risk of a new onset of low back pain also in-
creased the risk in developing episodes that go on to become
persistent. This finding increases substantially the potential
of having knowledge of triggers to make a difference to the
burden of low back pain. By controlling exposure to these
triggers it might be possible to prevent not only the cases of
Table 4
Odds ratios (ORs) with its 95% confidence interval (CI) for each trigger from the secondary exploratory analyses for our different definitions of persistent
low back pain
Triggers
3 Mo as definition of persistent low back pain 12 Mo as definition of persistent low back pain
Nonpersistent pain
(<3 mo, n=563)
Persistent pain
(≥3 mo, n=219)
Nonpersistent pain
(<12 mo, n=733)
Persistent pain
(≥12 mo, n=98)
Physical factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Manual tasks involving
Heavy loads 4.2 (2.6–6.8)† 8.0 (2.8–22.6)† 4.7 (3.0–7.5)† 8.5 (2.0–36.8)†
Awkward posture 6.1 (3.9–9.5)† 16.0 (5.0–51.4)† 7.2 (4.7–11.0)† 13.0 (3.1–54.8)†
Objects not close to the body 4.2 (1.6–11.1)† –* 5.0 (1.9–13.1)† 4.2 (1.6–11.1)†
Live people or animals 5.0 (1.4–17.3)† 3.5 (0.7–16.8) 5.5 (1.9–16.0)† 4.0 (0.4–35.8)
Unstable or difficult to hold loads 3.3 (1.4–7.7)† –* 4.1 (1.8–9.5)† –*
Moderate or vigorous physical activity 2.8 (1.9–4.1)† 2.4 (1.2–4.8)† 2.6 (1.9–3.6)† 4.0 (1.1–14.2)†
Vigorous physical activity only 3.7 (2.1–6.7)† 2.8 (1.0–7.8)† 3.1 (1.8–5.1)† –*
Slip or trip or fall – –* –* –*
Sexual activity 1.4 (0.4–4.4) –* 1.0 (0.4–2.9) –*
Psychosocial factors
Consumption of alcohol 2.3 (0.6–9.0) –* 1.6 (0.5–4.9) –*
Distracted during an activity or task 14 (1.8–106.5)† –* 16.0 (2.1–120.6)† –*
Fatigue or tired 9.7 (3.5–27.3)† 1.6 (0.7–3.9) 4.2 (2.2–7.8)† 2.0 (0.5–8.0)
* Due to small frequencies of exposures or patients overlapping both case and control windows, this trigger could not be included in the conditional
logistic regression analysis.
† Indicates statistically significant results.
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low back pain that are short-lived but most importantly the
cases that typically go on to be become persistent and account
for the major burden of the disease [4,5].
The triggers that did not increase odds of an acute episode
(sexual activity and alcohol consumption) also did not in-
crease the odds of persistent low back pain. The estimates for
persistent low back pain, however, were less precise as a con-
sequenceof having fewer participants in the analyses, particularly
for the strictest definition of persistent pain (pain ≥12months),
where there were only 98 participants.Althoughwe found that
some triggers, such as manual tasks involving heavy loads or
awkward postures, were more strongly associated with per-
sistent low back pain rather than with episodes that were short-
lived, there were no overall statistically significant differences
between these estimates. This means that persistent and non-
persistent cases of low back pain share the same triggers.
We acknowledge that there are other potential triggers that
would be worth evaluating in future studies. Further re-
search should also investigate the effectiveness of prevention
strategies that control exposure to the harmful triggers we iden-
tified in this study.
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Abstract
Background: Although recurrence is common after an acute episode of low back pain,
recurrence rates vary widely and predictors of recurrence remain largely unknown.
Objective: To determine the 1-year incidence of recurrence in participants that recovered from 
an acute episode of low back pain, and to identify predictors of recurrence.
Design: Inception cohort nested in a case-crossover study.
Methods: We followed for 12 months, 832 of the 999 participants who initially presented to 
primary care within the first seven days of an episode of low back pain. Of these, 469 recovered 
(1-month pain free) from the index episode within six weeks and were included in this study. 
Recurrence was defined as a new episode lasting more than one day, or as an episode of care 
seeking. Putative predictors were assessed at baseline and chosen a priori. Multivariable 
regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
Results: The 1-year incidence of recurrence of low back pain was 33%, and the 1-year 
incidence of recurrence of low back pain with care seeking was 18%. Participants reporting 
more than two previous episodes of low back pain had increased odds of future recurrences 
(OR: 3.18, CI: 2.11–4.78). This factor was also associated with recurrent episodes that led to 
care seeking (OR: 2.87, CI: 1.73–4.78). No other factors were associated with recurrences.
Limitations: Reliance on recall.
Conclusions: After an acute episode of low back pain, one third of patients will experience a 
recurrent episode, and approximately half of those will seek care. Having experienced more 
than two previous episodes of low back pain triples the odds of a recurrence within one year.
Word count: 3,115.
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Introduction
Low back pain is the leading cause of disability according to the 2015 Burden of Disease 
Study,1 and affects 9.4% of the global population.2 Although a great proportion of individuals 
with acute low back pain improve considerably in the first six weeks,3 there is evidence showing 
that rates of recurrence range widely from 15% to 84% within one year.4-6 This large variation 
may be explained by how recurrence is defined, with only a few studies using standardised 
definitions of episodes of low back pain, including both onset and recovery.7 Further, only a 
few studies have investigated predictors of recurrence.5, 6
Most studies that investigated recurrence of low back pain have focused on participants with 
persistent pain, therefore, unlikely to recover or have a recurrence.8 There are few studies using 
inception cohorts to investigate recurrence of low back pain.5, 6 Stanton et al reported recurrence 
rates of 24% and 33% (depending upon the analytic method used),5 while Hancock et al 
reported rates ranging from 26% to 54%, depending on how recurrence was defined (episode 
of care or 12-month recall).6 These two studies similarly found that only one factor, namely 
previous episodes of low back pain, was significantly associated with future recurrences. Other 
factors not showing an association included smoking, perceived global health, perceived risk 
of recurrence, red flags, physical activity,5 and imaging findings.6 Both studies used single 
items, rather than a validated questionnaire to assess physical activity so may have under-
estimated the risk associated with physical activity. Moreover, other factors such as leg pain, 
pain and disability levels in the first 24 hours of the episode, use of medications, and anxiety 
have not yet been investigated. There is, therefore a paucity of research in this area, leading to 
limited understanding of the risk factors for recurrence and the development of effective 
preventive management strategies for low back pain.9-11
38
In the current inception cohort study we aimed to investigate the 1-year incidence of recurrence 
of low back pain in a large representative sample of patients who had recently recovered from 
an acute episode of low back pain presenting to primary care. We also investigated the risk 
factors associated with recurrences within one year including novel factors not considered in 
previous studies.
Methods
This study is reported according to recommendations of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement.12
Participants
This is an inception cohort study with a 1-year follow-up nested in the case-crossover study 
Triggers for Low Back Pain.13 This study was approved by the Human Research Ethics 
Committee of The University of Sydney (protocol number 05-2011/ 13742), and obtained 
informed consent of participants. In brief, Triggers included 999 consecutive patients, DJH
years who presented to one of 300 primary care clinics (general practitioners, physiotherapists 
and chiropractors) in New South Wales, Australia between October 2011 and November 2012
with a new episode of sudden onset low back pain. To be included, patients needed to have 
presented for care within seven days from pain onset and report moderate pain intensity (item 
7 of the SF-36 questionnaire) in the first 24 hours.14 All patients were assessed within seven 
days of seeking health care for low back pain. Low back pain was defined as a primary 
complaint of pain between the 12th rib and the buttock crease, with or without leg pain, causing 
the patient to seek health care or take medication.15 Patients presenting with serious spinal 
pathology (e.g., metastatic, inflammatory or infective diseases of the spine) were excluded. In 
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this inception cohort study, we only included patients who had recovered after an acute episode 
of low back pain (i.e., within 6 weeks).
Predictors of recurrence
A baseline assessment was conducted through telephone interviews. Factors related to 
participants’ socio-demographics (age, gender, body mass index), current history (duration of 
episode, days to seek care, number of previous episodes, pain intensity, interference with 
function, pain beyond knee), general health (use of medications, physical activity level), work 
status (in paid employment, compensable case), and presence of yellow flags (depression,
tension/ anxiety) were collected. These variables, chosen a priori, have been associated with 
poorer prognosis,16-18 and were included in this study as putative predictors of recurrence of 
low back pain. We hypothesised that older age, female gender, higher body mass index, greater 
number of previous episodes, greater duration of current episode, greater days to seek care, 
higher pain and/or disability, presence of pain beyond knee, lower habitual physical activity, 
higher depression/tension/anxiety, being out of work, and presence of compensation would be 
associated with worse prognosis.
Given most participants in our study have reported previous episodes of low back pain, we 
decided to use the median number of previous episodes as a cut-off to define previous low back 
SDLQKLVWRU\HSLVRGHVDQGOLWWOHRUQRKLVWRU\HSLVRGHV7KLVDSSURDFKKDVEHHQXVHG
in previous studies investigating history of low back pain as a predictor of outcomes.19,20
Low back pain intensity was assessed using a numeric rating scale (range, 0–10), and through 
modification of item 7 from the SF-36 questionnaire: “how much back pain have you had during 
the first 24 hours of this episode”. Interference with function was similarly measured using a
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modification of item 8 from the SF-36 questionnaire: “during the first 24 hours of this episode 
how much did back pain interfere with your normal work”.14 Habitual physical activity was 
assessed using the Active Australia questionnaire, which estimates the amount of light, 
moderate, and vigorous physical activity in the week before pain onset.21 The proportion of 
people doing “sufficient” activity was calculated, defined as a minimum of 150 minutes (sum 
of time spent walking plus time spent in moderate and vigorous activity [weighted by two]) and 
five sessions of activity per week. We used items 13 and 14 of the Orebro Musculoskeletal Pain 
Questionnaire to evaluate anxiety (“how tense or anxious have you felt in the past week”) and 
depression (“how much have you been bothered by feeling depressed in the past week”),
respectively.22 Medication use was assessed by asking participants whether they were taking 
any medications during the current episode of low back pain. Work status was simply measured
by asking participants if they were in paid employment. Table 1 shows previously investigated 
factors associated with recurrence in other studies,5, 6 and those included in our analysis.
Outcome measures
The primary outcome for the study was recurrence of low back pain. Our primary definition of 
recurrence was an episode of low back pain that was still present 24 hours after the onset of 
symptoms, of at least mild pain intensity,23 and followed a period of at least 30 days pain-free 
(pain intensity 0 or 1).15 Trained research assistants made a clear distinction between pain that 
was still present 24 hours after the onset of low back pain (which was our outcome) and pain 
that lasted continuously for 24 hours. These data were obtained at 1-year follow-up interviews 
conducted via telephone and participants responded whether they had recovered from the 
original episode of low back pain. If participants had recovered, we then asked how long they 
took to recover, and from this we calculated the duration of the episode for each participant.
Thereafter, participants were asked whether they had experienced a recurrent episode, based on 
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the above definitions. Our secondary definition of recurrence required participants to also seek 
care for their new episode of low back pain. We also asked about the intensity of pain and 
interference with function associated with the recurrent episode, based on modified questions 
from the SF-36 questionnaire.14
Statistical analysis
We calculated the 1-year incidence of recurrence of low back pain as the proportion of 
participants who reported recurrence divided by the total number of people who had recovered 
within six weeks. Descriptive statistics were used to report the characteristics of participants, 
including means and standard deviations (SD) for continuous variables, and frequencies and 
proportions for categorical variables.
Univariate regression analyses were used to select putative factors with a p WRHQWHULQWRD
multivariable regression analysis in a single step. Multivariable logistic regression analysis was 
conducted for our main definition of recurrence and used to identify associations between 
baseline characteristics of participants and recurrence of low back pain within one year follow-
up. In a sensitivity analysis, we used our second definition of recurrence (episode of care) as 
the outcome. STATA 13 (StataCorp LP., College Station, Texas) was used for all analyses.
Results
Of the 999 participants presenting to primary care clinics for an acute episode of low back pain, 
832 were successfully contacted at 1-year follow-up. Reasons for loss to follow up include 
participants refusing to participate or unavailable to answer the telephone. Within one year, 469 
participants had recovered from the original episode within six weeks and comprised our 
sample (Figure 1). The mean age of those who recovered was 45.8 (SD: 13.3) years and 57% 
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were men. See Table 2 for other baseline characteristics of participants. The incidence of 
recurrence after an acute episode of low back pain based on 12-month recall was 33% (n =
157). Most participants reported having at least moderate pain intensity for the recurrent episode 
(n = 92, 60%), and nearly half (n = 74, 47%) had moderate to extreme interference with 
function. For our second definition, where participants were required to have sought care for 
their new episode, the 1-year incidence of recurrence of low back pain was 18% (n = 83).
Five factors (duration of episode, pain intensity, previous episodes of low back pain, depression 
and physical activity) showed associations (p  LQ WKH XQLYDULDWH UHJUHVVLRQ DQDO\VHV
(eAppendix available at academic.oup.com/ptj) and were entered into our multivariable 
regression model. The results of our multivariable regression analysis showed that only one 
factor, multiple SUHYLRXVHSLVRGHVRIORZEDFNSDLQSUHYLRXVHSLVRGHVZDVDVVRFLDWHGZLWK
a recurrence within one year. Using this definition of recurrence, participants who reported 
three or more previous episodes of low back pain had 3.18 times (95% CI 2.11–4.78; p <0.001) 
the odds of having a recurrence than those who reported less than three previous episodes. 
Nearly half (105/224, 47%) of those with multiple previous episodes of low back pain had a 
recurrence. No other factors were associated with recurrences. Table 3 shows odds ratios and p
values for the variables that entered into our multivariable regression analysis.
In our sensitivity analysis, where the outcome was recurrence and care seeking, we found that 
multiple SUHYLRXVHSLVRGHVRIORZEDFNSDLQHSLVRGHVUHPDLQHGVWURQJO\DVVRFLDWHGZLWK
future recurrences (OR: 2.87, 95% CI: 1.73–4.78; p <0.001). One-quarter of participants
(57/223, 25%) reporting more than two previous episodes of low back pain had a recurrence 
associated with care seeking. No other factors were associated with recurrences that required 
care seeking in our sensitivity analysis (Table 3). A post hoc analysis comparing any prior 
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history of low back pain with no prior history revealed similar results. Having any prior history 
of low back pain more than tripled the odds of recurrence (OR: 3.45, 95% CI: 1.90–6.23; 
p<0.001). Similarly, when we used care seeking as the definition of recurrence, any prior history 
of low back pain was also associated with future recurrences (OR: 2.29, 95% CI: 1.12–4.65; p
<0.001).
Discussion
Our inception cohort study revealed that 33% of participants had a recurrence after an acute 
episode of low back pain, and about half of those sought care. Although we investigated other 
factors not included in previous studies, we confirm that only one factor, having multiple 
previous episodes of low back pain, was associated with future recurrences. This factor 
remained associated with recurrence of low back pain when we used a second, and stricter, 
definition of recurrence, where participants needed to also seek care for the new episode.
Our study included a large sample (n = 469) of patients seeking primary care clinics for a 
sudden, onset of low back pain who recovered within six weeks. We used an inception cohort 
study design with minimal loss to follow-up (83% response rate), where participants were 
included within one week of the onset of the original episode of low back pain. Moreover, a 
range of factors not previously investigated were chosen a priori as putative risk factors for 
recurrence of low back pain, including factors related to socio-demographics, current history, 
general health, work status, and presence of yellow flags. We have also used previously 
recommended definitions of episodes of pain, for both recovery and recurrence of low back 
pain. Recovery was defined as experience of a period of at least one month without low back 
pain (pain intensity 0 or 1, on an 11-point scale),15 while a recurrent episode consisted of a new 
episode of at least mild intensity that lasted more than 24 hours.23 Given previous research has 
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shown that individuals who seek care because of low back pain are those with higher levels of 
disability and pain intensity,24 we used a second, and stricter, definition of recurrence, including 
only those who sought care for the recurrent episode.
A limitation of this study is the reliance on recall, as participants were asked to report recovery 
and recurrence information one year after the original episode of low back pain. Memory of 
painful events, such as an episode of low back pain, may be distorted by time. Some studies 
have reported that low back pain episodes tend to be underreported as the recall period 
increases,25, 26 while others have found that pain episodes is often overestimated.22, 27-29
Therefore, it is uncertain whether the dates reported by study participants were accurate and 
truly reflected the duration of the episode of low back pain. However, it seems that patients 
experiencing recurrent low back pain tend to have greater recall accuracy compared with 
patients with chronic pain.30
Despite our attempt to include different putative predictors of recurrence, other relevant factors 
not included in our study might have contributed to the onset of the recurrent episode. Previous 
studies investigating recurrence of low back pain have either failed to include habitual physical 
activity as a putative predictor,6 or have only included a single item to assess physical activity 
(“do you participate in at least 30 minutes of moderate intensity physical activity each day?”).5
Although we used a validated questionnaire to assess the level of habitual physical activity of 
participants at baseline,21 this factor was not associated with future recurrences of low back 
pain. We acknowledge, however, that self-reported measures of physical activity participation 
tend to yield overestimated results, and suggest therefore that future studies measure physical 
activity using accelerometers. To ensure the baseline interview was feasible and the duration of 
the interview acceptable to participants, we only included single questions (depression and 
45
anxiety) from the Orebro Questionnaire rather than administering the entire questionnaire. 
Therefore, in our regression model we used the responses to a subset of questions rather than 
the entire questionnaire as one possible predictor of recurrence. 
Another limitation of our study is the lack of data on the type of interventions participants 
received during the course of the low back pain episode, and whether this may have influenced 
our results. Further, our sample may not represent the general population, given we only 
included people who sought care for the original episode of low back pain. Although recruiting 
clinicians indicated whether patients presented radiating pain below the knee, we did not assess 
for signs of nerve root compression, such as by testing lower limb reflexes, muscle function or 
using the straight leg raise test. Therefore, these data were not available to be included in our 
analysis as potential predictors of recurrence.
Most studies investigating the incidence of recurrence of low back pain have not used 
standardised definitions of episodes as suggested by de Vet et al.15 Recurrence rates are highly 
reliant on how recovery and recurrence are defined, and as a result these studies have reported 
a wide range of incidence estimates.4, 5 For instance, the incidence of recurrence for an episode 
of work absence (10%) is usually much lower compared with estimates for an episode of pain.31
Another explanation for the high variability is the calculation of estimates of recurrence based 
on the total sample rather than using only those who recovered from the original episode, and 
thus were eligible for recurrence. Stanton et al. have used previously recommended definitions 
of episodes of low back pain and have included only participants who recovered within six 
weeks from the original episode, reporting recurrence rates similar to ours, ranging from 24% 
to 33%.5 Another recent study, however, reported higher recurrence rates for an episode of pain 
(54%) and for an episode of care (26%) compared with ours (33% and 18%, respectively).6 We 
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recommend future studies investigating recurrence of low back pain use a large inception cohort 
of participants recovered following an acute episode of low back pain, and use previously 
proposed definitions of episodes of low back pain, including onset, recovery and recurrence.15, 
23
Our multivariable regression analysis showed results similar to those found in a previous 
inception cohort study,5 which also reported that previous history of low back pain 
(dichotomised yes/no variable) was consistently predictive of recurrence of low back pain 
within one year (OR: 1.8, 95% CI: 1.0–3.2). Another cohort study using similar methodology 
has also revealed that previous episodes of low back pain (continuous variable) was the only 
significant factor associated with future recurrences (hazard ratio: 1.04, 95% CI: 1.02–1.07).6
Although we investigated various other factors not included in these two studies, we confirm 
that the only factor consistently associated with future recurrences was multiple previous 
episodes of low back pain. Hancock et al. also used a similar definition of recurrence related to 
an episode of care, though no estimates were reported due to limited number of events.6 Thus, 
to date previous episodes of low back pain is the only known factor associated with recurrence 
of low back pain. This is an important factor, given the strong association with cases of health 
care utilisation, which are usually the ones likely to be more disabling and account for the major 
burden of the condition.32, 33 Other factors investigated in our study but with no significant 
association with future recurrences included duration of the episode, pain intensity, and 
depression.
In conclusion, our results revealed that about one third of patients who recover from an acute 
episode of low back pain will have a recurrence within one year, with half of those requiring 
further care. Having three or more episodes of low back pain triples the odds of having a 
47
recurrence within one year. Further research is required in this field, with a particular focus on 
including potential predictors of recurrence not investigated in our study, such as objective 
measures of physical activity participation.
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Table 1 Putative predictors of recurrence of low back pain
Predictors Stanton et al (n = 353)5 Hancock et al (n = 76)6 Machado et al (n = 469)
Sociodemographics - Age, body mass index, 
educational level
Age, gender, body mass 
index
Current history Previous episodes, 
number of red flags
Previous episodes Previous episodes, duration 
of episode, days to seek 
care, pain and disability 
levels, leg pain
General health Smoking, habitual 
physical activity, 
perceived general health
Smoking Habitual physical activity, 
use of medications
Psychosocial Perceived risk of 
recurrence
Perceived risk of 
recurrence, depression
Depression, tension/ 
anxiety
Work-related - Involvement in heavy 
lifting/ awkward positions, 
job satisfaction
Work status, occupation, 
compensable case
Others Qualification of 
practitioner
MRI findings -
n number, MRI magnetic resonance imaging
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Table 2 Baseline characteristics of participants (n = 469)
Characteristics Value
Age, mean (SD), years 45.8 (13.3)
Male sex, No. (%) 291 (57)
Body-mass index, mean (SD), kg/m2 26.1 (4.5)
Duration of current episode, mean (SD), days 4.7 (2.7)
Number of previous episodes, mean (SD) 5.5 (9.4)
3 previous episodes of low back pain, No. (%) 226 (48)
Days to seek care, mean (SD) 2.8 (2.1)
Pain scores (0–10), mean (SD) 5.0 (2.1)
Leg pain below knee, No. (%) 27 (6)
Currently taking medication, No. (%) 193 (41)
Currently employed, No. (%) 405 (86)
Workers compensation, No. (%) 26 (6)
If in paid employment, what is done for a living
Not employed, No. (%) 64 (14)
Clerical and Administrative Worker, No. (%) 38 (8)
Community and Personal Service Worker, No. (%) 15 (3)
Labourer, No. (%) 17 (4)
Machinery Operator and Driver, No. (%) 12 (3)
Manager, No. (%) 76 (16)
Professional, No. (%) 180 (38)
Sales Worker, No. (%) 23 (5)
Technician and Trade Worker, No. (%) 44 (9)
Pain severity in first 24 hours*
Moderate, No. (%) 182 (39)
Severe, No. (%) 234 (50)
Very severe, No. (%) 53 (11)
Pain interfering with work in first 24 hours*
Not at all, No. (%) 10 (2)
A little bit, No. (%) 52 (11)
Moderately, No. (%) 119 (25)
Quite a bit, No. (%) 189 (40)
Extremely, No. (%) 99 (21)
Habitual physical activity in last week†
Insufficient activity, No. (%) 114 (24)
Sufficient activity, No. (%) 355 (76)
Tense/ anxious scores, mean (SD)‡ 2.5 (2.6)
Depression scores, mean (SD)‡ 3.8 (2.5)
n number, SD standard deviation
* Based on modified items 7 and 8 from SF-36
† Sufficient activity is defined as 150 minutes (using the sum of walking, moderate activity and vigorous 
activity [weighted by two]) and five sessions of activity per week
‡ Based on items 13 and 14 from the Orebro Musculoskeletal Pain Questionnaire
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Table 3 Risk factors for recurrence of low back pain
Recurrence of low back pain
>1 day duration
Recurrence of low back pain
& care seeking
Factors OR (95% CI) Sig. OR (95% CI) Sig.
Duration of episode 0.94 (0.87–1.02) 0.15 1.04 (0.95–1.14) 0.38
LBP intensity 1.29 (0.95–1.76) 0.10 1.31 (0.91–1.90) 0.15
Previous LBP* 3.18 (2.11–4.78)† 0.00 2.87 (1.73–4.78)† 0.00
Depression 1.05 (0.97–1.14) 0.21 0.95 (0.86–1.04) 0.28
Habitual physical activity 0.98 (0.95–1.01) 0.14 0.99 (0.95–1.02) 0.41
OR odds ratio, CI confidence interval, Sig p-values, LBP low back pain 
* SUHYLRXVHSLVRGHV v <3 previous episodes of low back pain
† Indicates statistically significant results
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eAppendix Results of univariate regression analyses
Recurrence of low back pain
>1 day duration
Factors (by domains) OR (95% CI) Sig.
Sociodemographics
Age 0.99 (0.97–1.01) 0.21
Gender 0.96 (0.65–1.42) 0.86
BMI 1.01 (0.97–1.06) 0.59
Current history
Duration of episode 0.95 (0.88–1.02) 0.13†
Previous LBP* 3.19 (2.13–4.78) 0.00†
LBP intensity 1.34 (1.00–1.80) 0.05†
Interference with work 0.95 (0.83–1.08) 0.40
Leg pain 1.61 (0.73–3.53) 0.23
General health
Medication use 1.10 (0.74–1.62) 0.64
Habitual physical activity 0.98 (0.95–1.01) 0.13†
Work-related
Employed 1.09 (0.61–1.92) 0.78
Worker’s compensation 0.86 (0.37–2.03) 0.73
Psychosocial
Depression 1.06 (0.99–1.14) 0.10†
Anxiety 1.04 (0.97–1.12) 0.30
OR odds ratio, CI confidence interval, Sig p-values, LBP low back pain, BMI body mass index
* SUHYLRXVHSLVRGHV v <3 previous episodes of low back pain
† Indicates statistically significant results
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Figure captions
Fig. 1 Flowchart of study participants
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Figure 1
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CHAPTER FOUR
Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review 
and meta-analysis of randomised placebo controlled trials
Chapter Four has been published as:
Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain 
and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. 
BMJ 2015;350:h1225. Copyright © 2015, British Medical Association. Reprinted with 
permission from BMJ Publishing Group.
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ABSTRACT
OBJECTIVE
To investigate the e3cacy and safety of paracetamol 
(acetaminophen) in the management of spinal pain 
and osteoarthritis of the hip or knee.
DESIGN
Systematic review and meta-analysis.
DATA SOURCES
Medline, Embase, AMED, CINAHL, Web of Science, 
LILACS, International Pharmaceutical Abstracts, and 
Cochrane Central Register of Controlled Trials from 
inception to December 2014.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials comparing the e3cacy 
and safety of paracetamol with placebo for spinal pain 
(neck or low back pain) and osteoarthritis of the hip or 
knee.
DATA EXTRACTION
Two independent reviewers extracted data on pain, 
disability, and quality of life. Secondary outcomes 
were adverse eRects, patient adherence, and use of 
rescue medication. Pain and disability scores were 
converted to a scale of 0 (no pain or disability) to 100 
(worst possible pain or disability). We calculated 
weighted mean diRerences or risk ratios and 95% 
conVdence intervals using a random eRects model. 
The Cochrane Collaboration’s tool was used for 
assessing risk of bias, and the GRADE approach was 
used to evaluate the quality of evidence and 
summarise conclusions.
RESULTS
12 reports (13 randomised trials) were included. There 
was “high quality” evidence that paracetamol is 
ineRective for reducing pain intensity (weighted mean 
diRerence −0.5, 95% conVdence interval −2.9 to 1.9) 
and disability (0.4, −1.7 to 2.5) or improving quality of 
life (0.4, −0.9 to 1.7) in the short term in people with 
low back pain. For hip or knee osteoarthritis there was 
“high quality” evidence that paracetamol provides a 
signiVcant, although not clinically important, eRect on 
pain (−3.7, −5.5 to −1.9) and disability (−2.9, −4.9 to 
−0.9) in the short term. The number of patients 
reporting any adverse event (risk ratio 1.0, 95% 
conVdence interval 0.9 to 1.1), any serious adverse 
event (1.2, 0.7 to 2.1), or withdrawn from the study 
because of adverse events (1.2, 0.9 to 1.5) was similar 
in the paracetamol and placebo groups. Patient 
adherence to treatment (1.0, 0.9 to 1.1) and use of 
rescue medication (0.7, 0.4 to 1.3) was also similar 
between groups. “High quality” evidence showed that 
patients taking paracetamol are nearly four times more 
likely to have abnormal results on liver function tests 
(3.8, 1.9 to 7.4), but the clinical importance of this 
eRect is uncertain.
CONCLUSIONS
Paracetamol is ineRective in the treatment of low back 
pain and provides minimal short term beneVt for 
people with osteoarthritis. These results support the 
reconsideration of recommendations to use 
paracetamol for patients with low back pain and 
osteoarthritis of the hip or knee in clinical practice 
guidelines.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO registration number CRD42013006367.
Introduction
Low back and neck pain (spinal pain) are leading 
causes of disability worldwide, and osteoarthritis of the 
hip or knee is the 11th highest contributor to global dis-
ability, when disability is measured by years lived with 
disability.1 The point prevalence of spinal pain is 9.4%, 
and osteoarthritis aCects nearly 4% of the global popu-
lation.2–4 The increasing healthcare expenditure for 
these conditions is mostly attributed to the increasing 
cost of prescription medicines, accounting for about 
20% of the total cost.5
Prescription of drugs is the most common approach 
to treatment used by general practitioners for spinal 
pain and osteoarthritis,6 and guidelines consistently 
recommend the prescription of paracetamol (acetamin-
ophen) as the Krst line analgesic for these conditions.7–11 
There has, however, been controversy about keeping 
paracetamol in the most recent guidance on osteoar-
thritis from the National Institute for Health and Care 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Clinical guidelines recommend paracetamol as Vrst line analgesic drug for both 
spinal pain (neck and low back pain) and osteoarthritis of the hip and knee
The evidence base supporting these recommendations has recently been called 
into question
WHAT THIS STUDY ADDS
High quality evidence suggests that paracetamol is ineRective in reducing pain and 
disability or improving quality of life in patients with low back pain
There is high quality evidence that paracetamol oRers a small but not clinically 
important beneVt for pain and disability reduction in patients with hip or knee 
osteoarthritis
Though high quality evidence shows that patients taking paracetamol are nearly 
four times more likely to have abnormal results on liver function tests compared 
with those taking oral placebo, the clinical relevance of this is unclear
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Excellence,12 mainly because of previous studies report-
ing small eCects of paracetamol compared with pla-
cebo.13–15 Moreover, optimal therapeutic beneKts of 
paracetamol might require regular doses of up to 
4000 mg/day.16 There are some concerns regarding 
safety of the full recommended dose,17 18 although the 
evidence on safety is still debatable.19 Potential adverse 
eCects and treatment schedule seem to also have a con-
siderable eCect on patient adherence20 as taking anal-
gesics constantly and regularly three or four times a day 
is inconvenient at least.
New randomised controlled trials15 21 have been con-
ducted since the last meta-analyses of paracetamol for 
spinal pain and osteoarthritis of the hip or knee were 
published. There is still uncertainty, however, whether 
consideration of new data changes the conclusions 
regarding the eWcacy and safety of paracetamol for 
these conditions. In this systematic review we investi-
gated the eWcacy and safety of paracetamol in patients 
with spinal pain or osteoarthritis of the hip or knee by 
including data from placebo controlled trials only, as 
these represent the highest standard of evidence to 
inform the optimal use of drugs.22
Methods
Data sources and searches
We conducted a systematic review following the 
PRISMA statement23 and prospectively registered the 
review on PROSPERO. We carried out a systematic elec-
tronic search in Medline, Embase, AMED, CINAHL, Web 
of Science, LILACS, International Pharmaceutical 
Abstracts, and Cochrane Central Register of Controlled 
Trials from inception to 8 December 2014. We used a 
combination of relevant keywords to construct the 
search strategy including paracetamol, acetamino-
phen, back pain, neck pain, osteoarthritis, osteoarthro-
sis, placebo, randomised, and controlled trial (see 
appendix 1). One author (GCM) conducted the Krst 
screening of potentially relevant records based on titles 
and abstract, and two authors (GCM and MBP) inde-
pendently performed the Knal selection of included 
 trials based on full text evaluation. Citation tracking 
was also performed on included studies and relevant 
systematic reviews, and relevant websites and clinical 
trials registries were searched for unpublished studies. 
Consensus between the two reviewers was used to 
resolve any disagreement.
Study selection
We included only randomised controlled trials compar-
ing the eWcacy of paracetamol versus placebo. To be 
eligible, trials had to include participants with non- 
speciKc spinal pain (neck or low back pain) or osteoar-
thritis of the hip or knee. We did not exclude trials in 
mixed populations of patients with spinal pain and 
osteoarthritis. The intensity and duration of symptoms 
were not restricted. There were also no restrictions for 
languages or publication date. Studies that included 
patients with a serious spinal pathology (such as cauda 
equina syndrome, tumour, or infection) were excluded. 
Studies with mixed populations of patients with 
 rheumatoid arthritis and osteoarthritis were also 
excluded, unless separate data were reported for osteo-
arthritis. Studies in which participants had previous 
spinal, hip, or knee surgery remained eligible, but trials 
evaluating analgesia in the immediate postoperative 
period were not included. We included only full reports 
in this systematic review (that is, no abstracts).
Trials were eligible for inclusion when they reported 
at least one of the following primary outcome measures: 
pain intensity, disability status, and quality of life. Sec-
ondary outcome measures were safety (adverse eCects), 
patient adherence, and use of rescue medication.
Data extraction and quality assessment
Using a standardised data extraction form, two review-
ers (GCM and MBP) independently extracted study 
characteristics (details of participants, interventions, 
and outcomes) from the included trials, and a third 
author (MLF) resolved any disagreement. We extracted 
means, standard deviations, and sample sizes for our 
primary outcome measures. Mean estimates were 
extracted in the following hierarchical order: mean dif-
ferences, change scores, and Knal values. For our sec-
ondary outcomes, we extracted the number of cases 
and the total sample size. The safety outcomes extracted 
from included trials were the number of patients report-
ing any adverse event, the number of patients reporting 
any serious adverse event (as deKned by each study), 
the number of patients withdrawn from study because 
of adverse events, and the number of patients with 
abnormal results on liver function tests (hepatic 
enzyme activity ≥1.5 times the upper limit of the refer-
ence range). We contacted authors to provide further 
information when there were insuWcient data reported 
in the paper. When authors were unavailable we esti-
mated data using the recommendations in the Cochrane 
Handbook for Systematic Reviews of Interventions.24
Two reviewers (GCM and MBP) independently 
assessed the risk of bias of the included studies using 
the Cochrane Collaboration’s tool.24 25 Consensus was 
used to resolve any disagreement. RevMan version 5.3.5 
was used to generate Kgures and summaries. The qual-
ity of evidence was rated for each pooled analysis with 
the GRADE (grading of recommendations assessment, 
development and evaluation) system,26 with outcomes 
of interest being ranked according to their relevance for 
clinical decision making as of limited importance, 
important, or critical.27 The quality of evidence was 
downgraded by one level according to the following cri-
teria: limitation of study design, inconsistency of 
results, imprecision, and publication bias. We did not 
consider the indirectness criterion in this review 
because we included a speciKc population with rele-
vant outcomes and direct comparisons.28 Briefly, 
GRADE was downgraded by one level for limitation of 
study design when more than a quarter of the studies 
included in an analysis were considered at high risk of 
bias (that is, one or more bias domains were judged as 
high risk) according to the Cochrane Handbook and 
thus plausible to affect the interpretation of our 
results.24 29 Results were considered inconsistent if there 
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was a wide variance of point estimates across studies or 
if the heterogeneity between trials was large (I2>50%).30 
Imprecision was identiKed when the upper or lower 
limits of the 95% conKdence interval crossed the mini-
mal clinically important diCerence of 9 points (range 
0–100).31 32 We visually judged a funnel plot (scatterplot 
of the eCect of estimates from individual studies against 
its standard error) and used Egger’s test to investigate 
publication bias (small study eCects).33 We included a 
total of 11 trials in the assessment of small study eCects 
(nine trials including patients with osteoarthritis and 
two trials including patients with back pain, reporting 
data on immediate or short term pain intensity). If the 
Egger’s test result was signiKcant (two tailed P<0.1) we 
would downgrade the quality of evidence (GRADE) by 
one level for all meta-analyses.34 The quality of evi-
dence was deKned as “high quality,” “moderate qual-
ity,” “low quality,” and “very low quality.”26
Data synthesis and analysis
We grouped the outcomes into four time points of 
assessment: immediate term (≤2 weeks), short term (>2 
weeks but ≤3 months), intermediate term (>3 months 
but ≤12 months), and long term (>12 months). If studies 
reported multiple time points within each category, we 
used the time point closest to one week for immediate 
term, eight weeks for short term, six months for inter-
mediate term, and 12 months for long term. When stud-
ies reported more than one scale to measure pain we 
extracted the more severe estimate reported at baseline. 
Scores for pain and disability were converted to a com-
mon 0 (no pain or disability) to 100 (worse pain or dis-
ability) scale. Pain intensity measures to calculate 
treatment eCects were numerical rating scale scores 
(range 0–10) or visual analogue scale scores (range 
0–100). These two pain measures are highly correlated 
and can be used interchangeably when transformed.35 
Other measures of pain were also obtained from visual 
analogue scale scores included in the Western Ontario 
and McMaster Universities osteoarthritis index 
(WOMAC) pain subscale (VA3 series range 0–100)36 and 
from the multi-dimensional health assessment ques-
tionnaire (MDHAQ) pain subscale (range 0–100).37 
 Disability measures in the meta-analyses were WOMAC 
function subscale or WOMAC total scores.38 One study 
reported pain and disability measures from the WOMAC 
Likert version (LK series), and the scores were also nor-
malised to a scale of 0 to 100.
To facilitate the interpretation of our pooled esti-
mates, we deKned the eCects of paracetamol compared 
with placebo as ineCective when the 95% conKdence 
interval crossed the no eCect line, showing no signiK-
cant diCerence between groups. We considered the 
minimal clinically important diCerence as a diCerence 
of 9 mm in a 0–100 mm visual analogue scale. This esti-
mate has been used in past systematic reviews32 to 
investigate the eWcacy of medicines compared with 
placebo for osteoarthritis and corresponds to the 
median minimal clinically important diCerence found 
in trials investigating patients with osteoarthritis. When 
our treatment eCects were smaller than 9 mm, although 
signiKcant, we considered the eCect as small and not 
clinically important.
We used the I2 statistic to assess heterogeneity 
between trials, and values higher than 50% were deKned 
to identify high heterogeneity.39 We calculated weighted 
mean diCerences or risk ratios and 95% conKdence 
intervals and used the random eCects model to pool esti-
mates for each analysis obtained with Comprehensive 
Meta-Analysis version 2.2.064 (Englewood, NJ, 011).
Secondary exploratory analysis
We performed sensitivity analyses to explore the inlu-
ence of each risk of bias domain on pooled treatment 
eCects. These stratiKed analyses were accompanied by 
meta-regression to generate a P value for interaction 
between the bias domain and estimate of treatment 
eCect. For these analyses we used data from all osteoar-
thritis trials included in the meta-analysis on short term 
pain (seven trials). As a previous study reported that 
small trials in osteoarthritis tend to report more beneK-
cial treatment eCects than large trials,40 we also con-
ducted a sensitivity analysis between large trials (sample 
size ≥100 per group) versus small trials (sample size 
<100 per group) for all trials investigating patients with 
osteoarthritis at immediate or short term follow-up. Neg-
ative diCerences in treatment eCects indicate that small 
trials have more beneKcial eCects than large trials.
Post hoc analysis
We carried out a post hoc analysis to assess the poten-
tial impact of a new trial on the current evidence and 
thus to determine if a further new trial is justiKed. We 
used extended funnel plots (graphical augmentations 
of the funnel plots commonly used to investigate publi-
cation bias in meta-analyses)41 to assess the impact of a 
new trial in our meta-analysis. The extended funnel 
plots provide shaded contours that represent the contri-
bution of a new trial to existing evidence based on sta-
tistical simulations.42 Addition of data from a new trial 
of a certain sample size and treatment eCect could 
Potentially relevant records aer excluding duplicates (n=4037):
  Medline (n=1183)
  AMED (n=208)
  Embase (n=1812)
CINAHL (n=1007)
Web of Science (n=575)
CENTRAL (n=376)
LILACS (n=85)
IPA (n=252)
Potentially relevant studies identi"ed
for full text evaluation (n=116)
Records included in review
(n=12; 13 randomised controlled trials)
Excluded aer screening titles and abstracts (n=3921)
Studies excluded (n=104):
  Not appropriate intervention (n=42)
  Not appropriate population (n=10)
  Not appropriate data (n=4)
  Not randomised controlled trial (n=48)
Fig 1 | Flow chart of trials investigating eVcacy of 
paracetamol in spinal pain and osteoarthritis. Numbers of 
records from each database include duplicates. 
IPA=International Pharmaceuticals Abstracts, 
CENTRAL=Cochrane Register of Controlled Trials
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result in the new conclusion that the eCect of interven-
tion is clearly worthwhile or clearly not worthwhile, for 
instance. We conducted extended funnel plots to assess 
the impact a further trial of paracetamol for spinal pain 
and hip or knee osteoarthritis would have on the current 
evidence presented in this meta-analysis. Stata 13 
(StataCorp, College Station, TX) was used for this analysis.
Results
Our search results yielded 5498 records, and aner 
excluding duplicates we screened 4037 titles and 
abstracts. Two independent reviewers evaluated 116 
potentially relevant studies, and 12 records (13 ran-
domised controlled trials) met the criteria to be 
included in this review, with one article reporting 
results of two trials (Kg 1).43–54 Ten trials reporting data 
from 3541 patients evaluated the efficacy of 
 paracetamol in patients with osteoarthritis of the hip 
or knee,43 44 46–51 54 and three trials (1825 patients) inves-
tigated the eWcacy of paracetamol in people with low 
back pain.45 52 53 We did not identify any trials in 
patients with neck pain. Overall, the included trials 
assessed 5366 patients. We identiKed two randomised 
trials published as abstracts and excluded them from 
this review.55 56 One randomised trial investigating the 
eWcacy of paracetamol for low back pain did not report 
results for the placebo group, and attempts to access 
these data from the authors and the company that 
funded the study were unsuccessful.45 This trial was 
included in the review but not in the meta-analysis.
In the included studies paracetamol was primarily 
administered orally (as tablets/capsules). One trial, 
however, reported the use of intravenous paracetamol 
in participants with chronic low back pain.52 The total 
oral dose and dose regimens for paracetamol varied 
across trials, with 10 trials using a total dose of 3900–
4000 mg/day and three trials using 3000 mg/day 
(table 1). Two trials used a three arm design, one 
Table 1 | Characteristics of randomised placebo controlled trials included in review of eVcacy and safety of paracetamol for spinal pain and osteoarthritis
Study Details of participants Interventions (Dose regimens) Outcomes and time points
Spinal pain
Nadler, 200245 133 patients (group 1=113, group 2=20); mean 
age (SD) group 1=34.9 (11.3), group 2=38.0 
(9.1); duration: acute (NR)
Group 1: paracetamol 500 mg, 2 tablets, 
4 times daily, 4000 mg total. Group 2: oral 
placebo
Pain (VRS, 0–5); Roland Morris questionnaire 
(0–24); adverse events; on days 2 and 4
Wetzel, 201452 
(cross over)
40 patients on chronic opioid therapy, mean 
age (SD)=57.2 (12.8); duration: chronic (>6 
months)
Group 1: single intravenous paracetamol 
1000 mg dose. Group 2: intravenous placebo
Pain (VAS, 0–10); Roland Morris questionnaire 
(0–24); immediately aher infusion
Williams, 201453 1652 patients (group 1=550, group 2=549, 
group 3=553); mean age (SD) group 1=44.1 
(14.8), group 2=45.4 (16.7), group 3=45.4 (16.7); 
duration: acute (<6 weeks)
Group 1: paracetamol 665 mg, 2 tablets, 3 times 
daily, 3990 mg total. Group 2: paracetamol 
500 mg, 1–2 tablets as required, 4–6 hours 
apart, maximum 8 tablets per day. Group 3: 
oral placebo. Rescue medication allowed
Pain (NRS, 0–10); Roland Morris questionnaire 
(0–24); SF-12 physical score (0–100); patient 
adherence; rescue medication; adverse events; 
at 1, 2, 4, and 12 weeks
Osteoarthritis
Amadio, 198343 (cross 
over)
25 patients; median age (range)=64 (43–80); 
duration: NR
Group 1: paracetamol 500 mg, 2 tablets, 
4 times daily, 4000 mg total. Group 2: oral 
placebo
50 h (15 m) walking test; adverse events; at 
4 weeks
Zoppi, 199544 60 patients (group 1=30, group 2=30); mean 
age (SD) group 1=57.6 (11.2), group 2=55.3 
(11.9); duration: group 1=75.0 (98.2) months, 
group 2=45.8 (58.6) months
Group 1: ekervescent paracetamol 500 mg, 
2 tablets, 3 times daily, 3000 mg total. Group 2: 
ekervescent placebo
Pain (VAS, 0–100); adverse events; at 1 week
Case, 200346 57 patients (group 1=29, group 2=28); mean 
age (SD) group 1=62.1 (11.4), group 2=61.7 
(9.0); duration: NR
Group 1: paracetamol 500 mg, 2 tablets, 
4 times daily, 4000 mg total. Group 2: Oral 
placebo
WOMAC pain (VAS, 0–500); WOMAC function 
(0–1700); adverse events; at 2 and 12 weeks
Golden, 200447 303 patients (group 1=148, group 2=155); 
mean age (SD) group 1=61.1 (13.1), group 
2=60.3 (13.0); duration: NR
Group 1: paracetamol 1000 mg, 1 tablet, 
4 times daily, 4000 mg total. Group 2: Oral 
placebo
Pain intensity on weight bearing (0–4); 50 h 
(15 m) walking test; adverse events; at 1 week
Miceli-Richard, 200448 779 patients (group 1=405, group 2=374); 
mean age (SD)=70 (11); duration: 46 (47) 
months
Group 1: paracetamol 1000 mg, 1 tablet, 
4 times daily, 4000 mg total. Group 2: oral 
placebo. Rescue medication not allowed
Pain (VAS, 0–100); WOMAC function (0–100); 
adverse events; patient adherence; at 1 and 
6 weeks
Pincus, 2004a (PACES-A 
cross over trial)49
524 patients; mean age (SE) group 1=63.7 (1.2), 
group 2=62.8 (1.3); duration group 1: 8.5 (1.0) 
years, group 2: 8.1 (1.1) years
Group 1: Paracetamol 1000 mg, 1 tablet, 
4 times daily, 4000 mg total. Group 2: Oral 
placebo. Rescue medication allowed
MDHAQ pain (VAS, 0–100); WOMAC (0–100); 
adverse events; at 6 weeks
Pincus, 2004b (PACES-B 
cross over trial)49
556 patients; mean age (SE) group 1=64.8 (1.3), 
group 2=63.4 (1.3); duration group 1: 10.4 (1.3) 
years, group 2: 9.5 (1.1) years
Group 1: paracetamol 1000 mg, 1 tablet, 
4 times daily, 4000 mg total. Group 2: oral 
placebo. Rescue medication allowed
MDHAQ pain (VAS, 0–100); WOMAC (0–100); 
adverse events; at 6 weeks
Herrero-Beaumont, 
200751
212 patients (group 1=108, group 2=104); 
mean age (SD) group 1=63.8 (7.2), group 
2=64.5 (6.9); duration: group 1: 6.5 (5.3) years, 
group 2: 7.2 (5.8) years
Group 1: paracetamol 1000 mg, 1 tablet, 
3 times daily, 3000 mg total. Group 2: oral 
placebo. Rescue medication allowed
WOMAC pain (Likert, 0–20); WOMAC function 
(0–68); rescue medication; adverse events; at 
6 months
Altman, 200750 483 patients (group 1=160, group 2=158, group 
3=165); mean age (range)=62.2 (40–90); 
duration: NR
Group 1: paracetamol ER 1300 mg, 3 times 
daily, 3900 mg total. Group 2: paracetamol 
650 mg, 3 times daily, 1950 mg total. Group 3: 
oral placebo. Rescue medication allowed
WOMAC pain (VAS, 0–100); WOMAC function 
(0–100); adverse events; at 12 weeks
Prior, 201454 542 patients (group 1=267, group 2=275); mean 
age (SD) group 1=61.7 (10.2), group 2=61.7 
(10.1); duration: NR
Group 1: paracetamol ER 650 mg, 2 tablets, 
3 times daily, 3900 mg total. Group 2: oral 
placebo. Rescue medication allowed, but limited
WOMAC pain (VAS, 0–100); WOMAC function 
(0–100); adverse events; at 2 and 12 weeks
VRS=verbal rating scale, VAS=visual analogue scale, NRS=numeric rating scale, NR=not reported, WOMAC=Western Ontario and McMaster Universities arthritis index, MDHAQ=multi-
dimensional health assessment questionnaire, SF-12=12-item short form health survey, Duration=duration of condition, ER=extended release.
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included a third group that received paracetamol as 
required,53 and another included a third group that 
received a lower dose of paracetamol (650 mg, one tab-
let, three times/day, 1950 mg total).50 All three treat-
ment groups were included in the meta-analyses 
following the recommendation in the Cochrane Hand-
book for Systematic Reviews of Interventions.24 The 
washout period before treatment started varied across 
trials, ranging from one day to six months. The wash-
out periods were 12 weeks for corticosteroids,51 six 
weeks for intra-articular steroids,43 and ranged from 
three days to two weeks for non-steroidal anti-inlam-
matories.43 46–48 Patients stopped taking simple analge-
sics from one to 10 days.43 46 48 52 One trial reported that 
the washout for glucosamine drugs was six months,51 
and two trials used “Kve half lives” to deKne this 
period.50 54
We included six trials that reported data from people 
with chronic pain,44 48 49 51 52 and two studies that 
included people with acute pain only.45 53 The remaining 
studies did not report the duration of pain or disability. 
Nine trials used the diagnosis of osteoarthritis based on 
image evidence and clinical assessment,43 46–51 54 
whereas one trial based the diagnosis solely on image 
evidence.44 Two trials used a clear deKnition of low 
back pain,52 53 and one trial used a simple question to 
deKne patients (“do the muscles of your low back 
hurt?”).45 Table 1 includes more detailed information on 
included trials.
Figure 2 summarises the assessment of risk of bias 
for individual trials. Twelve trials had at least one 
domain judged as unclear risk of bias. Four trials had 
at least one domain considered as high risk of bias, and 
only one trial had all bias domains judged as low risk of 
bias. Most trials (nine) failed to report the method used 
to generate the sequence allocation, though all 
reported being randomised studies. Three trials 
adopted an appropriate method of concealment of allo-
cation, and only one trial failed to report blinding of 
patients, personnel, and outcome assessors. Eight tri-
als were funded by companies that produce parac-
etamol and were considered as having unclear risk of 
bias for the other sources of bias domain. As only one 
study reported data for intermediate term follow-up, its 
results were pooled with trials reporting data for short 
term follow-up. None of the included trials reported 
data for long term follow-up. The inspection of the fun-
nel plot and the lack of signiKcance of the Egger’s test 
(P=0.21) suggested no serious small study eCects (see 
appendix 2, Kg A). We therefore considered that no 
meta-analysis presented serious publication bias 
according to the GRADE approach. Figure 3 sum-
marises pooled eCect sizes for pain and disability at 
immediate and short term follow-up. Tables 2 and 3 
present individual trial results and calculations of 
eCect sizes.
Spinal pain
Immediate term follow-up
Two trials including 1692 patients with low back pain 
tested the eCect of paracetamol compared with placebo 
in pain reduction.52 53 Pooling showed no eCect of parac-
etamol on pain (weighted mean diCerence 1.4, 95% con-
fidence interval −1.3 to 4.1; “moderate quality” 
evidence, downgraded for limitation of study design). 
For disability, one trial evaluating 1652 patients found 
no diCerence between paracetamol and placebo (−1.9, 
−4.8 to 1.0).53 The quality of evidence for disability in 
the immediate term was rated “high quality” according 
to the GRADE approach.
Short term follow-up
Only one trial investigated the short term eWcacy of 
paracetamol in 1652 patients with low back pain.53 
This trial showed no eCect of paracetamol on pain 
intensity (weighted mean diCerence −0.5, 95% conK-
dence interval −2.9 to 1.9), disability (0.4, −1.7 to 2.5), or 
quality of life measured by the 12-item short form 
health survey (SF-12 version 2) (0.4, −0.9 to 1.7) at short 
term follow-up. The quality of evidence (GRADE) for 
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Fig 2 | Risk of bias summary showing review authors’ 
judgments about each risk of bias domain in placebo 
controlled trials on eVcacy of paracetamol for spinal pain 
and osteoarthritis. Randomised clinical trials are listed 
alphabetically by author name
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all three outcomes was rated as “high quality.” Tables 4 
and 5 summarise the Kndings and quality assessment 
(GRADE) for outcomes ranked as critical for decision 
making.
Osteoarthritis
Immediate term follow-up
Five trials reported data from 1741 patients with hip or 
knee osteoarthritis and were included in a meta-analysis 
Spinal pain (pain/immediate term)
  Wetzel 2014
  Williams 2014a
  Williams 2014b
Pooled Eect: I2=0%
Spinal pain (pain/short term)
  Williams 2014a
  Williams 2014b
Pooled eect: I2=0%
Spinal pain (disability/immediate term)
  Williams 2014a
  Williams 2014b
Pooled eect: I2=0%
Spinal pain (disability/short term)
  Williams 2014a
  Williams 2014b
Pooled eect: I2=0%
Osteoarthritis (pain/immediate term)
  Zoppi 1995
  Case 2003
  Golden 2004
  Miceli-Richard 2004
  Prior 2014
Pooled eect: I2=33%
Osteoarthritis (pain/short term)
  Case 2003
  Miceli-Richard 2004
  Pincus 2004a
  Pincus 2004b
  Herrero-Beaumont 2007
  Altman 2007a
  Altman 2007b
  Prior 2014
Pooled Eect: I2=0%
Osteoarthritis (disability/immediate term)
  Case 2003
  Miceli-Richard 2004
  Prior 2014
Pooled eect: I2=84%
Osteoarthritis (disability/short term)
  Case 2003
  Miceli-Richard 2004
  Pincus 2004a
  Pincus 2004b
  Herrero-Beaumont 2007
  Altman 2007a
  Altman 2007b
  Prior 2014
Pooled eect: I2=33%
0.0 (-9.7 to 9.7)
1.0 (-2.9 to 4.9)
2.0 (-2.0 to 6.0)
1.4 (-1.3 to 4.1)
-1.0 (-4.4 to 2.4)
0.0 (-3.4 to 3.4)
-0.5 (-2.9 to 1.9)
-2.5 (-6.6 to 1.6)
-1.3 (-5.4 to 2.9)
-1.9 (-4.8 to 1.0)
0.0 (-2.9 to 2.9)
0.8 (-2.2 to 3.8)
0.4 (-1.7 to 2.5)
-9.2 (-19.6 to 1.2)
-0.6 (-6.6 to 5.3)
-4.2 (-8.2 to -0.2)
-1.0 (-4.0 to 2.0)
-5.9 (-10.0 to -1.8)
-3.3 (-5.8 to -0.8)
-1.7 (-12.8 to 9.4)
-0.8 (-4.4 to 2.8)
-6.9 (-12.3 to -1.5)
-6.2 (-11.4 to -1.0)
-2.5 (-7.7 to 2.7)
-6.9 (-13.4 to -0.4)
-3.2 (-9.0 to 2.6)
-4.2 (-8.5 to 0.1)
-3.7 (-5.5 to -1.9)
2.6 (-1.5 to 6.6)
-1.0 (-2.7 to 0.7)
-6.5 (-10.0 to -3.0)
-1.7 (-6.0 to 2.6)
2.6 (-5.1 to 10.3)
0.0 (-2.7 to 2.7)
-3.6 (-8.0 to 0.8)
-3.8 (-7.7 to 0.1)
-4.7 (-9.5 to -0.1)
-7.1 (-13.4 to -0.8)
-1.0 (-6.9 to 4.9)
-5.4 (-9.5 to -1.2)
-2.9 (-4.9 to -0.9)
8
48
44
50
50
50
50
51
49
5
14
25
33
23
3
26
11
12
12
8
10
18
30
38
32
6
23
13
16
12
8
9
13
-20 -10 0 10 20
Author, year
Favours paracetamol Favours placebo
Mean difference
(95% CI)
Mean difference
(95% CI)
Weight
(%)
51.0 (21.0)
37.0 (26.0)
38.0 (27.0)
12.0 (22.0)
13.0 (22.0)
32.1 (27.1)
33.3 (27.1)
10.0 (19.6)
10.8 (20.4)
-20.0 (21.5)
-0.9 (11.7)
-22.2 (18.1)
-16.0 (21.0)
-26.4 (24.2)
-4.8 (16.6)
–
-17.4 (26.0)
-13.8 (23.7)
–
-26.5 (25.5)
-22.8 (21.6)
-30.0 (20.9)
0.5 (7.2)
-8.0 (12.0)
-23.1 (21.7)
-2.5 (12.1)
-12.0 (17.0)
-8.4 (19.9)
-8.4 (17.7)
–
-24.9 (24.6)
-18.8 (21.9)
-26.6 (20.0)
Mean (SD)
36
517
499
506
514
513
498
504
514
28
27
145
385
267
22
298
171
185
108
160
158
177
27
385
267
22
298
171
185
108
160
158
177
Total
51.0 (21.0)
36.0 (26.0)
36.0 (26.0)
13.0 (23.0)
13.0 (23.0)
34.6 (27.1)
34.6 (27.1)
10.0 (18.8)
10.0 (18.8)
-10.8 (18.0)
-0.3 (10.5)
-18.0 (16.5)
-15.0 (21.0)
-20.5 (24.5)
-3.1 (19.7)
–
-10.5 (25.2)
-7.6 (26.9)
–
-19.6 (22.5)
-19.6 (22.5)
-25.8 (20.3)
-2.1 (7.6)
-7.0 (12.0)
-16.1 (19.9)
-5.0 (13.1)
-12.0 (16.0)
-4.8 (21.8)
-4.6 (20.2)
–
-17.8 (22.3)
-17.8 (22.3)
-21.3 (19.5)
Mean (SD)
Paracetamol Placebo
36
252
252
253
253
250
250
252
252
28
26
149
356
275
19
262
172
182
104
83
82
172
26
356
275
19
262
172
182
104
82
82
172
Total
Fig 3 | Weighted mean di_erences for pain and disability in placebo controlled trials on eVcacy of paracetamol for spinal 
pain and hip or knee osteoarthritis. Pain and disability are expressed on scale of 0–100. Immediate term=follow-up ≤2 
weeks; short term=follow-up evaluations >2 weeks but ≤3 months. Studies ordered chronologically within subgroups
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to evaluate the immediate eCect of paracetamol in pain 
reduction.44 46–48 54 Pooling showed that paracetamol 
has a small beneKt when compared with placebo in 
reducing pain (weighted mean diCerence −3.3, 95% con-
Kdence interval −5.8 to −0.8; “high quality” evidence). 
For disability, pooling of three trials with 1378 patients 
showed no immediate eCect of paracetamol (−1.7, −6.0 to 
2.6; “moderate quality” evidence, downgraded for 
inconsistency).46 48 54
Short term follow-up
At short term follow-up, seven trials including 3153 
patients with hip or knee osteoarthritis were pooled to 
estimate the eWcacy of paracetamol in reducing pain 
and disability.46 48–51 54 Pooling showed a signiKcant 
small eCect favouring paracetamol for pain (weighted 
mean diCerence −3.7, 95% conKdence interval −5.5 to 
−1.9). Similarly, a signiKcant but small beneKt of parac-
etamol was found for short term reduction in disability 
(−2.9, −4.9 to −0.9). The quality of evidence (GRADE) for 
both pooling was rated as “high quality.”
Secondary outcomes
Our secondary outcomes included adverse eCects, 
patient adherence, and use of rescue medication.  Fig 4 
summarises the results.
Adverse e6ects
The type of adverse events reported by patients varied 
substantially between trials. Nine trials investigated the 
number of participants reporting any adverse 
event.43 44 47–50 53 54 There was no diCerence in the number 
of patients reporting adverse events between the parac-
etamol and placebo groups (risk ratio 1.0, 95% conK-
dence interval 0.9 to 1.1; “moderate quality” evidence). 
The number of patients reporting any serious adverse 
event (as deKned by each study) was also similar in both 
paracetamol and placebo groups (1.2, 0.7 to 2.1; “moder-
ate quality” evidence).48–51 53 54 Ten trials reported data 
on the number of patients withdrawn from the study 
because of adverse events, with three of these trials 
reporting no drop outs from adverse events. We found 
no signiKcant diCerence between groups for this out-
come (1.2, 0.9 to 1.5; “high quality” evidence).44 46 48–51 
Three trials evaluated the results of liver function tests to 
detect adverse eCects of paracetamol (activities of ala-
nine aminotransferase, and/or aspartate aminotransfer-
ase) in participants with osteoarthritis,50 51 54 where an 
abnormal test was deKned as hepatic enzyme activity 1.5 
times the upper limit of the reference range or over. Pool-
ing showed that participants taking paracetamol are 
nearly four times more likely to have abnormal results 
on liver function tests than participants taking placebo 
(3.8, 1.9 to 7.4; “high quality” evidence).
Patient adherence
Two trials in patients with low back pain and osteoar-
thritis investigated adherence to study treatments, 
deKned as the number of patients reporting consump-
tion of more than 70%53 or 85%48 of the recommended 
dose. We found no diCerence in the number of partici-
pants adhering to study treatments between parac-
etamol and placebo groups from the pooling of two trials 
(risk ratio 1.0, 95% conKdence interval 0.9 to 1.1; “mod-
erate quality” evidence, downgraded for inconsistency).
Use of rescue medication
This was measured as the number of patients using a 
rescue medication (naproxen 250 mg, two tablets ini-
tially then one tablet every six to eight hours as 
needed,53 or ibuprofen 400 mg, one tablet every eight 
hours for a maximum of three days51) during the trial. 
Pooled analysis of two trials in low back pain and osteo-
arthritis showed no diCerence between the paracetamol 
and placebo groups (risk ratio 0.7, 95% conKdence 
interval 0.4 to 1.3; “high quality” evidence).
Secondary exploratory analysis
The results from our secondary analyses on the poten-
tial impact of individual risk of bias domains on our 
Table 2 | Calculation of e_ect sizes for immediate and short term pain and disability outcome measures in people with spinal pain randomised to 
paracetamol or placebo
Outcome 
scale Range
Mean (SD or SE), extracted Mean (SD), converted* No of patients Mean di_erence 
(95% CI)
Analytic 
method*Paracetamol Placebo Paracetamol Placebo Paracetamol Placebo
Pain/immediate term
Wetzel, 201452 VAS 0–10 5.1 (2.1) 5.1 (2.1) 51.0 (21.0) 51.0 (21.0) 36 36 0.0 (−9.7 to 9.7) FV
Williams, 2014a53† NRS 0–10 3.7 (2.6) 3.6 (2.6) 37.0 (26.0) 36.0 (26.0) 517 252 1.0 (−2.9 to 4.9) FV
Williams, 2014b53‡ NRS 0–10 3.8 (2.7) 3.6 (2.6) 38.0 (27.0) 36.0 (26.0) 499 252 2.0 (−2.0 to 6.0) FV
Pain/short term
Williams, 2014a53† NRS 0–10 1.2 (2.2) 1.3 (2.3) 12.0 (22.0) 13.0 (23.0) 506 253 −1.0 (−4.4 to 2.4) FV
Williams, 2014b53‡ NRS 0–10 1.3 (2.2) 1.3 (2.3) 13.0 (22.0) 13.0 (23.0) 514 253 0.0 (−3.4 to 3.4) FV
Disability/immediate term
Williams, 2014a53† RMQ 0–24 7.7 (6.5) 8.3 (6.5) 32.1 (27.1) 34.6 (27.1) 513 250 −2.5 (−6.6 to 1.6) FV
Williams, 2014b53‡ RMQ 0–24 8.0 (6.5) 8.3 (6.5) 33.3 (27.1) 34.6 (27.1) 498 250 −1.3 (−5.4 to 2.9) FV
Disability/short term
Williams, 2014a53† RMQ 0–24 2.4 (4.7) 2.4 (4.5) 10.0 (19.6) 10.0 (18.8) 504 252 0.0 (−2.9 to 2.9) FV
Williams, 2014b53‡ RMQ 0–24 2.6 (4.9) 2.4 (4.5) 10.8 (20.4) 10.0 (18.8) 514 252 0.8 (−2.2 to 3.8) FV
NRS=numerical rating scale, VAS=visual analogue scale, RMQ=Roland-Morris questionnaire, FV=pnal value, 
*Used to calculate treatment ekect.
†Paracetamol (as recommended; paracetamol 665 mg, 2 tablets, 3 times daily, 3990 mg total) v placebo. Placebo group sample size was divided by 2.
‡Paracetamol (as required; paracetamol 500 mg, 1–2 tablets as required, 4–6 hours apart, maximum 8 tablets per day) v placebo. Placebo group sample size was divided by 2.
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treatment eCects are presented in Kg B in appendix 2. 
None of the individual domains had a signiKcant inlu-
ence on the estimated treatment eCect. Our stratiKed 
analysis between small and large trials showed a diCer-
ence of eCects of 1.4 (95% conKdence interval −2.8 to 
5.6), indicating that smaller trials tend to report less 
beneKcial eCects, though this diCerence was not signif-
icant (P=0.51).
Extended funnel plot assessment
Aner consideration of the results we carried out a post 
hoc analysis to assess the eCect of a new trial in our 
meta-analysis using extended funnel plots. Our results 
conKrm that the results of a new trial added to current 
evidence would not change the conclusion that parac-
etamol does not deliver a clinically important beneKt 
(at least 9 points out of a 0–100 range) for spinal pain 
and osteoarthritis (see Kg C in appendix 2).
Discussion
There is “high quality” evidence that paracetamol has 
a signiKcant but small eCect in patients with hip or 
knee osteoarthritis compared with placebo in the short 
term. The small eCects, <4 points on a 0–100 point 
scale, are not likely to be meaningful for clinicians or 
patients. “High quality” evidence shows that parac-
etamol is ineCective for low back pain, but we found no 
trials investigating neck pain. We also found “high 
quality” evidence that paracetamol increases the risk 
of having an abnormal result on liver function tests by 
nearly fourfold, although the impact of this on clini-
cally relevant patient outcomes is unclear. Adherence 
to the treatment protocol was similar in both parac-
etamol and placebo groups, and there was also no dif-
ference in the use of rescue medication. Overall, our 
results are based on “high quality” evidence (GRADE), 
and therefore further research is unlikely to change 
this evidence. This systematic review should inform 
clinical practice and policy with regard to Krst line care 
of these patients.
Strengths and weaknesses of the study
This systematic review was prospectively registered, 
and we followed the protocol thoroughly. We included 
only placebo controlled trials in the review as they pro-
vide the best evidence on the eWcacy of pharmacologi-
cal treatment.22 We included 13 randomised trials, 10 in 
people with hip or knee osteoarthritis, and three inves-
tigating people with low back pain. We included two 
more trials than the last meta-analysis investigating 
people with osteoarthritis,15 and three more than the 
last review on people with spinal pain.21 To facilitate the 
Table 5 | Summary of fndings and quality of evidence assessment for outcomes classifed as critical for clinical decision 
making in patients with osteoarthritis randomised to paracetamol or placebo 
Time point
Summary of fndings Quality of evidence assessment (GRADE)
No of 
patients 
(trials)
E_ect size*  
(95% CI)
Study 
limitation Inconsistency Imprecision Quality Importance
Pain
Immediate term 1686 (5) −3.3 (−5.8 to −0.8) None None None High Critical
Short term 2355 (7) −3.7 (−5.5 to −1.9) None None None High Critical
Disability
Immediate term 1336 (3) −1.7 (−6.0 to 2.6) None −1† None Moderate Critical
Short term 2354 (7) −2.9 (−4.9 to −0.9) None None None High Critical
Adverse events (all short term)‡
Any 4846 (9) 1.0 (0.9 to 1.1) None −1† None Moderate Critical
Serious§ 4852 (7) 1.2 (0.7 to 2.1) None −1† None Moderate Critical
Drop out¶ 3023 (7) 1.2 (0.9 to 1.5) None None None High Critical
Liver** 1237 (3) 3.8 (1.9 to 7.4) None None None High Critical
*Weighted mean dikerence (negative value favours paracetamol) for pain and disability; risk ratio for adverse events.
†Wide variance of point estimates across studies or large heterogeneity between trials (I2>50%).
‡Includes patients with hip/knee osteoarthritis and low back pain.
§As depned by each study.
¶Patients withdrawn from study because of adverse events.
**No of patients with abnormal results on liver function test (AST/ALN >1.5 ULN).
Table 4 | Summary of fndings and quality of evidence assessment for outcomes classifed as critical for clinical decision 
making in patients with spinal pain randomised to paracetamol or placebo
Time point
Summary of fndings Quality of evidence assessment (GRADE)
No of patients E_ect size* (95% CI) Study limitation Inconsistency Imprecision Quality Importance
Pain
Immediate term 1592 (2 trials) 1.4 (−1.3 to 4.1) −1 None None Moderate Critical
Short term 1526 (1 trial) −0.5 (−2.9 to 1.9) None None None High Critical
Disability
Immediate term 1511 (1 trial) −1.9 (−4.8 to 1.0) None None None High Critical
Short term 1522 (1 trial) 0.4 (−1.7 to 2.5) None None None High Critical
*Weighted mean dikerence. Negative value favours paracetamol.
†>25% of studies included in analysis had at least one bias domain judged as high risk of bias according to Cochrane Collaboration’s tool.
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interpretation of our results, we provide precise esti-
mates and clinically interpretable scores on 0–100 
point scales of pain and disability. Overall, the quality 
of evidence for our outcomes considered critical for 
clinical decision making was ranked “high” according 
to the GRADE system. Moreover, this is the Krst review 
to report evidence of changes in hepatic enzyme activity 
associated with paracetamol, patient adherence, and 
use of rescue medication in patients with osteoarthritis 
and spinal pain. Other strengths of our review included 
lack of restrictions to publication language or date and 
use of hand search of clinical trial registries (for exam-
ple, ClinicalTrials.gov) and relevant websites for 
unpublished trials.
The number of studies in each meta-analysis was rel-
atively small because of small number of trials avail-
able on this topic (paracetamol versus placebo for 
spinal pain and osteoarthritis). For instance, in the 
meta-analyses investigating the efficacy of parac-
etamol on pain reduction for back pain we have 
Adverse e'ects (any)
  Amadio 1983
  Zoppi 1995
  Golden 2004
  Miceli-Richard 2004
  Pincus 2004a
  Pincus 2004b
  Altman 2007
  Prior 2014
  Williams 2014
Pooled Eect: I2=68%
Adverse e'ects (serious)
  Miceli-Richard 2004
  Pincus 2004a
  Pincus 2004b
  Herrero-Beaumont 2007
  Altman 2007
  Prior 2014
  Williams 2014
Pooled eect: I2=0%
Adverse e'ects (withdrawals)
  Zoppi 1995
  Miceli-Richard 2004
  Pincus 2004a
  Pincus 2004b
  Herrero-Beaumont 2007
  Altman 2007
  Prior 2014
Pooled eect: I2=0%
Adverse e'ects (liver)
  Herrero-Beaumont 2007
  Altman 2007
  Prior 2014
Pooled eect: I2=0%
Patient adherence
  Miceli-Richard 2004
  Williams 2014
Pooled Eect: I2=0%
Use of rescue medication
  Herrero-Beaumont 2007
  Williams 2014
Pooled eect: I2=47%
1.3 (0.6 to 2.6)
0.6 (0.2 to 1.8)
1.0 (0.7 to 1.4)
0.9 (0.7 to 1.2)
1.1 (0.8 to 1.4)
1.1 (0.9 to 1.5)
1.1 (0.9 to 1.4)
1.0 (0.8 to 1.1)
1.0 (0.8 to 1.3)
1.0 (0.9 to 1.1)
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1.6 (0.3 to 7.6)
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1.1 (0.7 to 1.8)
1.3 (0.7 to 2.7)
1.3 (0.5 to 3.3)
1.3 (0.6 to 2.9)
1.2 (0.5 to 2.6)
1.1 (0.7 to 1.9)
1.2 (0.9 to 1.5)
3.4 (1.4 to 8.0)
2.3 (0.5 to 10.7)
8.2 (1.9 to 35.5)
3.8 (1.9 to 7.4)
0.9 (0.9 to 1.0)
1.1 (1.0 to 1.2)
1.0 (0.9 to 1.1)
0.9 (0.8 to 1.0)
0.4 (0.2 to 1.1)
0.7 (0.4 to 1.3)
1
1
7
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9
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76
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(95% CI)
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36/405
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12/108
18/318
25/267
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Fig 4 | Risk ratio for safety outcome measures, patient adherence, and use of rescue medication in placebo controlled 
trials on eVcacy of paracetamol compared with placebo. Any=No of patients reporting any adverse event; serious=No of 
patients reporting any serious adverse event (as defned by each study); withdrawals=No of patients withdrawn from 
study because of adverse events; liver=No of patients with abnormal results on liver function tests. Studies are ordered 
chronologically within subgroups
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included a maximum number of two trials, and for 
osteoarthritis we included a maximum number of 
seven trials in a meta-analysis. Moreover, none of the 
trials reported data for long term follow-up, and our 
results are limited to the immediate and short term eW-
cacy of paracetamol. Although we included three trials 
investigating spinal pain, none of these trials included 
patients with neck pain. In addition, one of the 
included trials did not report results for the placebo 
group,45 and attempts to gain access to these data 
were unsuccessful. Most of the included trials used 
the maximum dose of 4000 mg/day recommended by 
the US Food and Drug Administration: seven trials used 
4000 mg/day as the maximum dose, two trials used 
3990 mg as the maximum dose, and two trials 
used 3900 mg as the maximum dose. Only two trials 
used 3000 mg/day as the maximum dose.
Strengths and weaknesses in relation to other studies
Previous meta-analyses have concluded that parac-
etamol signiKcantly reduces pain in people with hip or 
knee osteoarthritis.13–15 One of these reviews reported no 
diCerence in toxicity, deKned by the number of patients 
reporting any adverse event.14 All endorsed the use of 
paracetamol for pain reduction in such patients. Our 
review included two trials not previously identiKed in 
the most recent previous meta-analysis, and our results 
show only a small clinically irrelevant beneKt of parac-
etamol for pain and disability at short term follow-up.
Supratherapeutic doses of paracetamol can over-
whelm the normal metabolic pathways and protective 
mechanisms in the liver and produce dangerous 
amounts of a toxic metabolite, N-acetyl-p-benzoqui-
noneimine.57 Most commonly this is seen in intentional 
overdoses, and the consequence can be liver failure. 
However, the drug has been used extensively for 
decades for chronic musculoskeletal conditions, and 
there is scant evidence for clinically signiKcant toxicity 
with regular doses of up to 4000 mg/day in otherwise 
healthy adults, although some researchers contest 
this.17 The signiKcant eCect on hepatic enzymes that we 
show is well known,58 but a link with clinically import-
ant toxicity is still uncertain.
Implications for clinicians and policymakers
Interventions such as drugs that aim to provide symp-
tomatic relief have been associated with improvement 
of physical function in people with osteoarthritis.59 60 
Similarly, there is a high correlation of changes in pain 
scores and function scores in people with low back 
pain.61 62 This evidence supports the use of drugs for 
pain relief to improve function in these conditions, and, 
overall, we have shown consistent results across pain 
and disability outcome measures. We found that parac-
etamol is ineCective on both pain and disability out-
comes for low back pain in the immediate and short 
term and is not clinically superior to placebo on both 
pain and disability outcomes for osteoarthritis.
Although thresholds for clinically important diCer-
ences between groups are unknown for osteoarthritis, a 
recent study has used a minimal clinically important 
diCerence of 0.9 on a 0–10 scale (or 9 on a 0 to 100 scale) 
based on the median diCerence found in previous large 
trials including patients with osteoarthritis.32 Our larg-
est observed eCect size of −3.7 points on a 0–100 pain 
scale, favouring paracetamol, is unlikely to be consid-
ered clinically important by patients or clinicians. 
Moreover, the lower boundary of the 95% conKdence 
interval of this eCect size was −5.5 and still did not reach 
the minimal clinically important difference of −9 
deKned in this review. Our results therefore provide an 
argument to reconsider the endorsement of parac-
etamol in clinical practice guidelines for low back pain 
and hip or knee osteoarthritis.
Recent evidence on lower limb osteoarthritis shows 
that exercises (such as strengthening exercise) com-
pared with no exercise control result in large treatment 
eCects for pain reduction (mean diCerence −2.3, 95% 
conKdence interval −2.8 to −1.26; on a 10 cm visual ana-
logue scale).63 This eCect size is much larger than the 
largest eCect size from our pooled analyses on short 
term eCects of paracetamol for hip or knee osteoarthri-
tis. Paracetamol alone therefore might not be suWcient 
to treat hip or knee osteoarthritis and might need to be 
accompanied by other management strategies, such as 
exercises and advice/education. Future trials, however, 
are needed to assess the combined eCect of these inter-
ventions in patients with osteoarthritis.
Unanswered questions and future research
This systematic review shows precise and clinically 
interpretable estimates of the size of the eCect of parac-
etamol compared with placebo in the management of 
spinal pain and osteoarthritis of the hip or knee. 
Although our results provide “high quality” evidence 
that paracetamol does not provide a clinically 
 important eCect in the short term, the long term eCect of 
this drug in the treatment of spinal pain and osteoar-
thritis remains unknown. Moreover, we found higher 
risk of abnormal results on liver function tests in 
patients taking paracetamol, though the clinical impli-
cations of this are uncertain. The eCects of paracetamol 
for neck pain are unknown as we found no trials includ-
ing participants with this condition.
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Medline
1. acetaminophen.mp. OR exp acetaminophen/
2. *Analgesics, Non-Narcotic/tu, th [Therapeutic Use, Therapy]
3. analgesic*.ab,ti.
4. (aceta OR actimin OR anacin OR apacet OR "aspirin free anacin" OR acamol OR acetalgin OR adol OR aldolOR
OR alvedon OR apiretal OR atamel OR atasol OR benuron OR biogesic OR "biogesic kiddielets" OR buscapina 
OR banesin OR "ben u ron" OR calpol OR captin OR cemol OR coldex OR cotibin OR crocin OR dafalgan 
OR daleron OR "dawa ya magi" OR depon OR dexamol OR dolex OR dolgesic OR doliprane OR dolorol OR
dolprone OR "duiyixian anjifen pian" OR dapa OR dolo OR datril OR duatrol OR dayquil OR efferalgan OR
enelfa OR europain OR febrectal OR febricet OR febridol OR fensum OR feverall OR fibi OR "fibi plus" OR
gelocatil OR gripin OR gesic OR genapap OR genebs OR hedex OR hedanol OR herron OR influbene OR
kafa OR kitadol OR lekadol OR lupocet OR lemsip OR liquiprin OR pyrigesic OR mexalen OR milidon OR
minoset OR momentum OR napa OR "neo kiddielets" OR neopap OR "oraphen pd" OR pyrigesic OR pacol 
OR pamol OR parol OR panado OR panadol OR panamax OR panda OR panodil OR pyrigesic OR paracet 
OR paracetamol OR paracitol OR paralen OR paramed OR paramol OR parol OR perdolan OR perfalgan OR
pinex OR "pyongsu cetamol" OR pyrenol OR pyrigesic OR plicet OR panadrex OR paratabs OR paralgin OR
phenaphen OR revanin OR rokamol OR rubophen OR redutemp OR sara OR scanol OR "sinpro n" OR
"snaplets fr" OR suppap OR tachipirin OR tachipirina OR tafirol OR tapsin OR termalgin OR tempra OR
thomapyrin OR tipol OR "togal classic duo" OR treuphadol OR triaminic OR tylenol OR tamen OR tapanol 
OR tipol OR uphamol OR vermidon OR vitamol OR valorin OR xumadol OR zolben).tw.
5. OR (1-4)
6. osteoarthritis.mp. OR exp osteoarthritis/
7. exp low back pain/
8. exp back pain/
9. exp neck pain/
10. ("low back pain" OR "back pain" OR "neck pain" OR backache OR lumbago OR "neck ache" OR "spin* pain"
OR "knee pain" OR "hip pain").mp.
11. OR (6-10)
12. 5 AND 11
13. randomized controlled trial.pt. OR exp randomized controlled trial/
14. "randomized controlled trial".mp.
15. exp random allocation/
16. placebo.mp. OR exp placebos/ OR exp placebo effect/
17. (random* adj3 trial).ab,ti.
18. "controlled clinical trial".mp. OR exp controlled clinical trial/
19. Random*.ab,ti.
20. OR (13-19)
21. 12 AND 20
22. limit 21 to humans
AMED
1. exp Acetaminophen/ OR acetaminophen.mp.
2. exp Analgesics/ OR Analgesics.mp.
3. exp Drug therapy/ OR drug therapy.mp.
4. analgesic*.ab,ti.
5. (aceta OR actimin OR anacin OR apacet OR "aspirin free anacin" OR acamol OR acetalgin OR adol OR aldolor
OR alvedon OR apiretal OR atamel OR atasol OR benuron OR biogesic OR "biogesic kiddielets" OR buscapina 
OR banesin OR "ben u ron" OR calpol OR captin OR cemol OR coldex OR cotibin OR crocin OR dafalgan 
OR daleron OR "dawa ya magi" OR depon OR dexamol OR dolex OR dolgesic OR doliprane OR dolorol OR
dolprone OR "duiyixian anjifen pian" OR dapa OR dolo OR datril OR duatrol OR dayquil OR efferalgan OR
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enelfa OR europain OR febrectal OR febricet OR febridol OR fensum OR feverall OR fibi OR "fibi plus" OR
gelocatil OR gripin OR gesic OR genapap OR genebs OR hedex OR hedanol OR herron OR influbene OR
kafa OR kitadol OR lekadol OR lupocet OR lemsip OR liquiprin OR pyrigesic OR mexalen OR milidon OR
minoset OR momentum OR napa OR "neo kiddielets" OR neopap OR "oraphen pd" OR pyrigesic OR pacol 
OR pamol OR parol OR panado OR panadol OR panamax OR panda OR panodil OR pyrigesic OR paracet 
OR paracetamol OR paracitol OR paralen OR paramed OR paramol OR parol OR perdolan OR perfalgan OR
pinex OR "pyongsu cetamol" OR pyrenol OR pyrigesic OR plicet OR panadrex OR paratabs OR paralgin OR
phenaphen OR revanin OR rokamol OR rubophen OR redutemp OR sara OR scanol OR "sinpro n" OR
"snaplets fr" OR suppap OR tachipirin OR tachipirina OR tafirol OR tapsin OR termalgin OR tempra OR
thomapyrin OR tipol OR "togal classic duo" OR treuphadol OR triaminic OR tylenol OR tamen OR tapanol 
OR tipol OR uphamol OR vermidon OR vitamol OR valorin OR xumadol OR zolben).tw.
6. OR (1-5)
7. exp Osteoarthritis/ OR osteoarthritis.mp.
8. exp Low back pain/ OR low back pain.mp.
9. back pain.mp. OR exp Backache/
10. exp Neck pain/ OR neck pain.mp.
11. ("low back pain" OR "back pain" OR "neck pain" OR backache OR lumbago OR "neck ache" OR "spin* pain"
OR "knee pain" OR "hip pain").mp.
12. OR (7-11)
13. 6 AND 12
14. exp Randomized controlled trials/ OR randomized controlled trial.mp.
15. randomized controlled trial.pt.
16. exp Random allocation/ OR random allocation.mp.
17. exp Placebos/ OR placebo.mp.
18. (random* adj3 trial).ab,ti.
19. Random*.ab,ti.
20. OR (14-19)
21. 13 AND 20
Embase
1. 'acetaminophen'/exp OR 'acetaminophen'
2. (aceta OR actimin OR anacin OR apacet OR "aspirin free anacin" OR acamol OR acetalgin OR adol OR
aldolOR OR alvedon OR apiretal OR atamel OR atasol OR benuron OR biogesic OR "biogesic kiddielets"
OR buscapina OR banesin OR "ben u ron" OR calpol OR captin OR cemol OR coldex OR cotibin OR crocin
OR dafalgan OR daleron OR "dawa ya magi" OR depon OR dexamol OR dolex OR dolgesic OR doliprane
OR dolorol OR dolprone OR "duiyixian anjifen pian" OR dapa OR dolo OR datril OR duatrol OR dayquil
OR efferalgan OR enelfa OR europain OR febrectal OR febricet OR febridol OR fensum OR feverall OR
fibi OR "fibi plus" OR gelocatil OR gripin OR gesic OR genapap OR genebs OR hedex OR hedanol OR
herron OR influbene OR kafa OR kitadol OR lekadol OR lupocet OR lemsip OR liquiprin OR pyrigesic OR
mexalen OR milidon OR minoset OR momentum OR napa OR "neo kiddielets" OR neopap OR "oraphen
pd" OR pyrigesic OR pacol OR pamol OR parol OR panado OR panadol OR panamax OR panda OR panodil
OR pyrigesic OR paracet OR paracetamol OR paracitol OR paralen OR paramed OR paramol OR parol OR
perdolan OR perfalgan OR pinex OR "pyongsu cetamol" OR pyrenol OR pyrigesic OR plicet OR panadrex
OR paratabs OR paralgin OR phenaphen OR revanin OR rokamol OR rubophen OR redutemp OR sara OR
scanol OR "sinpro n" OR "snaplets fr" OR suppap OR tachipirin OR tachipirina OR tafirol OR tapsin OR
termalgin OR tempra OR thomapyrin OR tipol OR "togal classic duo" OR treuphadol OR triaminic OR
tylenol OR tamen OR tapanol OR tipol OR uphamol OR vermidon OR vitamol OR valorin OR xumadol OR
zolben)
3. 1 OR 2
4. 'osteoarthritis'/exp OR 'osteoarthritis'
5. 'low back pain'/exp OR 'low back pain'
6. 'backache'/exp OR 'backache'
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7. 'neck pain'/exp OR 'neck pain'
8. 'low back pain' OR 'back pain' OR 'neck pain' OR backache OR lumbago OR 'neck ache' OR 'spin$ pain' OR
'knee pain' OR 'hip pain'
9. OR (4-8)
10. 3 AND 9
11. 'randomized controlled trial (topic)'/exp OR 'randomized controlled trial (topic)'
12. 'randomization'/exp OR 'randomization'
13. 'placebo'/exp OR 'placebo'
14. randomized:ab
15. placebo:ab
16. randomly:ab
17. OR (11-16)
18. 10 AND 17
CINAHL
1. (MH "Acetaminophen") OR "acetaminophen"
2. (MH "Analgesics+/TU")
3. "analgesic$"
4. "paracetamol"
5. "tylenol"
6. "panadol"
7. OR (1-6)
8. (MH "Osteoarthritis+") OR "osteoarthritis" OR (MH "Osteoarthritis, Spine+") OR (MH "Osteoarthritis, Knee")
OR (MH "Osteoarthritis, Hip")
9. (MH "Low Back Pain") OR "low back pain" OR (MH "Back Pain+")
10. (MH "Neck Pain") OR "neck pain"
11. (MH "Knee Pain+") OR "knee pain"
12. "hip pain"
13. "backache"
14. OR (8-13)
15. 7 AND 14
Web of Science
1. acetaminophen
2. Paracetamol OR tylenol OR panadol
3. OR (1-2)
4. osteoarthritis
5. back pain
6. neck pain
7. (spin* pain" OR "knee pain" OR "hip pain")
8. OR (4-7)
9. 3 AND 8
10. randomized controlled trial
11. random allocation
12. placebo
13. controlled clinical trial
14. Random*
15. OR (10-14)
16. 9 AND 15
LILACS
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((Acetaminophen OR paracetamol OR tylenol OR panadol) AND (osteoarthritis OR back pain OR lumbago OR 
backache OR neck pain OR knee pain OR hip pain))
International Pharmaceutical Abstracts
1. acetaminophen.mp.
2. (aceta or actimin or anacin or apacet or "aspirin free anacin" or acamol or acetalgin or adol or aldolOR or alvedon
or apiretal or atamel or atasol or benuron or biogesic or "biogesic kiddielets" or buscapina or banesin or "ben 
u ron" or calpol or captin or cemol or coldex or cotibin or crocin or dafalgan or daleron or "dawa ya magi" or 
depon or dexamol or dolex or dolgesic or doliprane or dolorol or dolprone or "duiyixian anjifen pian" or dapa 
or dolo or datril or duatrol or dayquil or efferalgan or enelfa or europain or febrectal or febricet or febridol or 
fensum or feverall or fibi or "fibi plus" or gelocatil or gripin or gesic or genapap or genebs or hedex or hedanol 
or herron or influbene or kafa or kitadol or lekadol or lupocet or lemsip or liquiprin or pyrigesic or mexalen or 
milidon or minoset or momentum or napa or "neo kiddielets" or neopap or "oraphen pd" or pyrigesic or pacol 
or pamol or parol or panado or panadol or panamax or panda or panodil or pyrigesic or paracet or paracetamol 
or paracitol or paralen or paramed or paramol or parol or perdolan or perfalgan or pinex or "pyongsu cetamol" 
or pyrenol or pyrigesic or plicet or panadrex or paratabs or paralgin or phenaphen or revanin or rokamol or 
rubophen or redutemp or sara or scanol or "sinpro n" or "snaplets fr" or suppap or tachipirin or tachipirina or 
tafirol or tapsin or termalgin or tempra or thomapyrin or tipol or "togal classic duo" or treuphadol or triaminic 
or tylenol or tamen or tapanol or tipol or uphamol or vermidon or vitamol or valorin or xumadol or zolben).tw.
3. 1 OR 2
4. osteoarthritis.mp.
5. low back pain.mp.
6. back pain.mp.
7. neck pain.mp.
8. ("low back pain" or "back pain" or "neck pain" or backache or lumbago or "neck ache" or "spin* pain" or "knee
pain" or "hip pain").mp.
9. OR (4-8)
10. 3 AND 9
CENTRAL
1. acetaminophen.mp. or exp Acetaminophen/
2. Analgesics, Non-Narcotic/tu [Therapeutic Use]
3. (paracetamol or tylenol or panadol).mp.
4. 1 or 2 or 3
5. exp Osteoarthritis, Hip/ or exp Osteoarthritis/ or exp Osteoarthritis, Spine/ or exp Osteoarthritis, Knee/
6. Low back pain.mp. or exp Low Back Pain/
7. Neck pain.mp. or exp Neck Pain/
8. ("low back pain" or "back pain" or "neck pain" or backache or lumbago or "neck ache" or "spin* pain" or "knee
pain" or "hip pain").mp.
9. 5 or 6 or 7 or 8
10. 4 and 9
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EXTENDED REPORT
Non-steroidal anti-inﬂammatory drugs for spinal
pain: a systematic review and meta-analysis
Gustavo C Machado,1 Chris G Maher,1 Paulo H Ferreira,2 Richard O Day,3
Marina B Pinheiro,2 Manuela L Ferreira1,4
ABSTRACT
Background While it is now clear that paracetamol is
ineffective for spinal pain, there is not consensus on the
efﬁcacy of non-steroidal anti-inﬂammatory drugs
(NSAIDs) for this condition. We performed a systematic
review with meta-analysis to determine the efﬁcacy and
safety of NSAIDs for spinal pain.
Methods We searched MEDLINE, EMBASE, CINAHL,
CENTRAL and LILACS for randomised controlled trials
comparing the efﬁcacy and safety of NSAIDs with
placebo for spinal pain. Reviewers extracted data,
assessed risk of bias and evaluated the quality of
evidence using the Grade of Recommendations
Assessment, Development and Evaluation approach.
A between-group difference of 10 points (on a 0–100
scale) was used for pain and disability as the smallest
worthwhile effect, as well as to calculate numbers
needed to treat. Random-effects models were used to
calculate mean differences or risk ratios with 95% CIs.
Results We included 35 randomised placebo-controlled
trials. NSAIDs reduced pain and disability, but provided
clinically unimportant effects over placebo. Six
participants (95% CI 4 to 10) needed to be treated with
NSAIDs, rather than placebo, for one additional
participant to achieve clinically important pain reduction.
When looking at different types of spinal pain, outcomes
or time points, in only 3 of the 14 analyses were the
pooled treatment effects marginally above our threshold
for clinical importance. NSAIDs increased the risk of
gastrointestinal reactions by 2.5 times (95% CI 1.2 to
5.2), although the median duration of included trials
was 7 days.
Conclusions NSAIDs are effective for spinal pain, but
the magnitude of the difference in outcomes between
the intervention and placebo groups is not clinically
important. At present, there are no simple analgesics
that provide clinically important effects for spinal pain
over placebo. There is an urgent need to develop new
drug therapies for this condition.
INTRODUCTION
Spinal pain (neck or low back pain) is the leading
cause of disability worldwide,1 2 and commonly
managed in general practice by prescription of
medicines.3 4 Clinical guidelines recommend non-
steroidal anti-inﬂammatory drugs (NSAIDs) as a
second-line analgesic after paracetamol, with third
choice being opioids.5 However, recent
meta-analyses have shown that paracetamol is inef-
fective,6 7 and opioids appear only to offer small
beneﬁts for this condition.8 Thus, although the use
of NSAIDs has fallen in the past decade,9 their use
could rapidly rise, given the lack of efﬁcacy of para-
cetamol and increased awareness of risks associated
with opioid use.10 11
There is still not consensus on the efﬁcacy of
NSAIDs for spinal pain. The most recent
meta-analysis excluded participants with acute low
back pain or neck pain,12 and to date no reviews
have investigated NSAID injections or topical for-
mulations in this population. Furthermore, previous
meta-analyses have reported standardised mean dif-
ferences (MD) as effect sizes, which are non-
intuitive and difﬁcult to interpret;13 thus better
measures of treatment effects, such as numbers
needed to treat (NNT), are likely to enhance inter-
pretability for the clinician. There is also concern
about the cardiovascular safety of cyclo-oxygenase-2
(COX-2) inhibitors, while serious gastrointestinal
adverse reactions are more closely linked to non-
selective NSAIDs,14 although all NSAIDs have been
associated with cardiovascular and gastrointestinal
risks.15 Thus, there is far greater need to understand
the efﬁcacy and safety of this medicine for spinal
pain.
Therefore, the aim of this systematic review was
to investigate the efﬁcacy and safety of NSAIDs
compared with placebo in patients with spinal pain,
with or without radicular pain. We also aimed to
evaluate whether trial characteristics or methods
are associated with estimates of treatment effect.
METHODS
Literature search
We followed the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA)
statement,16 and prospectively registered the review
protocol on the International Prospective Register
of Systematic Reviews (CRD42015023746). We
searched MEDLINE, EMBASE, CINAHL,
CENTRAL and LILACS from their inception to
February 2016. The search strategy was constructed
based on a combination of the following keywords
and their variations: neck pain, back pain,
lumbago, sciatica, anti-inﬂammatory, placebo and
randomised controlled trial. There were no restric-
tions of language or publication period.
Translations were obtained for non-English studies
(two trials). The complete search strategy is shown
in online supplementary table S1. One author
(GCM) performed the ﬁrst selection of studies
based on titles and abstracts, and two authors
(GCM and MBP) independently screened full texts.
We also searched for potentially eligible trials in the
reference lists of included studies and relevant
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systematic reviews. We used consensus to resolve any
disagreement.
Study selection
Only randomised placebo-controlled trials published in peer-
reviewed journals and investigating the effects and safety of
NSAIDs for spinal pain were included in this review. Trials had
to include participants with neck or low back pain, with or
without radicular pain. Trials that included mixed populations
were included if they reported separate data for participants
with spinal pain. We included trials investigating acute or
chronic spinal pain of any intensity and eligible trials had to
compare any class, formulation or route of administration
(topical, oral or injection) of NSAIDs with a matching placebo.
Only trials that reported patient-relevant outcomes, such as pain
intensity, disability status, quality-of-life or adverse events were
included. The dose and frequency of NSAIDs intake were not
restricted, and we investigated the effects of both non-selective
NSAIDs (eg, acetic acids, enolic acids, propionic acids, salicy-
lates) and COX-2 inhibitors. We excluded trials of participants
with serious spinal pathology (cancer, infectious diseases or
cauda equina syndrome). Trials evaluating postoperative anal-
gesia using NSAIDs in participants with spinal pain were
excluded, as were non-randomised controlled trials, review arti-
cles, guidelines and observational studies.
Data extraction and quality assessment
We used a standardised data extraction form to record the
characteristics of included participants, NSAID class and dose,
route of administration, outcomes and duration of follow-up.
Two reviewers (GCM and MBP) independently recorded
the sample size, means and SDs for pain, disability and
quality-of-life measures. We extracted these data following a
hierarchical order: mean difference (MD), change scores and
post-treatment scores. When medians, IQRs, ranges or SEs were
reported, we used previously reported formulae to estimate
means and SDs.17 According to recommendations in the
Cochrane Handbook,18 we extracted data from the ﬁrst period
of crossover randomised trials, and in multi-arm trials we
extracted data from all groups and divided the number of parti-
cipants in the control group by the number of comparisons.
For the safety outcomes, we extracted the number of partici-
pants reporting any adverse event, any serious adverse event (as
deﬁned by each trial or events including myocardial infarction
and/or stroke), the number of dropouts due to adverse events
and the number of participants reporting gastrointestinal
adverse reactions. We also extracted the number of participants
taking additional analgesics and the number of tablets consumed
per day. We contacted authors of included trials to clarify any
relevant information or to request additional data in case of
incomplete reporting. Consensus or a third reviewer (MLF) was
used to resolve any disagreement.
The Cochrane Collaboration’s tool was used to assess the risk
of bias of included studies by two independent reviewers (GCM
and MBP).19 The quality of the evidence from each pooled ana-
lysis was evaluated using the Grade of Recommendations
Assessment, Development and Evaluation (GRADE) approach.20
The quality of evidence was downgraded by one level according
to the following criteria: limitation of study design (more than a
quarter of studies considered at serious risk of bias), inconsist-
ency of results (substantial heterogeneity, I2>50%), imprecision
(pooled sample size <300), indirectness (dissimilar population,
intervention, outcomes and time points) and publication bias
(funnel plot assessment and Egger’s test two-tailed p<0.1).
Consensus was used to resolve any disagreement. The quality of
evidence was then judged as high, moderate, low or very low.
Data synthesis and analysis
Trials were pooled for common outcomes and time points. As
our primary analysis we present overall pooled estimates includ-
ing all available trials, and as a secondary analysis we present
separate pooled effects for neck pain, acute/chronic low back
pain and sciatica. We deﬁned a follow-up period <2 weeks as
immediate-term, and a follow-up between 2 weeks and
3 months as short-term. When more than one time point was
available for the same deﬁnition, we extracted data at 1 week
for immediate-term, or at 8 weeks for short-term. Although we
attempted to extract data for medium (>3 months but
<12 months) and long-term (≥12 months) follow-ups, no trials
reported data for these time points.
Pain outcome measures reported in included trials were visual
analogue scales (range, 0–100), or numerical rating scales
(range, 0–10). These two pain measures are highly correlated
and can be used interchangeably when transformed.21 The dis-
ability scale used in trials was the Roland-Morris Disability
Questionnaire (range, 0–24). Pain and disability scores were con-
verted to a common 0-point (no pain or disability) to 100-point
(worst possible pain or disability) scale to facilitate the interpret-
ation of our results, and because smallest worthwhile effects for
pain and disability in this population are often reported in a 0–
100 scale.22–24 Quality-of-life measures included the 12-item or
the 36-item Short Form (SF) Health Survey (range, 0–100); no
score conversion was needed for this outcome.
A between-group difference of 10 points (on a 0–100 scale)
for pain, disability and quality-of-life was considered as the smal-
lest worthwhile effect;22 the mean effect sizes below this thresh-
old were considered clinically unimportant. The smallest
worthwhile effect describes the smallest effect of intervention
(compared with placebo) that patients perceive as important,
and is critical for clinical decision-making.25 We used
random-effects models to calculate MD or risk ratios (RR) and
95% CIs. We also present the results for the pain intensity ana-
lyses as numbers needed to treat (NNT), using the method pro-
posed by Norman.26 This expresses the number of patients who
need to be treated with an NSAID rather than placebo, for one
additional person to beneﬁt (based on a clinically important
change of 10 points on a 0–100 pain scale; and allowing for the
proportion of patients who were improved, the same and dete-
riorated in NSAID and placebo groups). All analyses were con-
ducted using Comprehensive Meta-Analysis V.2 (Biostat,
Englewood, New Jersey, USA).
Secondary exploratory analysis
We conducted subgroup analyses to explore the inﬂuence of dif-
ferent factors on our estimates of treatment effects. We used
meta-regression to generate the difference in effect sizes (with
95% CI) and p values between subgroups for pain at immediate-
term. Subgroups were deﬁned in terms of risk of bias judge-
ments (low, unclear or high), form of drug administration
(topical, oral or injection) and type of NSAID (COX-2 inhibi-
tors or non-selective NSAIDs). We also investigated the differ-
ence of effect sizes of discontinued drugs (eg, rofecoxib and
valdecoxib) and currently marketed NSAIDs, given the aim of
this review in informing current best practice.
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RESULTS
Initial search and results
Our search resulted in a total of 5208 individual records. After
the screening of titles and abstracts, two independent reviewers
assessed 302 full-text articles. We included 35 randomised trials
after full-text examination with data for 6065 participants with
spinal pain (ﬁgure 1).27–61 Twenty-two trials investigated the
effects of NSAIDs for low back pain, of which 11 included par-
ticipants with acute back pain and 11 (10 published reports)
included participants with chronic low back pain. Eleven trials
investigated participants with sciatica and two included neck
pain only. The median treatment duration in included trials was
7 (IQR, 5–7) days. NSAIDs were mostly administered orally, but
ﬁve trials used intravenous or intramuscular injection,35 37–39 59
and three used a topical formulation, such as a gel, patch or
cream.51 53 56 Nine trials had a three-arm parallel design and
two were randomised crossover trials. These trials compared
two different drugs, or two different dosages of the same drug
with a matching placebo. Online supplementary table S2 pro-
vides more detail on the characteristics of included trials and
the medications evaluated.
The risk of bias assessment (see online supplementary ﬁgure
S1) shows that overall, studies had no serious risk of bias.
However, about half of the trials had at least one bias domain
judged as high risk. A third of included trials reported an appro-
priate method of randomisation, and only four reported suitable
allocation concealment. Nearly all trials were therapist and
assessor-blinded, but 20% of trials had high dropout rates
(>15%). Seven trials did not report relevant outcomes or failed
to report results previously described in their methods and were
judged at high risk of reporting bias. Eleven trials were judged
at high risk for the ‘other’ bias domain as they reported that
pharmaceutical companies that funded the trial were involved in
running the study, analysing the data or writing the manuscript.
The risk of bias assessment for each individual trial is shown in
online supplementary ﬁgure S2. The inspection of the funnel
plot including all trials reporting data for immediate pain reduc-
tion and the non-signiﬁcant Egger’s test (p=0.86) revealed no
publication bias (see online supplementary ﬁgure S3).
Therefore, none of our meta-analyses was downgraded for pub-
lication bias according to the GRADE approach. Data extracted
from individual trials and calculations of effect sizes are shown
in online supplementary tables S3 and S4.
Efﬁcacy of NSAIDs for spinal pain
Pooling of all included trials revealed moderate-quality evidence
that NSAIDs reduced pain in the immediate (MD −9.2, 95% CI
−11.1 to −7.3) and short-term (MD −7.7, 95% CI −11.4 to
−4.1) compared with placebo (ﬁgure 2). The NNT to achieve a
clinically signiﬁcant effect of NSAIDs over placebo on pain
reduction in the immediate-term was 5 (95% CI 4 to 6) and 6
(95% CI 4 to 10) in the short-term. The effects of NSAIDs on
disability were slightly smaller than for pain, with effect at
immediate-term follow-up being −8.1 (95% CI −11.6 to −4.6),
and at short-term −6.1 (95% CI −9.5 to −2.8) (ﬁgure 3). The
magnitude of the difference in outcomes between the interven-
tion and placebo groups, however, was less than the 10-point
threshold for clinical importance.
There was high-quality evidence of clinically unimportant
effects of NSAIDs compared with placebo for the physical
component of the SF-12 (MD −2.9, 95% CI −3.7 to −2.1),
and no effects over placebo were found for the mental compo-
nent (MD −0.3, 95% CI −1.2 to 0.6). None of the included
studies used the SF-36 to measure quality-of-life. Table 1 pro-
vides more detailed information on the summary of ﬁndings
and the GRADE assessment. None of the included trials
reported medium-term or long-term effects of NSAIDs.
Safety of NSAIDs for spinal pain
For the safety analyses, we included up to 21 trials (5153 parti-
cipants) with median treatment duration of 7 (IQR, 5–7) days
(ﬁgure 4). No difference in any event rate between NSAIDs and
placebo was found (RR 1.1, 95% CI 1.0 to 1.2). Only two trials
including 635 participants reported serious adverse event data
and again there was no difference between groups (RR 1.5,
95% CI 0.4 to 5.2). Similarly, nine trials with 3283 participants
revealed no difference in the number of dropouts due to
adverse events (RR 1.0, 95% CI 0.6 to 1.6). However, we
found a signiﬁcantly higher number of participants in the
NSAIDs group reporting gastrointestinal adverse events com-
pared with placebo (RR 2.5, 95% CI 1.2 to 5.2); 28/702 partici-
pants taking NSAIDs had gastrointestinal adverse reactions
compared with 9/465 in the placebo groups. Overall, these
results were based on high-quality evidence according to the
GRADE evaluation.
Use of rescue medication
The use of rescue medication was measured in a variety of ways
in eight trials, such as the number of participants taking add-
itional analgesics and the number of tablets taken per day. Four
trials revealed moderate-quality evidence of no difference in the
number of participants taking an additional analgesic (RR 1.0,
95% CI 0.6 to 1.4). However, pooling of four trials showed
high-quality evidence that participants taking NSAIDs required
less tablets/day of a rescue medication (MD –0.4, 95% CI −0.5
to −0.3), a difference that is arguably not clinically important.
Figure 1 Study selection. CENTRAL, Cochrane Central Register of
Controlled Trials. *Number of citations listed for each database includes
duplicates.
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Secondary exploratory analysis
Results from our meta-regression analyses showed that trials
with low risk of selection bias had larger effects (MD −11.2,
95% CI −13.9 to −8.5) than trials judged at unclear risk (MD
−6.7, 95% CI −8.6 to −4.9). The difference between these sub-
groups (MD −4.2, 95% CI −7.7 to −0.8) was statistically sig-
niﬁcant (p=0.02). COX-2 inhibitors had larger effects (MD
−13.4, 95% CI −15.7 to −11.1) compared with non-selective
NSAIDs (MD −7.7, 95% CI −9.8 to −5.6). This difference was
Figure 2 Mean differences for pain in placebo-controlled trials on efﬁcacy of non-steroidal anti-inﬂammatory drugs (NSAIDs) for spinal pain. Pain
is expressed on scale of 0–100. Immediate-term=follow-up ≤2 weeks; short-term=follow-up >2 weeks but ≤3 months; LBP, low back pain. Studies
ordered chronologically within subgroups.
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also statistically signiﬁcant (MD −5.7, 95% CI −9.4 to −1.9;
p=0.003), but of questionable clinical relevance. There was no
difference between the effect sizes of discontinued drugs com-
pared with currently marketed NSAIDs (MD 0.3, 95% CI −3.7
to 4.3; p=0.88), although no trials investigating celecoxib were
found (table 2). Different delivery routes resulted in similar
effects compared with a matching placebo: topical (MD −13.2,
95% CI −18.5 to −7.9), oral (MD −8.5, 95% CI −10.4 to
−6.6) and injection (MD −9.5, 95% CI −14.7 to −4.4).
DISCUSSION
Our review of 35 randomised placebo-controlled trials demon-
strates that NSAIDs are effective in reducing pain and disability in
patients with spinal pain, although treatment effects above those
of placebo are small and arguably not clinically important. For
every six patients treated with NSAIDs, rather than placebo, only
one additional patient would beneﬁt considering a between-group
difference of 10 points for clinical importance in the short-term.
Furthermore, when looking at different spinal pain, outcomes or
time points in only 3 of the 14 analyses were the pooled effects
only marginally above our 10-point threshold for clinical rele-
vance. NSAIDs were associated with higher number of patients
reporting gastrointestinal adverse effects in the short-term
follow-up (ie, <14 days). No data on safety at medium-term or
long-term follow-ups were provided by included trials.
The strengths of our review include that it was prospectively
registered and followed the PRISMA recommendations, includ-
ing the use of GRADE to appraise the quality of the evidence.
We were able to identify a signiﬁcantly larger number of trials
than past reviews,12 62–70 which have often limited their inclu-
sion criteria to a speciﬁc language, population or type of
NSAID. Including more studies (35 randomised placebo-
controlled trials) enabled us to conduct a more thorough evalu-
ation of the effects of NSAIDs for various forms of spinal pain,
and to include a range of forms of drug administration. We have
also provided valuable information on pooled treatment effects
for speciﬁc populations, including neck pain, acute/chronic low
back pain and sciatica. Furthermore, we have provided clinically
interpretable estimates on a 0–100 scale, and compared our
effect sizes with a predetermined smallest worthwhile effect of
10 points, which reﬂects the smallest effect of the intervention
on outcomes compared with placebo that patients would con-
sider meaningful or important.22 Given physicians often ﬁnd
the interpretation of effect sizes reported in meta-analysis chal-
lenging,71 we have also presented our results on pain reduction
as the NNT for a clinically signiﬁcant effect of NSAIDs over
placebo. Moreover, potential factors that could have inﬂuenced
our treatment effects, such as risk of bias judegments, class of
NSAIDs and route of administration, were investigated through
meta-regression analyses. Although COX-2 inhibitors showed
larger effects than non-selective NSAIDs on pain reduction, the
size of the difference is of arguable clinical relevance. COX-2
inhibitors trials included in our review were fairly recent (all
were conducted after 2003) and substantially larger (mean
sample size of 280). They were also more likely to report safety
outcomes than older trials.
Figure 3 Mean differences for disability in placebo-controlled trials on efﬁcacy of non-steroidal anti-inﬂammatory drugs (NSAIDs) for spinal pain.
Disability is expressed on scale of 0–100. Immediate-term=follow-up ≤2 weeks; short-term=follow-up >2 weeks but ≤3 months; LBP, low back
pain. Studies ordered chronologically within subgroups.
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Our review has some limitations. First, we did not ﬁnd any
trials investigating the efﬁcacy and safety of celecoxib versus
placebo, a commonly used COX-2 selective drug. Second,
some of the trials included in our meta-analysis used drugs that
are discontinued or are no longer commercialised in major
markets (eg, rofecoxib and valdecoxib), but our
meta-regression revealed that this was not a factor that inﬂu-
enced our estimates; discontinued drugs (MD −8.9, 95% CI
−10.8 to −7.0) had similar effects as currently marketed
NSAIDs (MD −9.3, 95% CI −12.1 to −6.5). Third, there is no
evidence on the long-term effects and safety of NSAIDs, as the
median follow-up time was 1 week in included trials, with
some treatment schedules lasting <1 day. Fourth, our overall
pooled estimates resulted in substantial between-trial hetero-
geneity (I2 ranged from 59% to 87%), which, however, was
found considerably reduced in the stratiﬁed meta-analyses
according to the type of spinal pain (ie, neck pain, acute/
chronic low back pain, or sciatica). Finally, another limitation
of our study is that there were very few trials on neck pain,
and none on whiplash.
Table 1 Summary of findings and quality of evidence assessment
Summary of findings Quality of evidence assessment (GRADE)
Overall Trials Participants I2, % MD (95% CI) Study limitation Inconsistency Imprecision Quality
Immediate-term
Pain 23 5217 59 –9.2 (−11.1 to −7.3) None –1 None Moderate
Disability 12 2667 87 −8.1 (−11.6 to −4.6) None –1 None Moderate
Short-term
Pain 9 2611 81 −7.7 (−11.4 to −4.1) None –1 None Moderate
Disability 8 2086 85 −6.1 (−9.5 to −2.8) None –1 None Moderate
Quality-of-life (PC) 4 1330 0 −2.9 (−3.7 to −2.1) None None None High
Quality-of-life (MC) 4 1330 15 −0.3 (−1.2 to 0.6) None None None High
Neck pain
Immediate-term
Pain 2 225 36 −16.3 (−20.6 to −12.0) None None –1 Moderate
Disability 2 225 98 −12.2 (−34.3 to 10.0) None –1 –1 Low
Acute low back pain
Immediate-term
Pain 5 814 26 −6.4 (−10.3 to −2.5) None None None High
Disability 3 476 43 −7.1 (−12.4 to −1.9) None None None High
Short-term
Pain 1 120 0 −1.0 (−5.9 to 3.9) None None –1 Moderate
Disability 1 120 0 −0.4 (−5.4 to 4.5) None None –1 Moderate
Chronic low back pain
Immediate-term
Pain 9 2537 52 −11.1 (−13.8 to −8.4) None –1 None Moderate
Disability 6 1752 30 −8.4 (−10.6 to −6.3) None None None High
Short-term
Pain 7 2277 60 −9.8 (−12.7 to −7.0) None –1 None Moderate
Disability 6 1752 87 −7.9 (−11.8 to −4.0) None –1 None Moderate
Sciatica
Immediate-term
Pain 7 1641 0 −6.2 (−8.2 to −4.2) None None None High
Disability 1 214 0 1.2 (−3.8 to 6.1) None None –1 Moderate
Short-term
Pain 1 214 0 3.3 (−1.5 to 8.1) None None –1 Moderate
Disability 1 214 0 2.4 (−2.6 to 7.3) None None –1 Moderate
Safety outcomes
All time points
Adverse events (any)* 21 5153 16 1.1 (1.0 to 1.2) None None None High
Adverse events (serious)† 2 635 56 1.5 (0.4 to 5.2) None –1 None Moderate
Adverse events (dropout)‡ 9 3283 38 1.0 (0.6 to 1.6) None None None High
Adverse events (gastro)§ 3 1167 0 2.5 (1.2 to 5.2) None None None High
Negative values favours NSAIDs.
*Number of patients reporting any adverse effect.
†Number of patients reporting any serious adverse effect (as defined by each study).
‡Number of patients withdrawn from study due to adverse effects.
§Number of patients reporting gastrointestinal adverse effects.
MC, mental component; MD, mean differences; NSAIDs, non-steroidal anti-inflammatory drugs; PC, physical component.
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We provide sound evidence that NSAIDs are effective, but do
not offer clinically important beneﬁts for spinal pain above
those attributable to placebo, given overall pooled estimated dif-
ferences were <10 points. This is crucially important because
we now know paracetamol is ineffective,6 7 and opioids only
offer small beneﬁts for spinal pain.8 Thus, given our results and
evidence from these recent high-quality meta-analyses, it seems
that there are no analgesics with clinically important effects over
placebo for spinal pain. This is a problem, as current guidelines
for spinal pain endorse these three medicines.5 For instance, the
National Institute for Health and Care Excellence (NICE) guid-
ance on low back pain and sciatica now recommends NSAIDs as
ﬁrst analgesic option and suggests the use of opioids with para-
cetamol to treat spinal pain. In our review, even when the
effects of NSAIDs were analysed for different spinal pain strata
(ie, neck pain, acute/chronic low back pain or sciatica), only 3
of the 14 analyses revealed effects that were marginally above
our threshold for clinical relevance. The effects observed in
Figure 4 Risk ratio for safety outcome measures in placebo-controlled trials on efﬁcacy of non-steroidal anti-inﬂammatory drugs (NSAIDs)
compared with placebo. Any adverse event=no. of patients reporting any adverse event; serious adverse events=no. of patients reporting any serious
adverse event (as deﬁned by each study); GI adverse events=no. of patients reporting gastrointestinal adverse events; withdrawals=no. of patients
withdrawn from study because of adverse events. Studies are ordered chronologically within subgroups.
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trials including participants with neck pain were unexpected,
particularly because these trials investigated topical NSAIDs
only. Our safety analysis revealed that NSAIDs increased the risk
of gastrointestinal adverse effects by 2.5 times compared with
placebo, although safety data were limited to trials that used
non-selective NSAIDs. However, it is established that all
NSAIDs, including COX-2 inhibitors, have been linked to
gastrointestinal harms.15 72 Our safety results should be inter-
preted with caution given the short duration of exposure to
NSAIDs in included trials.
In summary, compared with placebo, NSAIDs do not provide
a clinically important effect on spinal pain, and six patients
must be treated with NSAIDs for one patient to achieve a clinic-
ally important beneﬁt in the short-term. When this result is
taken together with those from recent reviews on paracetamol
and opioids, it is now clear that the three most widely used, and
guideline-recommended medicines for spinal pain do not
provide clinically important effects over placebo. There is an
urgent need to develop new analgesics for spinal pain.
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Table S1. Search Strategy
MEDLINE (up to February 2016)
1. randomized controlled trial/ or controlled clinical trial.pt. or comparative study.pt or clinical trial.pt. or
randomized.ab. or randomised.ab or randomly.ab,ti. or trial.ab,ti.
2. placebos/ or placebo effect/ or placebo.tw or anti-inflammatory agents, non-steroidal/ or anti-inflammator*.tw
or nsaid*.tw. or acetylsalicyl* or diflunisal or aceclofenac or alclofenac or diclofenac or indometacin or
sulindac or meloxicam or piroxicam or dexibuprofen or dexketoprofen or fenoprofen or flurbiprofen or
ibuprofen or ketoprofen or naproxen or tiapro* or metamizol or phenylbutazone or phenazone or
propyphenazone or celecoxib or etoricoxib or nabumeton or parecoxib.tw
3. 1 and 2
4. back pain/ or low back pain/ or dorsalgia.ti,ab. or backache.ti,ab. or (lumbar adj pain).tw. or lumbago.tw or
back disorder*.tw. or neck pain/ or neck pain.tw.
5. 3 and 4
6. limit 5 to humans
EMBASE (up to February 2016)
1. 'randomized controlled trial (topic)' or randomized:ab or randomised:ab or randomly:ab
2. 'placebo'/exp or placebo:ti or placebo:ab
3. #1 and #2
4. 'nonsteroidal antiinflammatory agent'/exp or 'anti inflammatory':ti or 'anti inflammatory':ab or nsaid*:ti or
nsaid*:ab
5. #3 and #4
6. 'low back pain'/exp or 'low back pain' or 'backache'/exp or 'backache' or 'neck pain'/exp or 'neck pain'
7. #5 and #6
8. #7 and [embase]/lim
9. #8 and [humans]/lim
10. #9 and ([article]/lim or [article in press]/lim or [review]/lim)
CINAHL (up to February 2016)
1. (MH "Clinical Trials+") or (MH "Comparative Studies") or (MH "Randomized Controlled Trials") or (MH
"Clinical Trials+") or ti random* or ab random*
2. (MH "Antiinflammatory Agents, Non-Steroidal+") or (MH "Antiinflammatory Agents, Topical+") or
"Antiinflammatory" or "Anti-inflammatory" or ti nsaid* or ab nsaid*
3. 1 and 2
4. (MH "Low Back Pain") or (MH "Back Pain+") or "dorsalgia" or "backache" or "lumbago" or (MH "Neck Pain")
5. 3 and 4
6. 5 limited to humans
CENTRAL (up to February 2016)
1. MeSH descriptor: [Back Pain] explode all trees or MeSH descriptor: [Low Back Pain] explode all trees or
(lumbar next pain) or (coccyx) or (coccydynia) or (sciatica) or (spondylosis) or MeSH descriptor: [Spinal
Diseases] explode all trees or (lumbago) or (discitis) or (disc near degeneration) or (disc near prolapse) or
(disc near herniation) or back disorder* or back near pain or MeSH descriptor: [Neck Pain] explode all trees or
neck pain or neck disorder*
2. MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees or nsaid*
3. 1 and 2
4. 3 limited to trials
LILACS (up to February 2016)
1. (anti-inflammatory or antiinflamatorio or anti-inflamatorio or anti-inflammatories or antiinflamatorios or anti-
inflamatorios or NSAIDs or AINEs) and (osteoarthritis or osteoartrite or back pain or dor lombar or lumbago
or lombalgia or backache or neck pain or dor cervical or knee pain or hip pain)
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 d
a
ily
, 
7
5
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
P
la
c
e
b
o
 s
a
lin
e
 i
n
je
c
ti
o
n
A
c
e
ti
c
 a
c
id
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
1
 d
a
y
S
z
p
a
ls
k
i 
1
9
9
4
B
e
lg
iu
m
7
3
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
3
7
, 
g
ro
u
p
 2
=
3
6
);
 m
e
a
n
 
a
g
e
 (
S
D
)=
3
8
.2
 (
9
.8
) 
y
e
a
rs
; 
6
4
%
 
m
a
le
G
ro
u
p
 1
: 
T
e
n
o
x
ic
a
m
 2
0
 m
g
, 
in
tr
a
m
u
s
c
u
la
r 
in
je
c
ti
o
n
 o
n
 d
a
y
 1
, 
th
e
n
 1
 
ta
b
le
t,
 o
n
c
e
 d
a
ily
 f
o
r 
1
4
 d
a
y
s
, 
2
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
M
a
tc
h
in
g
 
in
tr
a
m
u
s
c
u
la
r 
in
je
c
ti
o
n
 o
r 
o
ra
l 
p
la
c
e
b
o
E
n
o
lic
 a
c
id
P
a
in
 (
1
0
 c
m
 V
A
S
);
 a
t 
1
 w
e
e
k
G
h
o
z
la
n
 1
9
9
6
F
ra
n
c
e
1
9
4
 s
c
ia
ti
c
a
 p
a
ti
e
n
ts
 (
g
ro
u
p
 
1
=
6
7
, 
g
ro
u
p
 2
=
6
6
, 
g
ro
u
p
 3
=
6
1
);
 
m
e
a
n
 a
g
e
 (
S
D
)=
4
2
.0
 (
1
2
.4
) 
y
e
a
rs
; 
6
3
%
 m
a
le
G
ro
u
p
 1
: 
E
to
d
o
la
c
 3
0
0
 m
g
, 
1
 t
a
b
le
t,
 s
in
g
le
 d
o
s
e
, 
3
0
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
T
e
n
o
x
ic
a
m
 2
0
 m
g
, 
in
tr
a
m
u
s
c
u
la
r 
in
je
c
ti
o
n
, 
s
in
g
le
 d
o
s
e
, 
2
0
 m
g
 t
o
ta
l;
 
G
ro
u
p
 3
: 
P
la
c
e
b
o
 s
a
lin
e
 i
n
je
c
ti
o
n
A
c
e
ti
c
 a
c
id
; 
E
n
o
lic
 a
c
id
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
U
s
e
 o
f 
re
s
c
u
e
 
m
e
d
ic
a
ti
o
n
; 
a
t 
4
 a
n
d
 1
2
 h
o
u
rs
D
re
is
e
r 
2
0
0
1
S
ix
c
o
u
n
tr
ie
s
5
3
2
 s
c
ia
ti
c
a
 p
a
ti
e
n
ts
 (
g
ro
u
p
 
1
=
1
7
1
, 
g
ro
u
p
 2
=
1
8
1
, 
g
ro
u
p
 
3
=
1
8
0
);
 m
e
a
n
 a
g
e
 (
S
D
)=
4
7
.0
 
(1
4
.3
) 
y
e
a
rs
; 
4
4
%
 m
a
le
G
ro
u
p
 1
: 
M
e
lo
x
ic
a
m
 1
5
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
1
5
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
M
e
lo
x
ic
a
m
 7
.5
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
7
.5
 m
g
 t
o
ta
l;
 G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
E
n
o
lic
 a
c
id
P
a
in
 (
1
0
0
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m
 V
A
S
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
1
 w
e
e
k
N
a
d
le
r 
2
0
0
2
U
n
it
e
d
 
S
ta
te
s
1
2
6
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
0
6
, 
g
ro
u
p
 2
=
2
0
);
 
m
e
a
n
 a
g
e
 (
S
D
)=
N
R
; 
4
0
%
 m
a
le
G
ro
u
p
 1
: 
Ib
u
p
ro
fe
n
 2
0
0
 m
g
, 
2
 t
a
b
le
ts
, 
3
 t
im
e
s
 d
a
ily
, 
1
2
0
0
 m
g
 t
o
ta
l;
 
G
ro
u
p
 2
: 
O
ra
l 
p
la
c
e
b
o
P
ro
p
io
n
ic
 
a
c
id
P
a
in
 (
6
-p
o
in
t 
s
c
a
le
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
2
 d
a
y
s
96
B
ir
b
a
ra
 2
0
0
3
U
n
it
e
d
 
S
ta
te
s
3
1
9
 c
h
ro
n
ic
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
0
7
, 
g
ro
u
p
 2
=
1
0
3
, 
g
ro
u
p
 3
=
1
0
9
);
 m
e
a
n
 a
g
e
 
(S
D
)=
5
2
.0
 (
1
3
.0
) 
y
e
a
rs
; 
3
9
%
 
m
a
le
G
ro
u
p
 1
: 
E
to
ri
c
o
x
ib
 9
0
 m
g
, 
1
 c
a
p
s
u
le
, 
o
n
c
e
 d
a
ily
, 
9
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
E
to
ri
c
o
x
ib
 6
0
 m
g
, 
1
 c
a
p
s
u
le
, 
o
n
c
e
 d
a
ily
, 
6
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
C
O
X
-2
in
h
ib
it
o
r
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 Q
u
a
lit
y
 o
f 
lif
e
 (
S
F
-1
2
);
 
A
d
v
e
rs
e
 e
ff
e
c
ts
; 
U
s
e
 o
f 
re
s
c
u
e
 
m
e
d
ic
a
ti
o
n
; 
a
t 
1
 a
n
d
 1
2
 w
e
e
k
s
D
re
is
e
r 
2
0
0
3
F
ra
n
c
e
3
7
2
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
2
4
, 
g
ro
u
p
 2
=
1
2
2
, 
g
ro
u
p
 3
=
1
2
6
);
 m
e
a
n
 a
g
e
 
(S
D
)=
4
0
.9
 (
1
1
.2
) 
y
e
a
rs
; 
4
9
%
 
m
a
le
G
ro
u
p
 1
: 
D
ic
lo
fe
n
a
c
 1
2
.5
 m
g
, 
1
 o
r 
2
 t
a
b
le
ts
, 
4
 t
o
 6
 t
im
e
s
 d
a
ily
, 
1
5
0
 m
g
 
m
a
x
im
u
m
; 
G
ro
u
p
 2
: 
Ib
u
p
ro
fe
n
 2
0
0
 m
g
, 
1
 o
r 
2
 t
a
b
le
ts
, 
4
 t
o
 6
 t
im
e
s
 d
a
ily
, 
1
2
0
0
 m
g
 m
a
x
im
u
m
; 
G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
A
c
e
ti
c
 a
c
id
; 
P
ro
p
io
n
ic
 
a
c
id
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 Q
u
a
lit
y
 o
f 
lif
e
 (
S
F
-1
2
);
 
A
d
v
e
rs
e
 e
ff
e
c
ts
; 
a
t 
1
 w
e
e
k
K
a
tz
 2
0
0
3
 (
2
tr
ia
ls
)
U
n
it
e
d
 
S
ta
te
s
6
9
0
 c
h
ro
n
ic
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
2
2
9
, 
g
ro
u
p
 2
=
2
3
3
, 
g
ro
u
p
 3
=
2
2
8
);
 m
e
a
n
 a
g
e
 
(S
D
)=
5
3
.4
 (
1
3
.1
) 
y
e
a
rs
; 
3
8
%
 
m
a
le
G
ro
u
p
 1
: 
R
o
fe
c
o
x
ib
 5
0
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
5
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
R
o
fe
c
o
x
ib
 2
5
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
2
5
 m
g
 t
o
ta
l;
 G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
C
O
X
-2
in
h
ib
it
o
r
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 Q
u
a
lit
y
 o
f 
lif
e
 (
S
F
-1
2
);
 
A
d
v
e
rs
e
 e
ff
e
c
ts
; 
a
t 
1
 a
n
d
 4
 
w
e
e
k
s
N
a
d
le
r 
2
0
0
3
-a
U
n
it
e
d
 
S
ta
te
s
1
0
8
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
2
, 
g
ro
u
p
 2
=
9
6
);
 m
e
a
n
 
a
g
e
 (
S
D
)=
3
6
.7
 (
1
0
.8
) 
y
e
a
rs
G
ro
u
p
 1
: 
Ib
u
p
ro
fe
n
 2
0
0
 m
g
, 
2
 t
a
b
le
ts
, 
3
 t
im
e
s
 d
a
ily
, 
1
2
0
0
 m
g
 t
o
ta
l;
 
G
ro
u
p
 2
: 
O
ra
l 
p
la
c
e
b
o
P
ro
p
io
n
ic
 
a
c
id
P
a
in
 (
6
-p
o
in
t 
s
c
a
le
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
5
 d
a
y
s
N
a
d
le
r 
2
0
0
3
-b
U
n
it
e
d
 
S
ta
te
s
3
8
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
3
4
, 
g
ro
u
p
 2
=
4
);
 m
e
a
n
 
a
g
e
 (
S
D
)=
N
R
G
ro
u
p
 1
: 
Ib
u
p
ro
fe
n
 2
0
0
 m
g
, 
2
 t
a
b
le
ts
, 
3
 t
im
e
s
 d
a
ily
, 
1
2
0
0
 m
g
 t
o
ta
l;
 
G
ro
u
p
 2
: 
O
ra
l 
p
la
c
e
b
o
P
ro
p
io
n
ic
 
a
c
id
P
a
in
 (
6
-p
o
in
t 
s
c
a
le
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
5
 d
a
y
s
C
o
a
ts
 2
0
0
4
U
n
it
e
d
 
S
ta
te
s
 &
 
C
a
n
a
d
a
2
9
3
 c
h
ro
n
ic
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
4
8
, 
g
ro
u
p
 2
=
1
4
5
);
 
m
e
a
n
 a
g
e
 (
S
D
)=
4
8
.6
 (
1
2
.9
) 
y
e
a
rs
; 
4
3
%
 m
a
le
G
ro
u
p
 1
: 
V
a
ld
e
c
o
x
ib
 4
0
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
4
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
O
ra
l 
p
la
c
e
b
o
C
O
X
-2
in
h
ib
it
o
r
P
a
in
 (
1
0
 c
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 A
d
v
e
rs
e
 e
ff
e
c
ts
; 
a
t 
1
 
a
n
d
 4
 w
e
e
k
s
P
a
lla
y
 2
0
0
4
U
n
it
e
d
 
S
ta
te
s
3
2
5
 c
h
ro
n
ic
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
1
0
6
, 
g
ro
u
p
 2
=
1
0
9
, 
g
ro
u
p
 3
=
1
1
0
);
 m
e
a
n
 a
g
e
 
(S
D
)=
5
2
.8
 (
1
3
.0
) 
y
e
a
rs
; 
3
8
%
 
m
a
le
G
ro
u
p
 1
: 
E
to
ri
c
o
x
ib
 9
0
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
9
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
E
to
ri
c
o
x
ib
 6
0
 m
g
, 
1
 t
a
b
le
t,
 o
n
c
e
 d
a
ily
, 
6
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
C
O
X
-2
in
h
ib
it
o
r
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 Q
u
a
lit
y
 o
f 
lif
e
 (
S
F
-1
2
);
 
A
d
v
e
rs
e
 e
ff
e
c
ts
; 
U
s
e
 o
f 
re
s
c
u
e
 
m
e
d
ic
a
ti
o
n
; 
a
t 
1
 a
n
d
 1
2
 w
e
e
k
s
H
a
n
c
o
c
k
 2
0
0
7
A
u
s
tr
a
lia
1
2
0
 a
c
u
te
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
6
0
, 
g
ro
u
p
 2
=
6
0
);
 m
e
a
n
 
a
g
e
 (
S
D
)=
4
0
.7
 (
1
5
.6
) 
y
e
a
rs
; 
5
6
%
 
m
a
le
G
ro
u
p
 1
: 
D
ic
lo
fe
n
a
c
 5
0
 m
g
, 
1
 t
a
b
le
t,
 2
 t
im
e
s
 d
a
ily
, 
1
0
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 
2
: 
O
ra
l 
p
la
c
e
b
o
A
c
e
ti
c
 a
c
id
P
a
in
 (
1
0
-p
o
in
t 
N
R
S
);
 D
is
a
b
ili
ty
 
(R
M
D
Q
);
 A
d
v
e
rs
e
 e
ff
e
c
ts
; 
a
t 
1
 
a
n
d
 1
2
 w
e
e
k
s
A
lle
g
ri
n
i 
2
0
0
9
It
a
ly
1
8
0
 c
h
ro
n
ic
 b
a
c
k
 p
a
in
 p
a
ti
e
n
ts
 
(g
ro
u
p
 1
=
6
0
, 
g
ro
u
p
 2
=
6
0
, 
g
ro
u
p
 
3
=
6
0
);
 m
e
a
n
 a
g
e
 (
S
D
)=
5
1
.0
 
(1
4
.8
) 
y
e
a
rs
; 
4
3
%
 m
a
le
G
ro
u
p
 1
: 
P
ir
o
x
ic
a
m
 p
a
tc
h
 1
4
 m
g
 d
a
ily
; 
G
ro
u
p
 2
: 
P
ir
o
x
ic
a
m
 1
%
 c
re
a
m
, 
1
.4
 g
 d
a
ily
; 
G
ro
u
p
 3
: 
P
la
c
e
b
o
 p
a
tc
h
E
n
o
lic
 a
c
id
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
9
 d
a
y
s
97
H
e
rr
m
a
n
n
 
2
0
0
9
G
e
rm
a
n
y
1
7
1
 s
c
ia
ti
c
a
 p
a
ti
e
n
ts
 (
g
ro
u
p
 
1
=
5
7
, 
g
ro
u
p
 2
=
5
7
, 
g
ro
u
p
 3
=
5
7
);
 
m
e
a
n
 a
g
e
 (
S
D
)=
4
9
.7
 (
1
3
.4
) 
y
e
a
rs
; 
4
4
%
 m
a
le
G
ro
u
p
 1
: 
L
o
rn
o
x
ic
a
m
 8
 m
g
, 
2
 c
a
p
s
u
le
s
, 
o
n
c
e
 d
a
ily
 p
lu
s
 1
 c
a
p
s
u
le
 a
ft
e
r 
8
 h
o
u
rs
, 
2
4
 m
g
 t
o
ta
l 
fo
r 
1
 d
a
y
, 
th
e
n
 2
 c
a
p
s
u
le
s
, 
o
n
c
e
 d
a
ily
, 
1
6
 m
g
 t
o
ta
l 
fo
r 
3
 d
a
y
s
; 
G
ro
u
p
 2
: 
D
ic
lo
fe
n
a
c
 5
0
 m
g
, 
1
 t
a
b
le
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 o
n
c
e
 d
a
ily
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5
0
 m
g
 t
o
ta
l 
fo
r 
1
 d
a
y
, 
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e
n
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 t
a
b
le
t,
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 t
im
e
s
 d
a
ily
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1
5
0
 m
g
 t
o
ta
l 
fo
r 
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 d
a
y
s
; 
G
ro
u
p
 3
: 
O
ra
l 
p
la
c
e
b
o
E
n
o
lic
 a
c
id
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A
c
e
ti
c
 a
c
id
P
a
in
 (
1
0
0
 m
m
 V
A
S
);
 A
d
v
e
rs
e
 
e
ff
e
c
ts
; 
a
t 
4
 d
a
y
s
H
s
ie
h
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0
1
0
T
a
iw
a
n
1
5
3
 n
e
c
k
 p
a
in
 p
a
ti
e
n
ts
 (
g
ro
u
p
 
1
=
9
7
, 
g
ro
u
p
 2
=
5
6
);
 m
e
a
n
 a
g
e
 
(S
D
)=
3
8
.4
 (
1
0
.7
) 
y
e
a
rs
; 
1
7
%
 
m
a
le
G
ro
u
p
 1
: 
D
ic
lo
fe
n
a
c
 p
a
tc
h
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0
 m
g
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h
y
d
ro
p
h
ili
c
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d
h
e
s
iv
e
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 t
im
e
s
 d
a
ily
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1
8
0
 m
g
 t
o
ta
l;
 G
ro
u
p
 2
: 
P
la
c
e
b
o
 p
a
tc
h
e
s
A
c
e
ti
c
 a
c
id
P
a
in
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1
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 c
m
 V
A
S
);
 D
is
a
b
ili
ty
 
(N
D
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; 
A
d
v
e
rs
e
 e
ff
e
c
ts
; 
a
t 
1
 w
e
e
k
K
a
tz
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1
1
U
n
it
e
d
 
S
ta
te
s
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9
 c
h
ro
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 b
a
c
k
 p
a
in
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a
ti
e
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ts
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u
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g
ro
u
p
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);
 m
e
a
n
 
a
g
e
 (
S
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2
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 (
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4
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) 
y
e
a
rs
; 
5
0
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m
a
le
G
ro
u
p
 1
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N
a
p
ro
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e
n
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0
0
 m
g
, 
1
 t
a
b
le
t,
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 t
im
e
s
 d
a
ily
, 
1
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0
 m
g
 t
o
ta
l;
 
G
ro
u
p
 2
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Figure S1. Risk of bias graph showing review authors' judgments about each risk of bias domain
presented as percentages across placebo-controlled trials on efficacy of NSAIDs for spinal pain
103
Figure S2. Risk of bias summary showing review authors' judgements about each risk of bias domain 
in placebo-controlled trials on efficacy of NSAIDs for spinal pain. Randomized trials are listed 
alphabetically by author name 
104
Figure S3. Funnel plot. Plot of effect size between NSAIDs and placebo versus their respective 
standard error. Each circle represents one trial 
105
CHAPTER SIX
Patients with sciatica still experience pain and disability 5 years after surgery: a
systematic review with meta-analysis of cohort studies
Chapter Six has been published as:
Machado GC, Witzleb AJ, Fritsch C, et al. Patients with sciatica still experience pain and 
disability 5 years after surgery: a systematic review with meta-analysis of cohort studies. Eur J 
Pain 2016;20:1700-09. Copyright © 2016, European Pain Federation. Reprinted with 
permission from John Wiley and Sons.
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Abstract
Background and objective: The clinical course of patients with
sciatica is believed to be favourable, but there is conflicting evidence on
the postoperative course of this condition. We aimed to investigate the
clinical course of sciatica following surgery.
Databases and data treatment: An electronic search was conducted
on MEDLINE, EMBASE and CINAHL from inception to April 2015. We
screened for prospective cohort studies investigating pain or disability
outcomes for patients with sciatica treated surgically.
Fractional polynomial regression analysis was used to generate pooled
means and 95% confidence intervals (CI) of pain and disability up to
5 years after surgery. Estimates of pain and disability (converted to a
0–100 scale) were plotted over time, from inception to last available
follow-up time.
Results: Forty records (39 cohort studies) were included with a total of
13,883 patients with sciatica. Before surgery, the pooled mean leg pain
score was 75.2 (95% CI 68.1–82.4) which reduced to 15.3 (95% CI 8.5–
22.1) at 3 months. Patients were never fully recovered in the long-term
and pain increased to 21.0 (95% CI 12.5–29.5) at 5 years. The pooled
mean disability score before surgery was 55.1 (95% CI 52.3–58.0) and
this decreased to 15.5 (95% CI 13.3–17.6) at 3 months, and further
reduced to 13.1 (95% CI 10.6–15.5) at 5 years.
Conclusions: Although surgery is followed by a rapid decrease in pain
and disability by 3 months, patients still experience mild to moderate
pain and disability 5 years after surgery.
What does this review add?: This review provides a quantitative
summary of the postoperative course of patients with sciatica. Patients
with sciatica experienced a rapid reduction in pain and disability in
the first 3 months, but still had mild to moderate symptoms 5 years
after surgery. Although no significant differences were found,
microdiscectomy showed larger improvements compared to other
surgical techniques.
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1. Introduction
The term sciatica, although considered controversial
(Fairbank, 2007), is widely used to define
lumbosacral radicular syndrome or radiating pain
below the knee (Koes et al., 2007). Sciatica affects
10–25% of the general population every year
(Konstantinou and Dunn, 2008), and compared to
patients with low back pain, sciatica is characterized
by more intense pain and disability, and worse
symptoms in the lower limb than the spine
(Frymoyer, 1988). As a result, patients with sciat-
ica consume more health care resources than
patients with low back pain alone, most of which is
used to cover its surgical management (Selim et al.,
1998).
Surgical procedures for sciatica generally focus on
removal of disc herniation, the most common
procedure being discectomy, performed with or
without magnifying tools, or minimally invasive
techniques (Gibson and Waddell, 2007). Discec-
tomy is the most common neurosurgical procedure
in the United States, where nearly 300,000 proce-
dures are performed each year (Bruske-Hohlfeld
et al., 1990). Although a favourable prognosis has
been attributed to sciatica (van Tulder et al., 2010),
to date there are no meta-analyses investigating the
course of this condition in surgically treated
patients.
The favourable prognosis attributed to sciatica is
largely based on data from randomized controlled
trials (Koes et al., 2007), which have strict inclusion
criteria and aim to evaluate the efficacy of
interventions, thus are rarely designed to investi-
gate the long-term clinical course of a condition.
Current systematic reviews of cohort studies
specifically designed to assess the prognosis of
sciatica have been limited to identifying the prog-
nostic factors associated with outcomes of interest
in non-surgically treated sciatica (Ashworth et al.,
2011; Verwoerd et al., 2013). These reviews
usually fail to provide any quantitative summary
of the clinical course of sciatica in terms of pain
or disability and therefore are in general
inconclusive.
The aim of this systematic review was to investi-
gate the clinical course of pain and disability in
patients that underwent surgery for sciatica and
were included in prospective cohort studies. We also
investigated whether different surgical techniques
showed similar courses.
2. Methods
2.1 Literature search
This review was prospectively registered with PROS-
PERO (registration number CRD42014015225), and
we followed the MOOSE statement for reporting sys-
tematic reviews of observational studies (Stroup
et al., 2000). We performed a systematic search of
MEDLINE, CINAHL and EMBASE databases from
inception to April 2015. A combination of relevant
keywords was used to construct our search strategy
and included terms such as sciatica, radiculopathy,
ischialgia, disc herniation, disc hernia, course, prog-
nosis, and cohort. The full search strategy is pre-
sented in Appendix S1. One author (CF) conducted
the first screening based on titles and abstract, and
two authors (GCM and AJW) selected relevant stud-
ies based on full text evaluation. We also performed
citation tracking of relevant systematic reviews and
of the reference list from included studies. Consen-
sus was used to resolve any disagreements.
2.2 Selection of studies
We included only cohort studies investigating the
course of patients with sciatica treated surgically in
terms of pain and disability with a minimum of
three months follow-up. To be eligible, the study
had to explicitly report that participants had sciatica
or leg pain below the knee or other synonym for sci-
atica. Sciatica could be caused by disc herniation or
degenerative disc diseases. The following synonyms
were considered: radiculopathy, radicular pain, nerve
root compromise, nerve root compression, lum-
bosacral radicular syndrome, nerve root pain, and
nerve root entrapment. Cohorts of mixed groups of
patients with low back pain were eligible when it
was possible to clearly identify a subgroup with sciat-
ica, and data only from these participants were
included in the analysis. Studies analysing acute,
subacute and/or chronic sciatica were also included
in the review. There was no restriction related to the
source of patients, intensity or duration of symp-
toms. Studies were included only if reporting pain or
disability outcomes as continuous variables, and
were a full report. We included only studies pub-
lished in English, German, Spanish and Portuguese
in this review. Studies including patients with seri-
ous spinal conditions (e.g. cancer, infectious diseases,
cauda equina syndrome), cervical radiculopathy,
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spondylolisthesis or spinal canal stenosis were
excluded as these conditions present different clinical
courses. Prospective cohorts nested in randomized
clinical trials were also excluded, as well as case
reports or case series. Studies investigating patients
undergoing repeat surgery for sciatica were not
included in this review.
2.3 Data extraction and quality assessment
Using a standardized data extraction form, two
reviewers (GCM and AJW) extracted study charac-
teristics (details of participants, sample source, type
of surgery, outcomes, follow-up times, and inception
time) and a third author (MLF) resolved any dis-
agreement. For pain and disability outcomes, mea-
sures of central tendency (mean or median) and
dispersion (standard deviation, standard error, or
95% confidence intervals) were extracted for each
assessment, including baseline and all available fol-
low-ups. Authors of included studies were contacted
by email when included studies reported incomplete
or missing data. We only used data reported in the
included studies, i.e. no imputation was performed.
For most studies, pain intensity was defined as leg
pain or radicular pain. When these outcomes were
not reported, we included measures of lower back
and leg pain, or overall pain. Pain scores were
reported in numerical rating scales (range, 0–10) or
visual analogue scales (range, 0–100). Disability
scales included the Oswestry Disability Index (range,
0–100) and the Roland–Morris Disability Question-
naire (range, 0–24). Both pain and disability scores
were converted to a common 0 (no pain or disabil-
ity) to 100 (maximum pain or disability) scale.
Methodological quality of the included studies was
assessed by two independent reviewers using an
adaptation of the methodological criteria suggested
by Altman (2001). These criteria relate to sampling
(2 items), completeness of follow-up (1 item), and
description of prognostic outcomes (1 item). These
criteria have been used by other systematic reviews
of observational studies (Pengel et al., 2003; Kamper
et al., 2008; da C Menezes Costa et al., 2012). Stud-
ies were considered at low risk of bias when they
fulfilled at least three of the criteria.
2.4 Data synthesis and analysis
Pain and disability were modelled as a function of
time, and time was defined as time since surgery.
Each study received a weight corresponding to the
inverse of the mean-squared standard error of the
estimates from the included studies. Fractional poly-
nomial analysis using generalized estimating equa-
tions was used to calculate pooled mean and 95%
confidence interval estimates for pain and disability
at baseline and at 1, 3, 6, 12, 24, and 60-month fol-
low-ups. (Royston and Sauerbrei, 2008). STATA ver-
sion 13 (StataCorp LP, College Station, TX, USA)
was used for all analyses.
2.5 Secondary exploratory analysis
A secondary exploratory analysis including only
studies that were classified as low risk of bias (stud-
ies that fulfilled at least three quality criteria) was
conducted. To identify if different surgical techniques
had similar clinical courses, we stratified our main
analysis based on the types of surgical technique.
For this, we conducted a subgroup analysis of studies
that used open discectomy, microdiscectomy, endo-
scopic discectomy, or nucleoplasty. An interaction
analysis was performed to test for statistically signifi-
cant differences between the courses of different sur-
gical techniques, and also to generate p-values for
interaction.
3. Results
We screened a total of 10,525 records, and after
excluding irrelevant studies based on titles and
abstracts we assessed 259 full text articles (Fig. 1).
Forty publications reporting on 39 cohort studies
were included in our review (Astrand et al., 2000;
Asch et al., 2002; Putzier et al., 2005; den Boer
et al., 2006; Carragee et al., 2006; Floman et al.,
2007; Guilfoyle et al., 2007; Hakkinen et al., 2007;
Mirzai et al., 2007; Sasani et al., 2007; Al-Zain et al.,
2008; Schaufele, 2008; Wu et al., 2008; Ahn et al.,
2009; Lierz et al., 2009; Schick and Elhabony, 2009;
Ebrahim et al., 2010; Johansson et al., 2010; Moran-
jkic et al., 2010; Ohtori et al., 2010; Peng et al.,
2010; Azzazi et al., 2011; Casal-Moro et al., 2011;
Cho et al., 2011; Choi et al., 2011; Chumnanvej
et al., 2011; Lebow et al., 2011a,b; Lee and Lee,
2011; Lee et al., 2011, 2015; Nie et al., 2011; Wang
et al., 2011; Dedering, 2012; Righesso et al., 2012;
Shabat et al., 2012; Crockett et al., 2014; Ratsep
et al., 2014; Sencer et al., 2014; Lagerback et al.,
2015). One cohort study reported the 12- and 24-
month follow-up results after surgery in two publi-
cations (Lebow et al., 2011a,b). Overall, the included
cohort studies investigated the prognosis of 13,883
patients with sciatica from 19 countries and included
follow-ups for up to 5 years. Patients were mainly
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diagnosed with lumbar disc herniation (36 studies,
92%) and three studies included patients with disco-
genic pain (no disc herniation present on imaging)
or lumbosacral radicular syndrome. Types of surgical
procedures varied across studies and were classified
as open discectomy (13 studies, 33%), microdiscec-
tomy (eight studies, 21%), endoscopic discectomy
(10 studies, 25%), and nucleoplasty (eight studies,
21%). Only two studies did not report inception
time (i.e. time when participants were assessed
before surgery). In 34 studies (87%), baseline assess-
ments were performed preoperatively, and two stud-
ies used 2 and 6 weeks prior to surgery as the
inception. The characteristics of included studies and
participants are described in Table S1.
3.1 Methodological quality
Only 17 studies fulfilled at least three quality criteria
and were considered as low risk of bias. Twenty-four
studies (62%) reported the source of participants
and described the inclusion and exclusion criteria.
Only 36% of the included studies clearly reported
selecting a representative sample of participants with
sciatica, i.e. consecutive or random sampling at a
common point in the course of the disease. About
three quarters of the cohorts had data available for
over 80% of participants at any one time point, and
62% reported an appropriate analysis (including
statistical adjustments for important prognostic fac-
tors). Fig. 2 summarizes the number of studies
Figure 1 Flow diagram of studies included in the systematic review.
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fulfilling each quality criterion. The risk of bias
assessment for each study is presented in Table S1.
3.2 The clinical course of sciatica after surgery
We included 27 studies with complete data (i.e.
studies reporting means and standard deviations) in
the meta-analysis on the course of leg pain intensity.
Overall, patients experienced a large reduction in leg
pain intensity in the first 3 months. Before surgery,
the pooled mean leg pain was 75.2 (95% CI 68.1–
82.4) and this became reduced to 15.3 (95% CI 8.5–
22.1) at 3 months. After 3 months, leg pain
remained stable till 6 months post-surgery (15.1,
95% CI 8.6–21.6), however, it increased progres-
sively after that, to 16.2 (95% CI 9.7–22.7) at
12 months, 18.0 (95% CI 11.0–25.1) at 24 months,
and 21.0 (95% CI 12.5–29.5) at 5 years follow-up
(Fig. 3C).
A total of 24 studies were included in the meta-ana-
lysis for disability. A marked improvement occurred
in the first 3 months. On average, patients had severe
disability at inception with a pooled mean disability
score of 55.1 (95% CI 52.3–58.0). Disability scores
reduced to 15.5 (95% CI 13.3–17.6) at 3 months
(15.5, 95% CI 13.3–17.6), with a further reduction to
14.2 (95% CI 12.0–16.5) at 6 months, 13.6 (95% CI
11.3–16.0) at 12 months, 13.3 (95% CI 10.8–15.7) at
24 months, reaching 13.1 (95% CI 10.6–15.5) at
5 years follow-up (Fig. 3D).
3.3 Secondary exploratory analyses
In our secondary exploratory analyses, we found
that studies with low risk of bias (n = 17) showed
lower pain scores throughout the course of the con-
dition compared to all studies, and a similar course
for disability (Fig. 4). We also investigated whether
different surgical techniques would result in similar
prognosis. We could not model the disability data for
endoscopic discectomy studies because of converge
problems. Overall, microdiscectomy showed lower
pain and disability scores overtime compared to
other surgical techniques. At 1 month after surgery,
microdiscectomy reduced leg pain to 12.7 (95% CI
5.1–20.4) and disability to 13.3 (95% CI 10.7–15.8),
with scores continuing to reduce up to 24 months
(Fig. 4). On average, we found a difference of 3.6
points across different surgical techniques in terms of
pain intensity; however, our interaction analysis
showed that this difference is not statistically signifi-
cant (p = 0.60). Similarly, no difference was found
for disability status between surgical techniques
(p = 0.24), confirming different techniques have a
similar prognosis in terms of disability.
4. Discussion and Conclusions
In this systematic review, we quantified the clinical
course of pain and disability over time based upon
39 prospective cohort studies (n = 13,883) enrolling
patients with sciatica managed by surgery. Our
meta-analyses showed that symptoms decrease
markedly in the first 3 months after surgery, but
patients never experienced full resolution of pain or
disability in the long-term. Patients treated with
microdiscectomy showed lower scores for pain and
disability over time compared to other surgical tech-
niques, though this difference was not statistically
significant.
This is the first systematic review to quantitatively
synthesize the course of pain and disability outcomes
after surgery for sciatica by including only prospec-
tive cohort studies with long-term follow-up. We
included 39 cohort studies in our review, of which
27 provided data to be included in the meta-analysis,
totalling nearly 14,000 patients with sciatica. Most of
Figure 2 Methodological quality and number of studies in each category.
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the studies excluded from the analyses did not pro-
vide measures of variability (standard deviation or
standard error), and attempts to have access to these
data from authors were unsuccessful. Previous sys-
tematic reviews investigating the prognosis of sciatica
have included patients treated non-surgically and
mainly focused on summarizing the role of prognos-
tic factors (e.g. age, gender, smoking, previous his-
tory of sciatica) on outcomes of interest (Ashworth
et al., 2011; Verwoerd et al., 2013). Our systematic
review adds important information on the prognosis
of patients with sciatica treated surgically, and can
be used to guide clinical decision making by sur-
geons and patients.
Our review reports pooled scores of pain and dis-
ability on scales of 0–100 points to provide easily
interpretable results for clinicians and patients. Pain
outcomes were generally reported in individual stud-
ies on numeric rating scales (range, 0–10) or visual
analogue scales (range, 0–100). Most of the included
studies (n = 36, 90%) reported leg pain intensity
measures as the outcome. Two studies assessed lower
back with radicular/leg pain (Putzier et al., 2005;
Peng et al., 2010). One study reported measuring
discogenic pain (Lee et al., 2015), but it was not
clear if this was a measure of leg or low back pain.
Another study including only patients with sciatica
used the body pain subscale of the SF-36 scale as the
outcome measure (Dedering, 2012). Disability out-
comes were usually reported as Oswestry Disability
Index (range, 0–100) or the Roland–Morris Disability
Questionnaire (range, 0–24) scores. Previous studies
Figure 3 Postoperative course of patients with sciatica. The raw data for (A) pain and (B) disability from studies included in the meta-analysis.
Each line joins data from a single study, and point estimates and its 95% confidence interval are also shown. Same raw data with filled circles rep-
resenting mean (C) pain and (D) disability scores reported at a specific time point. The regression line represents pooled mean and the shaded
area circumscribes its 95% confidence intervals. Fractional polynomial regression modelling was used to fit the data.
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have shown that these scales are highly correlated
and can be used interchangeably when transformed
(Leclaire et al., 1997; Hjermstad et al., 2011).
Our review also presents limitations. Only 17 stud-
ies (44%) met at least three quality assessment crite-
ria and were considered low risk of bias. Our
sensitivity analysis, however, showed that studies
with low risk of bias reported slight less pain scores
following surgery, compared to all studies, and a
similar course for disability. Differences on pain
scores were, however, not statistically significant.
The main methodological flaw in the included stud-
ies was failure to recruit a representative sample,
with only about a third of the studies reporting
appropriate sampling methods. About 30% of
included studies had very small sample sizes (50 par-
ticipants or less), and around 35% did not report an
appropriate analysis or defined the sample by clearly
stating the inclusion and exclusion criteria. Further-
more, none of the included studies reported if partic-
ipants had neuropathic pain characteristics, such as
dysaesthesia (impaired sensation) and allodynia
(pain resulting from a stimulus which would not
normally provoke pain). Previous research has
shown that higher scores of neuropathic pain and
the presence of neuropathic pain features are associ-
ated with persistent postoperative leg pain (Shamji
and Shcharinsky, 2016). It is unclear if included
studies are screened for these characteristics, and
could have potentially included participants more
likely to develop failed back surgery syndrome.
Another limitation of this review includes the impos-
sibility of evaluating the role of patient-level predic-
tors on pain and disability outcomes after surgery, as
we could not access individual patient data.
Open discectomy is commonly performed in
patients with sciatica, and consists of the surgical
removal of herniated disc material responsible for
nerve root or spinal cord compression (Mixter and
Barr, 1934). Although no significant differences in
the course of pain and disability for different surgical
techniques were found, patients treated with open
discectomy showed the least improvement (58%) in
pain intensity in the first 6 months, and still experi-
enced moderate disability after 2 years (ODI disabil-
ity score > 20 points). Microdiscectomy is considered
as a technical modification of open discectomy, but
with a smaller incision and less dissection, and
involves the use of an operating microscope or other
magnifying tools (Williams, 1978). In our review,
this technique showed the largest improvement in
pain (89%) and disability (77%) 6 months after sur-
gery, but no further significant improvements
occurred after that. Endoscopic discectomy has been
originally proposed to further decrease surgical com-
plications and speed recovery (Kambin and Savitz,
2000). Endoscopic surgery studies showed on aver-
age 83% pain reduction at 6-month follow-up, but
pain increased 45% after this and patients still expe-
rienced mild to moderate pain intensity at 5 years
follow-up (19.5, 95% CI 11.0–28.0). Nucleoplasty is
an alternative to open surgery and uses bipolar
radiofrequency energy to reduce intradiscal pressure
(Sharps and Isaac, 2002). Our meta-analysis showed
that patients treated with nucleoplasty had an aver-
age 66% reduction in pain and 50% reduction in
disability in the first month, but plateau after this.
Figure 4 Secondary exploratory analyses. The line of best fit for each
surgical technique (open discectomy in red, microdiscectomy in blue,
endoscopic discectomy in orange, and nucleoplasty in green) is
shown. The line of best fit derived from the primary meta-analysis
(grey line) and its 95% confidence interval (shaded grey), as well as the
line of best fit derived from studies with low risk of bias (RoB, dashed
line), are also shown.
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The evidence for the effectiveness of surgery for
sciatica over its natural course is still limited – no
surgical placebo-controlled trials have ever been
conducted in patients with sciatica and previous ran-
domized trials have shown no significant differences
in pain intensity between surgery and usual conser-
vative care at 2-year (mean difference 3.2, !2.0 to
8.4) or at 5-year follow-up (mean difference !2.7,
95% CI !8.4 to 2.9) (Weinstein et al., 2006; Lequin
et al., 2013). It is unclear, therefore, whether the
changes in pain and disability observed in our
review are associated with treatment itself or if a
result of surgery-associated placebo effects, or even
the condition’s natural course.
In conclusion, this review investigated the course
of pain and disability after surgery in patients with
sciatica. The results from our meta-analyses revealed
that on average patients experience rapid improve-
ments in the first 3 months following surgery, but
still report mild to moderate pain and disability at
5 years. Microdiscectomy showed larger improve-
ments compared to other surgical techniques,
though no significant differences were found. This
review is paramount for planning surgical interven-
tions in this population and should be used to
inform patients and clinicians of likely long-term
prognosis of sciatica in terms of pain and disability.
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Medline
1. exp sciatic neuropathy/
2. sciatic neuropath$.mp.
3. sciatic neuralgi$.mp.
4. sciatic pain$.mp.
5. sciatic hernia$.mp.
6. sciatic paraly$.mp.
7. sciatica/
8. sciatic$.mp.
9. ischialg$.mp.
10. piriformis.mp.
11. intervertebral disk displac$.mp.
12. herniated disk$.mp.
13. slipped disk.mp.
14. prolapsed disk.mp.
15. disk prolap$.mp.
16. disk hernia$.mp.
17. intervertebral disc displac$.mp.
18. herniated disc$.mp.
19. slipped disc.mp.
20. prolapsed disc$.mp.
21. disc prolap$.mp.
22. disc hernia.mp.
23. radicular syndr$.mp.
24. radiculopathy$.mp.
25. OR (1–24)
26. lumbosacral.mp.
27. lumbal.mp.
28. lumbar.mp.
29. OR (26–28)
30. 29 AND 25
31. exp cohort studies/
32. incidence/
33. follow-up study.mp.
34. prognos$.mp.
35. predict$.mp.
36. course.mp.
37. survival.mp.
38. logistic.mp.
39. Cox.mp.
40. life tables.mp.
41. log rank.mp.
42. OR (31–41)
43. 30 AND 42
44. human/ not animal/
45. 43 AND 44
46. editorial/
47. case report/
48. letter/
49. OR (46–48)
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49. 45 NOT 49
CINAHL
1. sciatic neuropath*
2. sciatic neural*
3. sciatic pain*
4. sciatic hernia*
5. sciatic paraly*
6. sciatica
7. sciatic*
8. ischial*
9. piriformis
10. intervertebral disk displac*
11. herniated disk*
12. slipped disk*
13. prolapsed disk*
14. disk prolap*
15. disk hernia*
16. intervertebral disc displac*
17. herniated disc*
18. slipped disc*
19. prolapsed disc*
20. disc prolap*
21. disc hernia*
22. radicular syndr*
23. radiculopath*
24. OR (1–23)
25. lumbosacral
26. lumbal
27. lumbar
28. OR (25–27)
29. 24 AND 28
30. (MH "Prospective Studies+")
31. mh incidence OR "predic*"
32. (MH "prognosis+")
33. "course"
34. (MH "Survival Analysis+")
35. (MH "Cox Proportional Hazards Model")
36. (MH "Logistic Regression+")
37. (MH "Log-Rank Test")
38. OR (30–37)
39. 38 and 29
40. MH human NOT MH animals
41. 39 and 40
42. prospective* NOT case report* letter* editorial*
43. 41 AND 42
Embase
1. sciatic NEAR/1 neuropath*
2. sciatic* NEAR/3 (neuralgi* OR pain* OR hernia* OR paraly* OR paresthe* OR paraesthe*)
3. ‘sciatica’/exp OR sciatica
4. ‘sciatics’ OR sciatics
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5. ischialg*
6. piriformis
7. lumbar AND disk AND hernia*
8. 'intervertebral disk hernia'/syn OR ‘intervertebral disk hernia’
9. (hernia* OR slipped OR prolaps*) NEAR/3 (disk* OR disc*)
10. radicular NEAR/1 syndr*
11. radiculopath*
12. lumbosacral OR lumba*
13. OR (1–11)
14. 12 AND 13
15. ('cohort analysis'/exp AND [embase]/lim)
16. ('incidence'/exp AND [embase]/lim)
17. ('follow up'/exp OR 'follow up' AND [embase]/lim)
18. ('prognosis'/exp OR prognos* AND [embase]/lim)
19. ('prediction'/exp OR predict* AND [embase]/lim)
20. ('disease course'/exp OR 'course' AND [embase]/lim)
21. ('survival'/exp OR 'survival' AND [embase]/lim)
22. ('logistic regression analysis'/exp OR 'logistic' AND [embase]/lim)
23. ('proportional hazards model'/exp OR 'cox' AND [embase]/lim)
24. ('life table'/exp OR 'life table' OR 'life tables'/exp OR 'life tables' AND [embase]/lim)
25. ('log rank test'/exp OR 'log rank' AND [embase]/lim)
26. OR (15–25)
27. 14 AND 26
28. 'animals'/exp OR animals NOT ('humans'/exp OR humans)
29. 27 NOT 28
30. case NEAR/1 report*
31. editorial*
32. letter*
33. OR (30–32)
33. 29 NOT 33
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Table S2 Risk-of-bias assessment of the included studies
Study
Defined 
Samplea
Representative 
Sampleb
Adequate 
Follow-upc
Appropriate Analysisd
Ahn, 2009 Yes No No No
Al-Zain, 2008 No No Yes No
Asch, 2002 Yes No No Yes
Astrand, 2000 No Yes Yes No
Azzazi, 2011 No No Yes Yes
Carragee, 2006 Yes Yes Yes Yes
Casal-Moro, 2011 Yes Yes Yes Yes
Cho, 2011 No No Yes Yes
Choi, 2011 No No Yes Yes
Chumnanvej, 2011 Yes Yes Yes No
Crockett, 2014 Yes Yes Yes No
Dedering, 2012 No Yes Yes Yes
den Boer, 2006 Yes No Yes No
Ebrahim, 2010 No No Yes No
Floman, 2007 Yes No No No
Guilfoyle, 2007 Yes No No Yes
Hakkinen, 2007 Yes No Yes Yes
Johansson, 2010 Yes No Yes Yes
Lagerback, 2015 Yes Yes No Yes
Lebow, 2011 No No No Yes
Lebow, 2011 No No Yes Yes
Lee, 2011 Yes Yes Yes Yes
Lee-a, 2015 Yes No No No
Lee-b, 2011 Yes Yes Yes Yes
Lierz, 2009 Yes Yes No No
Mirzai, 2007 Yes Yes Yes Yes
Moranjkic, 2010 Yes No Yes Yes
Nie, 2011 Yes No Yes Yes
Ohtori, 2010 No No Yes Yes
Peng, 2010 No No No No
Putzier, 2005 No No Yes No
Ratsep, 2014 Yes Yes Yes No
Righesso, 2012 Yes No Yes Yes
Sasani, 2007 No No Yes Yes
Schaufele, 2008 Yes No Yes Yes
Schick, 2009 No No Yes No
Sencer, 2014 Yes Yes No Yes
Shabat, 2012 No No Yes No
Wang, 2011 No No Yes No
Wu, 2008 Yes Yes Yes Yes
aSource of participants and sample selection described.
bConsecutive or random sampling of participants gathered at a common point in the course of the disease.
cOutcome data available for at least 80% of participants at 1 follow-up point.
dIncluding statistical adjustments for important prognostic factors.
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Abstract
Background
The management of spinal stenosis by surgery has increased rapidly in the past two de-
cades, however, there is still controversy regarding the efficacy of surgery for this condition.
Our aim was to investigate the efficacy and comparative effectiveness of surgery in the
management of patients with lumbar spinal stenosis.
Methods
Electronic searches were performed on MEDLINE, EMBASE, AMED, CINAHL, Web of Sci-
ence, LILACS and Cochrane Library from inception to November 2014. Hand searches
were conducted on included articles and relevant reviews. We included randomised con-
trolled trials evaluating surgery compared to no treatment, placebo/sham, or to another sur-
gical technique in patients with lumbar spinal stenosis. Primary outcome measures were
pain, disability, recovery and quality of life. The PEDro scale was used for risk of bias as-
sessment. Data were pooled with a random-effects model, and the GRADE approach was
used to summarise conclusions.
Results
Nineteen published reports (17 trials) were included. No trials were identified comparing
surgery to no treatment or placebo/sham. Pooling revealed that decompression plus fusion
is not superior to decompression alone for pain (mean difference –3.7, 95% confidence in-
terval –15.6 to 8.1), disability (mean difference 9.8, 95% confidence interval –9.4 to 28.9), or
walking ability (risk ratio 0.9, 95% confidence interval 0.4 to 1.9). Interspinous process spac-
er devices are slightly more effective than decompression plus fusion for disability (mean
PLOSONE | DOI:10.1371/journal.pone.0122800 March 30, 2015 1 / 18
OPEN ACCESS
Citation: Machado GC, Ferreira PH, Harris IA,
Pinheiro MB, Koes BW, van Tulder M, et al. (2015)
Effectiveness of Surgery for Lumbar Spinal Stenosis:
A Systematic Review and Meta-Analysis. PLoS ONE
10(3): e0122800. doi:10.1371/journal.pone.0122800
Academic Editor: Mohammed Shamji, Toronto
Western Hospital, CANADA
Received: November 10, 2014
Accepted: February 13, 2015
Published: March 30, 2015
Copyright: © 2015 Machado et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
128
difference 5.7, 95% confidence interval 1.3 to 10.0), but they resulted in significantly higher
reoperation rates when compared to decompression alone (28% v 7%, P< 0.001). There
are no differences in the effectiveness between other surgical techniques for our main
outcomes.
Conclusions
The relative efficacy of various surgical options for treatment of spinal stenosis re-
mains uncertain. Decompression plus fusion is not more effective than decompression
alone. Interspinous process spacer devices result in higher reoperation rates than bony
decompression.
Introduction
Lumbar spinal stenosis is a narrowing of the spinal canal by surrounding bone and soft tissues
that compromises neural structures. Radiographic findings of spinal stenosis are highly preva-
lent [1], and 85% of patients typically present with significant long-term symptoms of intermit-
tent neurogenic claudication (radicular pain during walking or standing that resolves with
lumbar flexion) [2]. When refractory to conservative treatment, patients are commonly re-
ferred for surgery [3, 4]. As a result, the number of surgical procedures performed for lumbar
spinal stenosis has increased steadily over the years (e.g., the rates of complex fusion surgery
had a 15-fold increase between 2002 and 2007) [5], with costs reaching USD $1.65 billion per
year [6]. However, there is still a substantial variation in the surgical technique chosen by sur-
geons [7, 8], although no clear superiority of one technique over the others has been yet identi-
fied [9–11].
The current evidence suggests that surgery for spinal stenosis is more effective than conser-
vative treatment when the latter has failed for up to six months [12, 13]. For instance, in the
Spine Patient Outcomes Research Trial (SPORT) patients treated surgically reported lower
pain levels compared to patients assigned to nonsurgical care [14]. The gold standard surgical
approach for lumbar spinal stenosis is bony decompression by laminectomy [15, 16]. However,
due to the occurrence of complications associated with this technique [17], less invasive surgi-
cal techniques have been proposed, such as unilateral or bilateral laminotomies [18–20], and
spinous process split–laminectomy [21]. Additionally, as spinal instability is a frequent finding
following bony decompression [22, 23], surgical fusion has been recommended in addition to
decompression of the spinal canal for the management of some patients with spinal stenosis
[24]. However, this practice can be associated with higher reoperation rates, post-surgical com-
plications, and costs when compared to decompression alone [25]. Although many surgical
techniques are available for the management of lumbar spinal stenosis, there seems to be a pau-
city of evidence supporting this rapid evolution of surgical techniques, and clinicians are usual-
ly asked to rely on their own opinions and experiences [26].
Therefore, in this systematic review we aimed to determine the efficacy of surgery in the
management of patients with lumbar spinal stenosis and the comparative effectiveness between
commonly performed surgical techniques to treat this condition.
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Material and Methods
Data sources and search
Weconductedasystematicreviewandmeta-analysisfollowingtherecommendationsofthe
PRISMAstatement[27].Themethodsofthisreviewhavebeenpreviouslyregisteredwith
PROSPERO,numberCRD42013005901.Weperformedasystematicelectronicsearchon
MEDLINE,EMBASE,AMED,CINAHL,WebofScience,LILACSandCochraneCentralReg-
isterofControlledTrialsfromthedateofinceptionuntil/PWFNCFS2014.Thesearchstrategy
isinS1Table.Handsearchesofreferenceswerealsoconductedonrelevantreviewsand
JODMVEFETUVEJFT
Study selection
Two independent reviewers (GM and MP/MR) performed the selection of studies and consen-
sus was used to resolve any disagreement. To be included, studies needed to be full published
randomised controlled trials comparing the efficacy of surgery to no treatment, placebo/sham,
or comparing the effectiveness of different types of surgical procedures. Trials were included if
they explicitly reported that subjects were treated for lumbar spinal stenosis, despite its ana-
tomical classification (central, foraminal or lateral), or diagnostic criteria. There were no re-
strictions regarding intensity or duration of symptoms, language or publication date. Studies of
patients with trauma, tumour, and previous spine surgery were excluded. As degenerative
spondylolisthesis is a common finding in patients with lumbar spinal stenosis, only trials in-
cluding patients with spondylolisthesis greater than grade I were excluded. Review articles,
guidelines, observational studies, trials comparing different types of fusion techniques, and sur-
gery for cervical spine stenosis were also excluded.
Data extraction and quality assessment
Using a standardised extraction form, data from each included study were independently ex-
tracted by two reviewers (GM and MP) and consensus used to resolve any disagreement. The
following information from each study was extracted: participants’ characteristics (age, stenosis
duration and diagnosis criteria), type of surgery and outcome measure. Primary outcomes of
interest were pain (e.g., back pain, leg pain, overall pain), disability (e.g., Oswestry Disability
Index, walking ability), quality of life, and recovery. Quality of life measures of our interest in-
cluded for example total scores of the 36-item short-form health survey (SF-36) or from the
EuroQol questionnaire. However, none of the trials included in our review reported the total
scores of these measures. Instead, they reported scores for the sub-items (e.g., Physical Func-
tion or Physical Component Scores) and therefore could not be included in our analyses. Re-
covery was measured using the differences between preoperative and postoperative Japanese
Orthopaedic Association (JOA) scores and reported in the included trials. Secondary outcomes
included perioperative surgical data (e.g., blood loss, operation time, length of hospitalisation),
complications, reoperations, and costs. To enable cross-trial comparisons, terms used to de-
scribe surgical complications were coded based on previously established standard definitions
for common complications post spine surgery [28]. We extracted sample sizes, means (final
values) and standard deviations for continuous outcomes, and number of cases for dichoto-
mous outcomes. If trials reported incomplete data, authors were contacted for further informa-
tion. If authors were unavailable, missing data were imputed according to recommendations in
the Cochrane Handbook for Systematic Reviews of Interventions [29].
We used the Physiotherapy Evidence Database (PEDro) scale to assess the methodological
quality of the included studies. The PEDro scale is widely used to assess the quality of clinical
Surgery for Spinal Stenosis: A Systematic Review and Meta-Analysis
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trials in various areas of medicine [30], and consists of an 11-item checklist that has been
shown to be a valid and reliable tool [31, 32]. Two raters (GM and MR) independently assessed
the methodological quality of each included study and a third author resolved any disagree-
ment. Trials were considered to be of high methodological quality when the PEDro final score
was!6 points.
Data synthesis and analysis
All data on leg pain, back pain or overall pain were extracted from included trials. If trials re-
ported more than one measure of pain intensity (e.g., back and leg pain), the more severe mea-
sure at baseline was included in the analyses. Pain and disability outcome measures were
converted to scales from 0 (no pain or disability) to 100 (worst possible pain or disability). For
data synthesis, follow-up times were categorized as short-term (less than 12 months) and long-
term (12 months or more). If studies reported multiple time points within each category, the
time point closest to three months for the short-term, and 12 months for the long-term were
used. When more than one scale to measure pain or disability was reported, the one cited by
the authors as the primary outcome was used. When studies reported results for more than
two intervention groups, we combined similar groups according to the recommendations in
the Cochrane Handbook [29].
Trials were grouped according to type of surgery comparison, outcomes, and assessment
time points. We used a random-effects model to calculate mean differences (MD) and 95%
confidence intervals (CI) for continuous measures. For dichotomous outcomes, risk ratio (RR)
and 95% CI was used. Descriptive and inferential statistics were used to present complication
and reoperation rates, with a significance level at 5%. The I2 statistic was used to assess hetero-
geneity between trials, and values higher than 50% were defined to identify high heterogeneity
[33]. Comprehensive Meta-Analysis version 2.2.064 (Englewood, NJ, USA, 2011) was used for
all analyses.
Grading the evidence and applicability
The GRADE (Grading of Recommendations Assessment, Development and Evaluation) sys-
tem was used to assess the overall quality of the evidence and strength of recommendations for
each outcome measure [34]. The quality of evidence was downgraded by one level according to
the following criteria: limitation of study design (> 25% of the studies with low methodological
quality [PEDro score< 6]), inconsistency of results (statistically significant heterogeneity [I2>
50%] or" 75% of trials with findings in the same direction), and imprecision (wide confidence
intervals or total number of participants< 300 for each pooled analysis). The indirectness cri-
terion was not considered in this review because we included a specific population with rele-
vant outcomes and direct comparisons. Where only single trials were available, evidence from
studies with< 300 participants was downgraded for inconsistency and imprecision and rated
as “low quality” evidence. They could be further downgraded to “very low quality” evidence if
limitations of study design were found. The quality of evidence was defined as: “high quality”,
“moderate quality”, “low quality”, and “very low quality” [34].
Results
Study characteristics
A total of 7,284 records were identified. After excluding duplicates 5,148 titles and abstracts
were reviewed, and 168 full text records were assessed. Of these, 19 published reports (17 ran-
domised controlled trials) remained eligible for inclusion in our review [9–11, 35–50]. Flow
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chart diagram of included studies with the main reasons for exclusion are shown in Fig 1. Two
records reported results from the same trial, a subgroup analysis and overall results [48, 49].
Therefore, only the full report was included in our analysis. One trial was published in English
as well as in German [9, 50], and as they reported similar results we included the English publi-
cation in our analyses. All remaining trials included in this review were published in English
and therefore no translation was required.
Participant characteristics
The 17 included trials investigated a total of 1,554 patients and most studies defined lumbar
spinal stenosis based on clinical assessment with a concordant imaging diagnosis [9–11, 36–38,
40–47, 49]. One study included patients based solely on imaging diagnosis [35], and another
study used clinical assessment only [39]. Fourteen out of 17 trials (82%) explicitly reported in-
cluding only patients who had failed to improve with conservative treatment [9–11, 36–38, 40–
43, 45–47, 49]. The characteristics of included studies and participants are described in
Table 1.
Quality assessment
The methodological quality of the included trials revealed a mean score of 5.5 (standard devia-
tion 1.8) using the PEDro scale (range, 0 to 10 score). The most common methodological flaws
were lack of blinding (therapist, patient and assessor) and failure to use an intention-to-treat
analysis. The three studies that blinded the patients reported that all patients gave informed
consent and only one trial described that patients were informed about the operation, timing,
Fig 1. Flow Diagram of Studies Included in the Systematic Review. RCT = randomised controlled trial.
*Number of citations includes duplicates.
doi:10.1371/journal.pone.0122800.g001
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Table 1. Characteristics of Included Studies.
Study Details of Participants Surgery Type Outcomes (Time Point)
Decompression v Decompression+Fusion
Bridwell et al,
1993
44 patients (G1 = 10, G2 and G3
combined = 34); Mean age (range): 66.1
(46–79) years; Stenosis duration: NR
G1: Decompression; G2: Decompression
plus fusion; G3: As G2 with instrumentation
Walking ability, complications,
reoperations; at mean follow-up of 3.1
years
Grob et al,
1995
45 patients (G1 = 15, G2 and G3
combined = 30); Mean age (range): 67 (48–
87) years; Stenosis duration: NR
G1: Decompression; G2: Decompression
plus fusion (most stenotic segment); G3: As
G2 (all stenotic segments)
VAS (overall pain), walking ability,
operation time, blood loss, complications,
reoperations; at 24 months
Hallet et al,
2007
44 patients (G1 = 14, G2 and G3
combined = 30); Mean age (range): 57 (34–
75) years; Stenosis duration: NR
G1: Decompression; G2: Decompression
plus instrumented postero-lateral fusion; G3:
As G2 plus transforaminal interbody fusion
VAS (back pain), RMDQ, operation time,
blood loss, reoperations, costs; at 24
months
Laminectomy v Laminotomy
Postacchini
et al, 1992
67 patients (G1 = 35, G2 = 32); Mean age
(range): 57 (43–79) years; Stenosis
duration: NR
G1: Multiple laminotomy; G2: Laminectomy VAS (leg pain, radicular symptoms),
operating time, blood loss, complications;
at mean follow-up of 3.7 years
Thome et al,
2005
120 patients (G1 and G2 combined = 80,
G3 = 40); Mean age (SD): 68 (9) years;
Mean stenosis duration (SD): 20.2 (29.7)
months
G1: Bilateral laminotomy; G2: Unilateral
laminotomy; G3: Laminectomy
VAS (overall pain), RMDQ, walking
distance, duration of operation, blood
loss, complications, reoperations; at 3
and 12 months
Cavusoglu
et al, 2007
100 patients (G1 = 50, G2 = 50); Mean age
(SD): 69.2 (12.2) years; Stenosis duration: 8
to 60 months
G1: Unilateral laminectomy; G2: Unilateral
laminotomy
SF-36 body pain, ODI, complications; at
3 months and 4 to 7 years
Celik et al,
2010
80 patients (G1 = 40, G2 = 40); Mean age
(SD): G1 = 61 (13), G2 = 59 (14) years;
Stenosis duration: NR
G1: Total laminectomy; G2: Bilateral
microdecompressive laminotomy
VAS (leg pain), ODI, walking distance,
operation time, blood loss, complications,
reoperations; at 3 and 12 months
Gurelik et al,
2012
52 patients (G1 = 26, G2 = 26); Mean age
(SD): G1 = 60.7 (10), G2 = 57.5 (8.5) years;
Stenosis duration: NR
G1: Unilateral laminotomy; G2:
Laminectomy
ODI, walking distance; at 6 months
Laminectomy v Split-laminectomy/laminotomy
Watanabe
et al, 2011
41 patients (G1 = 22, G2 = 19); Mean age
(SD): G1 = 69 (10), G2 = 71 (8) years;
Stenosis duration: NR
G1: Spinous process-splitting laminectomy;
G2: Laminectomy
JOA, recovery, operation time, blood
loss, reoperations; at 12 months
Liu et al, 2013 56 patients (G1 = 27, G2 = 29); Mean age
(SD): G1 = 59.4 (4.7), G2 = 61.1 (3.1) years;
Mean stenosis duration: G1 = 6.5, G2 = 5.9
years
G1: Modiﬁed unilateral laminotomy; G2:
Laminectomy
VAS (leg pain), JOA, operation time,
blood loss; at 24 months
Rajasekaran
et al, 2013
51 patients (G1 = 28, G2 = 23); Mean age
(SD): G1 = 57.3 (11.2), G2 = 54.5 (8.2)
years; Stenosis duration: NR
G1: Spinous process-splitting laminectomy;
G2: Laminectomy
VAS (leg pain), JOA, recovery, operation
time, blood loss, hospitalisation,
complications, reoperations; at 6 and 12
months
Laminectomy/laminotomy v Endoscopic-laminectomy/laminotomy
Ruetten et al,
2009
192 patients (G1 = 100, G2 = 92); Mean age
(range): 64 (38–86) years; Mean stenosis
duration (range): 19 (2–78) months
G1: Laminotomy; G2: Full endoscopic
laminotomy
ODI, operation time, complications,
reoperations; at 3 and 12 months
Yagi et al,
2009
41 patients (G1 = 20, G2 = 21); Mean age
(range): G1 = 73.3 (63–79), G2 = 70.8 (66–
73) years; Stenosis duration: NR
G1: Microendoscopic laminectomy; G2:
Laminectomy
JOA, operation time, blood loss,
hospitalisation; at 3 and 12 months
Laminectomy/laminotomy v Interspinous process spacer device
Stromqvist
et al, 2013
100 (G1 = 50, G2 = 50); Mean age (range):
69 (49–89) years; Stenosis duration: NR
G1: Laminectomy/laminotomy; G2: X-Stop
device
VAS (leg pain), ZCQ (physical function),
operation time, complications,
reoperations; at 6 and 12 months
Moojen et al,
2013
159 patients (G1 = 79; G2 = 80); Median
age (range): G1 = 64 (47–83), G2 = 66 (45–
83) years; Mean stenosis duration: G1 = 22,
G2 = 23 months
G1: Laminotomy/fecetectomy; G2: Coﬂex
Device
VAS (leg pain), ZCQ (physical function),
walking ability, operation time,
hospitalisation, complications,
reoperations; at 6 and 12 months
Decompression+Fusion v Interspinous process spacer device
(Continued)
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and potential complications before the procedure [37, 46, 49]. Only half of the included trials
reported concealed allocation (Fig 2). Full details of the final PEDro score for each trial is pre-
sented in S2 Table. Given the small number of trials included in each meta-analysis, small
study bias analysis was not possible.
Interventions
No trials comparing surgery to no treatment or placebo/sham were identified. Therefore, all in-
cluded trials compared different types of surgical techniques for lumbar spinal stenosis. Quality
of evidence assessment and summary of findings, as well as the results of perioperative surgical
outcomes (operation time, blood loss, and hospitalisation) are shown in Table 2. Pooled effect
sizes for pain and disability at both short and long-term follow-up are presented in Figs 3 and
4.
Decompression v Decompression plus fusion
The addition of fusion to bony decompression was investigated in three randomised trials re-
porting data from 133 patients at long-term follow-up [9, 44, 45]. Pooled analysis showed
Table 1. (Continued)
Study Details of Participants Surgery Type Outcomes (Time Point)
Azzazi et al,
2010
60 patients (G1 = 30, G2 = 30); Mean age
(range): 56.3 (27–79) years; Mean stenosis
duration: 5.3 (0.2–36.9) years
G1: Decompression plus transpedicular
screw ﬁxation; G2: X-Stop device
VAS (leg pain), ODI, operation time,
hospitalisation, complications; at 24
months
Davis et al,
2013
322 patients (G1 = 107, G2 = 215); Mean
age (SD): G1 = 64.1 (9); G2 = 62.1 (9.2);
Stenosis duration: NR
G1: Decompression plus transpedicular
screw ﬁxation; G2: Coﬂex device
VAS (leg pain), ODI, operation time,
blood loss, hospital length of stay,
complications, reoperations; at 24
months
SD = standard deviation; NR = not reported; VAS = visual analogue scale; RMDQ = Roland Morris Disability questionnaire; ODI = Oswestry Disability
Index; SF-36 = 36-item short-form health survey; JOA = Japanese Orthopaedic Association Score; ZCQ = Zurich Claudication Questionnaire
doi:10.1371/journal.pone.0122800.t001
Fig 2. Risk of Bias (PEDro) Criteria and Number of Trials in Each Category. PEDro = Physiotherapy
Evidence Database.
doi:10.1371/journal.pone.0122800.g002
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Table 2. Summary of Findings and Quality of Evidence Assessment (GRADE).
Summary of Findings Quality of Evidence Assessment (GRADE)
Outcomes Time Point No. Patients Effect Sizea (95% CI) Study
limitation
Consistency Precision Quality
Decompression v Decompression+Fusion
Pain Long-term 86[9, 45] –3.7 (–15.6 to 8.1) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Disability Long-term 41[45] 9.8 (–9.4 to 28.9) No limitation One study (–1) One study (–1) Low
Walking abilityb Long-term 88[9, 44] RR: 0.9 (0.4 to 1.9) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Operation time (min) Perioperative 89[9, 45] –105.2 (–227.6 to 17.3) Limitation (–1) No inconsistency Imprecision (–
1)
Low
Blood loss (mL) Perioperative 89[9, 45] –826.5 (–1582.7 to—
70.2)
Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Laminectomy v Laminotomy
Pain Short-term 281[10, 36, 37] –0.4 (–4.3 to 3.5) No limitation Inconsistency (–
1)
Imprecision (–
1)
Low
Pain Long-term 393[10, 35–37,
39]
1.7 (–4.4 to 7.8) Limitation (–1) Inconsistency (–
1)
No imprecision Low
Disability Short-term 333[10, 36–38] 1.6 (–1.0 to 4.2) No limitation No inconsistency No imprecision High
Disability Long-term 335[10, 36, 37,
39]
1.1 (–1.7 to 3.8) No limitation Inconsistency (–
1)
No imprecision Moderate
Walking ability (m) Short-term 233[36–38] –7.6 (–37.4 to 22.3) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Walking ability (m) Long-term 181[36, 37] –3.0 (–32.7 to 26.7) No limitation No inconsistency Imprecision (–
1)
Moderate
Operation time (min) Perioperative 279[35–37, 39] –3.6 (–30.0 to 22.9) Limitation (–1) No inconsistency Imprecision (–
1)
Low
Blood loss (mL) Perioperative 302[35–37, 39] 34.1 (15.1 to 53.0) Limitation (–1) No inconsistency No imprecision Moderate
Laminectomy v Split–laminectomy/laminotomy
Pain Long-term 105[39, 41] 2.3 (–3.8 to 8.4) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Disability Long-term 148[39–41] –1.0 (–4.8 to 2.9) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Recovery Long-term 137[39–41] 2.1 (–5.7 to 9.8) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Operation time (min) Perioperative 146[39–41] –2.8 (–19.2 to 13.5) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Blood loss (mL) Perioperative 146[39–41] 21.8 (16.4 to 27.2) Limitation (–1) No inconsistency Imprecision (–
1)
Low
Hospitalisation
(days)
Perioperative 51[41] –0.1 (–0.6 to 0.4) No limitation One study (–1) One study (–1) Low
Laminectomy/laminotomy v Endoscopic–laminectomy/laminotomy
Disability Short-term 202[42, 43] 5.2 (–2.2 to 12.5) Limitation (–1) No inconsistency Imprecision (–
1)
Low
Disability Long-term 202[42, 43] 3.1 (–0.7 to 7.0) Limitation (–1) No inconsistency Imprecision (–
1)
Low
Operation time (min) Perioperative 233[42, 43] 3.5 (–17.6 to 24.6) Limitation (–1) Inconsistency (–
1)
Imprecision (–
1)
Very low
Blood loss (mL) Perioperative 41[43] 34.0 (30.4 to 37.6) Limitation (–1) One study (–1) One study (–1) Very low
Hospitalisation
(days)
Perioperative 41[43] 8.6 (6.8 to 10.3) Limitation (–1) One study (–1) One study (–1) Very low
Laminectomy/laminotomy v Interspinous process spacer device
(Continued)
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“very low quality” evidence of nonsignificant difference between treatment groups on pain re-
duction (MD—3.7, 95% CI—15.6 to 8.1). One trial revealed “low quality” evidence of no be-
tween-group difference for disability (MD 9.8, 95% CI—9.4 to 28.9). Two trials evaluated the
effectiveness of decompression plus fusion compared to decompression alone on walking abili-
ty (i.e., patients were considered improved when able to increase their walking distance by 50%
at follow-up). The analysis provided “very low quality” evidence of no difference on walking
ability between groups (RR 0.9, 95% CI 0.4 to 1.9). Mean direct surgery costs was higher for pa-
tients treated by decompression plus fusion (USD $16,115) compared to decompression alone
(USD $10,392). However, no inferential statistics were reported for this outcome.
Laminectomy v Laminotomy
Six randomised controlled trials reporting data from 475 patients compared laminectomy to
unilateral [10, 36, 38, 39], and bilateral laminotomies [35–37]. For pain, we found “low quality”
evidence that laminotomy is not superior to laminectomy at short-term (MD—0.4, 95% CI—
4.3 to 3.5) and long-term follow-up (MD 1.7, 95% CI—4.4 to 7.8). Likewise, “high” to “moder-
ate quality” evidence revealed that laminotomy failed to show disability reduction when com-
pared to laminectomy at short-term (MD 1.6, 95% CI—1.0 to 4.2) and long-term follow-up
(MD 1.1, 95% CI—1.7 to 3.8). For short-term walking ability (i.e., walking distance in metres
Table 2. (Continued)
Summary of Findings Quality of Evidence Assessment (GRADE)
Outcomes Time Point No. Patients Effect Sizea (95% CI) Study
limitation
Consistency Precision Quality
Pain Short-term 247[11, 46] –4.8 (–11.1 to 1.5) No limitation No inconsistency Imprecision (–
1)
Moderate
Pain Long-term 247[11, 46] –2.4 (–13.6 to 8.9) No limitation Inconsistency (–
1)
Imprecision (–
1)
Low
Disability Short-term 248[11, 46] –0.4 (–6.9 to 6.2) No limitation Inconsistency (–
1)
Imprecision (–
1)
Low
Disability Long-term 246[11, 46] –0.8 (–8.4 to 6.7) No limitation Inconsistency (–
1)
Imprecision (–
1)
Low
Walking abilityb Short-term 145[46] OR: 0.8 (0.4 to 1.3) No limitation One study (–1) One study (–1) Low
Walking abilityb Long-term 136[46] OR: 1.3 (0.9 to 1.8) No limitation One study (–1) One study (–1) Low
Operation time (min) Perioperative 259[11, 46] 27.4 (10.8 to 44.1) No limitation Inconsistency (–
1)
Imprecision (–
1)
Low
Hospitalisation
(days)
Perioperative 159[46] 0.1 (–0.3 to 0.4) No limitation One study (–1) One study (–1) Low
Decompression+Fusion v Interspinous process spacer device
Pain Long-term 308[47, 49] 5.3 (–1.1 to 11.6) Limitation (–1) No inconsistency No imprecision Moderate
Disability Long-term 308[47, 49] 5.7 (1.3 to 10.0) Limitation (–1) No inconsistency No imprecision Moderate
Operation time (min) Perioperative 381[47, 49] 78.8 (30.1 to 127.6) Limitation (–1) No inconsistency No imprecision Moderate
Blood loss (mL) Perioperative 320[49] 238.9 (194.8 to 283.0) No limitation One study (–1) One study (–1) Low
Hospitalisation
(days)
Perioperative 382[47, 49] 1.6 (0.9 to 2.3) Limitation (–1) No inconsistency No imprecision Moderate
RR = risk ratio; OR = odds ratio; CI = conﬁdence interval; m = metres; mL = millilitres; min = minutes.
aEffect size is mean difference, unless otherwise speciﬁed. Negative value favours ﬁrst comparator. Effect sizes (95% CI) in bold indicate statistically
signiﬁcant results.
bDichotomous data: Walking ability better (ability to walk 50% farther or increase of 80 m in the walking distance postoperatively) or same/worse, effect
size reported as risk ratio or odds ratio.
doi:10.1371/journal.pone.0122800.t002
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without radicular pain), there is “very low quality” evidence that laminotomy is not superior to
laminectomy (MD—7.6, 95% CI—37.4 to 22.3), and “moderate quality” evidence of no differ-
ence at long-term follow-up (MD—3.0, 95% CI—32.7 to 26.7).
Laminectomy v Split–laminectomy/laminotomy
Three trials reported data of 148 patients treated with bony decompression by laminectomy or
with spinous process split–laminectomy/laminotomy at long-term follow-up [39–41]. Pooling
showed no statistically significant difference between treatments for pain (MD 2.3, 95% CI—
3.8 to 8.4) and disability (MD—1.0, 95% CI—4.8 to 2.9). We also found no difference on long-
term recovery rate (MD 2.1, 95% CI—5.7 to 9.8) assessed by the Japanese Association Score
(range, 0 to 100). The overall quality of evidence was rated as “very low quality” for all three
outcomes, according to the GRADE criteria.
Laminectomy/laminotomy v Endoscopic–laminectomy/laminotomy
The effectiveness of endoscopic–assisted laminectomy/laminotomy was investigated in two
randomised trials including 233 patients [42, 43]. Pooling revealed “low quality” evidence of
no significant effect of endoscopic approaches compared to conventional laminectomy/lami-
notomy on disability at short-term (MD 5.2, 95% CI—2.2 to 12.5), and long-term follow-up
(MD 3.1, 95% CI—0.7 to 7.0). Pain intensity was not reported in these two studies.
Fig 3. Mean Difference for Pain and Disability at Short-term Follow-up (less than 12months). *Decompression technique is laminectomy
or laminotomy.
doi:10.1371/journal.pone.0122800.g003
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Fig 4. Mean Difference for Pain and Disability at Long-term Follow-up (12 months or more).
*Decompression technique is laminectomy or laminotomy
doi:10.1371/journal.pone.0122800.g004
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Laminectomy/laminotomy v Interspinous process spacer device
Two high methodological quality trials reported data of 259 patients comparing bony decom-
pression by laminectomy or laminotomies to the X-Stop and Coflex interspinous process spac-
er devices [11, 46]. At short-term follow-up, “moderate quality” evidence showed no difference
on pain reduction (MD—4.8, 95% CI—11.1 to 1.5). Likewise, “low quality” evidence revealed
no long-term difference on pain between groups (MD—2.4, 95% CI—13.6 to 8.9). For disabili-
ty, “low quality evidence” did not reveal any difference at short-term (MD—0.4, 95% CI—6.9
to 6.2) and long-term follow-up (MD—0.8, 95% CI—8.4 to 6.7). Additionally, one study
showed “low quality” evidence of no benefit of interspinous spacers compared to decompres-
sion on walking ability (i.e., ability to walk 1200 m within 15 minutes or increase of 80 m com-
pared to baseline walking distance) at short-term (OR 0.8, 95% CI 0.4 to 1.3) and long-term
follow-up (OR 1.3, 95% CI 0.9 to 1.8).
Decompression plus fusion v Interspinous process spacer device
Two trials compared decompression plus fusion to the X-Stop and Coflex devices [47, 49], in-
cluding a total of 382 patients analysed at long-term follow-up only. There is “moderate quali-
ty” evidence of no difference between groups on pain reduction (MD 5.3, 95% CI—1.1 to 11.6).
However, we found “moderate quality” evidence that interspinous spacers are slightly superior
to decompression plus fusion on disability outcomes in the long-term (MD 5.7, 95% CI 1.3 to
10.0).
Adverse events and reoperations
We found high variability in the number of reported adverse events across surgical techniques,
with rates ranging from 4% to 45%. Trials reported a wide variety of minor and major surgical
adverse events, ranging from transient urinary retention to cerebrovascular accident. Overall,
reoperation rates ranged from 3% to 28%, with the interspinous process spacer devices reveal-
ing the highest rates.
“Very low” and “low quality” evidence revealed that patients undergoing decompression
plus fusion had an overall higher rate of adverse events (20/64, 31% v 3/24, 13%; P = 0.07) and
reoperations (9/92, 10% v 1/37, 3%; P = 0.47) when compared to decompression alone. This
difference was not statistically significant, however. “Moderate quality” evidence showed that
laminectomy had nonsignificant higher adverse events (23/154, 15% v 19/192, 10%; P = 0.60)
and reoperations rates (6/68, 9% v 4/114, 4%; P = 0.12) than the minimally invasive lamino-
tomies. We found “low” and “very low quality” evidence that conventional laminectomy re-
vealed nonsignificant higher adverse event (3/23, 13% v 1/28, 4%, P = 0.25) and reoperation
rates (1/38, 3% v 1/45, 2%, P = 0.90) than the spinous process splitting techniques. There is
“very low quality” evidence that laminectomy/laminotomy result in significantly higher ad-
verse event rates (16/100, 16% v 5/92, 5%; P = 0.03) than the endoscopic techniques. However,
no difference in reoperation rates was observed (2/80, 3% v 3/81, 4%; P = 0.66). In trials investi-
gating the effectiveness of interspinous process spacer devices, we found “moderate quality” ev-
idence that bony decompression is not associated with higher adverse events (9/129, 7% v 6/
130, 5%; P = 0.74). However, interspinous process spacers revealed a significantly higher reop-
eration rate (34/123, 28% v 9/122, 7%; P< 0.001). Trials comparing decompression plus fusion
to interspinous process spacer devices reported similar rates of adverse events for both tech-
niques (45%), and “low quality” evidence revealed no difference in rates of revision surgery
(23/215, 11% v 8/107, 7%; P = 0.36).
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Discussion
The results of this systematic review have revealed a paucity of evidence on the efficacy of sur-
gery for lumbar spinal stenosis, to date there are no published randomised controlled trials
comparing surgery to no treatment or placebo/sham surgery. Placebo-controlled trials in sur-
gery are feasible and powerful to show the efficacy of surgical procedures [51]. Therefore, we
identified 17 published randomised trials that reported the comparative effectiveness of differ-
ent surgical techniques. Our results show that overall there is no difference in the effectiveness
among the most commonly used surgical techniques for lumbar spinal stenosis. More impor-
tantly, we have demonstrated that the addition of fusion to traditional decompression for the
treatment of lumbar spinal stenosis adds no benefit in terms of pain or disability. We found
that the interspinous process spacer devices showed better outcomes (disability, operation
time, blood loss, and hospitalisation) compared to decompression plus fusion. However, inter-
spinous spacers have significantly higher reoperation rates than bony decompression.
There are several strengths to our review. We have used a prespecified registered protocol,
performed a sensitive electronic search on seven different databases, and selected studies with
no restrictions for language or publication date. To our knowledge, this is the first review to ob-
jectively estimate the effectiveness amongst all surgical techniques for lumbar spinal stenosis
focusing on patient-related outcomes, whereas past reviews performed pooled analysis based
on surgeon-related outcomes (i.e., the effectiveness of a surgical technique was rated by the sur-
geon) [16]. Our review included only randomised clinical trials, as causal inference of treat-
ment on clinical outcomes can only be made when patients are truly randomised to treatment
groups [52]. A further limitation of past reviews is that many have drawn conclusions based on
non-randomised trials (i.e., indirect comparisons, observational studies and case series) [53–
55]. Although it is debatable whether meta-analysis from randomised trials can provide accu-
rate estimates about harms of medical interventions [56, 57], this is the first review to assess
the safety of all surgical techniques for lumbar spinal stenosis by investigating reported
adverse events, reoperation rates, perioperative blood loss, operation time, and length
of hospitalisation.
Our review has identified important weaknesses in the literature. Overall, the methodologi-
cal quality of included studies was poor. Whereas blinding of the caregiver in surgical trials is
typically not possible, only six trials reported blinding of outcome assessors and three studies
reported that patients were blinded. The reporting of data was also poor among some included
studies, and we had to estimate the treatment effect from graphs or by adopting data (e.g., stan-
dard deviation) from similar studies. We recommend that future trials follow the CONSORT
statement when reporting randomised controlled trials [58]. The safety of surgical interven-
tions also varied largely across studies and not all trials have reported the numbers of adverse
events or reoperations. Therefore, it is possible we have underestimated the rates of complica-
tions and reoperations and alert that our conclusions on harms of included interventions
should be interpreted with caution. Future studies should be more thorough in reporting these
surgical outcomes [59]. Another limitation of our study is the inclusion of few studies in each
meta-analysis and the variability of techniques used by surgeons.
We found no trials investigating the efficacy of surgery for lumbar spinal stenosis compared
to placebo/sham surgery. Therefore its true efficacy rather than the effect of the patient's expec-
tation of the surgical intervention (placebo effect) remains unknown. Given the amount of sur-
gical techniques for the treatment of lumbar spinal stenosis the need for placebo/sham-
controlled trials has never been greater. Previous work has proposed the appropriate ethical
considerations for sham surgery [60], and demonstrated that placebo/sham-controlled trials in
surgery are feasible [51]. For instance, sham-controlled trials have been recently published in
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investigating the efficacy of vertebroplasty for painful osteoporotic vertebral fractures [61]. In
these trials, sham surgery was performed by inserting a blunt stylet and gently tapping the ver-
tebral body. Likewise, Flum has suggested performing minimally invasive approaches to the
spine, simulating the decompressive technique, but without actually removing any bone tissue
[62]. The addition of fusion to decompression for spinal stenosis has been previously investi-
gated in systematic reviews with conflicting conclusions [63, 64]. We have identified three ran-
domised trials comparing decompression alone to decompression plus fusion, and our results
revealed no significant differences between treatment groups on clinical outcomes. In fact, de-
compression plus fusion revealed significantly higher intraoperative blood loss when compared
to decompression alone. These findings are based on “low” to “very low” quality evidence,
however. One high quality trial revealed a cost difference of approximately USD $6,290 per pa-
tient for an additional fusion implant [45]. Therefore, the superiority of decompression plus fu-
sion to decompression alone is still uncertain and surgeons should choose between these
techniques with caution, especially considering the associated costs and perioperative compli-
cations of fusion. A systematic review has also investigated the effectiveness of interspinous
process spacer devices for spinal stenosis, suggesting that spacer devices are superior to bony
decompression [54]. However, this result was based on indirect comparisons through a net-
work meta-analysis. Similarly, a second systematic review has failed to identify trials directly
comparing these two techniques [53]. More recently, Wu et al reported results from meta-anal-
yses that included both randomised and non-randomised studies [65]. In our review, pooling
of two high methodological quality randomised trials has revealed no difference between treat-
ments on pain, disability, or walking ability. Although the spacer devices showed significantly
less operation time, they resulted in higher numbers of revision surgeries. Therefore, due to
lack of effectiveness and higher reoperation rates of interspinous process devices compared to
bony decompression, the recommendation for the use of decompressive devices is debatable.
Conclusions
In conclusion, there is relatively limited evidence to guide the use of surgery for the manage-
ment of lumbar spinal stenosis. Overall, the quality of the available evidence ranged from
“high” to “very low” revealing nonsignificant differences across surgical techniques for lumbar
spinal stenosis, and a small, but clinically debatable, benefit of interspinous spacer devices com-
pared to decompression plus fusion. The addition of fusion to decompression is more costly,
leads to more intraoperative blood loss, and fails to promote superior outcomes if compared to
decompression alone. Although the operation using interspinous spacers is quicker, these de-
vices are more expensive than conventional bony decompression and are associated with
higher revision surgeries. We, therefore, question the use of decompression plus fusion and the
safety of interspinous spacers in the management of patients with lumbar spinal stenosis. More
high quality trials comparing the effectiveness between techniques are needed to support our
findings. Patients and clinicians could use this review as an evidence-based tool to help decide
the best surgical option for this condition.
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Trends, Complications, and Costs for Hospital
Admission and Surgery for Lumbar Spinal Stenosis
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Study Design. Population-based health record linkage study.
Objective. The aim of this study was to determine trends in
hospital admissions and surgery for lumbar spinal stenosis, as
well as complications and resource use in Australia.
Summary of Background Data. In the United States, rates of
decompression surgery have declined, whereas those of fusion
have increased. It is unclear whether this trend is also happening
elsewhere.
Methods. We included patients 18 years and older admitted to
a hospital in New South Wales between 2003 and 2013 who
were diagnosed with lumbar spinal stenosis. We investigated the
rates of hospital admission and surgical procedures, as well as
hospital costs, length of hospital stay, and complications.
Surgical procedures were: decompression alone, simple fusion
(one to two disc levels, single approach), and complex fusion
(three or more disc levels or a combined posterior and anterior
approach).
Results. The rates of decompression surgery increased from
19.0 to 22.1 per 100,000 people. Simple fusion rates increased
from 1.3 to 2.8 per 100,000 people, whereas complex fusion
increased from 0.6 to 2.4 per 100,000 people. The odds of
major complications for complex fusion compared with decom-
pression alone was 4.1 (95% confidence interval [CI]: 1.7–
10.1), although no difference was found for simple fusion (odds
ratio 2.0, 95% CI: 0.7–6.1). Mean hospital costs with decom-
pression surgery were AU $12,168, whereas simple and com-
plex fusion cost AU $30,811 and AU $32,350, respectively.
Conclusion. In Australia, decompression rates for lumbar spinal
stenosis increased from 2003 to 2013. The fastest increasing
surgical procedure was complex fusion. This procedure
increased the risk of major complications and resource, although
recent evidence suggest fusion provides no additional benefits to
the traditional decompression surgery.
Key words: complications, costs, data linkage, decompression,
fusion, hospital admission, low back pain, mortality, spinal
stenosis, surgery.
Level of Evidence: 3
Spine 2017;42:xxx-xxx
L
umbar spinal stenosis is narrowing of the spinal canal
or vertebral foramen from degenerative changes of
bony or ligamentous structures, often resulting in
symptoms of neurogenic claudication.1 In older adults,
lumbar spinal stenosis is the most common indication for
spine surgery,2 and decompression without fusion is usually
the surgical procedure of choice. However, some surgeons
decide to include a fusion procedure, although indications
remain unclear.3,4 It appears that the decision to perform
fusion is largely based on surgeons’ preferences,5 leading to
large practice variations across different regions.2,6,7
Surgery for lumbar spinal stenosis has questionable
benefits over nonsurgical interventions,8 and different sur-
gical techniques have been shown to deliver similar clinical
outcomes in a recent Cochrane review.9 However, the
addition of fusion results in longer operation time and more
perioperative blood loss compared with decompression
surgery alone,9 and increases the risk of complications.10
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Rates of inpatient decompression surgery for lumbar spinal
stenosis have declined during the last decade in the United
States, whereas fusion rates have increased.11,12 Complex
fusion procedures three or more disc levels or a combined
posterior and anterior approach) showed the highest
increase,12 although this procedure tripled the risk of life-
threatening complications and had higher hospital costs
compared with decompression surgery.12 Although trends
in the surgical management of lumbar spinal stenosis have
come under close scrutiny, most data come from the United
States.11–13 It is unclear whether similar trends are occur-
ring elsewhere. Population-based studies outside the United
States would help elucidate whether similar trends are
occurring in health systems with different insurance
arrangements, financial incentives, surgical rates, and
cultural expectations.
We therefore investigated the trends in hospital admission
and surgical procedures for lumbar spinal stenosis and its
associated complications and health care use inAustralia.We
used data from themost populous state,NewSouthWales, to
examine trends in a 10-year period between 2003 and 2013.
MATERIALS AND METHODS
Study Population
This study sourced data from New South Wales where 7.3
million people, or one-third of the country’s population,
live. Data were derived from 226 public and 173 private
hospitals (30% of all hospitals in Australia). We used the
Centre for Health Record Linkage to link data from the
Admitted Patient Data Collection (APDC) to the New South
Wales Registry of Births, Deaths andMarriages (BDM). The
APDC includes admissions, discharges, and transfer records
for all public and private sector hospitals and day-procedure
centers in New South Wales. The BDM includes infor-
mation on date, cause, and contributing cause of death.
Our sample included adults aged 18 years or older and who
were admitted between January 2003 and December 2013,
with a diagnosis of lumbar spinal stenosis. We used the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision, Australian Modi-
fication (ICD-10-AM) to identify patients with a diagnosis
of lumbar spinal stenosis (codes M48.05, M48.06, and
M48.07). Patients with primary diagnosis codes of serious
spinal disease (i.e., cancer, spinal infection, spinal cord
injury, or inflammatory diseases), or codes for cervical/
thoracic spinal stenosis were excluded. Patients with diag-
nosis codes for spinal stenosis in the sacral and sacrococcy-
geal region were also excluded, as were those coded with
spinal stenosis of multiple sites in the spine (i.e., cervical and
lumbar) or unspecified location. This study was approved by
the NSW Population and Health Services Research Ethics
Committee (HREC/14/CIPHS/65).
Surgical Procedures
The codes from the Australian Classification of Health
Interventions (ACHI) 8th edition were used to identify
surgical procedures for lumbar spinal stenosis. We only
included cases in which the surgical procedure codes were
used for the principal procedure. We categorized surgical
interventions into 3 broad categories: decompression alone,
simple fusion, and complex fusion. These categories have
been used in previous studies, which showed an increased
risk of life-threatening complications and resource use with
increasing surgical complexity.11,12 Decompression alone
consisted of principal procedure codes for laminectomy
(90024–00, 90024–01), with or without discectomy
(40300–00, 40300–01) or rhizolysis (40330–00, 40330–
01), and no concomitant fusion. Simple fusion involved
single anterior (48660–00), posterior (48642–00,
48654–00), or posterolateral (48648–00, 48654–01)
fusion of one or two spinal disc levels, with or without
additional codes for decompression. Complex fusion was
defined as codes for anterior (48669–00), posterior
(48645–00, 48657–00), or posterolateral (48651–00,
48657–01) fusion of three or more disc levels, or a combi-
nation of anterior and posterior approaches with or without
additional codes for decompression.
Complications
Complications were categorized into major complications,
wound complications, and mortality. Major complications
included ICD-10-AM diagnosis codes for cardiorespiratory
arrest (R09.2, I46), acute respiratory failure (J96.0, J96.9),
pulmonary embolism (I26, I26.0, I26.9), pneumonia (J12–
J18), acute myocardial infarction (I21), and stroke (I60–
I64). To optimize the identification of more serious com-
plications,14 we also used additional ACHI procedure codes
for cardiopulmonary resuscitation (92052–00), postopera-
tive endotracheal intubation (22007–00), and mechanical
ventilation (13857–00, 13879–00). Wound complications
were diagnosis codes for hemorrhage (T81.0), postoperative
infection (T81.4), or additional procedure codes for wound
debridement (30023–00). Only complications occurring
during the course of the episode of care were considered.
Mortality was defined as deaths occurring within 30 days
after the surgical procedure.
Health Care Outcomes
The APDC also includes data on length of hospital stay
and rehospitalization. We defined rehospitalization as a
second hospital admission within 28 days of discharge
from the index admission.15 A revision surgery was
defined as reoperations within 24 months after index
procedure, and was identified using ACHI procedure
codes for revision of spinal procedure (90025–00,
90025–01, 90025–03) or postoperative reopening of
laminotomy or laminectomy site (90009–00), as well as
using codes for any lumbar spine surgery. The Australian
Refined Diagnosis Related Groups (AR-DRG 7.0) was
used to estimate total hospital admission costs, mean
admission cost per patient, and admission costs related
to different types of surgical procedures.
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Statistical Analysis
The rates of hospital admission and surgery, age-standar-
dized by the direct method to the 2003 New South Wales
population, were calculated and reported as per 100,000
people. Hospital costs were adjusted for inflation to 2011
AU dollars using the consumer price index, as published by
the Australian Bureau of Statistics. Descriptive statistics
were used to report rates of hospital admission and surgery
for lumbar spinal stenosis over time.
In our bivariate analyses, we used a logit link function
with binomial distribution to compare the proportion of
patients with complications (wound, major, and death) and
readmissions among subgroups (age categories, sex, type of
surgery, hospital type, and health insurance status). Logistic
regression was used for multivariable analyses, adjusted for
age categories (5-year groups), sex, and previous spine
surgery, or presence of comorbidities in the 12 months
before surgery. The results are reported as odds ratio
(OR) and 95% confidence intervals (CIs). Comorbidities
were defined using coding algorithms when using ICD-10
administrative data as proposed by Quan et al,16 and ACHI
codes were used to identify spine surgical procedures in the
previous year.
We used a logit link functionwith gamma distribution for
hospital costs and a log linear model for length of hospital
stay to compare subgroups. Results of this analysis are
reported as adjusted rate ratio and 95% CI, which reflects
a relative mean difference between the subgroups. Decom-
pression alone was used as the reference group in all
regression analyses. We considered statistically significant
results when P<0.05. All the statistical analyses were
performed in SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
Trends in Hospital Admission
Between 2003 and 2013, there were 30,680 hospital admis-
sions for lumbar spinal stenosis in New South Wales, of
which 19,628 patients underwent a surgical procedure. The
mean age of admitted patients was 69.3 (standard deviation
[SD]: 12.4) years and 52% were female. Nearly 70% of
hospitalized patients were 65 years or older (n¼18,888). In
one decade, the age-standardized rate of hospital admission
for lumbar spinal stenosis increased from 34.8 per 100,000
to 39.3 per 100,000 people (Figure 1).
Trends in Surgical Procedures
During the years 2003 to 2013, there were 17,123 decom-
pression-alone operations, 1458 simple fusions, and 1047
complex fusion procedures. The age-standardized rate of
decompression alone increased from 19.0 per 100,000
people to 22.1 per 100,000 people during this period
(Figure 2). The rate of simple fusion doubled in one decade,
from 1.3 per 100,000 people to 2.8 per 100,000 people,
whereas the rate of complex fusion procedures increased
from 0.6 per 100,000 people to 2.4 per 100,000 people
(Figure 3). From 2003 to 2011, 1166 of 18,449 patients
(6.3%) underwent revision surgery (i.e., any lumbar spine
surgery) within 2 years from index surgery.
Health Care Utilization
In2013alone, theaverage lengthofhospital staywas 6.2days
(SD: 6.4), with a significant difference observed across differ-
ent age categories (Table 1). Most hospital admissions
occurred in private hospitals (n¼2213, 69%), and among
Figure 1. Hospital admissions for lumbar spinal stenosis per 100,000
people in New South Wales, Australia. Adjusted for age and sex by
the direct method to the 2003 population.
Figure 2. Decompression procedures for lumbar spinal stenosis per
100,000 people in New South Wales, Australia. Adjusted for age
and sex by the direct method to the 2003 population.
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patients holding private health insurance (n¼2063, 64%).
Hospital admission costs for lumbar spinal stenosis totaled
AUD $46.1 million (2011 dollars), with a mean cost per
patient of AUD $15,216 (SD: 10,832). Hospital costs related
to surgical admissions were AUD $33.2 million, accounting
for 72% of the aggregate hospital bill. Other in-hospital
procedures included spinal injections, administration of
pharmacological agents, and allied health care interventions.
Patients who received complex fusion required longer
hospital stay (10 days, SD: 5) than those who received
simple fusion (8 days, SD: 4), or decompression surgery
(5 days, SD: 5). The mean hospital admission cost for a
complex fusion procedure was AUD $32,350 (SD: 8279),
whereas cost for simple fusion was AUD $30,811 (SD:
6823). The mean cost for decompression surgery was sig-
nificantly lower (AUD $12,168, SD: 4984) compared with
fusion procedures. Mean hospital costs for insured patients
were higher (AUD $16,670) than those for uninsured
patients (AUD $12,702), probably because of higher rates
of fusion procedures in the insured group (21%) compared
with patients without health insurance (9%). Table 2 pro-
vides results from the multivariable regression analyses
showing that the length of hospital stay of fusion procedures
was nearly twice as long compared with decompression
alone, whereas hospital costs were about 2.5 times greater.
Readmission rate within 28 days of discharge was 2%, but it
was significantly greater for patients in public facilities or
for those not insured (3.3%) compared with patients in
private hospitals or those holding private health insurance,
respectively (Table 1).
Complications
In 2013, 1.7% of admitted patients for lumbar spinal
stenosis had major complications within the episode of care,
0.2% had wound complications, and the 30-day mortality
rate was 0.4% (Table 1). Major complications and 30-day
mortality rates were significantly higher in patients aged 80
years or older (n¼705); nearly 4% had major compli-
cations, and mortality was around 1%. A substantial differ-
ence in complication rates was also noted for different types
of surgical procedures. Complex fusion procedures
increased the odds of major complications by 4.1 times
(95% CI: 1.7–10.1) compared with decompression alone.
Simple fusion was associated with a doubling of odds for
complications compared with decompression surgery alone
(OR 2.0, 95% CI: 0.7–6.1), a difference that was not
statistically significant (Table 2).
DISCUSSION
In this population-based study, we found that the rates of
hospital admission for lumbar spinal stenosis increased by
13% during the years 2003 to 2013, from 34.8 to 39.3 per
100,000 people. Although rates of all types of surgical
procedures for lumbar spinal stenosis increased during this
period, the rates of complex fusion procedures increased
four-fold, from 0.6 to 2.4 per 100,000 people. More com-
plex procedures, however, were associated with longer
length of hospital stay, increased risk of major compli-
cations, and greater hospital costs.
Few studies have addressed trends in surgical procedures,
associated complications, and resource use for lumbar spi-
nal stenosis outside the United States. A Swedish study13
reported no data for specific surgical procedures (i.e.,
decompression alone, simple fusion, or complex fusion),
and previous studies investigating trends in spine surgery in
Australia did not report separate data for patients with
lumbar spinal stenosis.7,17 We have defined complexity of
surgical procedures similarly to previous reports from the
United States,11,12 allowing a direct comparison of our
results. Furthermore, our regression analyses were adjusted
not only for age categories and sex, but also for previous
spinal surgery and comorbidities, according to coding algor-
ithms defined by Quan et al.16
Our study has some limitations. First, there may be errors
in the diagnosis and procedure codes used to identify our
population and the types of surgery. Second, it is likely that
our complication rates are underestimated, as some com-
plications may have not been coded or may have occurred
post-discharge. Third, the lack of information on associated
diagnoses, including spondylolisthesis or scoliosis, also pre-
vented us from identifying the number of fusion procedures,
associated complications, and hospital costs for these sub-
groups. Finally, our data are restricted to admissions in New
South Wales hospitals, so patients living near the borders of
the state but hospitalized in other states or territories of
Australia were not included. This may have been, however,
counterbalanced by hospital admissions of patients coming
in from adjacent states or territories.
Other studies that have investigated trends in surgery for
lumbar spinal stenosis have shown an increase in surgical
rates over time.2,11–13 However, only two studies from the
Figure 3. Fusion procedures for lumbar spinal stenosis per 100,000
people in New South Wales, Australia.
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United States have examined these trends according to
different surgical procedures revealing that decompression
rates have declined, whereas the rates of fusion procedures
have increased,11,12with themost significant increase occur-
ring for complex fusion.12 Our study confirms that in
Australia complex fusion is the fastest growing surgical
procedure for lumbar spinal stenosis, although we have also
observed a slight increase in the rates of decompression
surgery from 2003 to 2013. Our study, therefore, contrib-
utes to a global understanding of changes in surgical rates
for lumbar spinal stenosis.
A large study found an increased risk of life-threatening
complications and resource use with increasing surgical
complexity.12 Fusion procedures require longer operation
time and involve extensive dissection of spinal tissues,
factors that contribute to higher complication rates. The
implants usually placed during a fusion operation are also
responsible for increased tissue injury and costs involved
with the procedure. The costs with equipment for spinal
fusion, such as screws, rods, and plates might explain the
higher costs found for insured patients, as a greater pro-
portion of these patients (21%) received fusion procedures
compared with noninsured patients (9%). The additional
costs with equipment for spinal fusion allow surgeons to use
codes for fusion procedures for the billing of a higher
amount than that for decompression-alone procedures.
We have also found that complex fusion procedures not
only require longer hospital stay, but also increased the risk
of major complications, whereas the hospital costs were 2.5
times higher than conventional decompression surgery.
Despite the increase in fusion procedures in recent times,
it seems that there is no clear consensus regarding indica-
tions for fusion surgery in the presence of lumbar spine
stenosis among spine surgeons.3,4 The decision to perform
fusion is largely based on surgeons’ preferences and
opinions.5 This may reflect a paucity of evidence and lack
of evidence-based decision making when selecting the most
appropriate surgical procedure in this population. A recent
Cochrane review9 highlighted the paucity of randomized
clinical trials in this important area, and revealed no clinical
benefits of adding fusion to decompression surgery. How-
ever, it is important to note that the trends observed in the
present study, as well as in previous reports,11,12 preceded
this recent finding.
The increase in use of potentially harmful interventions
with questionable clinical effectiveness is a major health
policy concern and efforts to address this issue deserve a
high priority. A review of guidelines18 for the surgical
management of lumbar spinal stenosis is needed to inform
current best-practice evidence.9 However, more specific
strategies are required to change clinical practice, such as
reviewing funding of nonevidence-based procedures, so that
care delivered to patients more closely aligns with current
evidence. It is unclear why more complex surgical pro-
cedures for lumbar spinal stenosis are increasing at a much
faster rate. The ageing of the population is not a plausible
explanation for this trend, as our study and previous reports
adjusted the analyses for age categories and population
growth. Other possible explanations of the trends we
observed are the increasing number of spine specialists
trained to perform fusion, financial incentives to perform
more complex procedures, and advancements in surgical
technology19 allowing fusion procedures to be performed
more efficiently.
Further studies are required to determine whether the
trends we observed in decompression surgery for lumbar
spinal stenosis in New SouthWales, Australia, are occurring
elsewhere. Future research should particularly investigate
the reason why complex fusion is increasing at a faster rate,
including patients’ beliefs and preferences, their reasons for
undergoing surgery, and marketing of new surgical implants
and techniques. More prospective cohort studies are also
needed to investigate complication and mortality rates by
including a large sample of patients with lumbar spinal
stenosis receiving either decompression alone or fusion
procedures.
In conclusion, there was an increase in rates of hospital
admission for lumbar spinal stenosis between 2003 and
TABLE 2. Complications and Health Care Use as a Function of Type of Surgical Procedure
Simple Fusion Complex Fusion
Odds ratio (95% CI)
Wound complications No output 2.88 (0.29–28.30)
Major complications 2.04 (0.68–6.12) 4.09 (1.66–10.07)
28-day Rehospitalization 1.24 (0.43–3.61) 1.88 (0.71–4.97)
30-day Mortality No output 5.56 (0.47–65.49)
Adjusted rate ratio (95% CI)y
Length of hospital stay, d 1.58 (1.45–1.73)z 1.91 (1.76–2.06)
Hospital costs, AU$ 2.53 (2.43–2.64) 2.65 (2.53–2.78)
CI indicates confidence interval.
Adjusted for age group, sex, previous spine surgery, and comorbidity (excluding myocardial infarction and stroke). Decompression alone used as the
reference group with estimates presented as odds ratio using logistic regression.
yAdjusted estimates based on generalized linear model with log link function using decompression alone as the reference group.
zSignificant difference between complex and simple fusion (P<0.05).
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2013 in New South Wales, Australia. The rates of decom-
pression surgery have also increased, a trend not observed in
the United States. Our study confirms that the number of
complex fusion procedures is increasing at a much faster
rate than any other surgical procedure for this condition—a
four-fold increase in 10 years. Complex fusion procedures
were associated with an increased risk of major compli-
cations, longer length of hospital stay, and greater hospital
costs compared with decompression alone. The increasing
use of fusion surgery should be reassessed in light of recent
trials that fail to demonstrate the benefit of adding fusion
procedures to decompression surgery.
Key Points
In Australia, the rates of inpatient decompression
surgery for lumbar spinal stenosis have increased
slightly during the last decade, whereas fusion
rates have increased by four-fold.
Decompression surgery costs AU $12,168,
whereas simple and complex fusion costs AU
$30,811 and AU $32,350, respectively.
Complex fusion procedures increased the odds of
major complications by 4.1 times compared with
decompression alone.
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CHAPTER NINE
Conclusions
158
9.1 Overview of principal findings
The first aim of this thesis was to investigate the role of selected physical and psychosocial risk 
factors for new and recurrent episodes of low back pain. Chapter Two revealed that transient 
exposure to many of these factors, such as manual tasks involving heavy loads or being fatigued 
or tired during a manual task, significantly increased the risk of developing a new episode of 
persistent low back pain, defined as an episode of greater than six weeks in duration. For those 
who recovered within six weeks, Chapter Three showed that one third experienced recurrence 
of low back pain within one year, with half of those recurrences involving health care. The 
study also suggested that having three or more previous episodes of low back pain tripled the 
odds of future recurrent episodes.
The second aim of this thesis was to investigate the effects of analgesics for low back pain, a 
common treatment approach in primary care settings. Chapter Four revealed that, compared 
with placebo, paracetamol was ineffective in relieving pain and reducing disability for acute 
low back pain. This medication was also found to provide clinically unimportant benefits for 
patients with osteoarthritis, and increased the risk of liver toxicity. Chapter Five showed that 
NSAIDs, whilst increasing the risk of gastrointestinal adverse reactions, provided no clinically 
important benefits in terms of pain and disability reduction over placebo for low back pain,
neck pain or sciatica.
Patients with sciatica or lumbar spinal stenosis who do not respond to conservative treatments,
including analgesics, are often referred to surgery.1 Thus the following chapters investigated 
the effectiveness and long-term prognosis associated with the surgical management of these 
conditions. Chapter Six revealed that the prognosis of patients with sciatica following surgery 
is not as favourable as previously thought. Patients improved rapidly in the first three months 
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after surgery, but they were likely to experience incomplete recovery even when followed for 
up to five years. For lumbar spinal stenosis, Chapter Seven showed that the addition of fusion 
to decompression surgery does not lead to better outcomes compared with decompression 
alone. Furthermore, minimally invasive techniques were not clinically superior to conventional 
decompression. Despite the lack of evidence supporting surgery for lumbar spinal stenosis,
Chapter Eight demonstrated that rates of surgical procedures for this condition have increased 
between 2003 and 2013 in Australia. Complex fusion showed the highest increase, though this 
procedure was associated with an increased risk of major complications and resource use.
This thesis addresses important gaps in the literature about the risk factors and common 
management strategies for low back pain. The work it encompasses reveals the importance of 
removing the focus on pharmacological treatments for low back pain, and highlights the 
potential for the development and evaluation of preventive approaches. Low back pain is an 
endemic condition, and further research on its prevention is urgently needed. This thesis also 
provides advanced understanding of the most common specific pathologies affecting the lumbar 
spine (i.e., sciatica and spinal stenosis), which are often overlooked in research. The findings 
of the work presented in this thesis, therefore, have important implications for clinical practice 
and future research in the management of low back pain, including sciatica and lumbar spinal 
stenosis.
9.2 Implications and directions for future research
9.2.1 Risk factors for new and recurrent episodes of low back pain
The case-crossover study with 12 months follow-up presented in Chapter Two provides the
first investigation of transient risk factors for persistent low back pain. The triggers identified 
in this study (e.g., exposure to manual tasks involving heavy loads, live people or animals, and 
160
awkward postures) are likely to be modifiable and therefore potential targets for prevention 
interventions. Furthermore, a comparison of these results with the parent study2 revealed that 
there was no difference in the results, which means that both persistent and non-persistent cases 
of low back pain seem to share similar triggers.
Clinicians could use these results to advise patients about potential triggers to avoid in order to
reduce the risk for developing low back pain. Controlling the exposure to these triggers could 
help to not only prevent the cases of low back pain that are short-lived but also those that 
become persistent, which are often linked to the greatest burden of this condition.1 Previous 
research has also confirmed that patients can, in most cases, accurately nominate the activities 
that have triggered their low back pain episode when these are related to physical loading of 
the spine, such as performing work with heavy loads.3 Psychosocial triggers are, however, 
largely overlooked by patients. Therefore, it is important that clinicians provide additional 
advice on how to reduce exposure to the triggers that patients recognise but, most importantly, 
to the triggers that are not typically recognised as risky, such as distraction and fatigue and more 
complex forms of activities involving manual handling. Interestingly, consumption of alcohol 
and sexual activity were the only triggers not associated with onset of persistent symptoms, but 
they were also not associated with development of non-persistent low back pain.
It is possible that other transient factors not included in this study may also increase the risk for
onset of persistent low back pain. Therefore, additional factors would be worth evaluating in 
future studies, including stress and anxiety. Furthermore, future research should investigate the 
effects of prevention strategies that control exposure to the harmful triggers for persistent low 
back pain identified in this study.
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Although we are in the infancy of understanding the mechanisms and risk factors related to new 
or recurrent episodes of low back pain, these steps are essential in the development of 
preventative strategies. Chapter Two revealed that about two thirds of patients with low back 
pain will have recovered within six weeks after its onset. Patients who recovered were then 
followed-up for 12 months in a separate study to establish the prevalence and determinants of 
recurrence of low back pain. The results from the large inception cohort study presented in 
Chapter Three indicated that one third of participants who recover within six weeks from pain 
onset will have a recurrence within the first year. Moreover, nearly one in five participants 
reported a recurrence of low back pain that required care seeking. The analyses revealed only 
one predictor of recurrence: having three or more previous episodes of low back pain. Other 
factors (i.e., gender, duration of episode, days to seek care, pain and disability levels, use of 
medication, depression, tension or anxiety, work status, and compensable case) were not 
associated with recurrence of low back pain.
Although only previous episodes of low back pain increased the risk of recurrence, this factor 
remained strongly associated with cases that required health care. Further research is required 
in this field, given to date only two large inception cohort studies (including the study presented 
in this thesis) have investigated recurrence of low back pain.4 A particular focus should be made 
in including potential predictors of recurrence not investigated in this study, such as physical 
activity measured by accelerometers.
9.2.2 Management of low back pain: pharmacological interventions
Simple analgesics are often prescribed for patients with low back pain in primary care settings,5
where paracetamol is recommended as the first line treatment.6 Chapter Four, however,
showed that paracetamol is not superior to placebo in reducing pain and disability for people 
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with acute low back pain. Since this study was published, there have been changes in 
recommendations in some best practice guidelines. For instance, the most recent National 
Institute for Health and Care Excellence (NICE) guideline no longer recommend paracetamol
alone for low back pain and sciatica.
The study presented in Chapter Four was published with an editorial4 and reopened the 
discussion on the effects of paracetamol. The BMJ published two letters to the editor,5 6 and a
response from authors (Appendix A). The review was summarised with commentary in leading 
medical journals, such as the New England Journal of Medicine7 and Annals of Internal 
Medicine,8 and accompanied by an editorial (Appendix B). A number of prizes have been 
awarded to this study (Appendix C), including the BMJ 1st prize for the most accesses in 2015.
Moreover, this study was ranked in the top 20 studies with potential to change clinical practice 
of primary care physicians in American Family Physician.9 The study also generated great 
media interest (Appendix D), being ranked in the top 100 studies of 2015 by Altmetric. A
revision of all guidelines for the management of low back pain is urgently needed,10 and future 
studies should monitor whether changes in practice occur.
Given the recent evidence that paracetamol is ineffective for low back pain, the prescription of 
NSAIDs is likely to increase, despite concerns about its safety. The study presented in Chapter 
Five revealed that NSAIDs are effective but do not provide clinically important effects on pain 
and disability for patients with low back pain, as well as neck pain and sciatica. Most patients 
who were given an NSAID (6 out of 7) fared no better than if they were given a placebo, when 
considering a threshold of smallest worthwhile effect of 10-points (0–100 scale) as a between-
group difference. The findings also suggested an increased risk of gastrointestinal adverse 
events with NSAIDs compared with placebo.
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The thesis contributes to the body of evidence on the effects of pharmacological interventions 
for low back pain. Since a recent systematic review has also found small effects of opioids over 
placebo for chronic low back pain,11 it seems that current analgesics only offer trivial effects 
for this condition. The ethical implications of using placebo pills in clinical practice, the small 
effects of simple analgesics, and the increasing concerns on the risk of harm associated with 
opioid use highlight the important role of non-pharmacological treatments. Guidelines for the 
management of acute low back pain recommend that patients should receive reassurance and 
advice to stay active or increase physical activity levels.10 For chronic low back pain, exercise 
therapy12 or multidisciplinary biopsychosocial rehabilitation13 are recommended as treatment 
options.
9.2.3 Management of low back pain: surgical interventions
For patients with sciatica or lumbar spinal stenosis who show a lack of improvement after 
conservative treatments, surgery may be considered.1 Chapter Six revealed that despite the
rapid improvement of symptoms in the first three months after surgery, many patients with 
sciatica never fully recover even when followed up to five years. It is unclear whether changes 
in symptoms observed in this study were associated with surgery itself or if it was a result of 
the condition’s natural course, or even surgery-associated placebo effects, given the 
observational nature of the included studies. Another systematic review has shown similar 
trends for patients with lumbar spinal stenosis,14 a condition that is the fastest increasing 
indication for spine surgery in older people.15
Most of the evidence supporting the use of surgery for lumbar spinal stenosis comes from trials 
comparing surgery with non-surgical treatments.16 A summary of the current evidence 
(Appendix E), however, revealed that surgery has no clinically important benefits over non-
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surgical treatments. Moreover, Chapter Seven revealed that to date there are no trials 
comparing surgery with no treatment, sham or placebo surgery for lumbar spinal stenosis. The 
findings also suggested that adding fusion to decompression surgery does not lead to better 
clinical outcomes compared with decompression alone. Adding fusion to decompression was 
associated with more blood loss and longer length of hospital stay. Furthermore, new surgical 
devices, such as the interspinous process spacers X-Stop and Coflex, were not superior to 
conventional decompression surgery and increased the risk of reoperations. Finally, minimally 
invasive decompression surgery, such as spinous process-splitting laminectomy or unilateral or 
bilateral laminotomy, resulted in similar clinical outcomes compared with conventional 
decompression. The study reported in this chapter has been updated and converted into a 
Cochrane review, which is presented in Appendix F.
Despite the lack of evidence supporting the use of surgery for lumbar spinal stenosis, Chapter 
Eight revealed that rates of all surgical procedures for this condition have increased in the last 
GHFDGH LQ$XVWUDOLD7KH UDWHVRI FRPSOH[ IXVLRQSURFHGXUHV GLVF OHYHOVRU D FRPELQHG
posterior and anterior approach) have increased at a much faster rate than any other surgical 
procedure. Despite the rapid increase of complex fusion surgery, this procedure increased the 
risks of major complications, such as myocardial infarction and stroke, and led to longer length 
of hospital stay and greater hospital costs compared with decompression alone.
Collectively, the studies in Chapters Six to Eight have shown important findings on the 
surgical management of sciatica and lumbar spinal stenosis. The study reported in Chapter Six
may help inform surgeons and patients with sciatica about the most likely long-term prognosis 
after surgery. Although surgeons could use the results of the study presented in Chapter Seven
to decide the best surgical option for their patients, there is an urgent need for a placebo-
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controlled trial evaluating surgery for lumbar spinal stenosis. Future studies should also 
investigate the reason why the use of fusion procedures is increasing so fast, as shown in 
Chapter Eight. Only recently conducted high quality studies showed the lack of clinical benefit 
of fusion procedures over decompression surgery.17,18 Therefore, there is need for further 
research monitoring the trends in surgical procedures rates in order to investigate whether 
changes are occurring in light of recently published evidence.
9.3 Concluding Remarks
x Previously identified triggers, including transient physical and psychosocial activities,
are associated with onset of persistent low back pain. Whilst about 70% of patients with 
a new onset of low back pain will recover within six weeks, one third of those will 
experience future recurrences, with half of these seeking health care again.
x Paracetamol is ineffective for acute low back pain and only offers non-clinically
important benefits for osteoarthritis. NSAIDs are effective, but the magnitude of the 
effects over placebo is arguably clinically irrelevant.
x The prognosis of sciatica after surgery is not as good as previously thought, and patients
are likely to not fully recover in the long-term. For lumbar spinal stenosis, despite the
lack of evidence on the effects of surgery, surgical rates are increasing in Australia.
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Paracetamol, also known as acetaminophen, is 
the most widely used over-the-counter 
medication to treat back pain and osteoarthritis 
[1]. Clinical guidelines consistently recommend 
it as first line analgesic medication due to its 
safety, effectiveness and low cost [2, 3]. A 
recently published systematic review and meta-
analysis questions the efficacy of paracetamol 
and calls for a revision of clinical guidelines [4]. 
The systematic review included 13 randomized 
placebo-controlled trials investigating the safety 
and efficacy of paracetamol in 5,366 patients 
with low back pain (3 trials) or with hip or knee 
osteoarthritis (10 trials) [4]. No trial enrolling 
patients with neck pain were identified. The 
meta-analysis suggested that paracetamol is not 
effective in reducing pain and disability, or in 
improving quality of life in patients with low 
back pain. For hip and knee osteoarthritis, 
paracetamol has a statistically significant effect 
on pain and disability, but the effect is too small 
to be clinically worthwhile. These results were 
based on high quality evidence, and therefore 
further research is unlikely to change this 
conclusion [4]. 
The safety of paracetamol was recently 
questioned in a systematic review of long-term 
observational evidence, which showed an overall 
28% increased risk of mortality and up to 2 times 
greater risk of cardiovascular adverse events, 
gastrointestinal bleeds and impaired kidney 
function with the use of paracetamol in the 
general adult population [5]. Paracetamol is also 
associated with serious liver toxicity, including 
liver failure, at doses of more than 4 g/day [1]. 
The above noted systematic review also found 
that paracetamol at regular doses of up to 4 g/day 
can increase the risk of abnormal results on liver 
function tests up to four times (an abnormal test 
was defined as hepatic enzyme activity 1.5 times 
or more than the upper reference range) [4]. 
However, this result is based on the short-term 
use of paracetamol, and the clinical meaning of 
this transient alteration is unknown. The review 
also revealed that adverse side effects varied 
across trials, but no differences were found in  
terms of the number of patients using 
paracetamol reporting any adverse event, or to 
adverse events, compared to those using a 
placebo. Similarly, adherence to treatment 
schedule rates was similar between those taking 
paracetamol compared with those using a 
placebo [4]. 
Low back pain and osteoarthritis are the leading 
causes of global disability, and account for 10-
20% of all consultations with a general 
practitioner [6]. This systematic review 
contributes to the recent research that has 
highlighted opportunities to improve the health 
care provided for both conditions. Primary care 
patients with osteoarthritis typically skip the first 
line therapy with exercise and weight control [7], 
and instead rapidly progress to referral for 
imaging or surgery. Patients with low back pain 
often get referrals for opioid medicines and 
imaging [8]. A more liberal policy of imaging for 
patients with back pain does not provide better 
clinical outcomes, but the over-reporting of 
incidental findings may cause unnecessary 
concern to the patient and trigger unnecessary 
tests and treatments. Clinicians should carefully 
weigh benefits and harms when making 
treatment decisions.  
Paracetamol has minimal or no benefit for 
patients with low back pain or osteoarthritis, but 
may cause harm. In this context, its continued 
use for these prevalent musculoskeletal diseases 
may seem hard to justify. There are other 
effective treatment options for patients with low 
back pain and osteoarthritis. Reassurance of the 
benign nature of low back pain, together with 
advice and educational programs are known to be 
effective and help reduce recovery time [9]. 
Other treatments include physical therapies such 
as spinal manipulation and exercise as well as 
psychological therapies, such as cognitive 
behavioral therapy. Intra-articular corticosteroids 
are effective in short-term pain reduction for 
knee osteoarthritis, and land-based or water- 
based aerobic exercises, strength training, weight 
management and oral or topical anti-
inflammatory medicines have also been shown to 
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provide benefits for patients with lower limb 
osteoarthritis [3]. 
The editorial that accompanied this systematic 
review in The BMJ emphasized the importance of 
non-pharmacological options for musculoskeletal 
conditions but warns that adherence to exercise 
and access to physiotherapy are still poor in the 
United Kingdom National Health Service [10]. In 
the United States, same is also true, and only 
about 60% of patients with osteoarthritis report 
receiving needed rehabilitation services, common 
barriers being lack of service coverage by the 
health plan and high costs. Musculoskeletal 
conditions, such as low back pain and 
osteoarthritis, are still largely under-recognized 
as a health priority. Thus, it is necessary to take 
stock of the evidence for these common 
conditions, and make sure people are receiving 
appropriate care. 
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1. 1st Place Research Paper for the Most Number of Accesses, The British Medical Journal
(BMJ), London, UK.
The publication BMJ 2015;350:h1225 had over 80,000 downloads in 2015 and was awarded 
a prize at the BMJ’s yearly Friends of the Journal event.
2. Research Student 2015 Publication Award, School of Public Health, Sydney Medical
School, The University of Sydney, Sydney, Australia.
The publication BMJ 2015;350:h1225 was awarded the best research paper by a higher 
degree research student in terms of originality, quality and the significance.
3. Altmetric 2015 Top 100 Research Study, Altmetric, London, UK.
The publication BMJ 2015;350:h1225 was ranked in the top 1% of all articles ever tracked 
by Altmetric with a current score of 1,038 for media attraction in 2015.
4. Top 20 Research Studies of 2015 for Primary Care Physicians, American Family Physician,
Leawood, USA.
The publication BMJ 2015;350:h1225 was ranked in the top 20 among approximately 
20,000 research studies published during 2015 for greatest clinical relevance for family 
physicians likely to change clinical practice.
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Television
1. Channel ONE News. Interviewees: Manuela Ferreira, David Hunter
2. Channel 7 News. Interviewees: Manuela Ferreira, Chris Maher
3. Channel 9 News. Interviewee: David Hunter
4. Channel 10 Eyewitness News. Interviewees: Chris Maher, Manuela Ferreira
5. NBN News. Interviewee: David Hunter
Radio
1. ABC Radio National. Interviewee: Gustavo Machado
2. Triple J. Interviewee: Gustavo Machado
3. 4CRB. Interviewee: Manuela Ferreira
4. 3BA, Mixx FM, Coast FM, and Light FM. Interviewee: Manuela Ferreira
5. 2NURFM and Sunshine FM. Interviewee: Chris Maher
6. Spirit 96.5 FM and MIX 94.5. Interviewee: Chris Maher
7. 2MAX, 2YOU FM, Coast FM, and Great Lakes FM
Newspaper
1. Sydney Morning Herald
2. The Australian
3. Herald Sun
4. Adelaide Advertiser
5. Courier Mail
6. Geelong Advertiser
7. Gold Coast Bulletin
8. Townsville Bulletin
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Top 10 Online News
1. The New York Times: http://nyti.ms/1DeaCji
2. The Guardian: http://bit.ly/1I3v49A
3. The Telegraph: http://bit.ly/1NBjJvM
4. The Times: http://bit.ly/1Dp7VNP
5. BBC News: http://bbc.in/1IP1Zwk
6. Daily Mail: http://dailym.ai/2faSDmv
7. The Mirror: http://bit.ly/2f7QhHq
8. Wall Street OTC: http://bit.ly/2exDcDI
9. CBS News: http://cbsn.ws/1C8OEcl
10. The Australian: http://bit.ly/2faMeHY
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This section features a recent systematic review that is indexed on
PEDro, the Physiotherapy Evidence Database (http://www.pedro.
org.au). PEDro is a free, web-based database of evidence relevant
to physiotherapy.
No clinically important beneﬁts
of surgery over rehabilitation
for lumbar spinal stenosis
(PEDro synthesis)
▸ Zaina F, Tomkins-Lane C, Carragee E, et al. Surgical versus non-surgical treatment for
lumbar spinal stenosis. Cochrane Database Syst Rev 2016;(1):CD010264.
BACKGROUND
Lumbar spinal stenosis affects over 200 000 people in the USA
and is the most common indication for spine surgery in older
adults.1 Nearly 38 000 surgical procedures are performed every
year, and decompression is often the surgical procedure of
choice.2 Some surgeons, however, decide to perform fusion,
though this procedure has been associated with an increased
risk of complications and resource use.2 We currently lack
placebo-controlled trials of surgery for lumbar spinal stenosis,3
thus the evidence to support surgery for this population comes
largely from trials comparing surgery with non-surgical
treatments.4
AIM
The aim of the review was to investigate the effects of surgery for
lumbar spinal stenosis compared with non-surgical treatments.
For this PEDro synthesis, we updated the pooled analyses by
including data of a recently published randomised trial.5
SEARCHES AND INCLUSION CRITERIA
Searches were conducted on CENTRAL, MEDLINE, Embase,
CINAHL, PEDro and ICL up to February 2015. Studies were
included if they were: (1) randomised or quasi-randomised con-
trolled trials, (2) compared surgery with conservative treat-
ments, (3) evaluated pain, function and/or disability, quality of
life or adverse effects and (4) included adult patients with
lumbar spinal stenosis.
INTERVENTIONS
Surgical procedures included decompression with or without
fusion. Non-surgical treatments consisted of rehabilitation (exer-
cises, physiotherapy, manipulation, mobilisation, acupuncture,
bracing), cognitive–behavioural treatments, drugs or steroid
injections.
MAIN OUTCOME MEASURES
The review included only studies that reported measures of pain
intensity, functional and/or disability status, health-related
quality of life or safety outcomes.
STATISTICAL METHODS
Length of follow-up was deﬁned as short term (<6 months),
intermediate term (6–24 months) and long term (≥24 months).
Pooled mean differences (MD), standardised mean differences
(SMD), risk ratios and associated 95% CIs were calculated using
random-effects meta-analysis. Heterogeneity was evaluated
using the χ2 test and the I2 statistic. A MD <10 (0–100 scale)
or SMD <0.4 was deﬁned as a small and not clinically import-
ant effect. Data from a large randomised controlled trial5 not
included in the meta-analysis were extracted and pooled follow-
ing the methods described in the review using Comprehensive
Meta-Analysis V.2.02.
RESULTS
The review included 5 randomised trials with a total of 643
participants. The overall quality of the evidence was assessed
using the GRADE approach. Three trials compared surgery
with rehabilitation modalities, and two trials compared
surgery with steroid injection. The additional trial not
included in the meta-analysis had 169 participants (mean age
68 years, 52% men) who received surgical decompression or
physiotherapy.5
The review found that surgery had similar effects on disabil-
ity reduction as rehabilitation at short (MD −3.66, 95%
CI −10.12 to 2.80) or intermediate term (MD −6.18, 95%
CI −15.03 to 2.66). Non-clinically important effects were
found at long term (MD −4.43, 95% CI −7.91 to −0.96).
Adding data from the most recent randomised trial to the
meta-analyses did not change the conclusions, conﬁrming that
surgery is not superior to rehabilitation on disability at short
(SMD −0.12, 95% CI −0.41 to 0.16) or intermediate term
(SMD −0.23, 95% CI −0.56 to 0.10). Small and not clinically
important effects were observed at long term (SMD −0.21,
95% CI −0.39 to −0.03). The review did not report pooled
effects for pain outcomes measured in a continuous scale. Our
pooled analyses revealed no differences between surgery and
rehabilitation on pain at short term (SMD −0.21, 95%
CI −0.58 to 0.15). A small and not clinically important effect
was found at intermediate term (SMD −0.25, 95% CI −0.48 to
−0.03), but no difference was observed at long term (SMD
−0.26, 95% CI −0.53 to 0.01).
The review showed that surgery resulted in small but not clin-
ically important pain (MD −2.40, 95% CI −2.88 to 1.92) and
disability (MD −5.70, 95% CI −10.83 to 0.57) reduction com-
pared with epidural steroid injection. No long term data were
available for this comparison. Complication rates ranged from
11% to 24% in the surgical group, and reoperation rate was
13%. There were no side effects reported for any of the non-
surgical treatments.
LIMITATIONS
There was substantial heterogeneity in some pooled analyses,
with I2 values ranging from 17% to 81%. The review did not
report pooled effects for pain outcomes measured in a continu-
ous scale. A large randomised trial was included in the review,5
but not in the pooled analyses. Adding data from this new trial,
however, has not changed the ﬁnal conclusions.
CLINICAL IMPLICATIONS
Our updated pooled analyses conﬁrmed that there are at best
small and not clinically important effects of surgery compared
with rehabilitation on pain and disability. Furthermore, there
are no clinically important effects of surgery compared with
steroid injection on pain and disability. Surgery is associated
with high complication and reoperation rates, while no side
effects are reported for any of the conservative treatment
PEDro systematic review update
541Machado GC, Ferreira ML. Br J Sports Med 2017;51:541–542. doi:10.1136/bjsports-2016-097238
183
options. The included trials provide low-quality evidence;
therefore, high-quality evidence is still needed to conﬁrm
whether surgery is superior to non-surgical treatments for
these patients.
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A B S T R A C T
Background
Hospital charges for lumbar spinal stenosis have increased significantly worldwide in recent times, with great variation in the costs and
rates of different surgical procedures. There have also been significant increases in the rate of complex fusion and the use of spinal
spacer implants compared to that of traditional decompression surgery, even though the former is known to incur costs up to three
times higher. Moreover, the superiority of these new surgical procedures over traditional decompression surgery is still unclear.
Objectives
To determine the efficacy of surgery in the management of patients with symptomatic lumbar spinal stenosis and the comparative
effectiveness between commonly performed surgical techniques to treat this condition on patient-related outcomes. We also aimed to
investigate the safety of these surgical interventions by including perioperative surgical data and reoperation rates.
Search methods
Review authors performed electronic searches of theCochrane Central Register of ControlledTrials (CENTRAL),MEDLINE, Embase,
CINAHL, AMED, Web of Science, LILACS and three trials registries from their inception to 16 June 2016. Authors also conducted
citation tracking on the reference lists of included trials and relevant systematic reviews.
Selection criteria
This review included only randomised controlled trials that investigated the efficacy and safety of surgery compared with no treatment,
placebo or sham surgery, or with another surgical technique in patients with lumbar spinal stenosis.
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Data collection and analysis
Two reviewers independently assessed the studies for inclusion and performed the ’Risk of bias’ assessment, using theCochrane Back and
NeckReviewGroup criteria. Reviewers also extracted demographics, surgery details, and types of outcomes to describe the characteristics
of included studies. Primary outcomes were pain intensity, physical function or disability status, quality of life, and recovery. The
secondary outcomes included measurements related to surgery, such as perioperative blood loss, operation time, length of hospital stay,
reoperation rates, and costs. We grouped trials according to the types of surgical interventions being compared and categorised follow-
up times as short-term when less than 12 months and long-term when 12 months or more. Pain and disability scores were converted
to a common 0 to 100 scale. We calculated mean differences for continuous outcomes and relative risks for dichotomous outcomes.
We pooled data using the random-effects model in Review Manager 5.3, and used the GRADE approach to assess the quality of the
evidence.
Main results
We included a total of 24 randomised controlled trials (reported in 39 published research articles or abstracts) in this review. The trials
included 2352 participants with lumbar spinal stenosis with symptoms of neurogenic claudication.None of the included trials compared
surgery with no treatment, placebo or sham surgery. Therefore, all included studies compared two or more surgical techniques. We
judged all trials to be at high risk of bias for the blinding of care provider domain, and most of the trials failed to adequately conceal the
randomisation process, blind the participants or use intention-to-treat analysis. Five trials compared the effects of fusion in addition
to decompression surgery. Our results showed no significant differences in pain relief at long-term (mean difference (MD) -0.29, 95%
confidence interval (CI) -7.32 to 6.74). Similarly, we found no between-group differences in disability reduction in the long-term (MD
3.26, 95% CI -6.12 to 12.63). Participants who received decompression alone had significantly less perioperative blood loss (MD -0.52
L, 95% CI -0.70 L to -0.34 L) and required shorter operations (MD -107.94 minutes, 95% CI -161.65 minutes to -54.23 minutes)
compared with those treated with decompression plus fusion, though we found no difference in the number of reoperations (risk ratio
(RR) 1.25, 95% CI 0.81 to 1.92). Another three trials investigated the effects of interspinous process spacer devices compared with
conventional bony decompression. These spacer devices resulted in similar reductions in pain (MD -0.55, 95% CI -8.08 to 6.99)
and disability (MD 1.25, 95% CI -4.48 to 6.98). The spacer devices required longer operation time (MD 39.11 minutes, 95% CI
19.43 minutes to 58.78 minutes) and were associated with higher risk of reoperation (RR 3.95, 95% CI 2.12 to 7.37), but we found
no difference in perioperative blood loss (MD 144.00 mL, 95% CI -209.74 mL to 497.74 mL). Two trials compared interspinous
spacer devices with decompression plus fusion. Although we found no difference in pain relief (MD 5.35, 95% CI -1.18 to 11.88),
the spacer devices revealed a small but significant effect in disability reduction (MD 5.72, 95% CI 1.28 to 10.15). They were also
superior to decompression plus fusion in terms of operation time (MD 78.91 minutes, 95% CI 30.16 minutes to 127.65 minutes) and
perioperative blood loss (MD 238.90 mL, 95% CI 182.66 mL to 295.14 mL), however, there was no difference in rate of reoperation
(RR 0.70, 95% CI 0.32 to 1.51). Overall there were no differences for the primary or secondary outcomes when different types of
surgical decompression techniques were compared among each other. The quality of evidence varied from ’very low quality’ to ’high
quality’.
Authors’ conclusions
The results of this Cochrane review show a paucity of evidence on the efficacy of surgery for lumbar spinal stenosis, as to date no trials
have compared surgery with no treatment, placebo or sham surgery. Placebo-controlled trials in surgery are feasible and needed in the
field of lumbar spinal stenosis. Our results demonstrate that at present, decompression plus fusion and interspinous process spacers
have not been shown to be superior to conventional decompression alone. More methodologically rigorous studies are needed in this
field to confirm our results.
P L A I N L A N G U A G E S U M M A R Y
Effectiveness of surgery for people with leg or back pain due to symptomatic spinal stenosis
Review question
How well do different types of surgery work for lumbar spinal stenosis?
Background
Spinal stenosis is the narrowing of the spinal canal in the lower back region caused by thickening of the soft tissues and bones. It
is a common condition for which surgery is usually performed after non-surgical treatments (such as physiotherapy) have failed to
2Surgical options for lumbar spinal stenosis (Review)
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bring sufficient relief to patients. Spinal stenosis is a common cause of low back pain that radiates to the legs, and it is more common
in older adults. Surgery for lumbar spinal stenosis normally involves taking pressure off the spinal cord or spinal nerves (known as
decompression) by removing bone and soft tissues from around the spinal canal. Another common surgical approach is to fuse two or
more vertebrae together after decompression in the patient whose spine seems to be unstable. The usefulness of some types of surgery
for lumbar spinal stenosis, however, has been questioned, and previous studies have reported that patients who receive fusion are more
likely to have major complications and higher costs when compared with patients who undergo decompression only. More recently,
spinal implants were created to help indirectly reduce pressure in the spinal canal and at the same time stabilise the bones. However,
these implants have also been linked to worse outcomes (e.g., higher reoperation rates) when compared to conventional decompression.
Search date
This review includes all trials published up to June 2016.
Study characteristics
We included all trials that compared any surgical technique with no surgery or placebo surgery, and also trials comparing different
surgical techniques with each other, including fusion and spinal implants. All the patients included in these studies were diagnosed
with lumbar spinal stenosis and had symptoms in the leg or thigh that worsened by walking or standing and were generally relieved by
a change in position, such as bending forward or sitting. The main measure we used to compare how well the different types of surgery
worked was how much less pain people felt as they went about their daily lives. We also looked at whether their leg pain improved,
how much blood they lost during surgery, how long the surgery took, how long they had to stay in hospital, how many patients had
to have another operation for the problem and how much the treatment cost.
Key results and quality of the evidence
Twenty-four randomised controlled trials were included with a total of 2352 people. We did not find trials that compared surgery
with no treatment or placebo surgery, so all included trials compared different surgical techniques. The quality of the evidence from
these studies varied from very low quality to high quality. This large variation was mainly due to different study protocols, surgical
techniques and quality of reporting according to the ’Risk of bias’ assessment. We found that patients who had decompression plus
fusion fared no better than those who underwent decompression surgery alone. In fact, decompression plus fusion resulted in more
blood loss during surgery than decompression alone. Although the spinal spacers were slightly better than decompression plus fusion
in terms of improvements on daily activities, there were no differences when they were compared with decompression alone. Finally,
we found no differences between different forms of decompression.
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B A C K G R O U N D
Description of the condition
Lumbar spinal stenosis is a narrowing of the spinal canal or the
intervertebral foramina by surrounding bone and soft tissues that
compromises neural structures (Bailey 1911; Portal 1803). Al-
though it can be an incidental finding (Boden 1990), lumbar
spinal stenosis may cause leg or lower back symptoms and disabil-
ity, particularly in the older population (Kalichman 2009; Katz
2008). Radiographic findings of spinal stenosis are highly preva-
lent among those older than 60 years of age and can be as high as
80% in specific populations (Ishimoto 2013). Only 30%, how-
ever, present severe lumbar stenosis and about 17% have long-
term symptoms of intermittent neurogenic claudication. Neuro-
genic claudication is the most important feature of lumbar spinal
stenosis as it limits patients’ walking ability and causes a major
impact on their quality of life. Intermittent neurogenic claudica-
tion is defined as uni- or bilateral radicular pain during walking
or standing that is relieved by sitting down or flexing the lumbar
spine (Blau 1961).
The differential diagnosis from vascular intermittent claudication
is sometimes challenging as poor circulation in the muscles of the
legs might mimic neurogenic claudication. Pain sensation while
standing and pain relief with lumbar flexion are important char-
acteristics of neurogenic claudication that may help distinguish
between these conditions. Lumbar spinal stenosis can be classified
as primary (congenital) or secondary stenosis (degenerative, ia-
trogenic, spondylotic, post-traumatic and miscellaneous; Arnoldi
1976; Katz 2008; Siebert 2009). It is also anatomically classified
as central, lateral or foraminal and it can be a result of multiple
factors, such as intervertebral disc protrusion, loss of intervertebral
space height, hypertrophy of joint capsules and ligaments, and os-
teophytes (Siebert 2009).
Description of the intervention
Bony decompression by laminectomy was first described by Alban
Smith (Smith 1829), and first reported in a patient with spinal
stenosis in 1893 (Lane 1893). This surgical procedure is still con-
sidered the gold standard of surgery and the most common tech-
nique for lumbar spinal stenosis (Gibson 2005; Jansson 2003).
After intubation and anaesthesia the patient is positioned prone
on the operating table, and imaging techniques guide a midline
or posterolateral muscle splitting incision. The paraspinal muscles
are stripped to expose the lamina and retracted laterally. The sur-
geon performs partial removal of both osseous (vertebrae lamina,
spinous process, facet joints) and soft tissue elements (posterior
ligamentous complex), but at least 50% of each facet joint com-
plex is preserved to avoid iatrogenic instability. In cases of instabil-
ity, lumbar fusion may be necessary in addition to decompression
(Taylor 1994), which usually involves the use of spinal implants to
stabilise the fused segments, though recent trials have questioned
this view (Forsth 2016;Ghogawala 2016). In theUnited States, the
rate of fusion for lumbar spinal stenosis has increased significantly
in recent times (Deyo 2010). However, this procedure is associ-
ated with higher reoperation rates, post-surgical complications,
and costs when comparedwith decompression alone (Deyo 2013).
Furthermore, it is still debatable whether the addition of fusion is
more effective than decompression alone. To overcome the com-
plications associated with fusion, less invasive surgical techniques
have been developed, such as the interspinous process spacer de-
vices (Coflex, Paradigm Spine USA and X-Stop, Medtronic Spine
USA). These spacer devices were created to promote an indirect
decompression and provide stabilisation while preserving the bony
structures of the spinal column (Senegas 1991).However, themost
recent evidence on this topic has shown that these spacer devices
alone are not only more costly than conventional decompression,
but are also associated with higher reoperation rates (Deyo 2013).
Alternatives to conventional decompression by laminectomy have
been developed to minimise the damage on posterior structures
of the lumbar spine. Minimally invasive decompressive tech-
niques used to treat lumbar spinal stenosis include uni- or bilat-
eral laminotomies and spinal process-splitting laminectomy.These
techniques are also frequently performed with the use of an en-
doscope or microscope. The bilateral laminotomy technique pre-
serves the neural arch of the vertebrae and protects the dura. In
multisegmental stenosis this technique allows the reattachment
of the paravertebral muscles to the spinous processes. The sur-
geon partially removes the laminae and ligamentum flavum but
preserves the facet joint complex and the muscles attached to it
(Aryanpur 1988). Unilateral laminotomy refers to partial resection
of the facets and the medial portion of the lamina, and complete
removal of the ligamentum flavum (Spetzger 1997). This tech-
nique was developed to overcome the disadvantage of surgically
induced instability (Spetzger 1997a). More recently, the spinous
process-splitting laminectomy was developed (Watanabe 2005).
In this technique, the lamina is exposed by longitudinally splitting
the spinous process into halves, allowing muscles and ligamentous
attachments to be left intact. Recently, another Cochrane review
showed that these posterior decompression techniques delivered
no different results in terms of leg pain or disability reduction
compared to conventional laminectomy (Overdevest 2015).
How the intervention might work
Increasing the cross-sectional area of the spinal canal at the level of
stenosis (decompression) may decrease pain that is generated from
increased pressure on the nerves within the stenosed segment. The
complete removal of the vertebrae lamina and spinal process in an
extensive conventional laminectomy is, however, linked to post-
surgical spinal instability (Abumi 1990; Hopp 1988; Lee 1983).
Therefore, techniques that increase spinal stability after decom-
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pression, such as fusion, might have an advantage compared with
decompression alone. In a conventional laminectomy procedure,
the paraspinal muscles are detached extensively from the spinal
processes, vertebrae lamina and facets. Suchmuscle damage is asso-
ciated with significant atrophy of paraspinal muscles (Kawaguchi
1996; See 1975), and the spinal process-splitting decompression
technique has been proposed to preserve muscle integrity. In ad-
dition, other minimally invasive decompression techniques (e.g.,
uni- or bilateral laminotomies) preserve spinal integrity and are po-
tentially capable of reducing postoperative complications such as
muscle atrophy, weakness, postoperative pain, perioperative blood
loss, operation time and length of hospital stay. Endoscopic as-
sisted decompressive surgery has also been proposed to avoid scar-
ing of the epidural space (Cooper 1991).
Why it is important to do this review
Surgery for lumbar spinal stenosis is believed to be more effective
than conservative treatment when the latter has failed for up to
six months (Kovacs 2011; May 2013). However, the most recent
evidence does not confirm this belief. For instance, in the Spine
Patient Outcomes Research Trial (SPORT) patients treated sur-
gically did not report any difference in outcomes compared with
those treated non-surgically in the intention-to-treat analyses, al-
though the as-treated analyses showed statistically significant but
small differences in terms of pain and function favouring surgery
(Weinstein 2008). Further, a recent trial has also shown that surgi-
cal decompression yielded similar effects to a physiotherapy pro-
gramme (Delitto 2015). In this review we did not include trials
comparing surgery with non-surgical interventions, because this is
covered in another Cochrane review (Zaina 2016). Given most of
the evidence supporting the use of surgery for lumbar spinal steno-
sis comes largely from trials comparing surgery with non-surgical
interventions, it is not possible to distinguish the specific effects of
surgery from the effects of time, regression to themean, or placebo
effects (Flum2006).Moreover, many surgical techniques are avail-
able for the management of lumbar spinal stenosis, and the lack
of evidence to support the rapid evolution of surgical techniques
has led clinicians to rely on their own opinions and experiences
to choose the surgical technique for their patients (Katz 1997),
which leads to practice variation. The conflicting results from cur-
rent randomised trials (Cavusoglu 2007; Grob 1995; Stromqvist
2013), and the emerging evidence on this topic (Forsth 2016;
Ghogawala 2016) demand a synthesis of the available evidence.
O B J E C T I V E S
To determine the efficacy of surgery (i.e., surgery versus no treat-
ment, or placebo/sham surgery) in the management of patients
with symptomatic lumbar spinal stenosis and the comparative ef-
fectiveness of commonly performed surgical techniques to treat
this condition on patient-related outcomes. We also aimed to in-
vestigate the safety of these surgical interventions by including pe-
rioperative surgical data and reoperation rates.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included published randomised controlled trials.
Types of participants
The participants included in our review consisted of adults
with symptomatic degenerative lumbar spinal stenosis, despite its
anatomical classification (central, foraminal or lateral) or diagnos-
tic criteria (physical examination or radiographic imaging). There
were no restrictions regarding intensity or duration of symptoms.
Studies of participants with trauma, tumour and previous spine
surgery were excluded. As degenerative spondylolisthesis is a com-
mon finding in patients with lumbar spinal stenosis, only trials in-
cluding participants with spondylolisthesis up toMeyerding grade
I (translation of the cranial vertebra of up to 25%) were included
(Meyerding 1932).
Types of interventions
We considered studies that compared the efficacy of surgery with
no treatment, placebo or sham surgery. We also included trials
that compared the effectiveness of different surgical techniques
for lumbar spinal stenosis. However, trials comparing different
fusion techniques or interspinous spacer devices, and surgery for
cervical spinal stenosis, were excluded. We also excluded trials
that compared surgery with non-surgical interventions, as this is
covered in another recent Cochrane review (Zaina 2016).
Types of outcome measures
We included patient-centred outcomes of clinical relevance, as well
as safety and perioperative surgical outcomes. We did not consider
radiographic and biomechanical outcomes.
Primary outcomes
The primary outcomes of this review comprised:
• pain intensity;
• physical function or disability status;
• quality of life; and
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• recovery.
Pain intensity outcomes were back pain, leg pain or overall pain
reported in visual analogue scales or numeric rating scales. Disabil-
ity outcomes measures included Roland-Morris Disability Ques-
tionnaire (RMDQ), Owestry Disability Index (ODI) or any other
disability instrument used in low back pain research, and walk-
ing ability. Physical function was included if measured using the
Zurich Claudication Questionnaire (ZCQ). Quality of life out-
comes were, for example, total scores of the 36-item or 12-item
Short Form Health Survey (SF-36, SF-12), or the EuroQol ques-
tionnaire (EQ-5D). Trials that reported individual item scores,
rather than the total scores, of the quality of life scales were not
included in the meta-analysis. Recovery was measured using the
differences between preoperative and postoperative Japanese Or-
thopaedic Association (JOA) scores as reported by the included
trials.
Secondary outcomes
Secondary outcomes were:
• perioperative blood loss;
• operation time;
• length of hospital stay;
• reoperation rate; and
• costs.
Search methods for identification of studies
Electronic searches
Review authors developed the search strategy based on the Back
and Neck Review Group methods guidelines and a specialist was
consulted to revise it. Electronic searches of the followingdatabases
were performed up to 16 June 2016:
• Cochrane Back and Neck Review Group Trials Register
(OvidSP, 1991 to May 2016).
• Cochrane Central Register of Controlled Trials
(CENTRAL; OvidSP, Issue 5, 2016).
• MEDLINE (OvidSP, 1946 to June Week 2 2016).
• Embase (Embase.com, 1947 to 16 June 2016).
• CINAHL (EBSCO, 1981 to 16 June 2016).
• AMED (OvidSP, 1985 to 16 June 2016).
• Web of Science (Thomson Reuters, 1900 to 16 June 2016).
• Latin American and Caribbean Health Sciences Literature (
LILACS; 1967 to 16 June 2016).
There were no restrictions on language or publication date. The
search strategy for each database can be found in Appendix 1.
Searching other resources
Authors also searched ClinicalTrials.gov, Australian New Zealand
Clinical Trials Registry (ANZCTR), and World Health Organi-
zation (WHO) International Clinical Trials Registry Platform (
ICTRP) for registered, ongoing or completed trials and contacted
the main investigators of the relevant trials to identify any publi-
cation of the study. The keywords used for these searches included
spinal stenosis, surgery and decompression.
Data collection and analysis
Selection of studies
One reviewer (GM) performed the first screening for relevant
records based on titles and abstracts. Two independent reviewers
(GM andMP/MR/RY) performed the screening of full texts, used
consensus to resolve any disagreement and consulted a third re-
viewer (MF) when consensus could not be reached.
Data extraction and management
Using a standardised data extraction form, two reviewers (GMand
MP/RY) independently extracted data from each included study
and used consensus to resolve any disagreement. From each study,
the reviewers extracted participants’ characteristics (age, disease
duration and diagnostic criteria), type of surgery, type of compar-
ison and outcomes. Pain and disability outcome measures were
converted to scales from 0 (no pain or disability) to 100 (worst
possible pain or disability).
Assessment of risk of bias in included studies
Reviewers evaluated the risk of bias in the included trials using
the ’Risk of bias’ assessment tool as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
and the Cochrane Back and Neck Review Group (Furlan 2015).
Two reviewers (GM and MP/RY) independently performed the
’Risk of bias’ assessment of the included trials, used consensus if
there was any disagreement and consulted a third reviewer (MF)
when consensus could not be reached. We scored each study as
having ’high’, ’low’ or ’unclear’ risk of bias for each criterion (see
Table 1 and Table 2).
Measures of treatment effect
Trials were grouped according to the types of surgical interven-
tions being compared, outcomes and assessment time points. We
extracted sample sizes, means (final values) and standard devia-
tions (SD) for continuous outcomes and quantified the treatment
effects as mean differences (MD), or standardised mean differ-
ences (SMD) when trials used different methods to assess the same
outcome. For dichotomous outcomes, the number of cases and
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the total sample size were used to estimate risk ratios (RR). We,
therefore, used MD, SMD or RR and 95% confidence intervals
(CI) as measures of treatment effects.
Unit of analysis issues
We did not include cluster-randomised trials or cross-over trials.
Whenmultiple painmeasures were reportedwe extracted themost
severemeasure at baseline. For disability, we chose the scale defined
in the study as the primary outcome. For data synthesis, follow-
up times were categorised as short-term (closest to three months)
and long-term (closest to 12 months). When studies reported re-
sults for more than two intervention groups, we combined similar
groups according to the recommendations in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
If trials reported incomplete data, we contacted authors to request
further information. If authors were unavailable or when authors
refused to provided data, we imputed data according to recom-
mendations in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). For example, we calculated missing
SDs from reported standard errors or 95% CIs and sample size, or
we imputed missing SDs from the average SD reported in similar
studies. We also estimated SDs from graphs when these estimates
were missing in tables or not reported in the text of included trials.
When studies reported medians and interquartile ranges (IQR),
we considered that the median was equivalent to the mean and
the IQR was 1.35 times the SD (Higgins 2011).
Assessment of heterogeneity
We grouped similar trials (e.g., similar types of surgical compari-
son, outcomes, and assessment time points) into clusters and per-
formed a separate analysis for each cluster. To assess heterogeneity
for each pooled analysis we used the I² statistic to estimate the total
variation across studies that was due to heterogeneity, and consid-
ered heterogeneity values greater than 50% to be high (Higgins
2002).
Assessment of reporting biases
We planned to assess reporting bias for each meta-analysis with a
minimum of 10 trials using visual inspection of funnel plots and
Egger’s test. However, the number of studies in each meta-analysis
was insufficient for assessing this type of bias.
Data synthesis
Treatment effects were calculated using random-effects models
with inverse variance weighting for all meta-analyses. A summary
of findings table was created in Review Manager 5.3 and we used
the Grading of Recommendations Assessment, Development and
Evaluation (GRADE, see Appendix 2) to assess the quality of the
evidence for each outcome measure (Guyatt 2008). The quality of
evidence was downgraded by one level according to the following
criteria: limitation of study design (> 25% of the studies with high
risk of bias (at least one of the bias domain judged as high risk)),
inconsistency of results (statistically significant heterogeneity (I²
> 50%) or ≤ 75% of trials with findings in the same direction),
and imprecision (wide confidence intervals or the total number of
participants was fewer than 400 participants in the comparison for
continuous data or fewer than 300 events for dichotomous data
for each pooled analysis). The indirectness criterion was not con-
sidered in this review because we included a specific population
with relevant outcomes and direct comparisons. Where only sin-
gle trials were available, evidence from studies with less than 400
participants was downgraded for imprecision and rated as ’moder-
ate quality’ evidence. The quality of the evidence could be further
downgraded to ’low quality’ evidence if limitations of study design
were found. The quality of evidence was defined as: ’high qual-
ity’, ’moderate quality’, ’low quality’ or ’very low quality’ (Guyatt
2008).
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was planned according to type of surgical in-
tervention (e.g., decompression alone versus decompression plus
fusion) for all outcomes and duration of follow-up (e.g., short-
term and long-term). Although we planned analyses of sources of
heterogeneity according to different factors (e.g., surgeon’s expe-
rience) we did not have enough studies in each meta-analysis to
report accurate results.
Sensitivity analysis
We aimed to perform sensitivity analysis to investigate whether
our judgment of risk of bias of individual studies and time point
definitionwould affect our conclusions.However, this analysis was
not possible due to the limited number of studies in each meta-
analysis.
R E S U L T S
Description of studies
The description of included studies is summarised in
Characteristics of included studies.
Results of the search
Our search identified a total of 7494 records. After excluding du-
plicates, we screened 5358 titles and abstracts, and assessed 145
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full text records. Of these, 24 randomised controlled trials (re-
ported in 39 published research articles or abstracts) remained el-
igible for inclusion in our review (Azzazi 2010; Bridwell 1993;
Cavusoglu 2007; Celik 2010; Cho 2007; Davis 2013; Forsth
2016; Ghogawala 2016; Grob 1995; Gurelik 2012; Hallett 2007;
Komp 2015; Liu 2013; Lonne 2015;Mobbs 2014; Moojen 2013;
Postacchini 1993; Rajasekaran 2013; Ruetten 2009; Stromqvist
2013; Thome 2005; Usman 2013; Watanabe 2011; Yagi 2009).
The flow chart of studies with the main reasons for exclusion are
shown in Figure 1. All trials included in this review were published
in English and therefore no translation was required.
Figure 1. Study flow diagram.
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Included studies
The 24 included trials investigated a total of 2352 participants and
most studies defined lumbar spinal stenosis based on clinical assess-
ment with a concordant imaging diagnosis (Azzazi 2010; Bridwell
1993; Cavusoglu 2007; Celik 2010; Cho 2007; Davis 2013; Grob
1995;Gurelik 2012; Forsth 2016;Ghogawala 2016;Hallett 2007;
Lonne 2015; Mobbs 2014; Moojen 2013; Rajasekaran 2013;
Ruetten 2009; Stromqvist 2013; Thome 2005; Usman 2013;
Watanabe 2011; Yagi 2009). One study included participants
based solely on imaging diagnosis (Postacchini 1993), and two
studies used clinical assessment only (Komp 2015; Liu 2013).
Nineteen out of 24 trials (80%) explicitly reported including only
participantswhohad failed to improvewith conservative treatment
(Azzazi 2010; Bridwell 1993; Cavusoglu 2007; Celik 2010; Cho
2007;Davis 2013;Grob 1995;Gurelik 2012;Hallett 2007; Komp
2015; Lonne 2015; Moojen 2013; Rajasekaran 2013; Ruetten
2009; Stromqvist 2013; Thome 2005; Usman 2013; Watanabe
2011; Yagi 2009). The mean age of participants in included trials
ranged from 56 to 73 years, and trials were conducted in a range
of countries, including the United States, Australia, Turkey, Pak-
istan, Switzerland, Sweden, the United Kingdom, and Japan. See
Characteristics of included studies for additional information.
Excluded studies
We excluded 106 reports from our review; see Characteristics of
excluded studies. The reasons for exclusion were:
• not a randomised controlled trial (67): Abdu 2009;
Anderson 2011; Asazuma 2004; Bazan 2002; Blumenthal 2013;
Bresnahan 2009; Cakir 2009; Cannone 2010; Carrasco 1986;
Cassinelli 2007; Choi 2009; Dantas 2007; Delank 2002; Desai
2012; Epstein 2006; Escobar 2003; Fan 2009; Fast 1985;
Fitzgerald 1976; Försth 2013; Fu 2008; Fujiya 1990;
Ghahreman 2010; González 1992; Gotfryd 2012; Gotfryd
2012a; Gu 2009; Halm 2010; Herkowitz 1991; Hong 2010;
Hong 2011; Ikuta 2005; Imagama 2009; Ito 2010; Katz 1997;
Kawaguchi 2004; Kim 2007; Kim 2007a; Konno 2000;
Kornblum 2004; Lee 2009; Liao 2011; Pappas 1994; Parker
2013; Radcliff 2012; Rapp 2009; Rapp 2011; Richter 2010;
Rompe 1995; Rosa 2012; Rowland 2009; Satomi 1992; Schnake
2006; Sengupta 2006; Skidmore 2011; Smoljanovic 2010;
Smorgick 2013; Steffee 1993; Tani 2002; Tenhula 2000;
Tsutsumimoto 2009; Valesin 2009; Wang 1998; Willén 2008;
Yamada 2012; Yang 2011; Yu 2008;
• not lumbar spinal stenosis (23): Andersen 2008; Aoki
2012; Arriagada 2000; Benli 2006; Bjarke 2002; Carragee 1997;
Carreon 2009; Chen 2010; Cheng 2009; Dahdaleh 2013;
Delawi 2010; Dimar 2009; Feng 2011; Hwang 2010; Kim 2006;
Korovessis 2004; Lian 2010; Ledonio 2012; Michielsen 2013;
Videbaek 2010; Xiao 2007; Xiao 2007a; Zdeblick 1993; and
• inappropriate comparison (16): Auerbach 2012; Altaf
2011; Auerbach 2011; Dirisio 2011; Dryer 2012; Haley 2012;
Haley 2012a; Mahir 2012; McConnell 2011; Radcliff 2011;
Repantis 2009; Sears 2012; Shapiro 2005; Weinstein 2007;
Whang 2013; Zucherman 2004.
Risk of bias in included studies
As blinding of the therapist in surgical trials is not possible, we
judged all studies to be at high risk of bias for this domain. We
judged half of the included trials to be at low or unclear risk for all
of the remaining domains of the ’Risk of bias’ assessment. Only
one trial (Moojen 2013) had all bias domains (except therapist
blinding) judged as low risk. Most of the trials failed to adequately
conceal the randomisation process, blind the participants or use
an intention-to-treat analysis. The results from the risk of bias
assessments for the included studies are summarised in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Only seven trials reported an appropriate method of randomisa-
tion, such as a computer-generated randomisation list. Although
13 trials mentioned that study participants were randomised, they
failed to describe themethod used for randomisation andwe there-
fore judged them to be at unclear risk of bias. Two trials reported
that participants were randomly allocated according to the se-
quence of presentation to study site and we therefore considered
them to be at high risk of bias (Mobbs 2014; Yagi 2009). In two
trials, the authors reported that the randomisation protocol was
broken and we also considered these trials at high risk of selection
bias (Bridwell 1993; Postacchini 1993). Only six trials reported
an appropriate method of allocation concealment, and 18 failed
to report the method (Figure 2).
Blinding
In surgical clinical trials, it is not possible to blind care providers
(i.e., surgeons), therefore we judged all included studies to be
at high risk of bias for this domain. Only three studies blinded
participants (Celik 2010; Davis 2013; Moojen 2013), while three
trials reported not blinding participants leading us to judge them
as being at high risk of bias (Gurelik 2012; Komp 2015; Ruetten
2009). The remaining 18 trials failed to provide information on
blinding of participants, sowe considered them tobe at unclear risk
for this bias domain. Eleven trials reported blinding of outcome
assessors; 12 did not report this information and so we judged
them as being at unclear risk of bias. Only one trial mentioned that
outcome assessors were not blinded and we therefore considered
it to be at high risk of bias (Hallett 2007).
Incomplete outcome data
We considered most of the trials (n = 17) to be at low risk of bias
as they reported less than 15% drop-out. One study reported that
nearly 22% of participants were lost, but the number of drop-outs
and reasons were similar between the groups, therefore we judged
this trial as being at low risk of bias for this outcome (Mobbs 2014).
Six trials did not mention the number of participants withdrawn
from the study and we thus judged them as being at unclear risk.
Selective reporting
We judged three trials as being at high risk of bias for selective
reporting. Azzazi 2010 mentioned collecting short-term follow-
up data in the methods section, but failed to report results. Also,
although the authors mentioned measuring the amount of blood
lost during surgery, these data were not reported in the published
manuscript. Bridwell 1993 failed to report relevant patient-related
outcome measures (i.e., pain, disability), and Usman 2013 re-
ported that recovery rate was one of the outcome measures of the
trial, but it was not reported in the results section. We attempted
to contact authors in order to have access to these data, but none
replied.
Other potential sources of bias
Eleven trials reported not receiving funds for conducting the trial
or disclosed any conflicts of interest; we therefore judged them as
being at low risk of bias. The remaining trials did not provide a
conflict of interest or funding statement so we considered them to
be at unclear risk for other sources of bias.
Effects of interventions
See:
Summary of findings for the main comparison SUMMARY
OFFINDINGS FORDECOMPRESSIONVERSUS FUSION;
Summary of findings 2 SUMMARY OF FINDINGS FOR
DECOMPRESSION VERSUS INTERSPINOUS SPACERS;
Summary of findings 3 SUMMARY OF FINDINGS FOR
FUSION VERSUS INTERSPINOUS SPACERS
We did not identify trials comparing surgery with no treatment,
placebo or sham surgery. Therefore, all trials included in this re-
view compared different types of surgical interventions for lumbar
spinal stenosis. We divided the included trials into six comparisons
according to the surgical techniques being compared.
Decompression alone versus decompression plus
fusion
The addition of fusion to bony decompression by either con-
ventional laminectomy (Bridwell 1993; Forsth 2016; Ghogawala
2016; Grob 1995) or foraminotomy (Hallett 2007) was investi-
gated in five randomised trials reporting data from 446 partici-
pants. Overall, the studies included in this review were fairly ho-
mogeneous, thus most of our meta-analyses revealed no important
heterogeneity (I² < 50%). A few pooled analyses resulted in con-
siderable heterogeneity however (I² > 75%), especially the analy-
sis on operation time, where a great variability of estimates were
reported in included trials.
Primary outcomes
Our analyses showed no difference between groups on pain reduc-
tion in the short- (MD 4.50, 95% CI -0.70 to 9.70; Ghogawala
2016) and long-term (MD-0.29, 95%CI -7.32 to 6.74; see Figure
3). Similarly, we found that decompression plus fusion was not
superior to decompression alone on disability reduction at both
13Surgical options for lumbar spinal stenosis (Review)
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short- (MD 5.20, 95% CI -3.50 to 13.90; Ghogawala 2016) and
long-term follow-up (MD 3.26, 95% CI -6.12 to 12.63). We
judged the quality of evidence in the short-term for both outcomes
as ’low quality’ (downgraded for imprecision and inconsistency),
and further downgraded it to ’very low quality’ for limitation of
study design in the long-term. Three trials evaluated the effects of
decompression plus fusion compared with decompression alone
on walking ability (i.e., participants were considered improved
when able to increase their walking distance by 50% at follow-up).
This analysis provided ’very low quality’ evidence (downgraded
for imprecision, inconsistency, and limitation of study design) of
no difference between groups (RR 0.99, 95% CI 0.79 to 1.24; see
Summary of findings for the main comparison).
Figure 3. Forest plot of comparison: 1 Decompression alone versus decompression plus fusion, outcome:
1.1 Pain.
Secondary outcomes
Two trials reported themean direct surgery cost per patient. Forsth
2016 showed lower costs for decompression alone (USD 10,392)
compared with decompression plus fusion (USD 16,115). Simi-
larly, Hallett 2007 revealed that decompression incurred half the
cost of fusion surgery (USD 5,400 versus USD 12,200). However,
no measures of variability or inferential statistics were reported for
this outcome. We found ’very low quality’ evidence (downgraded
for imprecision, inconsistency, and limitation of study design)
that decompression alone required shorter operation time (MD -
107.94 minutes, 95% CI -161.65 minutes to -54.23 minutes; )
and was associated with less perioperative blood loss (MD -0.52
L, 95%CI -0.70 L to -0.34 L) compared with decompression plus
fusion. ’Moderate quality’ evidence (downgraded for limitation of
study design) revealed no difference in the number of reopera-
tions (RR 1.25, 95% CI 0.81 to 1.92), and ’low quality’ evidence
(downgraded for imprecision and inconsistency) showed shorter
hospital stays after decompression alone (MD -1.69 days, 95%
CI -2.12 days to -1.26 days) compared with decompression plus
fusion operations.
Decompression versus interspinous spacer
Three trials reported data of 355 participants comparing bony
decompression (laminectomy or laminotomy) with the X-Stop or
Coflex interspinous process spacer devices (Lonne 2015; Moojen
2013; Stromqvist 2013).
Primary outcomes
At short-term, ’low quality’ evidence (downgraded for impreci-
sion and inconsistency) showed no difference on pain reduction
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(MD -0.93, 95% CI -9.86 to 8.00). Likewise, ’moderate quality’
evidence (downgraded for imprecision) revealed no long-term dif-
ference on pain between the groups (MD -0.55, 95% CI -8.08
to 6.99; see Figure 4). For disability, ’moderate quality evidence’
(downgraded for imprecision) did not reveal any difference in the
short-term (MD 1.30, 95% CI -3.64 to 6.25), and ’low qual-
ity’ evidence (downgraded for imprecision and inconsistency) also
showed no superior benefits of interspinous spacers in the long-
term (MD 1.25, 95% CI -4.48 to 6.98). Pooling revealed ’moder-
ate quality’ evidence (downgraded for imprecision) that improve-
ment of function (as measured by the ZCQ function sub scale)
was similar in the two groups at short- (MD -0.06, 95% CI -0.27
to 0.14) and long-term follow-up (MD -0.00, 95% CI -0.30 to
0.29). One study (Lonne 2015) provided ’moderate quality’ evi-
dence (downgraded for imprecision) that there were no differences
between decompression and interspinous spacers for quality of life
improvement in the short- (MD -0.12, 95% CI -0.25 to 0.01)
and long-term (MD -0.05, 95% CI -0.18 to 0.07; see Summary
of findings 2).
Figure 4. Forest plot of comparison: 2 Decompression versus interspinous spacer, outcome: 2.1 Pain.
Secondary outcomes
Results from ’low quality’ evidence (downgraded for imprecision
and inconsistency) showed that participants receiving interspinous
spacers required longer operation time (MD 39.11 minutes, 95%
CI 19.43 minutes to 58.78 minutes), but there were no differ-
ences in terms of length of hospital stay (MD 0.51 days, 95%
CI -0.58 days to 1.60 days) and perioperative blood loss (MD
144.00 mL, 95% CI -209.74 mL to 497.74 mL). However, ’high
quality’ evidence demonstrated higher reoperation rates after in-
terspinous spacers (RR 3.95, 95%CI 2.12 to 7.37) compared with
conventional decompression. Two trials (Lonne 2015; Moojen
2013) providing ’moderate quality’ evidence (downgraded for im-
precision) reported the total health care cost associated with surgi-
cal procedures, and revealed a significantly higher cost associated
with the interspinous spacers; the incremental cost for an implant
was estimated at EUR 2,856.34 (95% CI EUR 1,970.40 to EUR
3,742.28) or USD 3,103.84 (95% CI USD 2,141.14 to USD
4,066.55).
Decompression plus fusion versus interspinous spacer
Two trials compared decompression plus fusion with the X-Stop
or Coflex interspinous spacer devices (Azzazi 2010; Davis 2013),
including a total of 382 participants analysed at long-term follow-
up only.
Primary outcomes
There was ’low quality’ evidence (downgraded for imprecision and
limitation of study design) of no difference between groups on
pain reduction (MD 5.35, 95% CI -1.18 to 11.88; see Figure
5), and ’moderate quality’ evidence (downgraded for imprecision)
also showed no superior benefit of interspinous spacers in terms
of quality of life (MD -3.10, 95% CI -6.30 to 0.10). However,
we found ’low quality’ evidence (downgraded for imprecision and
limitation of study design) that interspinous spacers were slightly
more effective than fusion on disability reduction (MD5.72, 95%
CI 1.28 to 10.15; see Summary of findings 3).
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Figure 5. Forest plot of comparison: 3 Decompression plus fusion versus interspinous spacer, outcome: 3.1
Pain.
Secondary outcomes
We found ’moderate quality’ evidence (downgraded for impreci-
sion) that decompression plus fusion resulted in more periopera-
tive blood loss (MD 238.90 mL, 95% CI 182.66 mL to 295.14
mL; Davis 2013) compared with interspinous spacers. ’Very low
quality’ evidence (downgraded for imprecision, inconsistency and
limitation of study design) revealed longer operation time (MD
78.91 minutes, 95% CI 30.16 minutes to 127.65 minutes) and
length of hospital stay (MD 1.58 days, 95% CI 0.90 days to 2.27
days) for decompression plus fusion. However, there was no differ-
ence in reoperation rates between the two groups (RR 0.70, 95%
CI 0.32 to 1.51; Davis 2013) from ’high quality’ evidence.
Laminectomy versus laminotomy
Six randomised controlled trials reporting data from 475 par-
ticipants compared laminectomy to unilateral (Cavusoglu 2007;
Gurelik 2012; Liu 2013; Thome 2005) or bilateral laminotomy
(Celik 2010; Postacchini 1993; Thome 2005). Data from unilat-
eral and bilateral laminotomy groups were combined according
to recommendations in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011).
Primary outcomes
We found ’moderate quality’ evidence (downgraded for impreci-
sion) that laminotomy is not superior to laminectomy in reducing
pain in the short-term (MD0.32, 95%CI -2.39 to 3.04), and ’low
quality’ evidence (downgraded for inconsistency and limitation of
study design) of no difference in the long-term (MD -1.92, 95%
CI -8.19 to 4.35; see Figure 6). Likewise, ’moderate quality’ ev-
idence (downgraded for imprecision) revealed no between-group
differences on disability reduction at short- (MD 1.56, 95% CI -
1.02 to 4.13) and long-term follow-up (MD -0.43, 95% CI -4.37
to 3.52). For walking ability (i.e., walking distance inmetres with-
out radicular pain), we found ’low quality’ evidence (downgraded
for imprecision and limitation of study design) of no difference
between these techniques in the short-term (SMD -0.07, 95%
CI -0.33 to 0.20). ’Moderate quality’ evidence (downgraded for
imprecision) also showed no difference in walking ability in the
long-term (SMD -0.02, 95% CI -0.33 to 0.28).
Figure 6. Forest plot of comparison: 4 Laminectomy versus laminotomy, outcome: 4.1 Pain.
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Secondary outcomes
Our results revealed ’low quality’ evidence (downgraded for im-
precision and limitation of study design) of no difference between
the two surgical procedures on the duration of operation (MD -
6.25minutes, 95%CI -13.76minutes to 1.27minutes).However,
there was significantly more blood loss (MD 38.80 mL, 95% CI
17.81 mL to 59.80 mL) and longer hospital stay (MD 1.55, 95%
CI 0.61 to 2.50) for laminectomy when compared with lamino-
tomy. ’Moderate quality’ evidence (downgraded for imprecision)
demonstrated no difference in the number of participants having
a revision surgery (RR 2.61, 95% CI 0.78 to 8.78).
Decompression versus split-decompression
Four trials reported data of 218 participants comparing decom-
pression (laminectomy) with spinous process split-decompression
(Cho 2007; Liu 2013; Rajasekaran 2013; Watanabe 2011). Only
long-term follow-up data was available in included trials.
Primary outcomes
Pooling showed ’low quality’ evidence (downgraded for inconsis-
tency and imprecision) of no differences between treatments on
pain reduction (MD 6.35, 95% CI -3.35 to 16.04). ’Moderate
quality’ evidence (downgraded for imprecision) also revealed no
differences between the two groups on disability reduction (MD
1.87, 95% CI -2.82 to 6.57). ’Low quality’ evidence (downgraded
for inconsistency and imprecision) suggested no superior benefits
of split-decompression on long-term recovery (MD -5.18, 95%
CI -19.81 to 9.45), as assessed by the JOA recovery score (range
0 to 100), compared with conventional decompression.
Secondary outcomes
We found no differences between the two groups based on ’low
quality’ evidence (downgraded for inconsistency and imprecision)
in terms of operation time (MD -10.57 minutes, 95% CI -34.39
minutes to 13.25 minutes), perioperative blood loss (MD -1.83
mL, 95% CI -27.65 mL to 23.98 mL), and length of hospital
stay (MD 1.49 days, 95% CI -1.70 days to 4.67 days). ’Moderate
quality’ evidence (downgraded for imprecision) also demonstrated
that the number of participants requiring reoperation was similar
between the groups (RR 1.22, 95% CI 0.22 to 6.85).
Decompression versus endoscopic decompression
The efficacy of endoscopic-assisted decompression was investi-
gated in three randomised trials including 393 participants (Komp
2015; Ruetten 2009; Yagi 2009).
Primary outcomes
Our meta-analysis revealed ’low quality evidence’ (downgraded
for imprecision and limitation of study design) of a small but sig-
nificant short-term disability reduction of endoscopic approaches
compared with conventional decompression (MD 4.12, 95% CI
0.91 to 7.33). However, ’very low quality evidence’ (downgraded
for inconsistency, imprecision and limitation of study design)
showed no difference between these surgical interventions for dis-
ability in the long-term (MD 1.44, 95% CI -2.66 to 5.54). Komp
2015 did not report estimates of between-group differences or
measures of variability for each treatment group, therefore we
could not calculate a treatment effect for this trial.
Secondary outcomes
’Very low quality’ evidence (downgraded for inconsistency, im-
precision, and limitation of study design) showed no between-
group difference on operation time (MD 10.05 minutes, 95% CI
-2.09 minutes to 22.18 minutes). However, Yagi 2009 provided
’low quality’ evidence (downgraded for imprecision and limitation
of study design) that conventional decompression was associated
withmore perioperative blood loss (MD34.00mL, 95%CI 30.40
mL to 37.60 mL) and longer hospital stay (MD 8.56 days, 95%
CI 6.78 days to 10.34 days) compared with endoscopic decom-
pression. ’Moderate quality’ evidence (downgraded for limitation
of study design) suggested that the number of participants having
a revision surgery was similar between the surgical interventions
(RR 0.81, 95% CI 0.22 to 2.97).
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D I S C U S S I O N
Summary of main results
Our results revealed a paucity of evidence on the efficacy of surgery
for lumbar spinal stenosis. We found no trials investigating the
efficacy of surgery for lumbar spinal stenosis compared with no
treatment, placebo or sham surgery. Therefore, the effects of time,
regression to the mean, and patients’ expectations (placebo effect)
regarding surgery remain unknown. Previous research has shown
that placebo-controlled trials in surgery are feasible and a powerful
tool to show the efficacy of surgical interventions (Wartolowska
2014). We identified 24 published randomised trials that com-
pared the effects of different surgical techniques for this condi-
tion. In our main comparison, we found that fusion does not add
benefits in terms of pain or disability reduction compared with
decompression alone for the treatment of lumbar spinal stenosis.
In addition, we found no differences on pain, disability and qual-
ity of life between interspinous process spacer devices and con-
ventional bony decompression. However, the interspinous spac-
ers resulted in significantly higher reoperation rates. We found no
further differences in outcomes among the other surgical decom-
pression techniques for lumbar spinal stenosis. In sum, at present,
newer surgical techniques have not proven superior to conven-
tional decompression for patients with lumbar spinal stenosis.
Overall completeness and applicability of
evidence
Given the number of surgical techniques for the treatment of lum-
bar spinal stenosis, the need for placebo-controlled trials has never
been greater. Through our search, we could not find published
placebo-controlled surgical trials in patients with lumbar spinal
stenosis. Previous studies have demonstrated the appropriate eth-
ical considerations for placebo surgery (Horng 2003), and con-
firmed their feasibility (Wartolowska 2014). Such trials, investi-
gating the efficacy of surgery compared with placebo for other
spinal conditions, such as painful osteoporotic vertebral fractures,
have been conducted and recently published. Buchbinder 2009
performed sham surgery by inserting a blunt stylet and gently tap-
ping the vertebral body and compared this with conventional ver-
tebroplasty. Likewise, Flum 2006 has suggested performing mini-
mally invasive approaches simulating the decompressive technique
to the spine for patients with lumbar spinal stenosis, but without
actually removing any bone tissue.
The addition of fusion to decompression is commonly performed
in this population, although a recent study has shown that fusion
is not only more costly but highly associated with major com-
plications and deaths when compared with decompression alone
(Deyo 2010). Our review provides relevant information on this
topic, showing that the addition of fusion was not associated with
better outcomes (pain or disability) compared with decompres-
sion alone. In fact, fusion was significantly associated with longer
operation time (nearly two hours difference) and more blood loss
during operation (over 500 mL difference), confirming the higher
risk for complications when performing this type of surgery. How-
ever, more studies are needed as we only included five trials pro-
viding ’very low quality’ to ’moderate quality’ evidence. For pa-
tients who present spinal instability and thus require stabilisation
of spinal segments after decompression, the interspinous spacer
devices might be an alternative as theywere linked to less perioper-
ative blood loss and shorter operation time and hospital length of
stay. The interspinous spacer devices, however, should not replace
conventional decompression surgery when only decompression of
the spinal canal is warranted (i.e., no further fusion). These devices
failed to be superior to conventional decompression on patient-
relevant outcomes, and resulted in significantly higher reopera-
tion rates. Moreover, our results showed that these implants can
cost on average 1.5 times more than conventional decompression.
Considering the higher risks and costs, we would not recommend
the spacer devices as an alternative to conventional decompression
surgery for lumbar spinal stenosis.
One may argue that differences in the proportion of patients with
mild spondylolisthesis included in the trials may affect the re-
sults. In trials that investigated fusion compared with interspinous
spacers, both Davis 2013 and Azzazi 2010 included only partici-
pants with up to grade I stable degenerative spondylolisthesis. In
Davis 2013, the proportion of participants with spondylolisthesis
was 47%; however, Azzazi 2010 did not report the proportion of
these participants. In the other included trials, the proportion of
participants with up to grade I spondylolisthesis varied. For ex-
ample, Ghogawala 2016 included only participants with lumbar
spinal stenosis and grade I spondylolisthesis, whereas Forsth 2016
stratified the randomisation process to the presence or absence
of degenerative spondylolisthesis, and Cavusoglu 2007 reported
that 15% of included participants had mild spondylolisthesis. Al-
though the differences between groups for some outcomes were
not statistically significant, some might be considered clinically
relevant. As most studies were very small, they were likely under-
powered. Larger studies are needed to confirm these findings, for
example the difference in revision rates between laminectomy and
laminotomy.
This review provides valuable information for clinical decision
making regarding the best surgical technique for patients with
lumbar spinal stenosis, and should be used to inform clinical prac-
tice guidelines about the benefits and harms of different surgical
options for this condition.
Quality of the evidence
Overall, the methodological quality of included studies was poor.
Whereas blinding of the caregiver in surgical trials is typically not
possible, eleven trials reported blinding of outcome assessors and
only three studies reported that participants were blinded. The
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quality of the available evidence (GRADE) ranged from ’high
quality’ to ’very low quality’. In most cases where the evidence
was downgraded, this was done because we found inconsistency
of findings (I² > 50%) or imprecision (pooled sample size < 300
or 400), hence the evidence was judged as ’moderate quality’. In
some pooled analyses, the evidence was downgraded for both in-
consistency and imprecision, being judged as ’low quality’. In a
few cases, evidence was further downgraded by one level because of
limitation of study design, resulting in ’very low quality’ evidence.
More high quality trials comparing the effects between surgical
techniques are needed to support our findings.
Potential biases in the review process
Although we tried to minimise various biases during the review
process, the reporting of datawas poor among some included stud-
ies, and in some circumstances we had to estimate data of treat-
ment effects from graphs or use imputation of data from similar
included trials. To overcome this issue, we recommend that future
clinical trial authors adequately follow the instructions outlined in
the CONSORT statement (Schulz 2010). It is also possible that
we have underestimated the rates of reoperation, and our conclu-
sions on harms of included interventions should be interpreted
with caution. This is because safety reporting across included trials
varied largely and not all trials have reported this outcome. Infor-
mation on safety of surgical procedures is paramount for clinical
decision making, therefore future trials should include complica-
tions and reoperations as outcomes and report them appropriately
(Ioannidis 2004). We acknowledge the limited number of trials
in each comparison, which also limited our ability to perform ad-
ditional subgroup or sensitivity analyses. The search strategy was
limited to humans in some of the databases (MEDLINE, EM-
BASE), so it is possible that we missed potentially relevant studies
not indexed as humans. However, we searched a variety of sources
as a way of trying to capture all relevant studies.
Agreements and disagreements with other
studies or reviews
This review is an update of a recently published systematic review
(Machado 2015), and included an additional seven randomised
trials (10 records). A recent Cochrane review has also investigated
the effects of decompression techniques for lumbar spinal steno-
sis, but limited the inclusion criteria to posterior decompression
techniques that did not involve fusion or the use of interspinous
process spacer devices (Overdevest 2015). Our results agree with
those from this recent publication showing that different decom-
pression techniques have similar effects on functional disability
and leg pain.
Another systematic review has also investigated the effectiveness
of interspinous process spacer devices for lumbar spinal stenosis,
suggesting that spacer devices are superior to bony decompression
(Chou 2011). However, this review could not find randomised
trials that made a direct comparison between spacer devices and
conventional decompression, therefore its conclusions were based
on indirect comparisons through a network meta-analysis. Sim-
ilarly, a second systematic review failed to identify trials directly
comparing these two techniques (Moojen 2011). As the first ran-
domised trial comparing these techniques was published in 2013,
these older systematic reviews did not include any randomised
studies. More recently, a systematic review of direct comparisons
was published (Wu 2014), but included both randomised and
non-randomised studies in their meta-analysis. Results of this re-
view also found higher reoperation rates and costs associated with
spacer devices when compared with conventional decompression.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is relatively limited evidence to guide the use of surgery for
the management of lumbar spinal stenosis, as there are no pub-
lished placebo-controlled trials investigating the effects of surgery
for this condition. Most of the evidence supporting the use of
surgery comes from randomised trials comparing surgery with
non-surgical interventions, with conflicting conclusions. The ad-
dition of fusion to decompression is not only more costly, but also
leads to more intraoperative blood loss and longer operation time,
and fails to result in superior clinical outcomes when compared
with decompression alone. Operation using interspinous spacer
devices is quicker, and results in less blood loss and shorter hos-
pital length of stay than fusion. These devices, however, do not
provide better outcomes than conventional decompression, and
are associated with higher reoperation rates. This review provides
valuable information for patients and clinicians to help decide the
best surgical option for this condition.
Implications for research
Future research should include high quality randomised placebo-
controlled trials, and trials comparing surgery with conservative
care in order to investigate the specific effects of surgery for lum-
bar spinal stenosis. More methodologically rigorous studies are
needed to compare the effects of the addition of fusion to decom-
pression as we only identified five trials. Trials should incorporate
a double-blinded (patient and assessors) design and include an ad-
equate randomisation process. The standardisation of outcomes is
also crucial and trials should report patient-related outcome mea-
sures, such as leg pain intensity using a visual analogue pain scale;
function measured by the ZCQ or the ODI; walking ability using
accelerometers; quality of life as reported using the SF-36 or the
EQ-5D; as well as surgically relevant outcomes (i.e., perioperative
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blood loss, operation time, length of hospital stay), and reopera-
tion rates. Also, future trials should include and report clinically
important complications, such as infections, blood transfusions,
and dural tears. Most included trials in this review reported one-
or two-year follow-up, so future research should focus on longer
follow-up times (i.e., five years) to establish the long-term effects
of surgery in this population.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Azzazi 2010
Methods Single-centre RCT
Setting: not reported
Country: Egypt
Period:March 2005 to May 2007
Participants Number: 60 patients (30/30)
Diagnosis: physical and neurological examinations and assessment of imaging studies
(computerized tomography and magnetic resonance imaging)
Included: degenerative spondylolisthesis up to grade I; lateral or central spinal stenosis;
predominant component of leg pain (preoperative score of 40 mm on a 100 mm VAS)
rather than back pain symptoms; moderate disability; unresponsive to conservative treat-
ment for a minimum of three months
Excluded: previous lumbar fusion, decompression or total facetectomy; trauma; diseases
that preclude surgical management; patients younger than 20 years or older than 80
years of age; BMI greater than 40
Age (years): mean (range) 56.3 (27-79)
BMI (kg/m²): mean 27/29
Lumbar stenosis duration (years): mean (range) 5.3 (0.2-36.9)
Interventions Group 1: decompression plus transpedicular screw fixation
Group 2: interspinous process spacer device (X-Stop)
Follow-up: 24 months
Outcomes Pain: 100 mm visual analogue scale leg pain
Disability: ODI
Operation time
Complications
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “60 patients enrolled and random-
ized to be treated with either...”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
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Azzazi 2010 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information about drop-outs.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) High risk The authors report in the methods that pe-
rioperative blood loss was recorded and pa-
tients returned for follow-up evaluations 3
weeks, then 3, 6, 12 and 24 months after
surgery. The results for blood loss were not
reported and only 24-month data were re-
ported. Attempts to access these data from
the authors was unsuccessful
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Unclear risk Not mentioned.
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
Bridwell 1993
Methods Single-centre RCT
Setting: Barnes-Jewish Hospital, St. Louis Missouri
Country: USA
Period: February 1985 to March 1990
Participants Number: 44 patients (9/11/24)
Diagnosis: magnetic resonance and computed tomographic imaging. Spinal claudica-
tion caused by spinal stenosis at the spondylolisthesis level
Included: no previous spine surgery
35Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
224
Bridwell 1993 (Continued)
Excluded: not reported
Age (years): mean (range) 66.1 (46-79)
Interventions Group 1: decompression alone. Surgical decompression comprised of laminectomy with
preservation of bilateral facet joints without discectomy or extensive foraminotomy
Group 2: decompression plus posterolateral (transverse processes) fusion without in-
strumentation or posterolateral (facets and transverse processes) fusion with instrumen-
tation. All fusions were performed with autogenous iliac bone graft
Follow-up: 37.2 months
Outcomes Disability: Walking ability: worse, same or significantly better after surgery
Complications
Reoperations
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “the patients were randomized so
that”. The authors report an error in the
randomisation process
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 43/44=97.7% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) High risk Protocol not available, and relevant out-
comes were not reported
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Bridwell 1993 (Continued)
Group similarity at baseline (selection bias) Unclear risk No information about patient characteris-
tics at baseline.
Co-interventions (performance bias) Unclear risk Only the surgical technique differed be-
tween treatment groups. No concomitant
discectomy, but foraminotomy was per-
formed in some patients
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest not reported. Financial
support was not reported in this study
Cavusoglu 2007
Methods Single-centre RCT
Setting: Sisli Etfal State Hospital, Istanbul
Country: Turkey
Period: January 2000 to January 2002
Participants Number: 100 patients (50/50)
Diagnosis: physical examination, preoperative radiological investigations with plain
roentgenogram, magnetic resonance and computed tomographic images
Included: symptoms of neurogenic claudication or radiculopathy; radiological/neu-
roimaging evidence of lumbar stenosis; absence of associated pathology; no history of
spinal surgery; non-respondents to minimal 3 months of conservative care
Excluded: not reported
Age (years): mean (SD) 69.2 (12.2)
Lumbar stenosis duration (years): range 0.7 to 5.0
Interventions Group 1: hemi-laminectomy with preservation of posterior midline structures
Group 2: unilateral laminotomy for bilateral decompression. Decompression of the
lateral recess was performed in the unilateral laminectomy group preserving the facet
joints, and discectomy was performed if necessary
Follow-up: 64.8 months
Outcomes Pain: 100-point SF-36 body pain
Disability: ODI
Complications
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
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Cavusoglu 2007 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a concealed computer-generated
randomization list was used to assign the
patient to one of the two treatment groups”
Allocation concealment (selection bias) Low risk Quote: “a concealed computer-generated
randomization list...”
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a single radiologist blinded to the
clinical results of decompression reviewed
all pre and postoperative studies”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97/100 = 97% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk It was clear that the published report in-
cluded all expected outcomes
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Unclear risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
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Celik 2010
Methods Single-centre RCT
Setting: Department of Neurosurgery, Beyoglu State Hospital, Istanbul
Country: Turkey
Period: July 2001 to May 2003
Participants Number: 80 patients (40/40)
Diagnosis: dynamic x-rays, thin-sliced CT and MRI; severe back/leg pain and neuro-
genic claudication; anteroposterior diameter less than 10 mm of the lumbar spinal canal
by CT scan and MRI
Included: patients who had not responded to conservative medical therapy and physical
therapy; more than 41% in ODI; more than 7 in VAS pain; walking distance less than
30 meters; severe lumbar spinal stenosis clinically
Excluded: patients requiring discectomy or showing any kind of instability before the
surgery
Age (years): mean (SD) 61 (13)/59 (14)
Interventions Group 1: total laminectomy
Group 2: bilateral micro decompressive laminotomy. Medial facetectomy and wide
foraminotomies were performed at the level of stenosis, preserving the lateral aspect of
the facet joints. No patient received discectomy
Follow-up: 60 months
Outcomes Pain: 10 cm VAS leg pain
Disability: ODI, walking distance
Operation time
Perioperative blood loss
Complications
Reoperations
Notes Surgeon’s experience: “both groups of patients were operated by the same senior surgeon
in the same time period”
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a chart system was used to process
randomizaton”.
Allocation concealment (selection bias) Low risk Quote: “a registered nurse informed sur-
geons about the type of surgery before the
operation”
Blinding of participants (performance
bias)
All outcomes
Low risk Quote: “patients were not informed as
which group they would be placed”
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Celik 2010 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the patients were preoperative ex-
amined and followed at regular intervals by
the operating neurosurgeons and by a neu-
rology specialist blinded to the study pro-
tocol.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 71/80 = 89% of the patients completed the
follow-up. The number of drop-outs is un-
likely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk It was clear that the published report in-
cluded all expected outcomes
Group similarity at baseline (selection bias) Low risk There were no preoperative differences be-
tween groups, based on Tables 1 to 3
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Unclear risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
Cho 2007
Methods Single-centre RCT
Setting: China Medical University and Hospital
Country: China
Period:May 2005 to January 2006
Participants Number: 70 patients (30/40)
Diagnosis:CT andMRI: antero-posterior diameter of the spinal canal less than 11 mm,
an interpediculate distance of less than 16 mm, and a lateral recess distance of less than
3 mm; clinical symptoms of lumbago and intermittent claudication
Included: patients with lumbar stenosis with surgical indication for repair
Excluded: patients > 80 years of age with high anaesthetic risks or severe co-morbidity;
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Cho 2007 (Continued)
patients requiring concomitant fusion
Age (years): mean (SD) 61 (11)/59 (15)
Lumbar stenosis duration (years): mean (SD) 4.0 (0.7)/5.3 (0.7)
Interventions Group 1: laminectomy
Group 2: split-spinous process laminotomy
Follow-up: 15 months
Outcomes Disability: JOA
Operation time
Perioperative blood loss
Complications
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information about drop-outs.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk It was clear that the published report in-
cluded all expected outcomes
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on the Table 3
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Cho 2007 (Continued)
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups. Similar percent-
age of concomitant discectomy. All partic-
ipants received the same postoperative care
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
Davis 2013
Methods Multi-centre RCT
Setting: 21 sites in the United States
Country: USA
Period: 2006 to 2010
Participants Number: 322 patients (215/107)
Diagnosis: central, foraminal or lateral stenosis; more than 25% reduction of the an-
teroposterior dimension compared with the next adjacent normal level, with nerve root
crowding compared with the normal level, as determined by the investigator on CT or
MRI
Included: patients with moderate radiographical diagnosis of spinal stenosis with low
back pain; spondylolisthesis up to Meyerding grade I; minimum ODI of 20 (0-50), and
VAS back pain score of 50 or more (0-100); minimum 6 months of conservative care
Excluded: prior lumbar surgery; trauma or tumour; isthmic spondylolisthesis; spondy-
lolysis; scoliosis > 25 degrees; disc herniation; serious disease
Age (years): mean (SD) 64.1 (9.0)/62.1 (9.2)
Interventions Group 1: decompression plus transpedicular screw fixation
Group 2: Coflex interspinous process spacer device (Paradigm spine, LLC, New York,
NY)
Follow-up: 24 months
Outcomes Pain: 100 mm VAS leg pain
Disability: ODI
Operation time
Perioperative blood loss
Complications
Reoperations
Length of hospital stay
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Davis 2013 (Continued)
Notes Surgeon’s experience: not reported
Funding: “Paradigm Spine, LLC (New York, NY) funds were received in support of this
work. Relevant financial activities outside the submitted work: consultancy, royalties,
payment for lecture, payment for manuscript preparation, patents, payment for devel-
opment of educational presentations”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated randomiza-
tion codes”
Allocation concealment (selection bias) Low risk Quote: “centralized by the study sponsor”
Blinding of participants (performance
bias)
All outcomes
Low risk Quote: “study subjects were blinded until
after surgery”
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “site study personnel were blinded
to the treatment assignment up until 5 days
prior to surgery”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% of the patients completed the follow-
up. The number of drop-outs is unlikely to
affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Tables 4 to 9
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
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Davis 2013 (Continued)
Other bias Unclear risk Quote: “Paradigm Spine, LLC (New York,
NY) funds were received in support of
this work. Relevant financial activities out-
side the submitted work: consultancy, roy-
alties, payment for lecture, payment for
manuscript preparation, patents, payment
for development of educational presenta-
tions.”
Forsth 2016
Methods Multi-centre RCT
Setting: 7 Swedish hospitals
Country: Sweden
Period: October 2006 to June 2012
Participants Number: 247 patients (124/123)
Diagnosis: pseudoclaudication and image findings as per inclusion criteria
Included: pseudoclaudication in one or both legs and back pain (score on VAS > 30), 1
or 2 adjacent stenotic segments (cross-section area of the dural sac ≤ 75 mm²) between
L2 and the sacrum on MRI, duration of symptoms > 6 months
Excluded: spondylolysis, degenerative lumbar scoliosis, history of lumbar spinal surgery
for spinal stenosis or instability, stenosis not caused by degenerative changes, stenosis
caused by a herniated disk, other specific spinal conditions, history of vertebral compres-
sion fractures in affected segments, psychological disorders
Age (years): mean (SD) 66.0 (8.0)/66.0 (9.0)
Interventions Group 1: decompression alone
Group 2: decompression plus fusion. The surgical technique was determined solely by
the surgeon
Follow-up: 24 months
Outcomes Pain: 100 mm VAS leg pain
Disability: ODI
Operation time
Perioperative blood loss
Complications
Reoperations
Length of hospital stay
Costs
Notes Surgeon’s experience: all the trial surgeons were senior consultants and were highly
experienced in performing the two trial interventions
Funding: funded by an Uppsala institutional Avtal om Läkarutbildning och Forskning
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Forsth 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Simple randomization was per-
formed with the use of aWeb-based system
that enabled computer-generated random
treatment assignment”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 92% of the patients completed the follow-
up. The number of drop-outs is unlikely to
affect the results
Intention-to-treat analysis (attrition bias) Low risk Authors used a modified intention-to-treat
analysis that included 9 patients who did
not initially receive the assigned treatment
but did undergo subsequent surgery
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 2
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “No institution or company had a
role in the data analysis, the preparation of
the manuscript, or the decision to submit
the manuscript for publication.”
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Ghogawala 2016
Methods Multi-centre RCT
Setting: 5 hospitals
Country: USA
Period:March 2002 to August 2009
Participants Number: 66 patients (35/31)
Diagnosis: standardized radiographic and magnetic resonance images
Included: patients with grade I lumbar spondylolisthesis (degree of spondylolisthesis: 3
to 14 mm) with lumbar stenosis and neurogenic claudication with or without lumbar
radiculopathy
Excluded: radiography revealed lumbar instability (motion of > 3 mm at the level of
listhesis, as measured on flexion-extension radiographs of the lumbar spine), previous
lumbar spinal surgery, severe systemic disease
Age (years): mean (SD) 66.5 (8.0)/66.7 (7.2)
Interventions Group 1: decompression alone by a complete laminectomy with partial removal of the
medial facet joint
Group 2: decompression plus fusion. Patients in the fusion group underwent a lumbar
laminectomy as well as implantation of pedicle screws and titanium alloy rods across the
level of listhesis, with a bone graft harvested from the iliac crest
Follow-up: 24 months
Outcomes Pain: SF-36 bodily pain subscale
Disability: ODI
Operation time
Perioperative blood loss
Reoperations
Length of hospital stay
Notes Surgeon’s experience: all surgeons routinely performed both operations tested in the
trial; each of the surgeons had performed at
least 100 laminectomies and 100 posterolateral fusions for lumbar spondylolisthesis
before joining the trial
Funding: There was no industry funding or any other industry involvement in the trial
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
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Ghogawala 2016 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “independent study coordinator
whowas not aware of the study hypothesis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88% of the patients completed the follow-
up. The number of drop-outs is unlikely to
affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “There was no industry funding or
any other industry involvement in the SLIP
trial.”
Grob 1995
Methods Single-centre RCT
Setting: Schutthess Hospital, Zurich
Country: Switzerland
Period: November 1989 to November 1990
Participants Number: 45 patients (15/15/15)
Diagnosis: history and clinical examination; CT and MRI (mid-sagittal diameter of the
spinal canal of less than 11 mm)
Included: degenerative spinal stenosis
Excluded: systemic disease; instability of the spine; previous operation
Age (years): mean (range) 67 (48-87)
Lumbar stenosis duration (years): mean (range) 1.3 (0.5-3.1)
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Grob 1995 (Continued)
Interventions Group 1: decompression alone. Decompression involved widening of the lateral recess,
undercut of lamina, and discectomy or foraminotomy in some patients
Group 2: decompression plus arthrodesis of the most stenotic segment
Group 3: decompression plus arthrodesis of all of the decompressed vertebral segments
Follow-up: 28 months
Outcomes Pain: 10 cm VAS overall pain
Disability: walking ability
Operation time
Perioperative blood loss:
Complications
Reoperations
Notes Surgeon’s experience: All the operations were performed by the same surgeon
Funding: “no funds were received in support to this study”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the patients were randomly as-
signed to the three treatment groups.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100%of the patients completed the follow-
up.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patients characteris-
tics at baseline.
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Grob 1995 (Continued)
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups. Similar percent-
age of concomitant discectomy. All partic-
ipants received the same postoperative care
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
High risk Patients were assessed at different time
points. The average duration of follow-up
was 38 months (range: 24 to 32)
Other bias Low risk Quote: “no funds were received in support
to this study”
Gurelik 2012
Methods Single-centre RCT
Setting: Department of Neurosurgery, Van Training and Research Hospital, Van
Country: Turkey
Period: January 2006 to February 2009
Participants Number: 52 patients (26/26)
Diagnosis: MRI of degenerative lumbar spinal stenosis with symptoms of neurogenic
claudication or radiculopathy
Included: symptoms of neurogenic claudication or radiculopathy; radiological evidence
of degenerative lumbar stenosis; absence of associated pathological entities such as in-
stability and significant disc herniation; absence of previous surgery for lumbar spine
disorder; non-respondents to conservative care
Excluded: not reported
Age (years): mean (SD) 57.5 (8.5)/60.7 (10.0)
Interventions Group 1: laminectomy
Group 2: unilateral laminotomy. Unilateral laminotomy was performed followed by
ipsilateral medial facetectomy and foraminotomy, and the ligamentum flavum were
resected partially. For both procedures, the medial aspects of the contralateral facet joints
were resected partially
Follow-up: 6 months
Outcomes Disability: ODI, walking distance
Notes Surgeon’s experience: “all operations were performed by one author”
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Gurelik 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned
to one of the following groups”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
High risk Quote: “patients were made aware of the
method” and “told which operative proce-
dure they were going to have”
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100%of the patients completed the follow-
up.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
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Hallett 2007
Methods Single-centre RCT
Setting: Spinal Unit, Royal Infirmary of Edinburgh, Edinburgh
Country: Scotland, UK
Period: January 1998 to August 2001
Participants Number: 44 patients (14/15/15)
Diagnosis: plain radiographs and magnetic resonance images
Included: foraminal stenosis; single-level degenerative disc disease; uni or bilateral leg
pain, with or without positive root tension sign, muscle weakness and/or sensory loss;
minimum 3 months of conservative care
Excluded: spondylolisthesis Grade II or greater; vertebral translocation > 1 cm (insta-
bility); disc space narrowing of greater than 50%; serious disease
Age (years): mean (range) 57 (34-75)
Interventions Group 1: decompression (single or bilateral foraminotomy)
Group 2: decompression plus instrumented pedicular postero-lateral fusion
Group 3: decompression plus fusionwith pedicular screw instrumentationwith titanium
interbody cages filled with autologous bone. Minimal microdiscectomy was performed
if necessary
Follow-up: 60 months
Outcomes Pain: 10 cm VAS from the Low Back Outcome Score
Disability: RMDQ
Costs
Operation time
Perioperative blood loss
Reoperations
Notes Surgeon’s experience: All surgery was performed by the same surgeon in a laminar
ventilated theatre
Funding: “supported by a grant from DePuy Ltd., U.K. Corporate/Industry funds were
received in support of this work. No benefits in any form have been or will be received
from a commercial party related directly or indirectly to the subject of this manuscript”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “type of treatment was randomly
allocated immediately before surgery.”
Allocation concealment (selection bias) Low risk Quote: “shuffled, closed, opaque en-
velopes, that were numbered 1 to 150 and
opened in sequence.”
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
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Hallett 2007 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “the 3 observers were not blinded
and any dispute was resolved by discussion.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93.1% of the patients completed the fol-
low-up. The number of drop-outs is un-
likely to affect the results
Intention-to-treat analysis (attrition bias) Low risk Quote: “analysis of the results was by in-
tention to treat.”
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patient characteris-
tics at baseline.
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups. Similar percent-
age of concomitant discectomy
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Quote: “supported by a grant from DePuy
Ltd., U.K. Corporate/ Industry funds were
received in support of this work. No bene-
fits in any formhave beenorwill be received
from a commercial party related directly or
indirectly to the subject of this manuscript.
”
Komp 2015
Methods Single-centre RCT
Setting: not reported
Country: Germany
Period: not reported
Participants Number: 160 patients (80/ 80)
Diagnosis: clinical assessment
Included: predominant leg symptoms; neurogenic claudication with or without paresis;
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Komp 2015 (Continued)
back pain maximum 30/100 on the VAS; conservative therapy exhausted or no longer
indicated due to the symptoms; mono segmental central stenosis caused by facet hyper-
trophy; hypertrophy of the ligamentum flavum; and disc protrusions or a combination
of those
Excluded: predominant back pain, foraminal stenosis in the lower level, fresh soft disc
herniations with bony stenosis; degenerative spondylolisthesis more than Meyerding
Grade I; multidirectional rotation slide; scoliosis more than 20°; prior surgery in the
same segment; and cauda equina syndrome
Age (years): mean (SD) 62 (41-84)
Lumbar stenosis duration (months): mean 17
Interventions Group 1: conventional microsurgical interlaminar decompression. The conventional
decompression operation was performed using the bilateral laminotomy technique with
partial facetectomy and flavum resection
Group 2: full-endoscopic interlaminar decompression.
Follow-up: 24 months
Outcomes Pain: 100 mm VAS leg pain
Disability: ODI
Operation time
Perioperative blood loss
Complications
Reoperations
Notes Surgeon’s experience: All operations were performed by 2 surgeons with many years of
experience in both techniques
Funding: “there was no external funding in the preparation of this manuscript”. The
authors declared no conflicts of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the randomization was carried out
as a block randomization.”
Allocation concealment (selection bias) Low risk Quote: “the secretary provided scheduling
in a closed envelope.”
Blinding of participants (performance
bias)
All outcomes
High risk Quote: “randomization was not blinded,
since the patients may identify the opera-
tion procedure.”
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the follow-up investigators were
not informed of which surgical procedure
had been carried out.”
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Komp 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 153/160 = 96% of the patients completed
the 3-month follow-up and 84% com-
pleted the 24-month follow-up. The num-
ber of drop-outs was similar in each group
and the reasons for drop-out are also re-
ported and are unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patient characteris-
tics at baseline
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups. Similar percent-
age of concomitant discectomy. All partic-
ipants received the same postoperative care
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “there was no external funding in
the preparation of this manuscript”. The
authors declared no conflicts of interest
Liu 2013
Methods Single-centre RCT
Setting: Department of Orthopedic Surgery, Qilu Hospital of Shandong University,
Jinan, Shandong
Country: China
Period: not reported
Participants Number: 56 patients (27/29)
Diagnosis: lumbar spinal stenosis diagnosis by an experienced spine specialist
Included: patients with lumbar spinal stenosis without degenerative spondylolisthesis
or interbody instability
Excluded: not reported
Age (years): mean (SD) 59.4 (4.7)/61.1 (3.1)
Lumbar stenosis duration (years): mean (range) 6.5/5.9 (0.6-13)
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Liu 2013 (Continued)
Interventions Group 1: conventional laminectomy
Group 2: spinous process-splitting unilateral laminotomy. The spinous process and the
interspinous ligaments were split longitudinally, preserving the paraspinal muscles. Then
unilateral laminotomy was conducted for bilateral decompression with removal of the
cranial and the caudal portion of the ipsilateral lamina, ligamentum flavum, and medial
part of the facet
Follow-up: 24 months
Outcomes Pain: 10 cm VAS leg pain
Disability: JOA
Operation time
Perioperative blood loss
Notes Surgeon’s experience: all patients were diagnosed and assessed by experienced spine
specialists
Funding: “no funds were received in support of this work. No relevant financial activities
outside the submitted work”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the patients were randomly cate-
gorized into 2 groups.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 54/57=94.7% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
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Liu 2013 (Continued)
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Tables 1 and 2
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “no funds were received in support
of this work. No relevant financial activities
outside the submitted work.”
Lonne 2015
Methods Multi-centre RCT
Setting: 6 different Norwegian hospitals
Country: Norway
Period: June 2007 to September 2011
Participants Number: 96 patients (49/47)
Diagnosis: symptoms of neurogenic intermittent claudication and magnetic resonance
images and radiographs
Included: patients with 1 or 2 stenotic levels (from L2 to L5) and with minor spondy-
lolisthesis (Meyerding, grade 1)
Excluded: spinal stenosis at more than 2 levels; previous low back surgery; unilateral
radiculopathy; severe paresis; cauda equina syndrome; degenerative spondylolisthesis >
grade 1; isthmic spondylolisthesis; severe scoliosis, idiopathic or degenerative (Cobb angle
>10° or sagittally imbalanced); osteoporosis or suspected osteoporotic fractures in lumbar
spine; symptomatic coxarthrosis; vascular intermittent claudication; polyneuropathy;
malignant disease
Age (years): mean (SD) 67 (8.7)/67 (8.8)
BMI (kg/m²): mean (SD) 28 (3.8)/28 (4.7)
Lumbar stenosis duration (years): more than 2 years for the majority of patients in
both groups
Interventions Group 1: minimally invasive decompression (bilateral laminotomy). Decompression
was performed by a partial excision of the lower part of the lamina and themedial aspects
of the facet joint
Group 2: interspinous process spacer device (X-Stop). The X-Stop was inserted be-
tween the spinous processes through the interspinous ligament and was secured by the
supraspinous ligament posteriorly and by the lamina anteriorly
Follow-up: 24 months
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Lonne 2015 (Continued)
Outcomes Pain: 11-point numerical rating scale leg pain
Disability: ODI
Quality of life: EQ-5D
Costs
Operation time
Perioperative blood loss
Complications
Reoperations
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: “the study was supported by non-commercial organisations (South-East Re-
gional Health Authority, Norway and the National Advisory Unit on Spinal Surgery, St.
Olavs Hospital, Norway)”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized with
randomly selected block sizes by a com-
puter-based web solution.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 81/96 = 84% of the patients completed the
follow-up. The number of drop-outs was
similar in each group and the reasons for
drop-out are also reported and are unlikely
to affect the results
Intention-to-treat analysis (attrition bias) Low risk Quote: “in the main evaluation, not only
was an intention-to-treat analysis per-
formed...”
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
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Lonne 2015 (Continued)
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Tables 2 and 4
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “the study was supported by non-
commercial organisations (South-East Re-
gional Health Authority, Norway and the
National Advisory Unit on Spinal Surgery,
St. Olavs Hospital, Norway).”
Mobbs 2014
Methods Single-centre RCT
Setting: Prince of Wales Hospital, Randwick, Sydney
Country: Australia
Period: 2007 to 2009
Participants Number: 79 patients (40/39)
Diagnosis: clinical assessment, MRI and CT myelogram
Included: symptomatic lumbar spinal stenosis with radiculopathy, neurogenic claudi-
cation, urinary dysfunction; radiologically confirmed spinal stenosis caused by degener-
ative changes; canal stenosis at a maximum of 2 levels
Excluded: concomitant fusion, instrumentation placement or lumbar laminectomy in-
volving discectomy; previous lumbar surgeries at the same level; spondylolisthesis of any
grade or degenerative scoliosis; evidence of instability on dynamic radiographs
Age (years): mean (SD) 65.8 (14.3)/72.7 (10.4)
Interventions Group 1: conventional laminectomy. In the laminectomy group, the spinous process,
lamina, ligamentum flavum and portion of the facet joints were removed
Group 2: microscopic unilateral laminectomy for bilateral decompression. In the uni-
lateral laminectomy group, a medial ipsilateral facetectomy was performed, and if nec-
essary, a contralateral foraminotomy
Follow-up: 44.3 (15)/36.9 (4.3) months
Outcomes Pain: 10 cm VAS leg pain
Disability: ODI
Perioperative blood loss
Complications
Length of hospital stay
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Mobbs 2014 (Continued)
Notes Surgeon’s experience: surgery performed by a single senior neurosurgeon with extensive
experience in lumbar spine surgery and minimally invasive spine surgery
Funding: The authors reported no conflict of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “assigned to either open de-
compressive laminectomy or microscopic
ULBD in a 1:1 split according to their se-
quence of presentation.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the observer and statistician were
blinded to treatment group by the use of
reference numbers.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 54/79 = 68.4%. Similar and proportional
number of drop-outs in each group and
similar reasons for withdraw
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) High risk Patiant characteristics varied substantially
for important variables, based on Table 3
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
High risk Quote: “the mean duration of follow-up
was higher in the open-surgery group than
in the ULBD group.”
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Mobbs 2014 (Continued)
Other bias Low risk The authors reported no conflict of inter-
est.
Moojen 2013
Methods Multi-centre double blinded RCT
Setting: 5 neurosurgical centres in the Netherlands
Country: Netherlands
Period: October 2008 to September 2011
Participants Number: 159 patients (79/80)
Diagnosis: clinical diagnosis of neurogenic claudication by a neurologist with MRI
findings of spinal canal stenosis
Included: patients between 40 and 85 years; 3 months of neurogenic claudication; single
or 2-level degenerative lumbar canal stenosis; indication for surgery
Excluded: cauda equina syndrome; herniated disc needing discectomy; history of
surgery; significant scoliosis
Age (years): mean 64/66
BMI (kg/m²): mean (range) 28 (20-37)/27 (20-48)
Lumbar stenosis duration (years): mean (range) 1.9 (0.1-17)
Interventions Group 1: decompression (laminotomy, flavectomy, facetectomy). In the decompression
group, a partial resection of the adjacent laminas was executed, followed by a flavectomy
with bilateral opening of the lateral recess and, if necessary, a medial facetectomy was
done
Group 2: interspinous process spacer device (Paradigm Spine, USA). In the experimen-
tal group, no bony decompression was done and the interspinous process device was
implanted by a posterior midline approach
Follow-up: 12 months
Outcomes Pain: 100 mm VAS leg pain
Disability: RMDQ
Function: ZCQ (physical function)
Costs
Operation time
Perioperative blood loss
Complications
Reoperations
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: “Paradigm Spine funded this trial. Paradigm Spine had no role in data col-
lection, design of the study, data analysis, interpretation of data, or writing the report
and had no influence over whether to submit the manuscript. All the researchers were
individually independent from funders”
Risk of bias Risk of bias
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Moojen 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomized design with variable
block sizes, with allocations stratified ac-
cording to center.”
Allocation concealment (selection bias) Low risk Quote: “opaque, coded and sealed en-
velopes”. “After induction of anaesthesia,
the prepared envelope was opened and the
patient allocated to one of the treatment
arms.”
Blinding of participants (performance
bias)
All outcomes
Low risk Quote: “patients, nurses on the hospital
wards, and research nurses remained blind
to the allocated treatment during the fol-
low-up period of one year.”
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all caregivers blind to the allocated
treatment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 151/159 = 95% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Low risk Quote: “we compared groups on the basis
of an intention to treat analysis.”
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups. All participants re-
ceived the same postoperative care
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
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Moojen 2013 (Continued)
Other bias Low risk Quote: “Paradigm Spine funded this trial.
Paradigm Spine had no role in data collec-
tion, design of the study, data analysis, in-
terpretation of data, or writing the report
and had no influence over whether to sub-
mit themanuscript. All the researcherswere
individually independent from funders.”
Postacchini 1993
Methods RCT
Setting: not reported
Country: Italy
Period: not reported
Participants Number: 67 patients (26/9/32)
Diagnosis: all patients had plain and flexion-extension radiographs of the lumbar spine
with one or more of myelography, plain or contrast-enhanced computed tomographic,
and magnetic resonance imaging
Included: patients with central lumbar stenosis who required surgery
Excluded: not reported
Age (years): mean (range) 57 (43-79)
Interventions Group 1: multiple laminotomies
Group 2: scheduled multiple laminotomies converted to total laminectomy
Group 3: total laminectomy. Disc excision was performed at a single level in four pa-
tients. A unilateral or bilateral intertransverse fusion was performed in four patients with
degenerative spondylolisthesis
Follow-up: 3.7 years (2.2-5.3)
Outcomes Pain: 100 mm VAS leg pain (radicular symptoms)
Operation time
Perioperative blood loss
Complications
Notes Surgeon’s experience: all the patients were operated on by the senior author.
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “we aimed to randomise the choice
of surgical procedure, but had to allow
the protocol to be broken when multiple
laminotomy appeared to be inadequate to
obtain sufficient decompression.”
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Postacchini 1993 (Continued)
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “at the latest follow-up, each patient
was interviewed and examined by one of
the authors, who was unaware of the type
of decompression performed.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 67/70 = 95.7% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patient characteris-
tics at baseline.
Co-interventions (performance bias) High risk Concomitant discectomy and fusion were
performed at different rates between the
groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
High risk Quote: “the mean follow-up was 3.7 years
(2.2 to 5.3).”
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
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Rajasekaran 2013
Methods Singe-centre RCT
Setting:Department of Orthopaedics and Spine Surgery, Ganga Hospital, Coimbatore,
Tamil Nadu
Country: India
Period: not reported
Participants Number: 51 patients (28/23)
Diagnosis: MRI exam correlating with typical neurogenic claudication symptoms due
to degenerative lumbar canal stenosis
Included: degenerative lumbar canal stenosis affecting 3 or less levels; typical neurogenic
claudication symptoms; MRI demonstrating good clinical correlation; and failure of
conservative methods of treatment for a minimum period of 6 months
Excluded: spondylolisthesis with slip Meyerding grade 2 or greater; instability at the
level of stenosis (as defined by > 3 mm translation or > 10° angular change on flexion
extension lateral radiographs); concomitant symptomatic cervical or thoracic stenosis;
comorbidities such as cardiopulmonary insufficiency; peripheral neuropathy; peripheral
vascular disease, prior lumbar spine surgery; severe hip or knee disease
Age (years): mean (SD) 57.3 (11.2)/54.5 (8.2)
Interventions Group 1: lumbar spinous process splitting decompression. In the experimental group,
the interspinous and supra spinous ligaments were cut longitudinally in line with the
spinous processes, then decompression proceeded according to the conventional method
Group 2: conventional midline decompression. In the conventional decompression
group the overhanging portion of the proximal spinous process, the interspinous and the
supraspinous ligaments were removed, and the ligamentum flavum and the distal half
of the proximal lamina were excised. Facetal undercutting was performed as needed
Follow-up: 16 months
Outcomes Pain: 10 cm VAS leg pain (neurogenic claudication)
Disability: JOA
Recovery
Operation time
Perioperative blood loss
Complications
Reoperations
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: “AO Spine India research grant and the Ganga Orthopaedic Research and
Education Foundation funds were received in support of this work”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the study was a prospective ran-
domized controlled study” and “surgical
treatment method for the patients was de-
termined by an automated computer-gen-
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Rajasekaran 2013 (Continued)
erated block randomization chart.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “patients outcomeswere assessed by
an independent observer who was blinded
to the type of surgery that a particular pa-
tient has undergone.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100%of the patients completed the follow-
up.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Tables 1, 2 and 4
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Unclear risk Quote: “the mean duration of follow-up
was 14.2 ± 2.9 months (12-16 mo).”
Other bias Unclear risk Quote: “AO Spine India research grant and
the Ganga Orthopaedic Research and Ed-
ucation Foundation funds were received in
support of this work.”
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Ruetten 2009
Methods Single-centre RCT
Setting: Centre for Orthopaedics and Traumatology, St. Anna-Hospital Herne, Univer-
sity of Witten/Herdecke, Herne
Country: Germany
Period: 2003 to 2005
Participants Number: 192 patients (100/92)
Diagnosis: MRI and CT
Included: neurogenic claudication with unilateral leg pain with or without paresis;
back pain with maximum score of 20/100 points on the VAS; and conservative therapy
exhausted or no longer indicated due to the symptoms; monosegmental recess stenosis;
no foraminal stenosis in the lower level; no disc herniation; degenerative spondylolisthesis
with maximum Meyerding Grade I; no multidirectional rotation slide; scoliosis with
maximum curvature of 20°; no prior surgery in the same segment
Excluded: not reported
Age (years): mean (range) 64 (38-86)
Lumbar stenosis duration (years): mean (range) 1.6 (0.17-6.5)
Interventions Group 1: conventional microsurgical decompression. Decompression was accomplished
by cranial and caudal laminotomy, partial facetectomy, and ligamentum flavum resection
Group 2: full-endoscopic transforaminal decompression. The operating instruments
and optics were products supplied by Richard Wolf GmbH
Follow-up: 24 months
Outcomes Disability: ODI
Operation time
Complications
Reoperations
Notes Surgeon’s experience: all operations were performed by 2 surgeons who havemany years
of experience in both techniques
Funding: “the authors report no conflict of interest concerning the materials or methods
used in this study or the findings specified in this paper”. Financial support was not
reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized assignment was made
by nonphysician study staff. This was ac-
complished using balanced block random-
ization.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
High risk Quote: “the patients are able to identify the
surgical procedure.”
66Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
255
Ruetten 2009 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The later examiners were not informed
about which operative procedure was ap-
plied.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 184/192 = 95.8% of the patients com-
pleted the follow-up. The number of drop-
outs is unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patients characteris-
tics at baseline.
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “the authors report no conflict of
interest concerning the materials or meth-
ods used in this study or the findings spec-
ified in this paper”. Financial support was
not reported in this study
Stromqvist 2013
Methods Multi-centre RCT
Setting: 3 Swedish spine centres
Country: Sweden
Period: not reported
Participants Number: 100 patients (50/50)
Diagnosis: MRI verified spinal stenosis on 1 or 2 levels in the lumbar spine
Included: symptoms of neurogenic claudication for minimum 6 months elicited by
walking and relieved by flexion of the spine or sitting down; age 40 years or more was
required; spinal stenosis was allowed to be present at maximum 2 levels and minor
spondylolisthesis (Meyerding, grade 1) was accepted
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Stromqvist 2013 (Continued)
Excluded: Previous spine surgery (except for successful disc surgery); infection or malig-
nant disorder; osteoporosis diagnosed before referral for surgery and subjected tomedical
treatment; stenosis of the L5-S1-level due to the small spinous process of S1
Age (years): mean (range) 69 (49-89)
Interventions Group 1: decompression alone. The decompressive procedures were performed using
laminectomy or laminotomies with facet-joint sparing techniques
Group 2: interspinous process spacer device (X-Stop)
All operations included open procedures
Follow-up: 24 months
Outcomes Pain: 100 mm VAS leg pain
Disability: ZCQ (physical function)
Operation time
Complications
Reoperations
Notes Surgeon’s experience: not reported
Funding: “no funds were received in support of this work”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomization was performed by
using envelopes.”
Allocation concealment (selection bias) Unclear risk Quote: “randomization was performed by
using envelopes.”
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96/100 = 96% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Low risk Quote: “in the main evaluation, not only
was intention-to-treat analysis used, but
also as-treated analysis was performed.”
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Stromqvist 2013 (Continued)
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “no funds were received in support
of this work.”
Thome 2005
Methods Single-centre RCT
Setting:Departments ofNeurosurgery,Neurology, andNeuroradiology, UniversityHos-
pital Mannheim
Country: Germany
Period: not reported
Participants Number: 120 patients (40/40/40)
Diagnosis: Radiological/neuroimaging evidence of lumbar stenosis
Included: symptoms of neurogenic claudication or radiculopathy; radiological/neu-
roimaging evidence of degenerative lumbar stenosis; absence of associated pathological
entities such as disc herniations or instability; no history of surgery for lumbar stenosis
or lumbar fusion
Excluded: patients who required discectomy
Age (years): mean (range) 68 (44-86)
BMI (kg/m²): mean (SD) 28 (4)/29 (6)/29 (4)
Lumbar stenosis duration (years): mean (SD) 1.7 (2.5)
Interventions Group 1: laminectomy
Group 2: unilateral laminotomy
Group 3: bilateral laminotomy
An operating microscope and high-speed burrs and Kerrison rongeurs were used in all
procedures. Special care was taken in all three groups to minimize facet joint resection
by using an undercutting technique
Follow-up: 12 months
Outcomes Pain: 10 cm VAS overall pain
Disability: RMDQ
Operation time
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Thome 2005 (Continued)
Perioperative blood loss
Complications
Reoperations
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated randomiza-
tion list was used to assign the patient to
one of the treatment groups.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 110/120=91.6% of the patients completed
the follow-up. The number of drop-outs is
unlikely to affect the results
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Low risk Patients did not differ in their baseline char-
acteristics, based on the Table 1
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
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Other bias Unclear risk Conflict of interest not reported. Financial
support was not reported in this study
Usman 2013
Methods Single-centre RCT
Setting: Neurosurgery department of PGMI, Lady Reading Hospital, Peshawar
Country: Pakistan
Period: January 2010 to December 2010
Participants Number: 60 patients (30/30)
Diagnosis: physical examination and radiological/neuroimaging evidence
Included: patients with symptoms of radiculopathy or neurogenic claudication; radio-
logical/neuroimaging evidence of lumbar spinal stenosis involving the central canal and/
or foraminal stenosis; failure of conservative treatment with medication and physiother-
apy for a minimum of three months
Excluded: Patients with spondylolisthesis; associated co-morbid conditions; recurrent
lumbar spinal stenosis
Age (years): 73.4% between 31-50 years old
Interventions Group 1: conventional laminectomy
Group 2: unilateral approach for bilateral decompression. Unilateral laminotomy was
performed with partial resection of the inferior aspect of the cranial hemilamina and the
superior aspect of the caudal hemilamina. Bilateral flavectomy was performed, and the
lateral recess and neural foramina were decompressed contralaterally
Follow-up:minimum 3 months
Outcomes Operation time
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: Conflict of interest and financial support were not reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A total of 60 patients with lum-
bar stenosis were randomly assigned to un-
dergo either a conventional laminectomy,
or a unilateral approach.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
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Usman 2013 (Continued)
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a database was compiled using in-
patients and outpatientsmedical records by
an independent observer who was not part
of the operative teamand/or in patient care.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100%of the patients completed the follow-
up.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) High risk In the methods the authors reported that
recovery rate was assessed as an outcomes
measure. However, in the results the au-
thors do not report data for this outcome
Group similarity at baseline (selection bias) Unclear risk No information about patients characteris-
tics at baseline.
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Unclear risk Not mentioned.
Other bias Unclear risk Conflict of interest and financial support
were not reported in this study
Watanabe 2011
Methods Single-centre RCT
Setting: Department of Orthopaedic Surgery, National Hospital Organization, Mu-
rayama Medical Center, Tokyo
Country: Japan
Period: December 2004 to December 2005
Participants Number: 41 (22/19)
Diagnosis: radiography of the lumbar spine, myelography, CT and MRI
Included: presence of neurogenic claudication; non-respondents to minimum 6months
of conservative care; clinical symptoms corresponding to MRI or myelography results;
1-2 level decompression necessary
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Watanabe 2011 (Continued)
Excluded: spinal stenosis due to congenital, spondylolytic, traumatic and iatrogenic
causes; previous surgery; presence of specific disorders; intermittent claudication due to
arterial disease; severe osteoarthrosis or arthritis in the lower limbs; neurological disease
causing impaired lower limb function; psychiatric disorders; 3 or more level requiring
decompression
Age (years): mean (SD) 69 (10)/71 (8)
Interventions Group 1: conventional laminectomy. In the conventional laminectomy group, the
spinous processes were detached from the lamina
Group 2: lumbar spinous process-splitting laminectomy. The cortex of the tip of the
spinous process is removed at the midline using a high-speed drill with a fine 2 mm
diamond-tipped bur, and then, using an osteotome, the spinous process is divided to
the base and detached from the lamina. The supra- and interspinous ligaments were also
split longitudinally with a scalpel
Follow-up: 12 months
Outcomes Disability: JOA
Recovery
Operation time
Perioperative blood loss
Reoperations
Notes Surgeon’s experience: not reported
Funding: “The authors report no conflict of interest concerning thematerials ormethods
used in this study or the findings specified in this paper”. Financial support was not
reported in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, randomized, con-
trolled study.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
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Watanabe 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 34/41 = 82.9%. “The reasons for the with-
drawal were the extension of decompres-
sion levels or the conversion of the pro-
cedure from decompression to fusion after
randomization. However, we do not think
that these withdrawals had a major impact
on the results.”
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patients characteris-
tics at baseline.
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Unclear risk Quote: “The authors report no conflict of
interest concerning the materials or meth-
ods used in this study or the findings spec-
ified in this paper”. Financial support was
not reported in this study
Yagi 2009
Methods Single-centre RCT
Setting: Department of Orthopedic Surgery, Kawasaki Municipal Hospital, Kawasaki
city
Country: Japan
Period: not reported
Participants Number: 41 patients (21/20)
Diagnosis: computed tomographic myelography and MRI
Included: symptoms of neurogenic claudication referable to the lumbar spine; failure of
conservative treatments; absence of associated pathological condition; 1-level spondylosis
Excluded: not reported
Age (years): mean (range) 73.3 (63-79)/70.8 (66-73)
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Yagi 2009 (Continued)
Interventions Group 1: conventional laminectomy
Group 2: median approach microendoscopic laminectomy. The operating microscope
was moved into the field and centralized on the laminar base. An osteotomy of the
spinous process at the involved level was performed
Follow-up: 24 months
Outcomes Disability: JOA
Operation time
Perioperative blood loss
Length of hospital stay
Notes Surgeon’s experience: not reported
Funding: “The authors received technical support fromMedtronic SofamorDanek. The
authors report no conflict of interest concerning the materials or methods used in this
study or the findings specified in this paper”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “patientswere divided into 2 groups
by turns when they came to our hospital.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants (performance
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
participants.
Bliding of personnel/ care providers (per-
formance bias)
High risk The surgeon could not have been blinded
to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of any attempts to blind the
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned.
Intention-to-treat analysis (attrition bias) Unclear risk No information about intention-to-treat
analysis.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Group similarity at baseline (selection bias) Unclear risk No information about patient characteris-
tics at baseline.
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Yagi 2009 (Continued)
Co-interventions (performance bias) Low risk Only the surgical technique differed be-
tween treatment groups
Compliance (performance bias) Low risk Compliance in both treatment groups:
100% (surgery).
Timing of outcome assessment (detection
bias)
Low risk All important outcome assessments for
both groups were measured at the same
time
Other bias Low risk Quote: “The authors received technical
support from Medtronic Sofamor Danek.
The authors report no conflict of interest
concerning the materials or methods used
in this study or the findings specified in this
paper.”
RCT: randomized controlled trial
VAS: visual analogue scale
BMI: body mass index
ODI: Oswestry Disability Index
EQ-5D: EuroQol
SD: standard deviation
SF-36: Short Form (36-item) Health Survey
CT: computerized tomography
MRI: magnetic resonance imaging
JOA: Japanese Orthopedic Association scale
RMDQ: Roland-Morris Disability questionnaire
ZDQ: Zurich Claudication Questionnaire
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdu 2009 Not a randomised controlled trial
Altaf 2011 Not appropriate comparison
Andersen 2008 Not lumbar spinal stenosis
Anderson 2011 Not a randomised controlled trial
Aoki 2012 Not lumbar spinal stenosis
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(Continued)
Arriagada 2000 Not lumbar spinal stenosis
Asazuma 2004 Not a randomised controlled trial
Auerbach 2011 Not appropriate comparison
Auerbach 2012 Not appropriate comparison
Bazan 2002 Not a randomised controlled trial
Benli 2006 Not lumbar spinal stenosis
Bjarke 2002 Not lumbar spinal stenosis
Blumenthal 2013 Not a randomised controlled trial
Bresnahan 2009 Not a randomised controlled trial
Cakir 2009 Not a randomised controlled trial
Cannone 2010 Not a randomised controlled trial
Carragee 1997 Not lumbar spinal stenosis
Carrasco 1986 Not a randomised controlled trial
Carreon 2009 Not lumbar spinal stenosis
Cassinelli 2007 Not a randomised controlled trial
Chen 2010 Not lumbar spinal stenosis
Cheng 2009 Not lumbar spinal stenosis
Choi 2009 Not a randomised controlled trial
Dahdaleh 2013 Not lumbar spinal stenosis
Dantas 2007 Not a randomised controlled trial
Delank 2002 Not a randomised controlled trial
Delawi 2010 Not lumbar spinal stenosis
Desai 2012 Not a randomised controlled trial
Dimar 2009 Not lumbar spinal stenosis
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(Continued)
Dirisio 2011 Not appropriate comparison
Dryer 2012 Not appropriate comparison
Epstein 2006 Not a randomised controlled trial
Escobar 2003 Not a randomised controlled trial
Fan 2009 Not a randomised controlled trial
Fast 1985 Not a randomised controlled trial
Feng 2011 Not lumbar spinal stenosis
Fitzgerald 1976 Not a randomised controlled trial
Fu 2008 Not a randomised controlled trial
Fujiya 1990 Not a randomised controlled trial
Försth 2013 Not a randomised controlled trial
Ghahreman 2010 Not a randomised controlled trial
González 1992 Not a randomised controlled trial
Gotfryd 2012 Not a randomised controlled trial
Gotfryd 2012a Not a randomised controlled trial
Gu 2009 Not a randomised controlled trial
Haley 2012 Not appropriate comparison
Haley 2012a Not appropriate comparison
Halm 2010 Not a randomised controlled trial
Herkowitz 1991 Not a randomised controlled trial
Hong 2010 Not a randomised controlled trial
Hong 2011 Not a randomised controlled trial
Hwang 2010 Not lumbar spinal stenosis
Ikuta 2005 Not a randomised controlled trial
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(Continued)
Imagama 2009 Not a randomised controlled trial
Ito 2010 Not a randomised controlled trial
Katz 1997 Not a randomised controlled trial
Kawaguchi 2004 Not a randomised controlled trial
Kim 2006 Not lumbar spinal stenosis
Kim 2007 Not a randomised controlled trial
Kim 2007a Not a randomised controlled trial
Konno 2000 Not a randomised controlled trial
Kornblum 2004 Not a randomised controlled trial
Korovessis 2004 Not lumbar spinal stenosis
Ledonio 2012 Not lumbar spinal stenosis
Lee 2009 Not a randomised controlled trial
Lian 2010 Not lumbar spinal stenosis
Liao 2011 Not a randomised controlled trial
Mahir 2012 Not appropriate comparison
McConnell 2011 Not appropriate comparison
Michielsen 2013 Not lumbar spinal stenosis
Pappas 1994 Not a randomised controlled trial
Parker 2013 Not a randomised controlled trial
Radcliff 2011 Not appropriate comparison
Radcliff 2012 Not a randomised controlled trial
Rapp 2009 Not a randomised controlled trial
Rapp 2011 Not a randomised controlled trial
Repantis 2009 Not appropriate comparison
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(Continued)
Richter 2010 Not a randomised controlled trial
Rompe 1995 Not a randomised controlled trial
Rosa 2012 Not a randomised controlled trial
Rowland 2009 Not a randomised controlled trial
Satomi 1992 Not a randomised controlled trial
Schnake 2006 Not a randomised controlled trial
Sears 2012 Not appropriate comparison
Sengupta 2006 Not a randomised controlled trial
Shapiro 2005 Not appropriate comparison
Skidmore 2011 Not a randomised controlled trial
Smoljanovic 2010 Not a randomised controlled trial
Smorgick 2013 Not a randomised controlled trial
Steffee 1993 Not a randomised controlled trial
Tani 2002 Not a randomised controlled trial
Tenhula 2000 Not a randomised controlled trial
Tsutsumimoto 2009 Not a randomised controlled trial
Valesin 2009 Not a randomised controlled trial
Videbaek 2010 Not lumbar spinal stenosis
Wang 1998 Not a randomised controlled trial
Weinstein 2007 Not surgical comparison
Whang 2013 Not appropriate comparison
Willén 2008 Not a randomised controlled trial
Xiao 2007 Not lumbar spinal stenosis
Xiao 2007a Not lumbar spinal stenosis
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Yamada 2012 Not a randomised controlled trial
Yang 2011 Not a randomised controlled trial
Yu 2008 Not a randomised controlled trial
Zdeblick 1993 Not lumbar spinal stenosis
Zucherman 2004 Not surgical comparison
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D A T A A N D A N A L Y S E S
Comparison 1. Decompression alone versus decompression plus fusion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 4 446 Mean Difference (IV, Random, 95% CI) 1.09 [-4.07, 6.26]
1.1 Short-term (less than 12
months)
1 66 Mean Difference (IV, Random, 95% CI) 4.50 [-0.70, 9.70]
1.2 Long-term (12 months or
more)
4 380 Mean Difference (IV, Random, 95% CI) -0.29 [-7.32, 6.74]
2 Disability 3 401 Mean Difference (IV, Random, 95% CI) 3.37 [-3.37, 10.11]
2.1 Short-term (less than 12
months)
1 66 Mean Difference (IV, Random, 95% CI) 5.2 [-3.50, 13.90]
2.2 Long-term (12 months or
more)
3 335 Mean Difference (IV, Random, 95% CI) 3.26 [-6.12, 12.63]
3 Walking ability 3 316 Risk Ratio (IV, Random, 95% CI) 0.99 [0.79, 1.24]
3.1 Long-term (12 months or
more)
3 316 Risk Ratio (IV, Random, 95% CI) 0.99 [0.79, 1.24]
4 Operation time 4 381 Mean Difference (IV, Random, 95% CI) -107.94 [-161.65, -
54.23]
5 Blood loss 4 383 Mean Difference (IV, Random, 95% CI) -0.52 [-0.70, -0.34]
6 Reoperations 5 443 Risk Ratio (IV, Random, 95% CI) 1.25 [0.81, 1.92]
7 Hospitalisation 2 295 Mean Difference (IV, Fixed, 95% CI) -1.69 [-2.12, -1.26]
Comparison 2. Decompression versus interspinous spacer
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 3 656 Mean Difference (IV, Random, 95% CI) -0.89 [-6.08, 4.31]
1.1 Short-term (less than 12
months)
3 328 Mean Difference (IV, Random, 95% CI) -0.93 [-9.86, 8.00]
1.2 Long-term (12 months or
more)
3 328 Mean Difference (IV, Random, 95% CI) -0.55 [-8.08, 6.99]
2 Disability 3 656 Mean Difference (IV, Random, 95% CI) 1.34 [-2.01, 4.69]
2.1 Short-term (less than 12
months)
3 329 Mean Difference (IV, Random, 95% CI) 1.30 [-3.64, 6.25]
2.2 Long-term (12 months or
more)
3 327 Mean Difference (IV, Random, 95% CI) 1.25 [-4.48, 6.98]
3 Function 2 360 Mean Difference (IV, Random, 95% CI) -0.03 [-0.19, 0.12]
3.1 Short-term (less than 12
months)
2 185 Mean Difference (IV, Random, 95% CI) -0.06 [-0.27, 0.14]
3.2 Long-term (12 months or
more)
2 175 Mean Difference (IV, Random, 95% CI) -0.00 [-0.30, 0.29]
4 Quality of life 1 162 Mean Difference (IV, Random, 95% CI) -0.09 [-0.18, 0.00]
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4.1 Short-term (less than 12
months)
1 81 Mean Difference (IV, Random, 95% CI) -0.12 [-0.25, 0.01]
4.2 Long-term (12 months or
more)
1 81 Mean Difference (IV, Random, 95% CI) -0.05 [-0.18, 0.07]
5 Costs 2 240 Mean Difference (IV, Random, 95% CI) 2856.34 [1970.40,
3742.28]
6 Operation time 3 340 Mean Difference (IV, Random, 95% CI) 39.11 [19.43, 58.78]
7 Blood loss 1 81 Mean Difference (IV, Random, 95% CI) 144.0 [-209.74, 497.
74]
8 Reoperations 3 326 Risk Ratio (IV, Random, 95% CI) 3.95 [2.12, 7.37]
9 Hospitalisation 2 240 Mean Difference (IV, Random, 95% CI) 0.51 [-0.58, 1.60]
Comparison 3. Decompression plus fusion versus interspinous spacer
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 2 308 Mean Difference (IV, Random, 95% CI) 5.35 [-1.18, 11.88]
1.1 Long-term (12 months or
more)
2 308 Mean Difference (IV, Random, 95% CI) 5.35 [-1.18, 11.88]
2 Disability 2 308 Mean Difference (IV, Random, 95% CI) 5.72 [1.28, 10.15]
2.1 Long-term (12 months or
more)
2 308 Mean Difference (IV, Random, 95% CI) 5.72 [1.28, 10.15]
3 Quality of life 1 226 Mean Difference (IV, Random, 95% CI) -3.10 [-6.30, 0.10]
3.1 Long-term (12 months or
more)
1 226 Mean Difference (IV, Random, 95% CI) -3.10 [-6.30, 0.10]
4 Operation time 2 381 Mean Difference (IV, Random, 95% CI) 78.91 [30.16, 127.
65]
5 Blood loss 1 320 Mean Difference (IV, Random, 95% CI) 238.90 [182.66,
295.14]
6 Reoperations 1 322 Risk Ratio (IV, Random, 95% CI) 0.70 [0.32, 1.51]
7 Hospitalisation 2 382 Mean Difference (IV, Random, 95% CI) 1.58 [0.90, 2.27]
Comparison 4. Laminectomy versus laminotomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 6 728 Mean Difference (IV, Random, 95% CI) -0.67 [-4.36, 3.02]
1.1 Short-term (less than 12
months)
3 281 Mean Difference (IV, Random, 95% CI) 0.32 [-2.39, 3.04]
1.2 Long-term (12 months or
more)
6 447 Mean Difference (IV, Random, 95% CI) -1.92 [-8.19, 4.35]
2 Disability 6 722 Mean Difference (IV, Random, 95% CI) 1.05 [-0.81, 2.90]
2.1 Short-term (less than 12
months)
4 333 Mean Difference (IV, Random, 95% CI) 1.56 [-1.02, 4.13]
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2.2 Long-term (12 months or
more)
5 389 Mean Difference (IV, Random, 95% CI) -0.43 [-4.37, 3.52]
3 Walking ability 3 414 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.25, 0.15]
3.1 Short-term (less than 12
months)
3 233 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.33, 0.20]
3.2 Long-term (12 months or
more)
2 181 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.33, 0.28]
4 Operation time 5 339 Mean Difference (IV, Random, 95% CI) -6.25 [-13.76, 1.27]
5 Blood loss 5 381 Mean Difference (IV, Random, 95% CI) 38.80 [17.81, 59.80]
6 Reoperations 2 182 Risk Ratio (IV, Random, 95% CI) 2.61 [0.78, 8.78]
7 Hospitalisation 2 139 Mean Difference (IV, Random, 95% CI) 1.55 [0.61, 2.50]
Comparison 5. Decompression versus split-decompression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 3 175 Mean Difference (IV, Random, 95% CI) 6.35 [-3.35, 16.04]
1.1 Long-term (12 months or
more)
3 175 Mean Difference (IV, Random, 95% CI) 6.35 [-3.35, 16.04]
2 Disability 4 207 Mean Difference (IV, Random, 95% CI) 1.87 [-2.82, 6.57]
2.1 Long-term (12 months or
more)
4 207 Mean Difference (IV, Random, 95% CI) 1.87 [-2.82, 6.57]
3 Recovery 4 207 Mean Difference (IV, Random, 95% CI) -5.18 [-19.81, 9.45]
4 Operation time 4 211 Mean Difference (IV, Random, 95% CI) -10.57 [-34.39, 13.
25]
5 Blood loss 4 211 Mean Difference (IV, Random, 95% CI) -1.83 [-27.65, 23.
98]
6 Reoperations 3 153 Risk Ratio (IV, Random, 95% CI) 1.22 [0.22, 6.85]
7 Hospitalisation 2 121 Mean Difference (IV, Random, 95% CI) 1.49 [-1.70, 4.67]
Comparison 6. Decompression versus endoscopic decompression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disability 3 724 Mean Difference (IV, Random, 95% CI) 2.86 [0.26, 5.45]
1.1 Short-term (less than 12
months)
3 362 Mean Difference (IV, Random, 95% CI) 4.12 [0.91, 7.33]
1.2 Long-term (12 months or
more)
3 362 Mean Difference (IV, Random, 95% CI) 1.44 [-2.66, 5.54]
2 Operation time 3 393 Mean Difference (IV, Random, 95% CI) 10.05 [-2.09, 22.18]
3 Blood loss 1 41 Mean Difference (IV, Random, 95% CI) 34.0 [30.40, 37.60]
4 Reoperations 2 321 Risk Ratio (IV, Random, 95% CI) 0.81 [0.22, 2.97]
5 Hospitalisation 1 41 Mean Difference (IV, Random, 95% CI) 8.56 [6.78, 10.34]
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Analysis 1.1. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 1 Pain.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 1 Pain
Study or subgroup Decompression Fusion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Ghogawala 2016 35 -7.7 (10.7572) 31 -12.2 (10.7572) 27.1 % 4.50 [ -0.70, 9.70 ]
Subtotal (95% CI) 35 31 27.1 % 4.50 [ -0.70, 9.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
2 Long-term (12 months or more)
Grob 1995 15 17 (11.9) 30 25.5 (17.08) 18.4 % -8.50 [ -17.08, 0.08 ]
Hallett 2007 13 48.1 (23) 28 44.2 (23) 8.9 % 3.90 [ -11.23, 19.03 ]
Forsth 2016 117 31.2 (31.8) 111 33.2 (30.3) 19.6 % -2.00 [ -10.06, 6.06 ]
Ghogawala 2016 35 -9.5 (11.5846) 31 -15.2 (11.5846) 26.0 % 5.70 [ 0.10, 11.30 ]
Subtotal (95% CI) 180 200 72.9 % -0.29 [ -7.32, 6.74 ]
Heterogeneity: Tau2 = 30.83; Chi2 = 8.08, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 215 231 100.0 % 1.09 [ -4.07, 6.26 ]
Heterogeneity: Tau2 = 18.56; Chi2 = 9.32, df = 4 (P = 0.05); I2 =57%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
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Analysis 1.2. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 2 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 2 Disability
Study or subgroup Decompression Fusion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Ghogawala 2016 35 -17 (17.9976) 31 -22.2 (17.9976) 26.4 % 5.20 [ -3.50, 13.90 ]
Subtotal (95% CI) 35 31 26.4 % 5.20 [ -3.50, 13.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Long-term (12 months or more)
Hallett 2007 13 56.29 (29.17) 28 46.54 (29.17) 9.8 % 9.75 [ -9.44, 28.94 ]
Ghogawala 2016 31 -17.9 (18.4113) 35 -26.3 (18.4113) 25.9 % 8.40 [ -0.50, 17.30 ]
Forsth 2016 117 23.61 (18.2) 111 26.6 (19.4) 37.9 % -2.99 [ -7.88, 1.90 ]
Subtotal (95% CI) 161 174 73.6 % 3.26 [ -6.12, 12.63 ]
Heterogeneity: Tau2 = 42.35; Chi2 = 5.85, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 196 205 100.0 % 3.37 [ -3.37, 10.11 ]
Heterogeneity: Tau2 = 25.00; Chi2 = 6.91, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
-50 -25 0 25 50
Favours Decompression Favours Fusion
86Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
275
Analysis 1.3. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 3 Walking
ability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 3 Walking ability
Study or subgroup Decompression Fusion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Bridwell 1993 3/9 23/34 5.3 % 0.49 [ 0.19, 1.28 ]
Grob 1995 14/15 24/30 39.1 % 1.17 [ 0.93, 1.46 ]
Forsth 2016 98/117 99/111 55.6 % 0.94 [ 0.85, 1.04 ]
Total (95% CI) 141 175 100.0 % 0.99 [ 0.79, 1.24 ]
Total events: 115 (Decompression), 146 (Fusion)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.4. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 4 Operation
time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 4 Operation time
Study or subgroup Decompression Fusion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Grob 1995 15 104 (22.5) 30 147 (22.35) 25.5 % -43.00 [ -56.91, -29.09 ]
Hallett 2007 14 120 (30) 30 288 (60) 24.4 % -168.00 [ -194.61, -141.39 ]
Ghogawala 2016 34 124.4 (34.2) 30 289.6 (66.3) 24.4 % -165.20 [ -191.56, -138.84 ]
Forsth 2016 117 88.46 (35.92) 111 149.4 (45) 25.7 % -60.94 [ -71.54, -50.34 ]
Total (95% CI) 180 201 100.0 % -107.94 [ -161.65, -54.23 ]
Heterogeneity: Tau2 = 2894.02; Chi2 = 118.78, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.94 (P = 0.000082)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours Decompression Favours Fusion
88Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
277
Analysis 1.5. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 5 Blood loss.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 5 Blood loss
Study or subgroup Decompression Fusion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Forsth 2016 117 0.3 (0.315) 111 0.67 (0.458) 30.8 % -0.37 [ -0.47, -0.27 ]
Ghogawala 2016 35 0.0834 (0.0635) 31 0.51 (0.3344) 29.7 % -0.43 [ -0.55, -0.31 ]
Grob 1995 15 0.3 (0.15) 30 0.76 (0.373) 27.3 % -0.46 [ -0.62, -0.31 ]
Hallett 2007 14 0.34 (0.348) 30 1.58 (1.032) 12.2 % -1.23 [ -1.65, -0.82 ]
Total (95% CI) 181 202 100.0 % -0.52 [ -0.70, -0.34 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 16.16, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 6
Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 6 Reoperations
Study or subgroup Decompression Fusion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Bridwell 1993 0/9 2/34 2.1 % 0.70 [ 0.04, 13.43 ]
Grob 1995 0/15 5/30 2.3 % 0.18 [ 0.01, 2.99 ]
Hallett 2007 1/13 2/28 3.5 % 1.08 [ 0.11, 10.83 ]
Ghogawala 2016 10/35 4/31 16.6 % 2.21 [ 0.77, 6.35 ]
Forsth 2016 25/113 25/135 75.5 % 1.19 [ 0.73, 1.96 ]
Total (95% CI) 185 258 100.0 % 1.25 [ 0.81, 1.92 ]
Total events: 36 (Decompression), 38 (Fusion)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.17, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Decompression alone versus decompression plus fusion, Outcome 7
Hospitalisation.
Review: Surgical options for lumbar spinal stenosis
Comparison: 1 Decompression alone versus decompression plus fusion
Outcome: 7 Hospitalisation
Study or subgroup Decompression Fusion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ghogawala 2016 33 2.6 (0.9) 30 4.2 (0.9) 94.8 % -1.60 [ -2.04, -1.16 ]
Forsth 2016 119 4.1 (6.1) 113 7.4 (8.4) 5.2 % -3.30 [ -5.20, -1.40 ]
Total (95% CI) 152 143 100.0 % -1.69 [ -2.12, -1.26 ]
Heterogeneity: Chi2 = 2.92, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 7.64 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Decompression versus interspinous spacer, Outcome 1 Pain.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 1 Pain
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Stromqvist 2013 48 22.9 (27.36) 48 29.8 (31.51) 13.9 % -6.90 [ -18.71, 4.91 ]
Moojen 2013 78 22 (20.28) 73 26 (26.16) 24.3 % -4.00 [ -11.50, 3.50 ]
Lonne 2015 41 35.8 (27.5) 40 26.2 (27.5) 13.6 % 9.60 [ -2.38, 21.58 ]
Subtotal (95% CI) 167 161 51.8 % -0.93 [ -9.86, 8.00 ]
Heterogeneity: Tau2 = 34.80; Chi2 = 4.53, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Long-term (12 months or more)
Moojen 2013 78 26 (29.29) 73 23 (28.34) 19.4 % 3.00 [ -6.19, 12.19 ]
Stromqvist 2013 48 21.65 (24.91) 48 30.2 (30.04) 15.3 % -8.55 [ -19.59, 2.49 ]
Lonne 2015 41 32 (27.5) 40 28.6 (27.5) 13.6 % 3.40 [ -8.58, 15.38 ]
Subtotal (95% CI) 167 161 48.2 % -0.55 [ -8.08, 6.99 ]
Heterogeneity: Tau2 = 14.93; Chi2 = 3.01, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 334 322 100.0 % -0.89 [ -6.08, 4.31 ]
Heterogeneity: Tau2 = 14.36; Chi2 = 7.62, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 2.2. Comparison 2 Decompression versus interspinous spacer, Outcome 2 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 2 Disability
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Stromqvist 2013 48 42.5 (16.75) 48 46.75 (20.75) 14.4 % -4.25 [ -11.79, 3.29 ]
Moojen 2013 78 45 (17.5) 74 42.5 (17.5) 21.5 % 2.50 [ -3.07, 8.07 ]
Lonne 2015 41 19.4 (16.6481) 40 14.4 (17.0763) 14.9 % 5.00 [ -2.35, 12.35 ]
Subtotal (95% CI) 167 162 50.8 % 1.30 [ -3.64, 6.25 ]
Heterogeneity: Tau2 = 7.32; Chi2 = 3.23, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.52 (P = 0.61)
2 Long-term (12 months or more)
Moojen 2013 79 45 (17.5) 73 42.5 (17.5) 21.5 % 2.50 [ -3.07, 8.07 ]
Stromqvist 2013 48 41.5 (18.5) 46 46.75 (20.75) 13.3 % -5.25 [ -13.21, 2.71 ]
Lonne 2015 41 18.3 (16.6481) 40 12.6 (17.7088) 14.5 % 5.70 [ -1.79, 13.19 ]
Subtotal (95% CI) 168 159 49.2 % 1.25 [ -4.48, 6.98 ]
Heterogeneity: Tau2 = 13.15; Chi2 = 4.10, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 335 321 100.0 % 1.34 [ -2.01, 4.69 ]
Heterogeneity: Tau2 = 5.51; Chi2 = 7.32, df = 5 (P = 0.20); I2 =32%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 2.3. Comparison 2 Decompression versus interspinous spacer, Outcome 3 Function.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 3 Function
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Stromqvist 2013 48 1.7 (0.7577) 48 1.88 (0.7577) 25.9 % -0.18 [ -0.48, 0.12 ]
Lonne 2015 41 1.73 (0.6403) 48 1.7 (0.6325) 33.8 % 0.03 [ -0.24, 0.30 ]
Subtotal (95% CI) 89 96 59.7 % -0.06 [ -0.27, 0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.59 (P = 0.55)
2 Long-term (12 months or more)
Stromqvist 2013 48 1.66 (1.5842) 46 1.9 (0.8082) 9.3 % -0.24 [ -0.75, 0.27 ]
Lonne 2015 41 1.7 (0.6403) 40 1.61 (0.6325) 31.0 % 0.09 [ -0.19, 0.37 ]
Subtotal (95% CI) 89 86 40.3 % 0.00 [ -0.30, 0.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 178 182 100.0 % -0.03 [ -0.19, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 2.4. Comparison 2 Decompression versus interspinous spacer, Outcome 4 Quality of life.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 4 Quality of life
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Lonne 2015 41 0.623 (0.2945) 40 0.74 (0.2846) 50.0 % -0.12 [ -0.25, 0.01 ]
Subtotal (95% CI) 41 40 50.0 % -0.12 [ -0.25, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
2 Long-term (12 months or more)
Lonne 2015 41 0.673 (0.2881) 40 0.73 (0.2909) 50.0 % -0.05 [ -0.18, 0.07 ]
Subtotal (95% CI) 41 40 50.0 % -0.05 [ -0.18, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 82 80 100.0 % -0.09 [ -0.18, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.5. Comparison 2 Decompression versus interspinous spacer, Outcome 5 Costs.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 5 Costs
Study or subgroup Interspinous Spacer Decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moojen 2013 80 10210 (8127.804) 79 7180 (8127.804) 12.3 % 3030.00 [ 503.26, 5556.74 ]
Lonne 2015 40 8247 (2171.8) 41 5415 (2171.8) 87.7 % 2832.00 [ 1886.01, 3777.99 ]
Total (95% CI) 120 120 100.0 % 2856.34 [ 1970.40, 3742.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 6.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Decompression versus interspinous spacer, Outcome 6 Operation time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 6 Operation time
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moojen 2013 79 43 (19) 80 24 (10) 35.0 % 19.00 [ 14.27, 23.73 ]
Stromqvist 2013 50 98 (14.5) 50 62 (14.5) 34.7 % 36.00 [ 30.32, 41.68 ]
Lonne 2015 41 112.9 (41) 40 46.9 (20.8) 30.2 % 66.00 [ 51.89, 80.11 ]
Total (95% CI) 170 170 100.0 % 39.11 [ 19.43, 58.78 ]
Heterogeneity: Tau2 = 281.76; Chi2 = 49.33, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.90 (P = 0.000098)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Decompression versus interspinous spacer, Outcome 7 Blood loss.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 7 Blood loss
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lonne 2015 41 184 (1100) 40 40 (350) 100.0 % 144.00 [ -209.74, 497.74 ]
Total (95% CI) 41 40 100.0 % 144.00 [ -209.74, 497.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Decompression versus interspinous spacer, Outcome 8 Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 8 Reoperations
Study or subgroup Interspinous Spacer Decompression Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Moojen 2013 21/73 6/72 54.3 % 3.45 [ 1.48, 8.05 ]
Stromqvist 2013 13/50 3/50 27.4 % 4.33 [ 1.31, 14.28 ]
Lonne 2015 10/40 2/41 18.4 % 5.13 [ 1.20, 21.94 ]
Total (95% CI) 163 163 100.0 % 3.95 [ 2.12, 7.37 ]
Total events: 44 (Interspinous Spacer), 11 (Decompression)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000016)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Decompression versus interspinous spacer, Outcome 9 Hospitalisation.
Review: Surgical options for lumbar spinal stenosis
Comparison: 2 Decompression versus interspinous spacer
Outcome: 9 Hospitalisation
Study or subgroup Decompression Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moojen 2013 79 1.89 (1.2) 80 1.83 (0.9) 60.7 % 0.06 [ -0.27, 0.39 ]
Lonne 2015 41 3.4 (3.1) 40 2.2 (1.7) 39.3 % 1.20 [ 0.11, 2.29 ]
Total (95% CI) 120 120 100.0 % 0.51 [ -0.58, 1.60 ]
Heterogeneity: Tau2 = 0.48; Chi2 = 3.88, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 1 Pain.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 1 Pain
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Azzazi 2010 30 35.5 (24.2) 30 25.5 (24.2) 28.4 % 10.00 [ -2.25, 22.25 ]
Davis 2013 86 24.1 (30.6) 162 20.6 (27.4) 71.6 % 3.50 [ -4.22, 11.22 ]
Total (95% CI) 116 192 100.0 % 5.35 [ -1.18, 11.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 2 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 2 Disability
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Azzazi 2010 30 34.5 (15.8) 30 26.5 (15.8) 30.8 % 8.00 [ 0.00, 16.00 ]
Davis 2013 86 26.7 (21.3) 162 22 (18.6) 69.2 % 4.70 [ -0.64, 10.04 ]
Total (95% CI) 116 192 100.0 % 5.72 [ 1.28, 10.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 3 Quality of
life.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 3 Quality of life
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Davis 2013 78 40.7 (12.2) 148 43.8 (10.6) 100.0 % -3.10 [ -6.30, 0.10 ]
Total (95% CI) 78 148 100.0 % -3.10 [ -6.30, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 4 Operation
time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 4 Operation time
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azzazi 2010 30 150 (48.3) 30 45 (48.3) 47.6 % 105.00 [ 80.56, 129.44 ]
Davis 2013 107 153.2 (55.5) 214 98 (41.1) 52.4 % 55.20 [ 43.33, 67.07 ]
Total (95% CI) 137 244 100.0 % 78.91 [ 30.16, 127.65 ]
Heterogeneity: Tau2 = 1143.92; Chi2 = 12.90, df = 1 (P = 0.00033); I2 =92%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 5 Blood loss.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 5 Blood loss
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Davis 2013 105 348.6 (281.8) 215 109.7 (120) 100.0 % 238.90 [ 182.66, 295.14 ]
Total (95% CI) 105 215 100.0 % 238.90 [ 182.66, 295.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 6
Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 6 Reoperations
Study or subgroup Fusion Interspinous Spacer Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Davis 2013 8/107 23/215 100.0 % 0.70 [ 0.32, 1.51 ]
Total (95% CI) 107 215 100.0 % 0.70 [ 0.32, 1.51 ]
Total events: 8 (Fusion), 23 (Interspinous Spacer)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Decompression plus fusion versus interspinous spacer, Outcome 7
Hospitalisation.
Review: Surgical options for lumbar spinal stenosis
Comparison: 3 Decompression plus fusion versus interspinous spacer
Outcome: 7 Hospitalisation
Study or subgroup Fusion Interspinous Spacer
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azzazi 2010 30 3 (1.345) 30 1 (1.345) 41.0 % 2.00 [ 1.32, 2.68 ]
Davis 2013 107 3.19 (1.61) 215 1.9 (1.08) 59.0 % 1.29 [ 0.95, 1.63 ]
Total (95% CI) 137 245 100.0 % 1.58 [ 0.90, 2.27 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 4.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Laminectomy versus laminotomy, Outcome 1 Pain.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 1 Pain
Study or subgroup Laminectomy Laminotomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Thome 2005 34 30.5 (27.3) 76 27.94 (28.87) 6.7 % 2.56 [ -8.68, 13.80 ]
Cavusoglu 2007 50 -62.64 (9.52) 50 -61.78 (11.92) 14.6 % -0.86 [ -5.09, 3.37 ]
Celik 2010 34 26 (7) 37 25 (9) 15.2 % 1.00 [ -2.73, 4.73 ]
Subtotal (95% CI) 118 163 36.6 % 0.32 [ -2.39, 3.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Long-term (12 months or more)
Postacchini 1993 32 -84 (15.34) 26 -71 (17.11) 9.3 % -13.00 [ -21.46, -4.54 ]
Thome 2005 34 40 (10) 76 29.67 (26.24) 11.2 % 10.33 [ 3.54, 17.12 ]
Cavusoglu 2007 50 -69.64 (10.52) 50 -68.32 (9.92) 14.9 % -1.32 [ -5.33, 2.69 ]
Celik 2010 34 23 (11) 37 25 (14) 12.4 % -2.00 [ -7.83, 3.83 ]
Liu 2013 27 17 (15.5885) 27 13 (10.3923) 10.9 % 4.00 [ -3.07, 11.07 ]
Mobbs 2014 27 39 (29) 27 56 (25) 4.8 % -17.00 [ -31.44, -2.56 ]
Subtotal (95% CI) 204 243 63.4 % -1.92 [ -8.19, 4.35 ]
Heterogeneity: Tau2 = 46.06; Chi2 = 25.14, df = 5 (P = 0.00013); I2 =80%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 322 406 100.0 % -0.67 [ -4.36, 3.02 ]
Heterogeneity: Tau2 = 19.63; Chi2 = 25.98, df = 8 (P = 0.001); I2 =69%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 4.2. Comparison 4 Laminectomy versus laminotomy, Outcome 2 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 2 Disability
Study or subgroup Laminectomy Laminotomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Thome 2005 34 35.67 (28.21) 76 37.97 (31.04) 2.5 % -2.30 [ -14.07, 9.47 ]
Cavusoglu 2007 50 14.22 (9.88) 50 12.22 (6.46) 32.2 % 2.00 [ -1.27, 5.27 ]
Celik 2010 34 21.2 (9.3295) 37 20.5 (10.949) 15.5 % 0.70 [ -4.02, 5.42 ]
Gurelik 2012 26 32.15 (28.94) 26 25.92 (20.43) 1.9 % 6.23 [ -7.39, 19.85 ]
Subtotal (95% CI) 144 189 52.0 % 1.56 [ -1.02, 4.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
2 Long-term (12 months or more)
Thome 2005 34 35.42 (30.42) 76 39.74 (30.62) 2.3 % -4.32 [ -16.65, 8.01 ]
Cavusoglu 2007 50 14.02 (9.27) 50 12.4 (6.3) 35.7 % 1.62 [ -1.49, 4.73 ]
Celik 2010 34 21.7 (13.9943) 37 22.3 (16.4235) 6.9 % -0.60 [ -7.68, 6.48 ]
Liu 2013 27 -83.79 (46.41) 27 -92.07 (37.62) 0.7 % 8.28 [ -14.25, 30.81 ]
Mobbs 2014 27 17.8 (15.4) 27 28.6 (27.7) 2.4 % -10.80 [ -22.75, 1.15 ]
Subtotal (95% CI) 172 217 48.0 % -0.43 [ -4.37, 3.52 ]
Heterogeneity: Tau2 = 4.77; Chi2 = 5.07, df = 4 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 316 406 100.0 % 1.05 [ -0.81, 2.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.45, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 4.3. Comparison 4 Laminectomy versus laminotomy, Outcome 3 Walking ability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 3 Walking ability
Study or subgroup Laminectomy Laminotomy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Thome 2005 34 2958 (3561) 76 2744.36 (3427.729) 24.7 % 0.06 [ -0.34, 0.47 ]
Celik 2010 34 85.5 (60.64) 37 90 (69.34) 18.6 % -0.07 [ -0.53, 0.40 ]
Gurelik 2012 26 203.65 (283.04) 26 288.65 (278.05) 13.5 % -0.30 [ -0.85, 0.25 ]
Subtotal (95% CI) 94 139 56.7 % -0.07 [ -0.33, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.07, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Long-term (12 months or more)
Thome 2005 34 2958 (3561) 76 2972.8 (3428.883) 24.7 % 0.00 [ -0.41, 0.40 ]
Celik 2010 34 94.4 (54.81) 37 97.4 (71.17) 18.6 % -0.05 [ -0.51, 0.42 ]
Subtotal (95% CI) 68 113 43.3 % -0.02 [ -0.33, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 162 252 100.0 % -0.05 [ -0.25, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 4.4. Comparison 4 Laminectomy versus laminotomy, Outcome 4 Operation time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 4 Operation time
Study or subgroup Laminectomy Laminotomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Postacchini 1993 32 85.937 (41.88) 26 109.42 (50.22) 8.4 % -23.48 [ -47.63, 0.67 ]
Thome 2005 38 73 (32) 79 83.42 (30.049) 23.6 % -10.42 [ -22.56, 1.72 ]
Celik 2010 22 107 (70.3562) 26 83 (61.1882) 3.7 % 24.00 [ -13.65, 61.65 ]
Liu 2013 29 57 (64.622) 27 67 (109.1192) 2.4 % -10.00 [ -57.41, 37.41 ]
Usman 2013 30 65 (0.5477) 30 69 (0.5477) 61.8 % -4.00 [ -4.28, -3.72 ]
Total (95% CI) 151 188 100.0 % -6.25 [ -13.76, 1.27 ]
Heterogeneity: Tau2 = 23.74; Chi2 = 5.76, df = 4 (P = 0.22); I2 =31%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Laminectomy Favours Laminotomy
107Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
296
Analysis 4.5. Comparison 4 Laminectomy versus laminotomy, Outcome 5 Blood loss.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 5 Blood loss
Study or subgroup Laminectomy Laminotomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Postacchini 1993 32 188.75 (79.4) 26 174.62 (63.15) 19.1 % 14.13 [ -22.55, 50.82 ]
Thome 2005 38 227 (154) 79 194.28 (125.451) 10.7 % 32.72 [ -23.52, 88.96 ]
Celik 2010 34 227 (74) 37 178 (53) 23.6 % 49.00 [ 18.83, 79.17 ]
Liu 2013 29 78 (54.9287) 27 56 (57.1577) 24.1 % 22.00 [ -7.40, 51.40 ]
Mobbs 2014 40 110 (79.4) 39 40 (63.15) 22.5 % 70.00 [ 38.40, 101.60 ]
Total (95% CI) 173 208 100.0 % 38.80 [ 17.81, 59.80 ]
Heterogeneity: Tau2 = 250.23; Chi2 = 7.21, df = 4 (P = 0.13); I2 =45%
Test for overall effect: Z = 3.62 (P = 0.00029)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Laminectomy versus laminotomy, Outcome 6 Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 6 Reoperations
Study or subgroup Laminectomy Laminotomy Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Thome 2005 4/34 4/77 83.7 % 2.26 [ 0.60, 8.53 ]
Celik 2010 2/34 0/37 16.3 % 5.43 [ 0.27, 109.19 ]
Total (95% CI) 68 114 100.0 % 2.61 [ 0.78, 8.78 ]
Total events: 6 (Laminectomy), 4 (Laminotomy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Review: Surgical options for lumbar spinal stenosis
Comparison: 4 Laminectomy versus laminotomy
Outcome: 7 Hospitalisation
Study or subgroup Laminectomy Laminotomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Usman 2013 30 4.67 (2.6236) 30 3.5 (2.7879) 47.4 % 1.17 [ -0.20, 2.54 ]
Mobbs 2014 40 4.2 (2.97) 39 2.3 (2.93) 52.6 % 1.90 [ 0.60, 3.20 ]
Total (95% CI) 70 69 100.0 % 1.55 [ 0.61, 2.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Decompression versus split-decompression, Outcome 1 Pain.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 1 Pain
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Cho 2007 30 40 (20) 40 23.8 (18.9) 33.2 % 16.20 [ 6.95, 25.45 ]
Rajasekaran 2013 23 17.4 (21.4) 28 19.3 (19.4) 28.9 % -1.90 [ -13.22, 9.42 ]
Liu 2013 27 17 (15.5885) 27 13 (10.3923) 38.0 % 4.00 [ -3.07, 11.07 ]
Total (95% CI) 80 95 100.0 % 6.35 [ -3.35, 16.04 ]
Heterogeneity: Tau2 = 51.50; Chi2 = 6.82, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Decompression versus split-decompression, Outcome 2 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 2 Disability
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Long-term (12 months or more)
Cho 2007 30 -39.31 (11.03) 40 -44.83 (6.79) 36.8 % 5.52 [ 1.05, 9.99 ]
Liu 2013 27 -83.79 (46.41) 27 -92.07 (37.62) 4.0 % 8.28 [ -14.25, 30.81 ]
Rajasekaran 2013 23 -39.28 (7.83) 28 -37.07 (8.72) 36.4 % -2.21 [ -6.76, 2.34 ]
Watanabe 2011 15 -87.59 (10) 17 -88.97 (11.72) 22.8 % 1.38 [ -6.15, 8.91 ]
Total (95% CI) 95 112 100.0 % 1.87 [ -2.82, 6.57 ]
Heterogeneity: Tau2 = 10.42; Chi2 = 5.97, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Decompression versus split-decompression, Outcome 3 Recovery.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 3 Recovery
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cho 2007 30 48.1 (31.1) 40 73.9 (22.4) 25.2 % -25.80 [ -38.92, -12.68 ]
Watanabe 2011 15 74 (17) 17 75 (21) 25.1 % -1.00 [ -14.18, 12.18 ]
Rajasekaran 2013 23 56.7 (22) 28 48.2 (23.9) 25.5 % 8.50 [ -4.12, 21.12 ]
Liu 2013 27 83.6 (34.47) 27 86.1 (16.11) 24.2 % -2.50 [ -16.85, 11.85 ]
Total (95% CI) 95 112 100.0 % -5.18 [ -19.81, 9.45 ]
Heterogeneity: Tau2 = 176.70; Chi2 = 14.53, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Decompression Favours Split-decompression
112Surgical options for lumbar spinal stenosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
301
Analysis 5.4. Comparison 5 Decompression versus split-decompression, Outcome 4 Operation time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 4 Operation time
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cho 2007 30 193 (68) 40 259 (122) 16.6 % -66.00 [ -110.96, -21.04 ]
Watanabe 2011 16 82 (36) 18 69 (29) 30.2 % 13.00 [ -9.15, 35.15 ]
Liu 2013 29 57 (64.62) 27 67 (109.12) 15.6 % -10.00 [ -57.41, 37.41 ]
Rajasekaran 2013 23 57.1 (17.4) 28 62.3 (22.1) 37.6 % -5.20 [ -16.04, 5.64 ]
Total (95% CI) 98 113 100.0 % -10.57 [ -34.39, 13.25 ]
Heterogeneity: Tau2 = 361.90; Chi2 = 9.65, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Decompression versus split-decompression, Outcome 5 Blood loss.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 5 Blood loss
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cho 2007 30 132 (128) 40 154 (135) 12.9 % -22.00 [ -84.03, 40.03 ]
Watanabe 2011 16 51.9 (45.3) 18 41.5 (70.8) 23.2 % 10.40 [ -29.13, 49.93 ]
Rajasekaran 2013 23 61.3 (38.94) 28 85.7 (56.1) 33.3 % -24.40 [ -50.57, 1.77 ]
Liu 2013 29 78 (54.93) 27 56 (57.16) 30.6 % 22.00 [ -7.40, 51.40 ]
Total (95% CI) 98 113 100.0 % -1.83 [ -27.65, 23.98 ]
Heterogeneity: Tau2 = 341.97; Chi2 = 6.15, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Decompression versus split-decompression, Outcome 6 Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 6 Reoperations
Study or subgroup Decompression Split-decompression Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Cho 2007 1/30 1/40 39.8 % 1.33 [ 0.09, 20.47 ]
Watanabe 2011 0/15 1/17 30.3 % 0.38 [ 0.02, 8.57 ]
Rajasekaran 2013 1/23 0/28 29.8 % 3.63 [ 0.15, 84.98 ]
Total (95% CI) 68 85 100.0 % 1.22 [ 0.22, 6.85 ]
Total events: 2 (Decompression), 2 (Split-decompression)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Decompression versus split-decompression, Outcome 7 Hospitalisation.
Review: Surgical options for lumbar spinal stenosis
Comparison: 5 Decompression versus split-decompression
Outcome: 7 Hospitalisation
Study or subgroup Decompression Split-decompression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cho 2007 30 7.18 (2.89) 40 4.03 (1.56) 48.8 % 3.15 [ 2.01, 4.29 ]
Rajasekaran 2013 23 4.4 (1.1) 28 4.5 (0.9) 51.2 % -0.10 [ -0.66, 0.46 ]
Total (95% CI) 53 68 100.0 % 1.49 [ -1.70, 4.67 ]
Heterogeneity: Tau2 = 5.07; Chi2 = 25.10, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Decompression versus endoscopic decompression, Outcome 1 Disability.
Review: Surgical options for lumbar spinal stenosis
Comparison: 6 Decompression versus endoscopic decompression
Outcome: 1 Disability
Study or subgroup Decompression
Endoscopic
Decompres-
sion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short-term (less than 12 months)
Ruetten 2009 80 22 (11.16) 81 20 (11.16) 20.3 % 2.00 [ -1.45, 5.45 ]
Yagi 2009 21 -69.55 (8.69) 20 -79.14 (13.48) 9.6 % 9.59 [ 2.61, 16.57 ]
Komp 2015 80 28 (9.93) 80 24 (9.93) 21.9 % 4.00 [ 0.92, 7.08 ]
Subtotal (95% CI) 181 181 51.8 % 4.12 [ 0.91, 7.33 ]
Heterogeneity: Tau2 = 3.65; Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 2.52 (P = 0.012)
2 Long-term (12 months or more)
Ruetten 2009 80 22 (11.16) 81 20 (11.16) 20.3 % 2.00 [ -1.45, 5.45 ]
Yagi 2009 21 -77.83 (13.9) 20 -84.34 (8.69) 9.5 % 6.51 [ -0.55, 13.57 ]
Komp 2015 80 27 (12.53) 80 29 (12.53) 18.5 % -2.00 [ -5.88, 1.88 ]
Subtotal (95% CI) 181 181 48.2 % 1.44 [ -2.66, 5.54 ]
Heterogeneity: Tau2 = 7.63; Chi2 = 4.96, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 362 362 100.0 % 2.86 [ 0.26, 5.45 ]
Heterogeneity: Tau2 = 5.57; Chi2 = 11.44, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
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Analysis 6.2. Comparison 6 Decompression versus endoscopic decompression, Outcome 2 Operation time.
Review: Surgical options for lumbar spinal stenosis
Comparison: 6 Decompression versus endoscopic decompression
Outcome: 2 Operation time
Study or subgroup Decompression
Endoscopic
Decompres-
sion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ruetten 2009 100 48 (11.97) 92 34 (10.16) 34.4 % 14.00 [ 10.87, 17.13 ]
Yagi 2009 21 63.6 (11.43) 20 71.1 (12.57) 31.2 % -7.50 [ -14.87, -0.13 ]
Komp 2015 80 64 (12.5) 80 42 (7.75) 34.4 % 22.00 [ 18.78, 25.22 ]
Total (95% CI) 201 192 100.0 % 10.05 [ -2.09, 22.18 ]
Heterogeneity: Tau2 = 108.74; Chi2 = 53.92, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Not applicable
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Review: Surgical options for lumbar spinal stenosis
Comparison: 6 Decompression versus endoscopic decompression
Outcome: 3 Blood loss
Study or subgroup Decompression
Endoscopic
Decompres-
sion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagi 2009 21 71 (5.88) 20 37 (5.88) 100.0 % 34.00 [ 30.40, 37.60 ]
Total (95% CI) 21 20 100.0 % 34.00 [ 30.40, 37.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 18.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Decompression versus endoscopic decompression, Outcome 4 Reoperations.
Review: Surgical options for lumbar spinal stenosis
Comparison: 6 Decompression versus endoscopic decompression
Outcome: 4 Reoperations
Study or subgroup Decompression
Endoscopic
Decompres-
sion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ruetten 2009 2/80 3/81 54.7 % 0.68 [ 0.12, 3.93 ]
Komp 2015 2/80 2/80 45.3 % 1.00 [ 0.14, 6.93 ]
Total (95% CI) 160 161 100.0 % 0.81 [ 0.22, 2.97 ]
Total events: 4 (Decompression), 5 (Endoscopic Decompression)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Review: Surgical options for lumbar spinal stenosis
Comparison: 6 Decompression versus endoscopic decompression
Outcome: 5 Hospitalisation
Study or subgroup Decompression
Endoscopic
Decompres-
sion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagi 2009 21 12.62 (3.21) 20 4.06 (2.57) 100.0 % 8.56 [ 6.78, 10.34 ]
Total (95% CI) 21 20 100.0 % 8.56 [ 6.78, 10.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Sources of Risk of Bias
Bias Domain Source of Bias PossibleAnswers
Selection (1) Was the method of randomization adequate? Yes/No/Unsure
Selection (2) Was the treatment allocation concealed? Yes/No/Unsure
Performance (3) Was the patient blinded to the intervention? Yes/No/Unsure
Performance (4) Was the care provider blinded to the intervention? Yes/No/Unsure
Detection (5)Was the outcome assessor blinded to the intervention? Yes/No/Unsure
Attrition (6) Was the drop-out rate described and acceptable? Yes/No/Unsure
Attrition (7) Were all randomized participants analysed in the
group to which they were allocated?
Yes/No/Unsure
Reporting (8) Are reports of the study free of suggestion of selective
outcome reporting?
Yes/No/Unsure
Selection (9)Were the groups similar at baseline regarding themost
important prognostic indicators?
Yes/No/Unsure
Performance (10) Were cointerventions avoided or similar? Yes/No/Unsure
Performance (11) Was the compliance acceptable in all groups? Yes/No/Unsure
Detection (12) Was the timing of the outcome assessment similar
in all groups?
Yes/No/Unsure
Other (13) Are other sources of potential bias unlikely? Yes/No/Unsure
Furlan 2015
Table 2. Criteria for a Judgment of “Yes” for the Sources of Risk of Bias
1 A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for studies with 2
groups), rolling a dice (for studies with 2 or more groups), drawing of balls of different colours, drawing of
ballots with the study group labels from a dark bag, computer-generated random sequence, preordered
sealed envelopes, sequentially-ordered vials, telephone call to a central office, and preordered list of
treatment assignments.Examples of inadequate methods are: alternation, birth date, social insurance/security number,
date in which they are invited to participate in the study, and hospital registration number
2 Assignment generated by an independent person not responsible for determining the eligibility of the patients.
This person has no information about the persons included in the trial and has no influence on the
assignment sequence or on the decision about eligibility of the patient
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Table 2. Criteria for a Judgment of “Yes” for the Sources of Risk of Bias (Continued)
3 Index and control groups are indistinguishable for the patients or if the success of blinding was tested among
the patients and it was successful.
4 Index and control groups are indistinguishable for the care providers or if the success of blinding was tested
among the care providers and it was successful.
5 Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored
“yes” if the success of blinding was tested among the outcome assessors and it was successful or:
-for patient-reported outcomes in which the patient is the outcome assessor (e.g., pain, disability): the blinding
procedure is adequate for outcome assessors if participant blinding is scored “yes”
-for outcome criteria assessed during scheduled visit and that supposes a contact between participants and
outcome assessors (e.g., clinical examination): the blinding procedure is adequate if patients are blinded, and
the treatment or adverse effects of the treatment cannot be noticed during clinical examination
-for outcome criteria that do not suppose a contact with participants (e.g., radiography, magnetic resonance
imaging): the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be
noticed when assessing the main outcome
-for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between
patients and care providers (e.g., cointerventions, hospitalisation length, treatment failure), in which the care
provider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item “4”
(caregivers) is scored “yes”
-for outcome criteria that are assessed from data of the medical forms: the blinding procedure is adequate if
the treatment or adverse effects of the treatment cannot be noticed on the extracted data
6 The number of participants who were included in the study but did not complete the observation period or
were not included in the analysis must be described and reasons given. If the percentage of withdrawals and
drop-outs does not exceed 20% for short-term follow-up and 30% for long-term follow-up and does not lead
to substantial bias a “yes” is scored. (N.B. these percentages are arbitrary, not supported by literature)
7 All randomized patients are reported/analysed in the group they were allocated to by randomization for the
most important moments of effect measurement (minus missing values) irrespective of noncompliance and
cointerventions.
8 All the results from all prespecified outcomes have been adequately reported in the published report of the
trial. This information is either obtained by comparing the protocol and the report, or in the absence of the
protocol, assessing that the published report includes enough information to make this judgment
9 Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints,
percentage of patients with neurological symptoms, and value of main outcome measure(s)
10 If there were no cointerventions or they were similar between the index and control groups
11 The reviewer determines if the compliance with the interventions is acceptable, based on the reported
intensity, duration, number and frequency of sessions for both the index intervention and control
intervention(s). For example, physiotherapy treatment is usually administered for several sessions; therefore it
is necessary to assess how many sessions each patient attended. For single-session interventions (e.g.,
surgery), this item is irrelevant.
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Table 2. Criteria for a Judgment of “Yes” for the Sources of Risk of Bias (Continued)
12 Timing of outcome assessment should be identical for all intervention groups and for all primary outcome
measures.
13 Other types of biases. For example:
-When the outcome measures were not valid. There should be evidence from a previous or present scientific
study that the primary outcome can be considered valid in the context of the present.
-Industry-sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers
have had full possession of the trial process from planning to reporting without funders with potential COI
having any possibility to interfere in the process. If, for example, the statistical analyses have been done by a
funder with a potential COI, usually “unsure” is scored.
Furlan 2015
A P P E N D I C E S
Appendix 1. Search strategy
CENTRAL
Last searched 16 June 2016
1. spinal stenosis.mp. or Spinal Stenosis/
2. canal stenosis.mp.
3. lumbar stenosis.mp.
4. 1 or 2 or 3
5. neurosurgery/ or orthopedics/
6. decompression.mp. or Decompression, Surgical/
7. Spinal Fusion/
8. surgery.mp.
9. 5 or 6 or 7 or 8
10. 4 and 9
MEDLINE
Last searched 16 June 2016
1. Exp spinal stenosis/
2. “canal stenosis”.mp.
3. (spin* adj3 stenosis).mp.
4. (lumbar adj3 stenosis).mp.
5. (lateral adj3 stenosis).mp.
6. (central adj3 stenosis).mp.
7. (foramin* adj3 stenosis).mp.
8. “neurogenic claudication”.mp.
9. Exp radiculopathy/
10. Radiculopathy.mp.
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11. “radicular pain”.mp.
12. “lumbar radicular pain”.mp.
13. Exp spondylolisthesis/
14. Spondylolisthesis.mp.
15. (lumb* adj5 spondyl*).mp.
16. Exp spondylosis/
17. Spondylosis.mp
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. Exp general surgery/
20. Surgery.mp.
21. Exp decompression, surgical/
22. “decompres* surgery”.mp.
23. Decompression.mp
24. (spin* adj3 decompress*).mp.
25. Exp laminectomy/
26. Laminectom*.mp.
27. Laminotom*.mp.
28. Laminoplasty.mp.
29. Exp spinal fusion/
30. (spin* adj3 fusion).mp.
31. (pedicle adj3 screw).mp.
32. “lumbar fusion”.mp.
33. “vertebrae fusion”.mp.
34. “vertebral fixation”.mp.
35. “spinal fixation”.mp.
36. Spondylodesis.mp
37. Spondylosyndesis.mp
38. Arthrodesis.mp. Or exp arthrodesis/
39. (posterolateral adj3 fusion).mp
40. (interbody adj3 fusion).mp
41. (anterior adj3 fusion).mp
42. (posterior adj3 fusion).mp
43. (transforaminal adj3 fusion).mp
44. (transpsoas adj3 fusion).mp
45. (facet adj3 fusion).mp
46. (bone adj3 graft).mp
47. (fixation adj3 spin*).mp
48. (pedicle adj3 fusion).mp
49. Graft.mp
50. (cage adj3 fusion).mp
51. (screw adj3 fusion).mp
52. Foraminotomy.mp. Or exp foraminotomy/
53. Foraminectomy.mp
54. Exp surgical procedures, minimally invasive/
55. “minim* invasive”.mp.
56. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55
57. 18 and 56
58. Exp randomized controlled trial/
59. Randomized controlled trial.pt.
60. “randomized controlled trial”.mp.
61. (random* adj3 trial).ab,ti.
62. Exp controlled clinical trial/
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63. “controlled clinical trial”.mp.
64. Randomized.ab,ti.
65. Placebo.ab,ti.
66. Randomly.ab,ti.
67. Random*.ab,ti.
68. Trial.ab,ti.
69. Exp clinical trial/
70. “clinical trial”.pt.
71. “clinical trial”.mp.
72. “clinical study”.ab,ti.
73. 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72
74. 57 and 73
75. Limit 74 to humans
EMBASE
Last searched 16 June 2016
1. ’vertebral canal stenosis’/exp OR ’vertebral canal stenosis’
2. ’spine NEAR/3 stenosis’
3. ’lumbar NEAR/3 stenosis’
4. ’lateral NEAR/3 stenosis’
5. ’central stenosis’
6. ’foraminal stenosis’
7. ’neurogenic claudication’
8. ’radiculopathy’/exp OR radiculopathy
9. ’radicular pain’/exp OR ’radicular pain’
10. ’lumbar radicular pain’
11. ’spondylolisthesis’/exp OR spondylolisthesis
12. ’spondylosis’/exp OR spondylosis
13. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
14. ’surgery’/exp OR surgery
15. ’decompression surgery’/exp OR ’decompression surgery’
16. ’decompression spinal cord’/exp OR ’decompression spinal cord’
17. ’decompression’/exp OR decompression
18. ’laminectomy’/exp OR laminectomy
19. laminotomy
20. ’laminoplasty’/exp OR laminoplasty
21. ’spine fusion’/exp OR ’spine fusion’
22. ’spinal fusion’/exp OR ’spinal fusion’
23. ’lumbar NEAR/3 fusion’
24. ’vertebrae fusion’
25. ’vertebral fixation’
26. ’spondylodesis’/exp OR spondylodesis
27. ’spinal fixation’
28. ’spinal fixation device’/exp OR ’spinal fixation device’
29. ’spondylosyndesis’/exp OR spondylosyndesis
30. posterolateral NEAR/3 fusion
31. interbody NEAR/3 fusion
32. anterior NEAR/3 fusion
33. posterior NEAR/3 fusion
34. transforaminal NEAR/3 fusion
35. ’transpsoas fusion’
36. facet NEAR/3 fusion
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37. ’arthrodesis’/exp OR arthrodesis
38. bone NEAR/5 graft
39. fixation NEAR/5 spin*
40. pedicle NEAR/5 fusion
41. cage NEAR/5 fusion
42. screw NEAR/5 fusion
43. pedicle NEAR/5 screw
44. ’foraminotomy’/exp OR foraminotomy
45. foraminectomy
46. ’minimally invasive procedures’/exp OR ’minimally invasive procedures’
47. ’minim$ invasive’
48. 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR
31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47
49. 13 AND 48
50. ’randomized controlled trial’/exp OR ’randomized controlled trial’
51. ’controlled clinical trial’/exp OR ’controlled clinical trial’
52. ’clinical trial’/exp OR ’clinical trial’
53. randomized:ab
54. placebo:ab
55. randomly:ab
56. trial:ab
57. ’clinical study’:ab
58. 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34
59. 26 AND 35
60. 59 AND ’human’/de
CINAHL
Last searched 16 June 2016
57. 19 AND 56
56. 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR
37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54
OR 55
55. (MH “Minimally Invasive Procedures”) OR “Minimally Invasive”
54. “Foraminectomy”
53. “Foraminotomy”
52. “Screw fusion”
51. “Cage fusion”
50. “Pedicle fusion”
49. (MH “Grafts+”) OR “Bone graft”
48. (MH “Arthrodesis+”)
47. “Facet fusion”
46. “Transpsoas fusion”
45. “Transforaminal fusion”
44. “Posterior fusion”
43. “Anterior fusion”
42. “Anterior near/5 fusion”
41. “Interbody fusion”
40. “Posterolateral fusion”
39. “Spondylosyndesis”
38. “Spinal fixation” OR (MH “Orthopedic Fixation Devices+”)
37. “Spondylodesis”
36. “vertebral fixation”
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35. “vertebrae fusion”
34. “lumbar fusion”
33. (MH “Orthopedic Fixation Devices+”) OR “pedicle screw”
32. “spin* fusion”
31. (MH “Arthrodesis+”) OR “arthrodesis”
30. (MH “Spinal Fusion”) OR “Spinal Fusion”
29. “Laminoplasty”
28. “Laminotom*”
27. “Laminectom*”
26. (MH “Laminectomy”) OR “Laminectomy”
25. “lumbar decompress*”
24. “spin* decompress*”
23. “Decompres* surgery”
22. (MH “Decompression, Surgical+”) OR “Decompression”
21. “surgery”
20. (MH “Surgery, Operative+”)
19. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18
18. (MH “Spondylolysis+”) OR “spondilolisys”
17. “Spondylosis”
16. (MH “Spondylosis+”)
15. “lumb* spondyl*”
14. (MH “Spondylolisthesis”) OR “Spondylolisthesis”
13. “lumbar radicular pain”
12. “radicular pain”
11. (MH “Radiculopathy”) OR “Radiculopathy”
10. “neurogenic claudication”
9. (MH “Intermittent Claudication”)
8. “foramin* stenosis”
7. “central stenosis”
6. “lateral stenosis”
5. “lumbar stenosis”
4. “Canal stenosis”
3. “spin* stenosis”
2. “spinal stenosis”
1. (MH “Spinal Stenosis”)
AMED
Last searched 16 June 2016
1. Exp Spinal stenosis/
2. Canal stenosis.mp.
3. (spin* adj3 stenosis).mp.
4. (lumbar adj3 stenosis).mp.
5. (lateral adj3 stenosis).mp.
6. (central adj3 stenosis).mp.
7. (foramin* adj3 stenosis).mp.
8. “neurogenic claudication”.mp.
9. Radiculopathy.mp.
10. “radicular pain”.mp.
11. “lumbar radicular pain”.mp.
12. Exp Spondylolisthesis/
13. Spondylolisthesis.mp.
14. (lumb* adj5 spondyl*).mp.
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15. Spondylosis.mp.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. Exp surgery/
18. Surgery.mp.
19. Surgery operative.mp.
20. Decompression.mp.
21. “Decompres* surgery”.mp.
22. (spin* adj3 decompress*).mp.
23. Exp Laminectomy/
24. Laminectom*.mp.
25. Laminotomy.mp.
26. Laminoplasty.mp.
27. Exp arthrodesis/
28. (spin* adj3 fusion).mp.
29. (pedicle adj3 screw).mp.
30. “lumbar fusion”.mp.
31. “vertebrae fusion”.mp.
32. “Vertebral fixation”.mp.
33. “Spinal fixation”.mp.
34. Spondylodesis.mp.
35. Spondylosyndesis.mp.
36. Exp Arthrodesis/ or Arthrodesis.mp.
37. (Posterolateral adj3 fusion).mp.
38. (Interbody adj3 fusion).mp.
39. (Anterior adj3 fusion).mp.
40. (Posterior adj3 fusion).mp.
41. (Transforaminal adj3 fusion).mp.
42. (Transpsoas adj3 fusion).mp.
43. (Facet adj3 fusion).mp.
44. (Bone adj3 graft).mp.
45. (Fixation adj3 spin*).mp.
46. (Pedicle adj3 fusion).mp.
47. Graft.mp.
48. (Cage adj3 fusion).mp.
49. (Screw adj3 fusion).mp.
50. Foraminotomy.mp.
51. “Minim* invasive”.mp.
52. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
53. 16 and 52
Web of Science
Last searched 16 June 2016
54. 53 and 43
53. 52 or 51 or 50 or 49 or 48 or 47 or 46 or 45 or 44
52. “clinical study”
51. “clinical trial”
50. Trial)
49. Random*
48. Placebo
47. Randomized
46. “controlled clinical trial”
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45. “randomized clinical trial”
44. “randomized controlled trial”
43. 42 and 14
42.41 or 40 or 39 or 38 or 37 or 36 or 35 or 34 or 33 or 32 or 31 or 30 or 29 or 28 or 27 or 26 or 25 or 24 or 23 or 22 or 21 or 20 or
19 or 18 or 17 or 16 or 15
41. “minimally invasive”
40. Foraminectomy
39. Foraminotomy
38. “pedicle screw”
37. “cage fusion”
36. Arthrodesis
35. ”facet fusion“
34. ”transpsoas fusion“
33. ”transforaminal fusion“
32. ”posterior fusion“
31. ”anterior fusion“
30. ”interbody fusion“
29. ”posterolateral fusion“
28. Spondylosyndesis
27. ”spinal fixation“
26. Spondylodesis
25. ”vertebral fixation“
24. ”vertebrae fusion“
23. Arthrodesis
22. ”lumbar fusion“
21. ”spin* fusion“
20. Laminoplasty
19. Laminotom*
18. Laminectomy
17. Decompressive
16. Decompression
15. Surgery
14. 13 or 12 or 11 or 10 or 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 or 1
13. Spondylolysis
12. Spondylosis
11. ”spondylolisthesis“
10. ”lumbar radicular pain“
9.” radicular pain“
8. ”radiculopathy“
7. ”neurogenic claudication“
6. ”foramin* stenosis“
5. ”central stenosis“
4. ”lateral stenosis“
3. ”lumbar stenosis“
2. ”canal stenosis“
1. ”spin* stenosis“
LILACS
Last searched 16 June 2016
(”spine stenosis“ OR ”spinal stenosis“ OR ”canal stenosis“ OR ”lumbar stenosis“ OR ”central stenosis“ OR ”lateral stenosis“ OR
”foraminal stenosis“ OR ”spondylolisthesis“ OR spondylosis OR ”neurogenic claudication“ OR radiculopathy OR ”radicular pain“)
AND (surgery OR decompression OR decompressive OR laminectomy OR laminotomy OR laminoplasty OR ”spinal fusion“ OR
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”spine fusion“ OR arthrodesis OR ”lumbar fusion“ OR ”vertebrae fusion“ OR ”vertebral fixation“ OR spondylodesis OR ”spinal
fixation“ OR spondylosyndesis OR ”posterolateral fusion“ OR ”interbody fusion“ OR ”anterior fusion“ OR ”posterior fusion“ OR
”transforaminal fusion“ OR ”transpsoas fusion“ OR ”facet fusion“ OR ”bone graft“ OR ”pedicle fusion“ OR ”cage fusion“ OR ”screw
fusion“ OR ”pedicle screw“ OR screw OR rod OR foraminotomy OR foraminectomy OR ”surgical procedure“ OR ”minimally
invasive“)
ClinicalTrials.gov, WHO ICTRP and ANZCTR
Last searched 16 June 2016
ClinicalTrials.gov: Search: (surgery OR decompression) AND Condition: spinal stenosis
WHO ICTRP: Title: (surgery OR decompression) AND Condition: spinal stenosis
ANZCTR: Search terms: (surgery OR decompression) AND Health condition(s) or problem(s) studied: spinal stenosis
Appendix 2. The GRADE approach to evidence synthesis
The quality of evidence will be categorised as follows:
• High (⊕⊕⊕⊕): further research is very unlikely to change the confidence in the estimate of effect.
• Moderate (⊕⊕⊕©): further research is likely to have an important impact in the confidence in the estimate of effect.
• Low (⊕⊕©©): further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
• Very Low (⊕©©©): any estimate of effect is very uncertain.
The evidence available to answer each sub-question will be graded on the domains in the following manner:
1. Risk of bias
Limitations in the study design and implementation may bias the estimates of the treatment effect. Our confidence in the estimate of
the effect and in the following recommendation decreases if studies suffer from major limitations. We will examine all studies on five
types of biases:
a) Selection (random sequence generation, allocation concealment, group similarities at baseline)
b) Performance (blinding of participants, blinding of healthcare providers)
c) Attrition (dropouts and intention-to-treat analysis)
d) Measurement (blinding of the outcome assessors and timing of outcome assessment)
e) Reporting bias (selective reporting)
The quality of evidence will be downgraded as follows:
• by one level: when most of the evidence comes from individual studies either with a crucial limitation for one criterion, or with
some limitations for multiple criteria
• by two levels: when most of the evidence comes from individual studies with crucial limitations for multiple criteria
2. Inconsistency
Inconsistency refers to an unexplained heterogeneity of results. Widely differing estimates of the treatment effect (i.e. heterogeneity or
variability in results) across studies suggest true differences in underlying treatment effect. Inconsistency may arise from differences in:
populations (e.g. drugs may have larger relative effects in sicker populations), interventions (e.g. larger effects with higher drug doses),
or outcomes (e.g. diminishing treatment effect with time).
The quality of evidence will be downgraded as follows:
• by one level: when the heterogeneity or variability in results is large.
• by two levels: when the heterogeneity or variability in results is large AND there was inconsistency arising from populations,
interventions, or outcomes.
3. Indirectness
Indirect population, intervention, comparator, or outcome: the question being addressed in this systematic review is different from the
available evidence regarding the population, intervention, comparator, or an outcome in the included randomised trial.
The quality of evidence will be downgraded as follows:
• by one level: when there is indirectness in only one area
• by two levels: when there is indirectness in two or more areas
4. Imprecision
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Results are imprecise when studies include relatively few participants and few events and thus have wide confidence intervals around the
estimate of the effect. In such a case we judge the quality of the evidence to be lower than it otherwise would be because of uncertainty
in the results. Each outcome is considered separately.
For dichotomous outcomes
We will consider imprecision for either of the following two reasons:
1. There is only one study (unless the study provide data from more than 300 participants). When there is more than one study, the
total number of events is less than 300 (a threshold rule-of-thumb value) (Guyatt 2011).
2. 95% confidence interval around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit or
appreciable harm. The threshold for ’appreciable benefit’ or ’appreciable harm’ is a relative risk reduction (RRR) or relative risk increase
(RRI) greater than 25%.
The quality of the evidence will be downgraded as follows:
• by one level: when there is imprecision due to (1) or (2)
• by two levels: when there is imprecision due to (1) and (2)
For continuous outcomes
We will consider imprecision for either of the following two reasons:
1. There is only one study (unless the study provide data from more than 400 participants). When there is more than one study, total
population size is less than 400 (a threshold rule-of-thumb value; using the usual α and β , and an effect size of 0.2 standard deviations,
representing a small effect).
2. 95%confidence interval includes no effect and the upper or lower confidence limit crosses an effect size (standardisedmean difference)
of 0.5 in either direction.
The quality of the evidence will be downgraded as follows:
• by one level: when there is imprecision due to (1) or (2)
• by two levels: when there is imprecision due to (1) and (2)
5. Publication bias
Publication bias is a systematic underestimate or an overestimate of the underlying beneficial or harmful effect due to the selective
publication of studies.
The quality of evidence will be downgraded as follows:
• by one level: when the funnel plot suggests publication bias
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a review published in PLoS One (Machado 2015). The study protocol was previously registered on PROSPERO
(registration number CRD42013005901). We followed the new recommendations of the Cochrane Back and Neck Group in this
review (Furlan 2015), which was not stated in the protocol or previous version of this review as it was not yet published. There were
no substantial changes from the protocol or the previous version of this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Lumbar Vertebrae; Back Pain [surgery]; Blood Loss, Surgical [statistics & numerical data]; Decompression, Surgical [∗methods]; Leg;
Operative Time; Pain Management; Randomized Controlled Trials as Topic; Reoperation [statistics & numerical data]; Spinal Stenosis
[∗surgery]; Treatment Outcome
MeSH check words
Humans
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